<SEC-DOCUMENT>0001010549-17-000112.txt : 20170331
<SEC-HEADER>0001010549-17-000112.hdr.sgml : 20170331
<ACCEPTANCE-DATETIME>20170331162120
ACCESSION NUMBER:		0001010549-17-000112
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170331
DATE AS OF CHANGE:		20170331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34471
		FILM NUMBER:		17730661

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cphi10k123116.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT><B>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the fiscal year ended December 31, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>or</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Wingdings"><B>&#168;</B></FONT><B>
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the transition period from _________
to _____________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commission file number: 001-34471</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>China Pharma Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>(Exact name of registrant as specified
in its charter)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Nevada</B></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>73-1564807</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(State or other jurisdiction of</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>incorporation or organization)</I></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><I>(IRS Employer Identification No.)</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Second Floor, No. 17, Jinpan Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Haikou, Hainan Province, China 570216</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Address of Principal Executive Offices)
(Zip Code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number: <B>(011)
86 898-6681-1730</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 49%; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">Common Stock, $0.001 Par Value Per Share</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">NYSE MKT</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities registered pursuant to Section 12(g)
of the Act: <B>None.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT>
No <FONT STYLE="font-family: Wingdings"><B>x</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT>
No <FONT STYLE="font-family: Wingdings"><B>x</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s)), and (2)
has been subject to such filing requirements for the past 90 days. Yes <FONT STYLE="font-family: Wingdings"><B>x</B></FONT> No
<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT>
No <FONT STYLE="font-family: Wingdings"><B>o</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to
the best of Registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K. <FONT STYLE="font-family: Wingdings"><B>x</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.
See definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 48%; padding-left: 0.5in; text-align: justify">Large accelerated filer <FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="width: 52%; text-align: justify">Accelerated filer <FONT STYLE="font-family: Wingdings">o</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Non-accelerated filer <FONT STYLE="font-family: Wingdings">o</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Do not check if a smaller reporting
        company</P></TD>
    <TD STYLE="vertical-align: top; text-align: justify">Smaller reporting company <FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT>
No <FONT STYLE="font-family: Wingdings"><B>x</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate market
value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the
common equity was last sold, or the average bid and ask price of such common equity, as of the last business day of the
registrant&rsquo;s most recently completed second fiscal quarter: $5,812,057 as of June 30, 2016, based on the closing price
of $0.24 of the Company&rsquo;s common stock on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The number of outstanding
shares of the registrant&rsquo;s common stock on March 27, 2016, was 43,579,557.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Documents Incorporated
by Reference: None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-K ANNUAL REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FISCAL YEAR ENDED DECEMBER 31, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 80%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right">PAGE</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify">PART I</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 1.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Business.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">5</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 1A.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Risk Factors.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">27</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 1B.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Unresolved Staff Comments.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">48</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 2.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Properties.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">48</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 3.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Legal Proceedings.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">49</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 4.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Mine Safety Disclosures.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">49</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">PART II</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 5.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Market for the Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">49</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 6.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Selected Financial Data.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">50</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 7.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">51</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 7A.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Quantitative and Qualitative Disclosures about Market Risk.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">61</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 8.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Financial Statements and Supplementary Data.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">61</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 9.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">62</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 9A.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Controls and Procedures.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">62</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 9B.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Other Information.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">63</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">PART III</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 10.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Directors, Executive Officers and Corporate Governance.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">63</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 11.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Executive Compensation.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">65</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 12.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">67</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 13.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Certain Relationships and Related Transactions, and Director Independence.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">68</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">Item 14.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Principal Accountant Fees and Services.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">68</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top; text-align: justify">PART IV</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; text-align: justify">Item 15.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Exhibits, Financial Statement Schedules.</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">69</TD></TR>
<TR STYLE="background-color: azure">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: justify">SIGNATURES</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">70</TD></TR>
<TR STYLE="background-color: azure">
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: justify">EXHIBIT INDEX</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">71</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: justify">FINANCIAL STATEMENTS</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">F-1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The statements contained
in this report with respect to our financial condition, results of operations and business that are not historical facts are &ldquo;forward-looking
statements&rdquo;. Forward-looking statements can be identified by the use of forward-looking terminology, such as &quot;anticipate&quot;,
&quot;believe&quot;, &quot;expect&quot;, &quot;plan&quot;, &quot;intend&quot;, &quot;seek&quot;, &quot;estimate&quot;, &quot;project&quot;,
&quot;could&quot;, &quot;may&quot; or the negative thereof or other variations thereon, or by discussions of strategy that involve
risks and uncertainties. Management wishes to caution the reader of the forward-looking statements that any such statements that
are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties
and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general
business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described
in this report including in &ldquo;Risk Factors&rdquo; in Item 1A and some of which are discussed in our other filings with the
SEC. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of
future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from
the assumptions underlying the statements that have been made regarding anticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These risk factors should
be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf
may issue. All written and oral forward looking statements made in connection with this report that are attributable to our company
or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties,
we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm
analysts&rsquo; expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events
or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable
law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section 21E of the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) expressly state that the safe harbor for forward-looking statements does
not apply to companies that issue penny stock. If we are ever considered to be an issuer of penny stock, the safe harbor for forward-looking
statements may not apply to us at certain times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 1.</B>&nbsp;<B>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We are principally
engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of
high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China (the &quot;PRC&quot;).
All of our operations are conducted in the PRC, where our manufacturing facilities are located. We manufacture pharmaceutical products
in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of
our pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications
by the China Food and Drug Administration (the &quot;CFDA&quot;), based upon demonstrated safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">As of December
31, 2016, we manufactured 19  pharmaceutical products for a wide variety of diseases and medical indications, each of which
may be classified into one of three general categories:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Basic generic drugs, which are common drugs in the PRC for which
there is a very large market demand;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First-to-market generic drugs, which are generic Western drugs that
are new to the PRC marketplace; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Modern Traditional Chinese Medicines, which generally are a non-synthetic,
plant-based medicinal compounds of the type that have been widely used in the PRC for thousands of years, to which we apply modern
production techniques to produce pharmaceutical products in different formulations, such as tablets, capsules or powders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In selecting generic
drugs to develop and manufacture, we consider several factors, including the number of other manufacturers currently producing
a particular drug, the size of the market for that drug, the proposed or required method of distribution, the existing and expected
pricing for that particular drug in the marketplace, the costs of manufacturing that drug, and the costs of acquiring or developing
the formula for that drug. We believe we have historically selected generic drugs for manufacture that have large addressable markets
and higher profit margins relative to other generic drugs being manufactured and distributed in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We currently own
and operate an approximately 8,000-square-meter manufacturing facility in Haikou, Hainan Province, built by us in 2002, that supports
eight modern, scalable production lines. We implement quality control procedures in this facility in compliance with the PRC's
Good Manufacturing Practices, or GMP standards, and applicable CFDA regulations to ensure consistent quality in our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The CFDA promulgated
<I>Good Manufacturing Practices for Pharmaceutical Products</I> (2010 revised version) (the &quot;new GMP&quot;) on February 12,
2011 (effective as of March 1, 2011). The new GMP standards outline the basic principles and standards for the manufacturing of
pharmaceutical products and the management of quality controls in the pharmaceutical products manufacturing industry in the PRC.
Pursuant to those mandatory requirements, upgrades to our two injectables production lines were required to be finalized by the
end of 2013. From January 1, 2014 to November 3, 2014, we suspended production at our dry powder injectables and liquid injectables
production lines due to a failure to meet new the GMP upgrade deadline. However, in 2014, we completed construction of a new 20,000
square-meter factory equipped with four sterilize production lines (two liquid injectables and two dry powder injectables production
lines), in full compliance with the latest GMP standard. In November 2014, the CFDA completed GMP certification of our new facility
and issued us with a GMP certificate, enabling us to commence manufacturing at our two liquid injectables and two dry powder injectables
production lines. In January and December 2015, we completed further upgrades and received new GMP certificates for the tablet
and capsule production lines and the cephalosporin production lines in our old factories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We market and sell
our products through 16 sales offices covering all major cities and provinces in the PRC. To comply with applicable Chinese law
relating to sales of prescription drugs to certain hospitals and clinics, we also use a distribution system comprised of over
1,000 independent prefecture-level, city-level, and county-level distributors. Our sales system has further developed and expanded
with the expansion of Chinese healthcare reform, and our 16 provincial offices deliver our products to basic health care institutions
as well as tier two and tier three hospitals through the above mentioned distributors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Corporate
History</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;We are a holding
company and conduct substantially all of our production, marketing, finance, development and administrative activities through
our wholly-owned subsidiary located in the PRC. We were incorporated in the State of Delaware under the name &quot;Softstone, Inc.&quot;
on January 28, 1999. From mid-2003 to October 19, 2005, we did not generate any significant revenue and we accumulated no significant
assets while we explored business opportunities as a publicly-held &quot;shell&quot; corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We entered into
our current line of business on October 19, 2005, through the acquisition of Onny Investment Limited, a holding company formed
in the British Virgin Islands (&quot;Onny&quot;), and its operating subsidiary located in the PRC, Hainan Helpson Medical &amp;
Biotechnology Co., Ltd. (&quot;Helpson&quot;). On March 16, 2006, we changed our corporate name to China Pharma Holdings, Inc.
On December 31, 2012, we reincorporated from the State of Delaware to the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Helpson was established
on February 25, 1993, in Haikou, Hainan Province, PRC as a foreign-invested enterprise. The company was originally an &quot;equity
joint venture,&quot; as defined by China's laws on foreign-invested enterprises, between Haikou Biomedical Engineering Co., Ltd.,
a PRC company, and Hong Kong Fudao Development Co., Ltd., a Hong Kong company (&quot;Fudao&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">On June 16, 2001,
Fudao entered into an Equity Interest Transfer Agreement with Hainan Kaidi Science and Technology Co., Ltd., a PRC company (&quot;Kaidi&quot;),
pursuant to which Fudao transferred all of its ownership interest in Helpson to Kaidi. As a result of this transfer, Helpson became
a PRC domestic company, rather than a foreign-invested company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Onny was incorporated
on January 12, 2005, under the laws of the British Virgin Islands. On May 25, 2005, Helpson&rsquo;s three then-existing shareholders
entered into an equity interest transfer agreement with Onny, as a result of which, effective as of June 21, 2005, Helpson became
a wholly foreign-owned enterprise (&ldquo;WFOE&rdquo;), and Onny became the sole shareholder of Helpson.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">On October 19, 2005,
we acquired all of the issued and outstanding shares of Onny in exchange for 27,499,940 shares of our common stock and became Onny's
sole shareholder. In connection with this share exchange, all of our officers and directors at that time resigned from their positions
as officers and directors of our Company, and new directors and executive officers were appointed. Also as a result of this share
exchange, commonly referred to as a &quot;reverse acquisition,&quot; Helpson became our indirect wholly-owned subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Our corporate organizational
chart is set forth below.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 220px; width: 240px"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 24pt 0 12pt; text-align: justify">Industry Background and
Market Opportunities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&ldquo;Chemical
drugs&rdquo; refers to drugs with active ingredients prepared by chemical synthesis. This category of drugs may be divided into
patented drugs and generic drugs according to the degree of innovation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Patented drugs are
the originally developed drugs. The development process for patented drugs includes drug molecular screening, preclinical study,
clinical trials (Phase I, Phase II, Phase III), submission of a New Drug Application (NDA), etc., all of which can take as long
as 10-15 years, and the finally selected chemical compound among tens of thousands of molecules. During the development process,
the manufacturer generally applies for a series of patents regarding the drug&rsquo;s molecular structure, the preparation process,
dosage forms and so on, in order to guarantee exclusivity in the market during the patent period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pharmaceutical companies
may also leverage follow-up research and development to create so-called me-too or me-better drugs. Most of these studies are based
on existing drugs as lead compounds, and attempt to find unpatented molecules with similar chemical structures, which sometimes
may be more effective than the original drug or result in fewer adverse reactions. This R&amp;D model enjoys the benefits of not
only has the potentiality to apply for patent, but also requires less investment, has a higher success rate, lower risk, and a
shorter R&amp;D cycle, thanks to the known drug target, mechanism and screening model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Generic drugs are
patented drugs (originally-developed drugs) manufactured by pharmaceutical companies other than the original developer, after patent
expiration. According to the release &quot;Drug Registration Management Measures&quot; issued by the CFDA in 2007, generic drugs
must be consistent with the originally developed drug in five aspects: active ingredient, delivery system, dosage form, specification,
and function. At present, the majority of our currently existing products are generic drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The pharmaceutical
industry has the characteristics of high required investment input and low demand elasticity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">High investment
input: the pharmaceutical industry requires significant investment throughout the drug development process: from drug molecule
screening, preclinical research, and clinical trials to drug registration. On the production side, drug manufacturers are also
required to obtain GMP certification through PP&amp;E (Property, Premise and Equipment) upgrades, SOP (Standard Operating Procedure)
upgrades, and personnel training, all of which requires continuous investment. And on the sales side, the manufacturer again needs
to invest in building up and maintaining sales channels and implementing academic promotion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Low demand elasticity:
consumers value their health, especially in the face of disease, and generally accept the importance of pharmaceutical remedies
and medicine. In the context of China&rsquo;s current universal health insurance system, patients show less sensitivity in to pharmaceuticals
consumption as long as the cost of treatment is within their budgets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In 2015, China's
pharmaceutical manufacturing industry recognized revenue of RMB2553.7 billion, representing year-over-year growth of 9.1%; and
net income of RMB262.7 billion, representing year-over-year growth of 12.9%. As a major component of the industry, chemical drug
manufacturing recognized revenue of RMB681.6 billion and net income of RMB81.7 billion in the same period. It has been difficult
for the chemical drug industry to maintain the same high growth rate it experienced before 2012 due to the completion of the expansion
of health insurance, with the positive impacts of its policies gradual declines, as well as the existence of Medicare cost-controls
and drug pricing pressures resulting from drug bidding. However, in the context of China&rsquo;s aging population, the consumption
of pharmaceuticals is expected to increase, and although the growth rate of health insurance expenditures will not remain at the
previous high level, the industry will still be able to maintain growth. In addition, personal expenditures and fiscal expenditures
in healthcare are expected to continue to increase. Therefore, we believe that demand for pharmaceuticals and consumer ability
to pay are still enjoying steady growth. Although the growth rate has been declined, and our industry is now very large-scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Consistency
Evaluations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">On March 5, 2016,
the Chinese State Council issued &quot;Opinions on Carrying out Consistency Evaluations of the Quality and Efficacy of Generic
Drugs&quot; (the &ldquo;Opinions&rdquo;). Over 95% of the currently-sold drugs in China are generics which are subject to the &ldquo;Opinions&rdquo;.
Per the &ldquo;Opinions&rdquo;, any solid oral solution generics listed in the National Essential Drugs List (2012 edition)that
received production approval before October 1, 2007, shall complete a Consistency Evaluation by the end of 2018,while an applicant
which needs to carry out clinical trials and has certain special circumstances shall complete a Consistency Evaluation by the end
of 2021. Overdue applicants may no longer be eligible for re-registration. According to CFDA statistics, a total of 289 formulas,
17740 production approval numbers, 1817 domestic pharmaceutical manufacturers, and 42 overseas manufacturers will be affected by
the Opinions. 25.22% of approved manufacturers commenced production within the last three years. Assuming that manufacturers abandon
drugs not in production, there will be nearly 4,500 approvals requiring evaluation by the end of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Bioequivalence testing
(BE testing) is an important component of Consistency Evaluations. Unfortunately, there are a limited number of institutions that
currently carry out BE testing, which has become for a significant brake on the progress of the Consistency Evaluation program.
The PRC has more than 400 clinical drug trial institutions, while, per the &ldquo;Notice on the Clinical Trial Practice by Clinical
Trial Institutions and Contract Research organizations&rdquo; issued by CFDA on September 9, 2015, there were only 82 clinical
drug trial institutions that had undertaken BE testing and Phase I clinical trial in recent years. Due to the limited availability
of BE testing, certain generics may not be able to complete the Consistency Evaluations by the CFDA deadline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The imbalance in
supply and demand of BE testing has also led to an increase in BE testing costs, such that the overall costs of Consistency Evaluations
have increased as well, which in turn will increase capital expenditures for our industry. In addition, if a generic drug under
evaluation cannot achieve the same consistency of quality and efficacy as the originally-developed drug, the generic manufacturer
must re-develop and optimize its existing formula and production process through further analysis of the quality standards and
physical and chemical characteristics&nbsp;of the originally-developed drug, including study of the crystal form and solubility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The PRC's medical
insurance system. The PRC started putting basic medical insurance in place for urban workers in 1998, kicked off the &quot;New
Rural Cooperative Program&quot; (new rural cooperative medical care program) in 2003, and implemented basic medical insurance for
urban residents in 2007 to cover unemployed and low-income urban residents. After development over nearly two decades, China's
health insurance coverage and the number of people enrolled have both increased significantly. The number of insured persons in
the PRC increased from 18.78 million in 1998 to 1.34 million in 2015, and the coverage rate increased from 1.51% to 97.2% in the
same period. The general consensus is that the PRC has now essentially established a health insurance system with universal coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">There are other
factors that may also affect the pharmaceutical industry, such as Medicare cost-controls. In order to control the rapid increase
in medical expenditures, the government of the PRC has, since 2010, introduced a series of policies to strengthen supervision and
control effects of Medicare on healthcare services, to reform the Medicare payment methods, to establish a hierarchical treatment
system, to eliminate pharmaceutical mark-ups, and to reduce the proportion of drug costs to total healthcare costs, etc. In June
2016, the PRC&rsquo;s National Health Commission called on each province to determine the growth rate of medical expenditures as
soon as possible and further proposed limiting the national medical expenditure growth rate to no higher than 10% by the end of
2017. Although this policy applies only in the year 2017, we believe that the Medicare cost-controls will be adopted as a long-term
policy because of the PRC&rsquo;s aging population, universal health insurance coverage, and the Medicare fund&rsquo;s importance
as a payer for overall healthcare expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The CFDA promulgated
<I>Good Manufacturing Practices for Pharmaceutical Products (2010 revised version) </I>(the &quot;new GMP&quot;) on February 12,
2011 (effective as of March 1, 2011). The new GMP standards outline basic principles and standards for the manufacturing of pharmaceutical
products and the management of quality controls in pharmaceutical manufacturing processes in the PRC. Since they were first adopted
in 1988, GMP have over two decades of history in China, and were revised in 1992 and 1998. As of June 30, 2004, all manufacturing
of active pharmaceutical ingredients (&ldquo;API&rdquo;) and finished dosages must be in compliance with the GMP standards. The
new GMP standards that became effective on March 1, 2011, include improvements based upon foreign manufacturing advancements, and
have taken into consideration local conditions in China. Based on the principle of &quot;equal importance between hardware and
software&quot;, strictly implementing the idea of risk control during the manufacturing process of pharmaceutical products, and
increased focus on scientific guidance and operability, the new GMP standards are consistent with the World Health Organization
(WHO) standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The four main prongs
of the new GMP standards are: (1) strengthening quality control systems during the manufacturing process of pharmaceutical products
by significantly increasing requirements regarding quality control software; (2) improving requirements regarding the quality of
practitioners; (3) refining operational procedures, rules on document management (including manufacturing records), improving guidance
and operability; and (4) further improvements related to measures to ensure the safety of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The Drug Marketing
Authorization Holder (&ldquo;MAH&rdquo;) model is a management model that separates marketing authorization from independent production
licensing. License holders may delegate production to manufacturers and are only&nbsp;responsible for the safety, effectiveness
and quality control&nbsp;of drugs manufactured for public consumption. The MAH model is a common worldwide practice for review
and approval of new drugs, and h encourages investment in research and development and the adoption of Contract&nbsp;Manufacturing
Organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In August 2015,
the PRC State Council issued &quot;Opinions on the Reform of Drug and Medical Devices Evaluation and Approval of System Review&quot;,
which proposed to implement the MAH system experiments. Because the Company is considered a manufacturer pursuant to this policy,
we believe this policy will benefit our Company in the long run, given our new GMP certified production facility and because we
have the potential to manufacture products for license holders in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Our
Strategy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We believe
we are well positioned in a comparatively steadily growing industry in one of the fastest-growing economies in the world.
We currently manufacture a number of off-patent branded generic drugs that were among the first to market in the PRC. We
expect to continue to gain additional competitive advantages through the growing pipeline of new pharmaceutical products we
are developing for specific target patient groups. Our diverse portfolio of products and our new product pipelines
include products for high-incidence and high-mortality conditions in the PRC, such as cardiovascular, central nervous
system (&ldquo;CNS&rdquo;), infectious, and digestive diseases. Furthermore, the Healthcare Reform initiated by the State
Council in 2008 in the PRC has significantly expanded the landscape of the Chinese healthcare industry. According to the <I>2016
National Economic and Social Development Statistics Bulletin of the People's Republic of China</I> issued by National Bureau
of Statistics of the PRC, the total number of Chinese healthcare institutions has reached 993,000 as of the end of
2016, including 29,000 hospitals, 931,000 grass-root healthcare institutes (comprised of 37,000 township healthcare
centers, 35,000 community health service centers (stations), 217,000 clinics, 642,000 village healthcare centers), and
29,000 professional public health institutions. We believe the increase in demand from these sources should allow us to
grow organically. In addition, the total number of medical personnel in the PRC&nbsp;has reached 8.44 million, including
3.17 million practicing physicians and practicing assistant physicians and 3.5 million registered nurses. The number of beds
in medical and health institutions has reached 7.47 million, including 5.75 million in hospitals and 1.23 million in
township healthcare centers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Production approval
from the CFDA for Candesartan, an angiotensin II receptor antagonist serving as a first-line treatment for hypertension, developed
in November 2013 and launched towards the end of 2014, and for new products from our pipeline of products under development (such
as a generic version of Crestor and novel anti-drug-resistant combination antibiotics), would offer us significant growth opportunities.
Finally, healthcare reform has started to change the landscape of the Chinese pharmaceutical industry, which we believe will create
many attractive acquisition opportunities. We plan to explore these opportunities in an effort to add synergistic products that
can help us grow our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Our objective is
to leverage our expertise in the PRC for the development, manufacture and commercialization of pharmaceutical products. We intend
to achieve this objective by:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Promoting Our Existing Brands to Increase Our National Recognition</I>.
We intend to support and grow the existing recognition and reputation of our brands and to maintain our branded pricing strategy
through continued sales and marketing efforts and through our new, upgraded GMP-compliant production lines. To achieve this goal,
we plan to promote the efficacy and safety profile of our established prescription pharmaceutical products to physicians at hospitals
and clinics in all provinces of PRC through the efforts of our sales force, independent distributors and educational physician
conferences and seminars.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Developing and Introducing Additional Products to Expand or Strengthen
Our Existing Product Portfolio</I>. We plan to focus our development capabilities towards expanding our existing portfolio of approved
products. We have a number of products in various stages of the CFDA approval process. In addition, we intend to conduct clinical
trials for new generic or modernized products to expand our existing product portfolio. We plan to introduce new generic or modernized
products to leverage our branded market leadership position, particularly in therapeutic areas in which we already have a strong
presence.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Expanding Our Distribution Network to Increase Market Penetration</I>.
We intend to expand our reach beyond our current 16 offices in the PRC to drive additional growth of our existing and future products.
We currently contract with over 1,000 distributors in the PRC and plan to expand on these relationships to target new markets.
We will continue our conservative sales strategy of increased cooperation with customers with reliable accounts receivable collection
performance. In addition, we plan to continue to broaden our marketing efforts outside of major cities in the PRC and to increase
our market penetration in cities and rural areas where we already have a presence. Over the long term, we also intend to expand
our presence beyond the PRC to international markets by working with international pharmaceutical companies in cross-selling our
products.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Acquiring Complementary Products Lines, Technologies, Distribution
Networks and Companies.</I> We intend to selectively pursue strategic acquisition opportunities that we believe will grow our customer
base, expand our product lines and distribution network, enhance our manufacturing and technical expertise or otherwise complement
our business or further our strategic goals. Pursuing strategic acquisitions is a significant component of our growth strategy.
The Company has not identified any strategic acquisition opportunities as of the date of this report on Form 10-K.</FONT></TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 24pt 0 12pt; text-align: justify">Products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We currently
have a product portfolio of 19  pharmaceutical products that address a wide variety of diseases and medical indications. All
of our pharmaceutical products have demonstrated safety and efficacy in clinical trials sufficient to obtain approval by the
CFDA and are sold on a prescription basis. The following table summarizes the approved indications for our marketed
pharmaceutical products and the year in which each of such products was first marketed to our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; background-color: white">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Product</B></P></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; background-color: white">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Indication</B></P></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 1pt solid; background-color: white">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Year of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commercial</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Launch</B></P></TD>
    <TD STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; background-color: white; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases</I></B></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; background-color: white; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">CerebroproteinHydroloysate Injection</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Memory decline and attention deficit disorder caused by the sequela of craniocerebral trauma and cerebrovascular diseases.</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1996</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Gastrodin Injection</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain, including vertigo, neuralgia and headaches.</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2005</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Propylgallate for Injection</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cerebral thrombosis, coronary heart disease and complications after surgery such as thrombus deep phlebitis.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2006</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Ozagrel Sodium for Injection</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cerebral thrombosis, coronary heart disease and complications after surgery such as thrombus deep phlebitis.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2006</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Alginic Sodium Diester Injection</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis, cerebral embolism and coronary heart disease) and high lipoprotein blood disease.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2006</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Bumetanide for Injection</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Various edema diseases (including those associated with heart failure, hepatic cirrhosis, nephropathy, and pulmonary edema), hypertension, acute renal failure, hyperkalemia, hypercalcemia and for the rescue from acute drug poisoning.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2007</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Candesartan</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Hypertension</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2013</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt"><B><I>Anti-infection and Respiratory Diseases</I></B></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Roxithromycin Dispersible Tablets</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pharyngitis and tonsillitis caused by Streptococcus pyogenes;
    sinusitis, tympanitis, acute and chronic bronchitis caused by acute bacterial infection, Mycoplasma pneumonia and Chlamydia
    pneumoniae; urethritis and cervical infection caused by chlamydia trachomatis; skin soft tissue infection caused by sensitive
    bacteria.</FONT></TD>
    <TD STYLE="padding-left: 29.25pt; text-align: right"><FONT STYLE="font-size: 10pt">1995</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 29.25pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 31%; text-align: left"><FONT STYLE="font-size: 10pt">Cefaclor Dispersible Tablets</FONT></TD>
    <TD STYLE="width: 56%; text-align: justify"><FONT STYLE="font-size: 10pt">Tympanitis, lower respiratory tract infection, urinary tract infections and skin/skin tissue infection.</FONT></TD>
    <TD STYLE="width: 13%; padding-left: 29.25pt; text-align: right"><FONT STYLE="font-size: 10pt">2002</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cefalexin
                                 Capsules</FONT></P>



</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Acute tonsillitis caused by sensitive fungi, airway infections,
    such as pharyngitis, otitis media, nasal sinusitis and bronchitis; pneumonia, respiratory tract infection, urinary tract infections
    and skin soft tissue infections.</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">2002</FONT></P>


</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Anhydroandrographolide</FONT></P>



</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis,
    cerebral embolism and coronary heart disease) and high lipoprotein blood disease.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2003</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Clarithromycin Granules and Capsules</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Nasopharynx infection, lower respiratory tract infection, skin tissue infection, acute tympanitis and mycoplasma pneumonia caused by clarithromycin susceptible organisms; urethritis and cervical infection caused by chlamydia trachomatis; and the treatment of legionella infection, mycobacterium avium complex (MAC) infection and helicobacter pylori infection.</FONT></TD>
    <TD STYLE="padding-left: 29.25pt; text-align: right"><FONT STYLE="font-size: 10pt">2004</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Naproxen Sodium and PseudophedrineHydrochlorida Sustained Release Tablets</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Relieves cold, sinus and flu symptoms, blocked nose caused by anaphylaxis rhinitis, runny nose, fever, sore throat, symptoms of myalgia in the limbs and pain around the joints.</FONT></TD>
    <TD STYLE="padding-left: 29.25pt; text-align: right"><FONT STYLE="font-size: 10pt">2005</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>Digestive Diseases</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Hepatocyte Growth-promoting Factor for Injection</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Serious viral hepatitis symptoms caused by various viral hepatitis types (acute, subnormal temperature, chronic serious disease early or middle period of hepatitis).</FONT></TD>
    <TD STYLE="padding-left: 29.25pt; text-align: right"><FONT STYLE="font-size: 10pt">2005</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Tiopronin</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Acute and chronic Hepatitis B, and for the relief of drug-induced liver injury.</FONT></TD>
    <TD STYLE="padding-left: 29.25pt; text-align: right"><FONT STYLE="font-size: 10pt">2009</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Compound Ammonium Glycyrrhetate S for Injection</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Liver dysfunction caused by acute and chronic hepatitis; supplemental treatment to toxic/trauma hepatitis, liver cancer; also for the indication of food/drug poisoning, and drug allergy.</FONT></TD>
    <TD STYLE="padding-left: 29.25pt; text-align: right"><FONT STYLE="font-size: 10pt">2009</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Omeparzole</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Gastroesophageal reflux disease, and other conditions caused by excess acidic formulations in the stomach, including gastric ulcers, recurrent duodenal ulcers and Zollinger-Ellison Syndrome.</FONT></TD>
    <TD STYLE="padding-left: 24.75pt; text-align: right"><FONT STYLE="font-size: 10pt">2009</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>Others</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Vitamin B6 for Injection</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Vitamin supplement.</FONT></TD>
    <TD STYLE="padding-left: 29.25pt; text-align: right"><FONT STYLE="font-size: 10pt">2005</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Granisetron Hydrochloride Injection</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors.</FONT></TD>
    <TD STYLE="padding-left: 29.25pt; text-align: right"><FONT STYLE="font-size: 10pt">2006</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The following table
sets forth the aggregate amount and percentage of our revenues attributed to our product portfolio by indication group for the
years ended December 31, 2016 and 2015.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Product Category</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Fiscal Year Ended December 31,</FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Net Change</FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">% Change</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">CNS Cerebral &amp; Cardio Vascular</FONT></TD>
    <TD STYLE="width: 19%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2.72 </FONT></TD>
    <TD STYLE="width: 19%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">3.11 </FONT></TD>
    <TD STYLE="width: 14%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-0.39 </FONT></TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-12%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Anti-Viral/ Infection &amp; Respiratory</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">10.27 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">13.51 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-3.24 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-24%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Digestive Diseases</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0.79 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0.76 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0.03 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">4%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Other</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.78 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2.97 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-1.19 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-40%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Due to the nature
of the pharmaceutical industry, we continually strive to change our product portfolio to respond to changes in market demand. Based
on a foundation established by a number of our widely-recognized prescription products, such as Cefaclor and Roxithromycin, we
have launched and will continue to launch a variety of pharmaceuticals. The core criteria for our selection of potential pipeline
products are strong market demand, proven efficacy, and safety. In an effort to gain an advantage in the marketplace, we often
seek to improve the production process of the new generic products we elect to manufacture or to improve the quality of a proposed
product to increase its efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We also adjust
the delivery systems and marketing for each of our products based on the product's target patient group. We believe that maintaining
a variety of delivery systems (e.g. tablet, capsules, injectables and dry powders) for certain of our products targeted at different
groups enhances our competitive position in the marketplace. As a result, our sales and marketing personnel work closely with
management and our research and development personnel to determine which of our products can successfully be marketed for more
than one delivery system and which generics in the marketplace may be good candidates for us to manufacture and distribute in
the marketplace using different delivery systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Product
Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Our product portfolio
includes both branded and generic drugs that we either develop independently, in joint research efforts with our academic institutional
partners, or, to a lesser extent, acquire from third parties. We develop new products in-house as well as in cooperation with several
research institutes, including the Chinese Academy of Sciences, China University of Pharmaceuticals, Sichuan University, Chongqing
Medical Industry Institute and the Military Medical Academy Basic Medical Science Institute. We only pay these institutes for their
research efforts and expenses if our research goals are accomplished as evidenced by the certification of an applicable drug candidate
and the approval of drug production by the CFDA. Following receipt of such certification and approval, the rights to the applicable
drug candidate are transferred to us. Upon any such payment and transfer, we become the sole owner of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">drug
certifications and/or the approvals of drug production and any related research, and we have no further payment or other obligations
to the research institute from which we acquired such assets. We obtained certificates and approvals of drug production for our
Naproxen Sodium and PseudophedrineHydroclorida sustained-release tablets through our cooperative relationship with the Chongqing
Medical Industry Institute, and we also obtained certificates and approvals of drug production for our Cefalcor dispersible tablets
through our cooperative relationship with the China University of Pharmaceuticals. We are now manufacturing and selling both drugs.
We expect to continue to develop additional new drugs using this method. We also intend to continue purchasing or obtaining licenses
from third parties to produce certain drug products on a limited basis, as we regard this as an important and effective means
for us to develop our business. New products in our pipeline have experienced delays because the CFDA enhanced its approval criteria
and processes, resulting in additional supplemental materials and trials, higher cost, and longer approval time for certain applications
across all pharmaceutical products, including all of our product types. We commenced leading formulation screening, a new technology
exploration and technical criteria improvement activity, in 2013. We expect this new model to accelerate our development timelines
and expand exploration channels for our pipeline products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Generic drugs are
the drugs with the same active ingredient, dosage form, delivery channel and therapeutic effects as the originally-developed drug.
The Consistency Evaluations require currently marketed generic products to prove consistency in term of quality and therapeutic
effect, and substitutability with original drug during clinical trials. The Consistency Evaluations could enhance the development
of the pharmaceutical industry, ensure drug safety and effectiveness, promote the upgrading and restructuring of the pharmaceutical
industry, and improve international competitiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The PRC State Council
issued the &quot;Opinions on Carrying out Consistency Evaluation on Quality and Efficacy of Generic Drugs&rdquo; on March 5, 2016,
requiring all manufacturers of generic chemical pipeline products to carry out Consistency Evaluations before they may obtain final
registration approval. In addition, all oral solution generic drugs listed in National Essential Drugs List (2012 edition) and
launched into the market before October 1, 2007, must undergo Consistency Evaluations by the end of 2018, and Consistency Evaluation
should be completed by the end of 2021 for drugs with existing special conditions or those which require clinical efficacy trials.
Drugs failing to meet these requirements may not be re-registered. As of today, all of our pipeline products have been delayed
in receiving their CFDA approval because of these new requirements. The Company will strive to accelerate the compliance process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Due to the complex
implementation rules of Consistency Evaluations that are still being introduced, we suspended the development of our pipeline products
in 2016. The following list sets forth the current status of our main pipeline products:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 28%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Indication of Product Candidate</B></FONT></TD>
    <TD STYLE="width: 72%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>CFDA Status</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Anti-infection</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In Phase II Clinical Study, Supplement Clinical Study Due to Improved Technology Criteria</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Cholesterol Control Drug</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we have submitted an application for production approval, and are supplementing Consistency Evaluation experiments per the New Policy</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Alzheimer's Disease drug</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">At the latest stage of supplementing Consistency Evaluation experiments per the New Policy</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Coronary Heart Disease Drug</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Phase III Clinical Study Completed, and are supplementing clinical trials pursuant to the updated criteria</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Digestive Diseases Drug </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">At the latest stage of supplementing Consistency Evaluation experiments per the New Policy</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We have several
other pipeline products in various stages of development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Distribution
and Customers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We believe we have
a well-developed sales network. As our current pharmaceutical product portfolio is comprised mainly prescription drugs, our major
sales targets are hospitals. As of December 31, 2016, we also had&nbsp;16 sales offices covering all major provinces of China,
and over 1,000 sales representatives who assist in managing many of our relationships with hospitals, doctors and local drug distributors.
Overall, our distribution model is rather flat, with relatively few intermediaries compared to many other pharmaceutical companies
in China<B>. </B>Due to this advantage, we believe we are able to keep our selling cost lower than the industry average.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Due to the nature
of our products and current governmental regulations, all of our customers are located in the PRC. We have established long-standing
relationships with most of our key customers as our operating subsidiary, Helpson, formed in 1993.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Production
Facilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We manufacture and
package our products at our manufacturing facility in the Haikou Free Trade Zone in Haikou, Hainan Province. Our old manufacturing
facility, which was built in 2002, is approximately 8,000 square meters; and our new building, approximately 20,000 square meters,
was completed in 2013. We have production lines with new GMP certificates for different forms including: tablets, capsule, dry power,
liquid injectables, solid oral solution Cephalosporins (specifically designated).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The CFDA promulgated
Good Manufacturing Practices for Pharmaceutical Products (2010 revised version) (the &quot;New GMP Standards&quot;) on February
12, 2011, which became effective on March 1, 2011. The new GMP outlines the basic principles and standards for the manufacturing
of pharmaceutical products and the management of quality controls in the manufacturing process in the PRC. Pursuant to those mandatory
requirements, the upgrading of our two sterilization production lines - liquid injectables and dry powder injectables production
lines were required to be completed by the end of 2013. As of January 1, 2014, we had suspended such two production lines due
to the failure to meet the GMP upgrading deadline. However, construction of our new main building has been completed, and two
new sterilization production lines have been installed. In November 2014 the CFDA completed their process of the GMP certification
for our new
facility and issued the GMP certificate to enable us to commence manufacturing our liquid injectables and dry powder
injectable product lines. In January and December 2015, we also completed the upgrading and received new GMP certificates for
the tablet and capsule production lines, and cephalosporin production lines in our old factories respectively.</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Raw
Materials</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We require a supply
of a wide variety of raw materials to manufacture our products. We employ purchasing staff with extensive knowledge of our products
who work with our product development, and formulations and quality control personnel to source raw materials for our products.
Currently, we rely on numerous suppliers in the PRC and overseas to deliver our required raw materials and believe we have at least
three principal suppliers for each of our most critical raw materials. Historically, we have not had difficulty obtaining raw materials
from suppliers. For the year ended December 31, 2016, our purchases from one supplier accounted for approximately 21.1% of raw
material purchases. For the year ended December 31, 2015, purchases from one supplier accounted for approximately 27% of raw material
purchases.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 24pt 0 12pt; text-align: justify">Competition</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We believe we have
established a commercially competitive position in the highly-fragmented pharmaceutical industry in China through our core competitive
advantages, as described below:</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We have a
highly-efficient commercialization process for new products, including significant experience with the CFDA registration process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8in 12pt; text-align: justify">We have over 20 years of product-development
experience during which time we have implemented processes to efficiently introduce and market new and existing products to the
Chinese market.&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We have a
market-oriented product portfolio and product lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Our product focus
is on developing and manufacturing medicines that help large patient groups, such as the infectious disease and cardio vascular
disease patient groups. Our diversified GMP-certified manufacturing facility includes eight production lines targeting a variety
of delivery mechanisms, such as tablets, capsules, cephalosprine tablets, cephalosprine capsules, liquid-injectables and dry powder
injectables, which enables us to effectively manufacture a broad range of new drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8in 12pt; text-align: justify">We attempt to differentiate our
products from those of our competitors by changing, and, in many cases, improving, and certain physical aspects of our products
to address to different market segments. For example, to make our Cefaclor product more patient friendly to children and patients
with swallowing problems, we added an enteric coating to make our tablets easier to swallow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8in 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8in 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We have a
national sales network and a highly-trained marketing team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8in 12pt; text-align: justify">Our experienced sales team has the
industry knowledge and know-how to synergistically combine our strong market insight with a successful commercialization platform.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We have developed
high-quality relationships with leading hospital and clinic administrators and physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8in 12pt; text-align: justify">While sales of our pharmaceutical
products to hospitals are made through our distributors, we believe our long-term relationships with leading hospitals and healthcare
clinics throughout China resulting from our long-term promotional efforts and periodic physician seminars improve the perception
of our products in the marketplace and help us identify and select high-volume drugs to develop into new generic products relatively
early in the process.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We cooperate
effectively with a number of leading academic research institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8in 12pt; text-align: justify">Through our cooperative efforts
with leading academic research institutions, which are our research partners, we are able to develop new product candidates in
a cost-effective manner and currently have a number of significant projects in active development in our pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Notwithstanding
such favorable positioning, we are subject to intense competition. There are both local and overseas pharmaceutical enterprises
that are engaged in the manufacture and sale of potential substitute or similar pharmaceutical products in the PRC. These competitors
may have more capital and better research and development resources, and manufacturing and marketing capability and experience
than we do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Our profitability
may be adversely affected if</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of our competitors increases;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">competitors engage in increased price competition; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">competitors develop new products or product substitutes having comparable
medicinal applications or therapeutic effects that are more effective, less costly and/or have more perceived benefits than those
produced by us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In addition, competition
from imported products and China's admission as a member of the World Trade Organization (&quot;WTO&quot;) creates increased competition.
The PRC became a member of the WTO in December 2001. As a result of the admission into the WTO, competition in the pharmaceutical
industry in the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">PRC
intensified generally in two respects. With lower import tariffs, imported pharmaceutical products manufactured overseas may become
increasingly competitive in terms of pricing. We also believe that well-established foreign pharmaceutical manufacturers may set
up production facilities in the PRC and compete with domestic manufacturers directly. With the expected increased supply of competitively-priced
pharmaceutical products in the PRC, we may face increased competition from foreign pharmaceutical products, especially in terms
of high-end pharmaceutical products, including certain types of products manufactured by U.S. manufacturers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Intellectual
Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We regard our packaging
designs, trademarks, trade secrets, patent and similar intellectual property as part of our core competence that is critical to
our success. We rely on patent, trademark and trade secret law, as well as confidentiality agreements with certain of our employees,
distributors and others to protect our intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In November 2008,
we purchased the patented medical formula for a cerebral/cardio-vascular indication and the manufacturing processes for that product
candidate from a third party laboratory. In connection with that acquisition, we obtained the title of the patent. This patent
expires in 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In 2012, we acquired
another patent related to a medical formula for the treatment of cerebral/cardio-vascular diseases. This patent expires in 2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">As of
December 31, 2016, we owned 17 registered trademarks, including marks for nine of the  19 pharmaceutical products we
manufacture, including the tradenames Funalin, Fukexing, Beisha, Shiduotai, Xinuo, Pusenlitai, Pusenouke, Shuchang and
Shenkaineng, as well as marks for our AFGF logo, our HPS logo, our two HELPSON logos and four other logos. The registration
numbers of the 17 registered trademarks are as follows: No.1280259, No.1500459, No.1511770, No.1535416, No.1537828,
No.1535420, No.1272792, No.1272759, No.1272760, No.1330294, No.1327731, No.1330295, No.1476339, No.3993785, No. 4074317,
No.4074321 and No. 4315247.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Environmental
Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We comply with the
Environmental Protection Law of China as well as applicable local regulations. In addition to statutory and regulatory compliance,
we actively ensure the environmental sustainability of our operations. Penalties may be levied upon us if we fail to adhere to
and maintain certain standards. Such failure has not occurred in the past, and we generally do not anticipate that it will occur
in the future, but no assurance can be given in this regard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Regulations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><I>Regulations Relating
to Pharmaceutical Industry</I>. The pharmaceutical industry in China is highly regulated. The primary regulatory authority is the
CFDA, including its provincial and local branches. As a developer and producer of medicinal products, we are subject to regulation
and oversight by the CFDA and its provincial and local branches. The Law of the PRC on the Administration of Pharmaceuticals provides
the basic legal framework for the administration of the production and sale of pharmaceuticals in China and covers the manufacturing,
distribution, packaging, pricing and advertising of pharmaceutical products. These regulations set forth detailed rules with respect
to the administration of pharmaceuticals in China. We are also subject to other PRC laws and regulations that are applicable to
business operators, manufacturers and distributors in general.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><I>Registration
and Approval of Medicine</I>. Pursuant to the PRC Provisions for Drug Registration, a medicine must be registered and approved
by the CFDA before it can be manufactured and sold. The registration and approval process requires the manufacturer to submit to
the CFDA a registration application containing detailed information concerning the efficacy and quality of the medicine and the
manufacturing process and the production facilities the manufacturer expects to use. This process generally takes two to five years
and could be longer, depending on the nature of the medicine under review, the quality of the data provided and the workload of
the CFDA. If a manufacturer chooses to manufacture a pre-clinical medicine, it is also required to conduct pre-clinical trials,
apply to the CFDA for permission to conduct clinical trials and go through the clinical trials. If a manufacturer chooses to manufacture
a post-clinical medicine, it only needs to go through the clinical trials. In both cases, a manufacturer needs to file clinical
data with the CFDA for approval for manufacturing after clinical trials are completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><I>New Medicine</I>.
If a medicine is approved by the CFDA as a new medicine, the CFDA will issue a new medicine certificate to the manufacturer and
impose a monitoring period of one to five years. During the monitoring period, the CFDA will monitor the safety of the new medicine,
and will neither accept new medicine certificate applications for an identical medicine by another pharmaceutical company, nor
approve the production or import of an identical medicine by other pharmaceutical companies. As a result of these regulations,
the holder of a new medicine certificate has the exclusive right to manufacture the new medicine during the monitoring period.
We currently have new medicine certificates for our Pusenouke, Cefaclor dispersible tablets and Roxithromycin dispersible tablets
and Bumetanide for injection products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><I>National Production
Standard and Provisional Standard</I>. In connection with the CFDA's approval of a new medicine, the CFDA will normally direct
the manufacturer to produce the medicine according to a provisional national production standard, or a provisional standard. A
provisional standard is valid for two years, during which time the CFDA closely monitors the production process and quality consistency
of the medicine to develop a national final production standard for the medicine, or a final standard. Three months before the
expiration of the two-year period, the manufacturer is required to apply to the
CFDA to convert the provisional standard to a final standard. Upon approval, the CFDA will publish the final standard for the
production of this medicine. There is no statutory timeline for the CFDA to complete its review and grant approval for the conversion.
In practice, the approval for conversion to a final standard is time-consuming and could take a number of years. However, during
the CFDA's review period, the manufacturer may continue to produce the medicine according to the provisional standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><I>Transitional
Period</I>. Prior to the latter of (1) the expiration of a new medicine's monitoring period or (2) the date when the CFDA grants
a final standard for a new medicine after the expiration of the provisional standard, the CFDA will not accept applications for
an identical medicine nor will it approve the production of an identical medicine by other pharmaceutical companies. Accordingly,
the manufacturer will continue to have an exclusive production right for the new medicine during this transitional period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Continuing
CFDA Regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pharmaceutical manufacturers
in China are subject to continuing regulation by the CFDA. If the labeling or its manufacturing process of an approved medicine
is significantly modified, a new pre-market approval or pre-market approval supplement will be required by the CFDA. A pharmaceutical
manufacturer is subject to periodic inspection and safety monitoring by the CFDA to determine compliance with regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The CFDA has a
variety of enforcement actions available to enforce its regulations and rules, including fines and injunctions, recall or seizure
of products, the imposition of operating restrictions, partial suspension or complete shutdown of production and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Pharmaceutical
Product Manufacturing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><I>Permits and Licenses
for Pharmaceutical Manufacturers</I>. A pharmaceutical manufacturer must obtain a pharmaceutical manufacturing permit from the
CFDA's relevant provincial branch. This permit is valid for five years and is renewable for an additional five-year period upon
its expiration. Our current pharmaceutical manufacturing permit, issued by the CFDA, will expire on December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><I>Good Manufacturing
Practice.</I> A pharmaceutical manufacturer must meet the Good Manufacturing Practice standards, or GMP standards, for each of
its production facilities in China in respect of each form of pharmaceutical product it produces. GMP standards include staff qualifications,
production premises and facilities, equipment, raw materials, environmental hygiene, production management, quality control and
customer complaint administration. If a manufacturer meets the GMP standards, the CFDA will issue to the manufacturer a Good Manufacturing
Practice certificate, or a GMP certificate, with a five-year validity period. However, for a newly-established pharmaceutical manufacturer
that meets the GMP standards, the CFDA will issue a GMP certificate with only a one-year validity period. The New GMP Standards
became effective on March 1, 2011 and pharmaceutical manufacturers (except manufacturers of injectables, blood products or vaccines,
which have a three-year grace period) have a five-year grace period to upgrade existing facilities to comply with the revisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We obtained three
GMP certificates for our manufacturing facility in respect of the majority form of pharmaceutical product we produce, one valid
until October 30, 2019 (lyophilized powder for injection, small volume parenteral solutions), one valid until January 2020 (tablets,
capsules), and one valid until December 6, 2020 (tables, capsule - cephalosprins). All of our GMP certificates are valid for five
years. While we are required to implement certain upgrades to our manufacturing facilities to comply with the new GMP standards,
we do not currently anticipate any difficulty in renewing these certificates when we finish the facility upgrading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Product
Liability and Consumers Protection</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Product liability
claims may arise if any pharmaceutical products sold have a harmful effect on the consumers, and the injured party may claim for
damages or compensation. The General Principles of the Civil Law of the PRC, which became effective in January 1987, state that
manufacturers and sellers of defective products causing property damage or injury shall incur civil liabilities for such damage
or injuries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The Product Quality
Law of the PRC was enacted in 1993 and amended in 2000 to strengthen the quality control of products and protect consumers' rights
and interests. Under this law, manufacturers and distributors who produce or sell defective products may be subject to confiscation
of earnings from such sales, revocation of business licenses and imposition of fines, and in severe circumstances, may be subject
to criminal liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The Law of the
PRC on the Protection of the Rights and Interests of Consumers was promulgated on October 31, 1993 and became effective on January
1, 1994 to protect consumers when they purchase or use goods or services. All business operators must comply with this law when
they manufacture or sell goods and/or provide services to customers. In extreme situations, pharmaceutical product manufacturers
and distributors may be subject to criminal liability if their goods or services lead to the death or injuries of customers or
other third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Price
Controls</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The retail prices
of some pharmaceutical products sold in China, primarily those included in the Essential Drug and Reimbursement Lists and those
pharmaceutical products for which production or distribution are deemed to constitute monopolies, are subject to price controls
in the form of retail price ceilings. In particular, manufacturers or distributors cannot freely set or change the retail price
for any price-controlled product above the applicable price ceiling or deviate from the applicable fixed price imposed by the PRC
government. The prices of medicines that are not subject to price controls are determined freely at the discretion of the respective
pharmaceutical companies, subject to notification to the provincial pricing authorities. The National Development and Reform Commission
(NDRC) may grant premium pricing status to certain pharmaceutical products that are subject to price controls, and may set the
price-ceiling for pharmaceutical products that have obtained such status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">However, per the
&quot;Notice on Advancing Drug Price Reform &quot; issued by National Development and Reform Commission of PRC, except for narcotic
drugs and the first class psychoactive drugs, the prices originally set by the government should be disregarded after June 1st,
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The essential ideas
of NDRC upon drugs price reform include elimination of government pricing, medical insurance cost-control, and bidding procedure.
It believes that actual transaction price of drugs should be formed through market competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">However, eliminating
only one controlling factor does not bring immediate transfer into pure marketization. There is no real change upon centralized
drug bidding system which has more decisive impact on pricing. In this regard, this movement of NDRC might not cause any significant
trend upon price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Reimbursement
under the National Medical Insurance Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Per Social Security
Center of the Ministry of Social Security of China, over 1.34 billion people had been enrolled into the National Medical Insurance
Program (NMIP) by the end of 2015. The Ministry of Labor and Social Security, together with other government authorities, determines
which medicines are to be included in or removed from the national medicine catalog for the NMIP, and under which tier a medicine
should fall, both of which affect the amounts reimbursable to program participants for their purchases of those medicines. These
determinations are based on a number of factors, including price and efficacy. A NMIP participant can be reimbursed for the full
cost of a Tier 1 medicine and 80-90% of the cost of a Tier 2 medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Although it is designated
as a national program, the implementation of the NMIP is delegated to various provincial governments, each of which has established
its own medicine catalog. A provincial government must include all Tier 1 medicines listed in the national medicine catalog in
its provincial medicine catalog, but may use its discretion based on its own selection criteria to add other medicines to, or exclude
Tier 2 medicines listed in the national medicine catalog from its provincial medicine catalog, so long as the combined numbers
of the medicines added and excluded do not exceed 15% of the number of the Tier 2 medicines listed in the national catalog. In
addition, provincial governments may use their discretion to upgrade a nationally classified Tier 2 medicine to Tier 1 in their
provincial medicine catalogs, but may not downgrade a nationally classified Tier 1 medicine to Tier 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The total amount
of reimbursement for the cost of prescription and OTC medicines, in addition to other medical expenses, for an individual program
participant in a calendar year is capped at the amount in that participant's individual account. The amount in a participant's
account varies, depending upon the amount of contributions from the participant and his or her employer. Generally, on average,
program participants who are from relatively wealthier eastern parts of China and relatively wealthier metropolitan centers have
greater amounts in their individual accounts than those from less developed provinces.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Currently, all
of our pharmaceutical products are listed on the National Insurance Catalogue (NIC), and four of our products -Vitamin B6, Cefalexin,
Clarithromycin and Omeprazole - are listed on the Essential Drug List (EDL). However, some of our non-EDL drugs have been selected
to enter the provincial EDL, which varies from province to province. We believe these drugs will experience an increase in sales
volume due to the government-initiated promotion of those drugs, while remaining free from the pricing pressures often experienced
by drugs listed on the EDL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Other
Regulations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In addition to the
regulations relating to pharmaceutical industry in China, we are also subject to the regulations applicable to a foreign invested
enterprise in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><I>Foreign Currency
Exchange.</I> Pursuant to the Foreign Currency Administration Rules promulgated in 1996 and amended in 1997 and various regulations
issued by State Administration of Foreign Exchange, or the SAFE, and other relevant PRC government authorities, Renminbi is freely
convertible only to the extent of current account items, such as trade-related receipts and payments, interests and dividends.
Capital account items, such as direct equity investments, loans and repatriation of investment, require the prior approval from
the SAFE or its local counterpart for conversion of Renminbi into a foreign currency, such as U.S. dollars, and remittance of the
foreign currency outside the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Payments for transactions
that take place within the PRC must be made in Renminbi. Unless otherwise approved, PRC companies other than foreign investment
enterprises (FIEs) must convert foreign currency payments they receive from abroad into Renminbi. On the other hand, FIEs may retain
foreign exchange in accounts with designated foreign exchange banks, subject to a cap set by the SAFE or its local counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><I>Dividend Distribution.</I>
Under the PRC regulations governing dividend distributions by wholly foreign-owned enterprises and Sino-foreign equity joint ventures,
wholly foreign-owned enterprises and Sino-foreign equity joint ventures in the PRC may pay dividends only out of their accumulated
profits, if any, determined in accordance with PRC accounting standards and regulations. Additionally, these foreign-invested enterprises
are required to set aside certain amounts of their accumulated profits each year, if any, to fund certain reserve funds. These
reserves are not distributable as cash dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B><I>Employees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">As of December 31,
2016, we had 385 employees, among which 343 employees were full-time employees and 42 employees were temporary employees. None
of our employees is represented by a labor union and, in general, we consider our relationship with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">As required by applicable
Chinese law, we have entered into employment contracts with substantially all of our officers, managers and employees. We are working
towards entering into employment contracts with those employees who do not currently have employment contracts with us. The PRC
enacted a new Labor Contract Law, which became effective on January 1, 2008. We have updated our employment contracts and employee
handbook and are in compliance with such law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 1A. RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to our Business and our Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The commercial success of our products
depends upon the degree of their market acceptance among the medical community. If our products do not attain market acceptance
among the medical community, our operations and profitability would be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The commercial success
of our products depends upon the degree of market acceptance they achieve among the medical community, particularly among physicians
and hospital administrators. Physicians may not prescribe or recommend our products to patients and procurement departments of
hospitals may not purchase our products if physicians or hospital pharmacists do not find our products attractive. The acceptance
and use of our products among the medical community will depend upon a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">perceptions by physicians, patients and others in the medical community about the safety and effectiveness of our products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the prevalence and severity of any side effects;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the pharmacological benefit of our products relative to competing products and products under development;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">the efficacy and potential advantages of our products relative to competing products and products under development;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the relative convenience and ease of administration of our products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the methods by which our pharmaceutical products may be delivered to patients;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the effectiveness of our education, marketing and distribution efforts and those of our distributors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">publicity concerning our products or competing products and treatments; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the price of our products and competing products.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we fail to meet the New GMP Standards,
the production at certain of our old production lines will be suspended and our operations and profitability would be adversely
affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are in the process of
upgrading our old production facilities to bring them in line with the New GMP Standards which became effective as of March 1,
2011. In November 2014, the CFDA completed their process of reviewing our new facility and issued GMP certificates authorizing
us to commence manufacturing liquid injectable and dry powder injectable product lines. In January and December 2015, we completed
upgrades and received new GMP certificates for tablet and capsule production lines and cephalosporin production lines in our old
factories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we are not able to satisfy
the requirements of the new GMP guidelines and obtain clearance from the CFDA, our existing dry powder injectable and granule production
lines may be suspended and we may be subject to fines or other penalties if we continue to produce any products from such lines,
all of which may have a material and adverse impact on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject from time to time to
product recalls initiated by us or by the CFDA. Product recalls could impose significant costs on us and adversely affect our ability
to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 22pt; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
our course of business, we must comply with a variety of product safety and product testing regulations. In particular, our products
are subject to, among other statutes and regulations, those issued by the CFDA. If the CFDA issues any notices to cease the production,
sale and use of any of our products, we should comply with such requirements. As a result, we may incur significant costs in complying
with cessation requirements, and our financial results could be materially and adversely affected. Furthermore, concerns about
potential liability or potential future changes in product safety regulations may lead us to voluntarily recall or otherwise discontinue
selling selected products, which could materially and adversely affect our results of operations. In March 2013, CFDA issued a
nationwide notice (the &ldquo;CFDA Notice&rdquo;) for the cessation of the production, sale and use of Buflomedil effective immediately.
The CFDA Notice was a result of the reevaluation done by the CFDA based on the indications from the recent Chinese and international
research materials, which found that the risks of side effects to the nervous system and the cardiovascular system from Buflomedil
have surpassed its clinical treatment benefits. The CFDA Notice was applicable to all the manufacturers and distributers in China
who are in the business of the production and sale of Buflomedil-related products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Recalls could also harm
our reputation, increase our costs and reduce our net sales. Governments and regulatory agencies in the markets where we manufacture
and sell products may enact additional regulations relating to product safety and consumer protection in the future or take other
actions. The CFDA has the authority to revoke drug approvals previously granted and remove from the market previously approved
products for various reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we fail to develop new products with
high profit margins and our high-profit-margin products are replaced by competitors&rsquo; products, then our gross and net profits
margins will be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We had gross profit margins
of 20.7% for the year ended December 31, 2016, compared to gross profit margins of 7.2% for the year ended December 31, 2015. Without
the effect of inventory obsolescence, management estimates that our gross profit would have been approximately 20.7% in 2016 and
22.5% in 2015. The pharmaceutical market in the PRC remains very competitive, and there may be pressure to reduce sale prices of
products without a corresponding decrease in the cost of sold products. To the extent that we fail to develop new products with
high profit margins and our high-profit-margin products are substituted by competitors&rsquo; products, our gross profit margins
and net profit margins will be adversely affected. In addition, in the event that our products are included in the National Essential
Drug List (the &ldquo;EDL&rdquo;), which is subject to high level of governmental price control, our gross profit margin and net
profit margins could be adversely affected notwithstanding any increase in our revenues that may result from the listing of such
products on EDL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our products face substantial competition.
Other companies may discover, develop, acquire or commercialize products earlier or more successfully than we do.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We operate in a highly
competitive environment. Our products compete with other products or treatments for diseases for which our products may be indicated.
Many of our products may compete against products that have lower prices, superior performance, greater ease of administration
or other advantages compared to our products. We would face enhanced competition if competitive products are added to the National
Medical Insurance Program. Our inability to compete effectively could reduce sales or margins, which could have a material adverse
effect on our results of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Some of our competitors
are actively engaged in research and development in areas in which we have products or in which we are developing product candidates
or new indications for existing products. In the future, we expect that our products will compete with new drugs currently in development,
drugs approved for other indications that may be approved for the same indications as those of our products and drugs approved
for other indications that are used off-label. If alternatives to our products are dispensed or prescribed to patients, the volume
of our competing products may decline or we may be required to lower the price of our competing products to remain competitive,
either of which could negatively impact our sales. In addition, an increasing number of foreign pharmaceutical companies have introduced
their pharmaceutical products into the Chinese market. Competitive products introduced by these companies can also negatively impact
our sales and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Large Chinese state-owned
and privately owned pharmaceutical companies and foreign-invested or foreign pharmaceutical companies may have greater clinical,
research, regulatory, manufacturing, marketing, financial and human resources than we do. In addition, some of our competitors
may have technical or competitive advantages over us with respect to the development of technologies and processes. These resources
may make it difficult for us to compete with them to successfully discover, develop and market new products and for our current
products to compete with new products or new product indications that these competitors may bring to market. There may also be
significant consolidation in the pharmaceutical industry among our competitors. Alliances may develop among competitors, and these
alliances may rapidly acquire significant market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Furthermore, in order to
gain market share in China, competitors may significantly increase their advertising expenditures and promotional activities or
engage in irrational or predatory pricing behavior. In addition, our competitors may engage in inappropriate competition or illegal
acts, such as bribery. Third parties may actively engage in activities designed to undermine our brand name and product quality
or to influence customer confidence in our products. Increased competition may result in price reductions, reduced margins and
loss of market share, any of which could materially adversely affect our profit margins. We may not be able to compete effectively
against current and future competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Most of our products are off-patent branded
generics that can be manufactured and sold by other pharmaceutical manufacturers in the PRC once the relevant protection or monitoring
periods, if any, elapse.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Most of our products are
off-patent branded generic pharmaceuticals and are not protected by intellectual property rights. As a result, other pharmaceutical
companies may sell equivalent products at a lower cost, and this might result in a commensurate loss in sales of our branded generic
products or require us to lower our prices to compete. Certain of our generic products are subject to protection during the CFDA&rsquo;s
monitoring period. During such period, the CFDA will not accept applications for new medicine certificates for the same product
by other pharmaceutical companies or approve the production or import of the same product by other pharmaceutical companies. Once
such monitoring period expires, other manufacturers may obtain relevant production approvals and will be entitled to sell generic
pharmaceutical products with similar formulae or production methods in China. The maximum monitoring period currently granted by
the CFDA is five years from the date the CFDA production approval is issued. As a result, we expect to face increased competition
for our products following the expirations of their respective monitoring periods. If other pharmaceutical companies sell pharmaceutical
products that are similar to our unprotected products or our protected products for which the relevant protection or monitoring
period has expired, we may face additional competition and our business and profitability may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our business depends in part on our well-known
Helpson brand name, and if we are not able to maintain and enhance our brand recognition to maintain our competitive advantage,
our reputation, business and operating results may be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that market
awareness of our Helpson brand has contributed significantly to the success of our business. We also believe that maintaining and
enhancing the Helpson brand is critical to maintaining our competitive advantage. Although our sales and marketing staff will continue
to further promote our brand to remain competitive, we may not be successful. If we are unable to further enhance our brand recognition
and increase awareness of our products, or if we are compelled to incur excessive marketing and promotion expenses in order to
maintain our brand awareness, our business and results of operations may be materially and adversely affected. Furthermore, our
sales and results of operations could be adversely affected if the Helpson brand or our reputation is impaired by recalls or negative
publicity for one of our branded products, and certain actions taken by our distributors, competitors, third-party marketing firms
or relevant regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Reimbursement may not be available for
our products, which could diminish our sales or affect our ability to sell our products profitably.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Market acceptance and sales
of our products also depend to a large extent on the reimbursement policies of the PRC government. The Ministry of Labor and Social
Security of the PRC or provincial or local labor and social security authorities, together with other government authorities, review
the inclusion or removal of drugs from the national medical insurance catalog or provincial or local medical insurance catalogs
for the National Medical Insurance Program every other year, and catalogs under which a drug will be classified affects the amounts
reimbursable to program participants for their purchases of those medicines. These determinations are made based on a number of
factors, including price and efficacy. Generally, there are two catalogs, the National Insurance Catalogue (&ldquo;NIC&rdquo;)
and the EDL on which a product can be included. The products selected for the EDL generally are selected from the NIC. A consumer
can be reimbursed for the full cost of a medicine on the EDL and can be reimbursed for 80% to 90% of the cost of a medicine listed
on the NIC. Our Vitamin B6, Cefalexin, Clarithromycin and Omeprazole products are currently included in the EDL. If government
authorities decide to remove these products from the medicine catalogs, such removal may reduce the affordability of our products
and change the public perception regarding our products, which, in turn, would adversely affect the sales of these products and
reduce our net revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Furthermore,
if we are unable to obtain approval from the relevant government authorities to include our new products in the national, provincial
or local medicine catalogs, sales of our new products maybe materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The growth and success of our business
depend on our ability to successfully market our principal products to hospitals and their selection in tender processes used by
hospitals for medicine purchases.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future growth and success
significantly depend on our ability to successfully market our principal products to hospitals as prescription medicines. Approximately
90% of the end-customers of our products are hospitals. Hospitals may make bulk purchases of a medicine included in the national
and provincial medicine catalogs only if that medicine is selected under a government-administered tender process. The interest
of a hospital in a medicine is evidenced by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">the inclusion of this medicine on the hospital&rsquo;s formulary, which establishes the scope of medicines physicians at this hospital may prescribe to their patients, and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the willingness of physicians at a hospital to prescribe this medicine to their patients.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe effective marketing
efforts are critical in making and keeping hospitals and physicians interested in purchasing our products. If our marketing efforts
are not effective, hospital administrators may not want to include our products in their formularies or may remove them from their
formularies, or physicians may not be interested in prescribing our products to their patients. As a result, we may find it difficult
to maintain the existing level of sales of our products, and our revenues and profitability may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our future research and development projects
may not be successful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The successful development
of pharmaceutical products can be affected by many factors. Products that appear to be promising at their early phases of research
and development may fail to be commercialized for various reasons, including the failure to obtain the necessary regulatory approvals.
In addition, the research and development cycle for new products for which we may obtain an approval certificate is long. The process
of conducting basic research and various stages of tests and trials of a new product before obtaining an approval certificate and
commercializing the product may require ten years or longer. A few of our product candidates are in the early stages of pre-clinical
study and clinical trial and we must conduct significant additional clinical trials before we can seek the regulatory approvals
necessary to begin commercial production and sales of these products. There is no assurance that our future research and development
projects will be successful or completed within the anticipated time frame or budget or that we will receive the necessary approvals
from relevant authorities for the production of these newly developed products, or that these newly-developed products will achieve
commercial success.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Others may obtain approval
for a competitive product before the product we are developing is approved. In that case, we may be precluded from getting approval
until the competitor&rsquo;s monitoring period expires and realize little or no benefit from our research and development investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if such products can
be successfully commercialized, they may not achieve the level of market acceptance that we expect. In addition, the pharmaceutical
industry is characterized by rapid changes in technology, constant enhancement of industrial know-how and frequent emergence of
new products. Future technological improvements and continual product developments in the pharmaceutical market may render our
existing products obsolete or affect their viability and competitiveness. Therefore, our future success will largely depend on
our development capability, including our ability to improve our existing products, diversify our product range and develop new
and competitively-priced products that can meet the requirements of the changing market. Should we fail to respond to these frequent
technological advances by improving our existing products or developing new products in a timely manner or these products do not
achieve a desirable level of market acceptance, our business and profitability will be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We cooperate with research institutions
and universities in the PRC for the research and development of certain new products and any failure of such research institutions
to meet our timing and quality standards or our failure to continue such collaborative arrangement or enter into such new arrangements
could adversely affect our ability to develop new pharmaceuticals and our overall business prospects</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
collaborating with third parties for research and development of new products. We maintained long-term cooperative relationships
with a number of research institutions and universities in the PRC. These research institutions and universities have collaborated
with us in a number of research projects and certain of our products that have obtained approval certificates were developed by
such research institutions. At present, several research institutions and universities are working with us on various research
and development projects. Any failure of such research institutions to meet the required quality standards and timetables set forth
in their research agreements with us, or our inability to enter into additional research agreements with these research institutions
on terms acceptable to us in the future, may have an adverse effect on our ability to develop new medicines and on our business
prospects. In addition, the growth of our business and development of new products may require that we seek additional research
institutions. We cannot assure you that we will be able to enter into agreements with new parties on terms acceptable to us. Our
inability to enter into such agreements or our failure to maintain such arrangements could limit the number of new products that
we develop and ultimately decrease our sources of future revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may not be able to obtain regulatory
approval for any of the new products and failure to obtain these approvals could materially harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All new medicines must
be approved by the CFDA before they can be marketed and sold in the PRC. The CFDA requires successful completion of clinical trials
and demonstrated manufacturing capability before it grants approval. It often takes a number of years before a medicine can be
ultimately approved by the CFDA. In addition, the CFDA and other regulatory authorities may apply new standards for safety, manufacturing,
packaging, and distribution of future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Complying with such standards
may be time-consuming and expensive and could result in delays in obtaining CFDA approval for our future product candidates, or
possibly preclude us from obtaining CFDA approval altogether. For example, due to the enhanced criteria introduced during the implementation
process of the trial of one of our products in the dried powder injectable and granule production lines in our old plant, the clinical
trials lasted longer than originally expected. Furthermore, our future products may not be effective or may prove to have undesirable
or unintended side effects, toxicities or other characteristics that may preclude us from obtaining regulatory approval or prevent
or limit commercial use. The CFDA and other regulatory authorities may not approve the products that we develop and even if we
do obtain regulatory approvals, such regulatory approvals may be subject to limitations on the indicated uses for which we may
market a product, which may limit the size of the market for such product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>New product development in the pharmaceutical
industry is time-consuming and costly and has a low rate of successful commercialization</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success will depend
in part on our ability to enhance our existing products and to develop new products. The development process for pharmaceutical
products is complex and uncertain, as well as time-consuming and costly. Relatively few research and development programs produce
a commercial product. A product candidate that appears promising in the early phases of development may fail to reach the market
for a number of reasons, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 92%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the failure to demonstrate safety and efficacy in preclinical and clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the failure to obtain approvals for intended use from relevant regulatory bodies, such as the CFDA;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">our inability to manufacture and commercialize sufficient quantities of the product economically; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">proprietary rights, such as patent rights, held by others to our product candidates and their refusal to sell or license such rights to us on reasonable terms, or at all.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Delays in any part of the
development process or our inability to obtain regulatory approval of our products could adversely affect our operating results
by restricting or delaying our introduction of new products. Even if we successfully commercialize new products, these products
may address markets that are currently being served by our mature products and may result in a reduction in the sales volume of
our mature product or vice versa. Failure to develop, obtain necessary regulatory clearances or approvals for or successfully commercialize
or market potential new products or technologies could have a material adverse effect on our financial condition and results of
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may not be able to successfully identify
and acquire new products or businesses</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to our own
product development efforts, our growth strategy also relies on our acquisitions of new product candidates, products or businesses
from third parties. Any future growth through acquisitions will be dependent upon the continued availability of suitable acquisition
candidates at favorable prices and upon advantageous terms and conditions. Even if such opportunities are present, we may not be
able to successfully identify them. Moreover, other companies, many of which may have substantially greater financial, marketing
and sales resources, are competing with us for the right to acquire such product candidates, products or businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We depend on distributors for all of
our revenues and failure to maintain relationships with our distributors or to otherwise expand our distribution network would
materially and adversely affect our business</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We sell our products exclusively
to pharmaceutical distributors in the PRC and depend on distributors for all of our revenues. We have business relationships with
over 1,000 distributors in the PRC. For the year ended December 31, 2016, no customer accounted for more than 10.0% of sales, and
one customer accounted for 46.3% of accounts receivable. In line with industry practices in the PRC, we enter into written sales
agreements with our distributors. However, such sales agreements are not in substance equivalent to a typical distribution agreement
in the United States. Each sales agreement is more in the form of a sales order and specifies one or several purchases of one or
more products without any continuing obligation to purchase any additional amount of products. In the event certain distributors
choose not to continue their relationship with us after completing their existing sales agreements, they can do so without breaching
any contract or agreement and our financial results could be adversely affected if we cannot find the equivalent distributors in
time under such circumstances. In addition, some of our distributors may sell products that compete with our products. We compete
for desired distributors with other pharmaceutical manufacturers, many of which may have higher visibility, greater name recognition
and financial resources, and broader product selection than we do. Consequently, maintaining relationships with existing distributors
and replacing distributors may be difficult and time consuming. Any disruption of our distribution network, including our failure
to renew our existing distribution agreements with our desired distributors, could negatively affect our ability to effectively
sell our products and would materially and adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We rely on a limited number of distributors
for the majority of sales of our products</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely on a limited number
of distributors for most of our net revenue. Our top five distributors in the aggregate accounted for 21% and 22% of our net revenues
in 2016 and 2015, respectively. We expect that a relatively small number of our distributors will continue to account for a major
portion of our net revenue in the near future. Our dependence on a few distributors could expose us to the risk of substantial
losses if a single large distributor stops purchasing our products, purchases fewer of our products or goes out of business and
we cannot find substitute distributors on equivalent terms. If any of our significant distributors reduces the quantity of the
products they purchase from us or stops purchasing from us, our net revenue would be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our operations may be affected if we
could not pass the Consistency Evaluation requirement issued by the State Council for any of our current existing products. </I></B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; border-bottom: #C8D8F2 0.5pt solid">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Generic drugs refer
to the drugs with the same active ingredient, dosage form, delivery channel and therapeutic effects compared to the original drugs.
&ldquo;Consistency Evaluation&rdquo; requires currently marketed generic products to prove consistency in term of quality and therapeutic
effect, and substitutable during clinical trials with original drug. The Consistency Evaluation could enhance the development of
pharmaceutical industry, ensure drug safety and effectiveness, promote the upgrading and restructuring the pharmaceutical industry,
and improve international competitiveness.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The PRC State Council
issued the &quot;Opinions on Carrying out Consistency Evaluations on Quality and Efficacy of Generic Drugs&rdquo; (&ldquo;Opinions&rdquo;)
on March 5, 2016, requiring all chemical generic pipeline products to carry out Consistency Evaluations before final registration
approval. In addition, all oral solution generic drugs listed in National Essential Drugs List (2012 edition) and launched into
market before October 1, 2007, must complete Consistency Evaluations by the end of 2018. Consistency Evaluations must be completed
by the end of 2021 for drugs with existing special condition or those require clinical efficacy trials. Drugs fail to meet requirements
shall not be re-registered. As of today, all of our products in pipe lines were postponed in receiving its CFDA approval due to
this additional new requirement and the Company strives to accelerate the process.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><BR>
&#9;The &quot;Opinions&quot; stress that the drug manufacturers are subject to Consistency Evaluations. Therefore, if we fail to
complete Consistency Evaluations for our generic drugs per the government&rsquo;s requirement, our business and operation will
be negatively impacted.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our operations may be affected
if we could not obtain raw materials from our current key suppliers on acceptable terms.</I></B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We require a supply
of a wide variety of raw materials to manufacture our products. Currently, we rely on numerous suppliers in the PRC and overseas
to deliver our required raw materials and believe we have at least three principal suppliers for each of our most critical raw
materials. For the year ended December 31, 2016 and 2015, purchases from one supplier accounted for 21.1% and 27.0% of our raw
material purchases, respectively.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Historically, we
have not had difficulty obtaining raw materials from suppliers. However, we cannot predict the impact on our suppliers of the current
economic environment and other developments in their respective businesses. Insolvency, financial difficulties or other factors
may result in our suppliers not being able to fulfill the terms of their agreements with us. Furthermore, such factors may render
suppliers unwilling to extend contracts that provide favorable terms to us or may force them to seek to renegotiate existing contracts.
Although we believe we have alternative sources of supply for the raw materials used in our business, termination of our relationship
with any of our key suppliers could have a material adverse effect on our business, financial condition or results of operations
in the unlikely event that we are unable to obtain adequate raw materials from other sources in a timely manner or at all.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may not be able to effectively manage
our employees and distribution network, and our reputation, business, prospects and brand may be materially and adversely affected
by actions taken by our distributors and third party marketing firms.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have limited ability
to manage the activities of our distributors and third-party marketing firms that we contract to promote our products and brand
name, both of which are independent from us. Our distributors and third-party marketing firms could take one or more of the following
actions, any of which could have a material adverse effect on our business, prospects and brand:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">sell our products outside their designated territory, possibly in violation of the exclusive distribution rights of other distributors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">fail to adequately promote our products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 92%; font: 10pt Times New Roman, Times, Serif; text-align: justify">promote competing products in lieu of our products; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">violate the anti-corruption laws of China, the United States or other countries.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, although our
company policies prohibit our employees from making improper payments to hospitals or otherwise engaging in improper activities
to influence the procurement decisions of hospitals, we may not be able to effectively manage our employees, as the compensation
of our sales and marketing personnel is partially linked to their sales performance. As a result, we cannot assure you that our
employees will not violate the anticorruption laws of the PRC, the United States and other countries. Such violations could have
a material adverse effect on our reputation, business, prospects and brand.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Failure to adequately manage
our employees, distribution network or third-party marketing firms, or their non-compliance with employment, distribution or marketing
agreements could harm our corporate image among hospitals and end users of our products and disrupt our sales, resulting in a failure
to meet our sales goals. Furthermore, we could be liable for actions taken by our employees, distributors or third-party marketing
firms, including any violations of applicable law in connection with the marketing or sale of our products, including China&rsquo;s
anticorruption laws and the Foreign Corrupt Practices Act of the United States, or the FCPA. In particular, if our employees, distributors
or third-party marketing firms make any payments that are forbidden under the FCPA, we could be subject to civil and criminal penalties
imposed by the U.S. government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Recently, the PRC government
has increased its anti-corruption measures. In the pharmaceutical industry, corrupt practices include, among others, acceptance
of kickbacks, bribes or other illegal gains or benefits by the hospitals and medical practitioners from pharmaceutical manufacturers
and distributors in connection with the prescription of certain pharmaceuticals. Our employees, affiliates, distributors or third-party
marketing firms may violate these laws or otherwise engage in illegal practices with respect to their sales or marking of our products
or other activities involving our products. If our employees, affiliates, distributors or third-party marketing firms violate these
laws, we could be required to pay damages or fines, which could materially and adversely affect our financial condition and results
of operations. In addition, PRC laws regarding what types of payments to promote or sell our products are impermissible are not
always clear. As a result, we, our employees, affiliates, our distributors or third-party marketing firms could make certain payments
in connection with the promotion or sale of our products or other activities involving our products which at the time are considered
by us or them to be legal but are later deemed impermissible by the PRC government. Furthermore, our brand and reputation, our
sales activities or the price of our common stock could be adversely affected if we become the target of any negative publicity
as a result of actions taken by our employees, affiliates, distributors or third-party marketing firms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have limited insurance coverage and
may incur losses resulting from product liability claims, business interruptions or claims that could be covered by D&amp;O Insurance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The nature of our business
exposes us to the risk of product liability claims that is inherent in the research and development, manufacturing and marketing
of pharmaceutical products. Using product candidates in clinical trials also exposes us to product liability claims. These risks
are greater for our products that receive regulatory approval for commercial sale. Even if a product is approved for commercial
use by an appropriate governmental agency, there can be no assurance that users will not claim effects other than those intended
resulted from the use of our products. While to date no material claim for personal injury resulting from allegedly defective products
has been brought against us, a substantial claim or a substantial number of claims, if successful, could have a material adverse
impact on our business, financial condition and results of operations. Such lawsuits may divert the attention of our management
from our business strategies, may be costly to defend and may negatively impact our reputation and our Helpson brand&rsquo;s reputation,
and harm the sales of our other branded products. In addition, product liability insurance for pharmaceutical products is not available
in the PRC. In the event of allegations that any of our products are harmful, we may experience reduced consumer demand for our
products or our products may be recalled from the market. We may also be forced to defend lawsuits and, if unsuccessful, to pay
a substantial amount in damages. In addition, business interruption insurance available in the PRC offers limited coverage compared
to that offered in many other countries. We do not have any business interruption insurance. Any business disruption or natural
disaster could result in substantial costs and diversion of resources. Lastly, we currently do not have directors and officers
insurance. In the event we or any of our directors or officers are sued under any proceedings or actions that could be covered
by a standard D&amp;O insurance, we may incur substantial costs and expenses to defend such case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our future liquidity needs are uncertain
and we may need to raise additional funds in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on our current operating
plans, we expect our existing resources to be sufficient to fund our existing operations for at least 12 months. However, we may
be required to raise additional funds to expand our operations. In addition, we may, need to raise additional funds if our expenditures
exceed our current expectations. This could occur for a number of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">we determine to devote significant amount of financial resources to the development of products that we believe to have significant commercialization potential;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 92%; font: 10pt Times New Roman, Times, Serif; text-align: justify">we determine to acquire or license rights to additional product candidates or new technologies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">some or all of our product candidates fail in clinical trials or pre-clinical studies or prove to be not as commercially promising as we expect and we are forced to develop or acquire additional product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">our product candidates require more extensive clinical or pre-clinical testing or clinical trials of these product candidates take longer to complete than we currently expect; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">we determine or are required to conduct more high-throughput screening than expected against current or additional disease targets to develop additional product candidates.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ability to raise additional
funds in the future is subject to a variety of uncertainties, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">our future financial condition, results of operations and cash flows;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">general market conditions for capital-raising activities by pharmaceutical companies; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">economic, political and other conditions in China and elsewhere.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
our revenues will be sufficient to meet our operational needs and capital requirements. If we need to obtain external financing,
we cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all. Our future liquidity
needs and other business reasons could require us to sell additional equity or debt securities or obtain a credit facility. The
sale of additional equity or equity-linked securities could result in additional dilution to our stockholders. The incurrence of
additional indebtedness would result in increased debt service obligations and could result in operating and financing covenants
that would restrict our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may undertake acquisitions in the
future, and any difficulties in integrating these acquisitions may damage our profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the future, we may acquire
additional businesses or products that complement our existing business and expand our business scale. The integration of new businesses
and products may prove to be an expensive and time consuming procedure. We can offer no assurance that we will be able to successfully
integrate the newly acquired businesses and products or operate the acquired business in a profitable manner. Failure to locate
an appropriate acquisition target, failure to successfully integrate and operate acquired businesses and products, and failure
to identify substantial liabilities associated with acquired businesses, may materially adversely impact our operations and profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The failure to manage growth effectively
could have an adverse effect on our business, financial condition and results of our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The rapid market
growth of our pharmaceutical products may require us to expand our employee base for managerial, operational, financial and
other purposes. As of December 31, 2016, we had 385 employees. Our future development will impose significant
responsibilities upon the members of management to identify, recruit, maintain, integrate and motivate new employees. Aside
from the increased difficulties in the management of human resources, we may also encounter working capital issues, as we
need increased liquidity to finance the purchases of raw materials and supplies, research and development and purchase of
drug formulas for new products, acquisition of new businesses and technologies, and the hiring of additional employees. For
effective growth management, we will be required to continue improving our operations, management, and financial systems and
control. Our failure to manage growth effectively may lead to operational and financial inefficiencies that will have a
negative effect on our profitability.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We depend upon key employees and consultants
in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect
our ability to develop and market our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are highly dependent
upon the principal members of our management team, especially Ms. Zhilin Li, our Chairman, President and Chief Executive Officer.
The loss of the services of Ms. Li would adversely affect our ability to develop and market our products. We also depend in part
on the continued services of our key scientific personnel and our ability to identify, hire and retain additional personnel, including
marketing and sales staff. We face intense competition for qualified personnel, and the existence of noncompetition agreements
between prospective employees and their former employers may prevent us from hiring those individuals or subject us to suit from
their former employers. While we attempt to provide competitive compensation packages to attract and retain key personnel, many
of our competitors are likely to have greater resources and more experience than we have, making it difficult for us to compete
successfully for key personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain of our employees
and consultants were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential
competitors, or at universities or other research institutions. Although no claims against us are currently pending, we may be
subject to claims that these employees or consultants have, inadvertently or otherwise, used or disclosed trade secrets or other
proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful
in defending against these claims, litigation could result in substantial costs and be a distraction to our management. If we fail
in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to environmental regulations
and may be exposed to liability and potential costs for environmental compliance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to PRC laws
and regulations concerning the discharge of waste water, gaseous waste and solid waste during our manufacturing processes. We are
required to establish and maintain facilities to dispose of waste and report the volume of waste to the relevant government authorities,
which conduct scheduled or unscheduled inspections of our facilities and treatment of such discharge. We may not at all times comply
fully with environmental regulations. Any violation of these regulations may result in substantial fines, criminal sanctions, revocations
of operating permits, shutdown of our facilities and obligation to take corrective measures. Our cost of complying with current
and future environmental protection laws and regulations and our liabilities which may potentially arise from the discharge of
effluent water and solid waste may materially adversely affect our business, financial condition and results of operations. The
government may take steps towards the adoption of more stringent environmental regulations. Due to the possibility of unanticipated
regulatory or other developments, the amount and timing of future environmental expenditures may vary substantially from those
currently anticipated. If there is any unanticipated change in the environmental regulations, we may need to incur substantial
capital expenditures to install, replace, upgrade or supplement our pollution control equipment or make operational changes to
limit any adverse impact or potential adverse impact on the environment in order to comply with new environmental protection laws
and regulations. If such costs become prohibitively expensive, we may be forced to cease certain aspects of our business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Power shortages, natural disasters, terrorist
acts or other calamities could disrupt our production and have a material adverse effect on our business, financial position and
results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products are
produced at our manufacturing facility in Hainan, China. A significant disruption at that facility, even on a short-term basis,
could impair our ability to timely produce and ship products, which could have a material adverse effect on our business, financial
position and results of operations. Our manufacturing operations are vulnerable to interruption and damage from natural and other
types of disasters, including earthquake, fire, floods, environmental accidents, power loss, communications failures and similar
events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously impaired. For example,
a once-in-forty-year 16 grade super typhoon Rammasun hit Haikou
on July 18, 2014, which caused us approximately $2.3 million (RMB14.2 million) in losses. Part of a warehouse was flooded, some
damage was caused to our new facility, and the water and electricity supply was suspended for several days, causing a brief halt
to our production activities and a delay in our obtaining GMP certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we do not
maintain any insurance other than property insurance for some of our buildings and equipment. Accordingly, unexpected business
interruptions resulting from disasters could disrupt our operations and thereby result in substantial costs and diversion of resources.
Our production process requires a continuous supply of electricity. We have encountered power shortages historically due to restricted
power supply to industrial users during summers when the usage of electricity is high and supply is limited or as a result of damage
to the electricity supply network. Because the duration of those power shortages was brief, they had no material impact on our
operations. Interruptions of electricity supply could result in lengthy production shutdowns, increased costs associated with restarting
production and the loss of production in progress. Any major suspension or termination of electricity or other unexpected business
interruptions could have a material adverse impact on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The discontinuation of any preferential
tax treatments or other incentives currently available to us in the PRC could materially and adversely affect our business, financial
condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to January 1, 2008,
pursuant to the original Income Tax Law of the PRC for Enterprises with Foreign Investment and Foreign Enterprises and its implementation
rules, a foreign invested enterprise as defined under PRC laws was required to pay a 30% corporate income tax and a 3% local income
tax; an enterprise with foreign investment of a production nature scheduled to operate for a period of not less than ten years
was, from the year of making profits, exempt from enterprise income tax in the first and second years and allowed a fifty percent
reduction in the third to fifth years. Pursuant to the State Council&rsquo;s Regulations on Encouraging Investment in and Development
of Hainan Island promulgated in May 1988, the corporate income tax for all companies incorporated in Hainan Province was reduced
to 15%. Pursuant to the Regulations on Foreign Investment in Hainan Special Economic Zone promulgated by Hainan Province in March
1991 (the &ldquo;Regulation on Foreign Investment&rdquo;), all foreign-invested enterprises incorporated in Hainan Province are
exempt from the local income tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">However, on March 16, 2007,
China&rsquo;s national congress approved the Enterprise Income Tax Law of the PRC (&ldquo;New Income Tax Law&rdquo;), which took
effect on January 1, 2008. The New Income Tax Law unified the enterprise income tax rate, cost deduction and tax incentive policies
for both domestic and foreign invested enterprises. Under the New Income Tax Law, enterprises that were established and already
enjoyed preferential tax rates or tax holidays before March 16, 2007 will (i) in the case of preferential tax rates, gradually
increase to a 25% rate over a period of five years, (ii) in the case of tax holidays, continue to receive the benefit of such holidays
until the expiration of such term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result, we enjoyed
a preferential tax rate of 9%, 10% and 11% in the years of 2008, 2009 and 2010. We obtained the High Tech Enterprise status from
the PRC government in 2010 and we enjoyed a 15% income tax rate for a three-year period from 2011 to 2013. We applied for continued
High Tech Enterprise status in 2013, with its associated favorable tax rate, and we received an extension of the 15% income tax
rate for a second three-year period from 2014 to 2016. However, our recent net loss results have put the Company in an unfavorable
position for the potential renewal of &quot;National High-Tech Enterprise&quot; status in 2017, and after evaluating the feasibility
of such a renewal, the Company has decided not to renew this status. As a result, our tax rate for 2017 and the foreseeable future
will be 25%. The discontinuation of any of our existing special or preferential tax treatment as mentioned above or other incentives
could have an adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We cannot guarantee the protection of
our intellectual property rights, and if infringement or counterfeiting of our intellectual property rights occurs, then our reputation
and business may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To protect the brand names
of our products, we have registered and applied for registration of certain of our trademarks in the PRC. Currently eight of the
20 pharmaceutical products we manufacture are marketed under a brand registered as a trademark in China. We also purchased from
a third party for a pharmaceutical compound that we are seeking to develop into a further product. To date, we have not experienced
any infringements of our trademarks for sales of pharmaceutical products or our exclusive patent license, and we are not aware
of any infringement of our intellectual property rights. However, there is no assurance that there will not be any infringement
of our brand name or other registered trademarks or counterfeiting
of our products in the future. There is no assurance that there will not be any third-party infringement of our patent. Should
any such infringement or counterfeiting occur, our reputation and business may be adversely affected. We may also incur significant
expenses and substantial amounts of time and effort to protect our intellectual property rights in the future. Such diversion
of our resources may adversely affect our existing business and future expansion plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Litigation may be necessary
in the future to enforce our intellectual property rights or to determine the validity and scope of the intellectual property rights
of others. However, because the validity, enforceability and scope of protection of intellectual property rights in the PRC are
uncertain and still evolving, we may not be successful in prosecuting these cases. In addition, any litigation or proceeding or
other efforts to protect our intellectual property rights could result in substantial costs and diversion of our resources and
could seriously harm our business and operating results. Furthermore, the degree of future protection of our proprietary rights
is uncertain and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we are unable
to protect our trade names, trade secrets and other propriety information from infringement, our business, financial condition
and results of operations may be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Doing Business in China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Adverse changes in political and economic
policies of the PRC government could have a material and adverse effect on the overall economic growth of China, which could reduce
the demand for our services and materially and adversely affect our competitive position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We conduct substantially
all of our business and have historically derived all of our revenues in China. Accordingly, our business, financial condition,
results of operations and prospects are affected significantly by economic, political and legal developments in China. The Chinese
economy differs from the economies of most developed countries in many respects, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the degree of government involvement;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the level of development;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the growth rate;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the control of foreign exchange;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">access to financing; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">the allocation of resources.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">While the Chinese economy
has experienced significant growth in the past 30 years, growth has been uneven, both geographically and among various sectors
of the economy. The Chinese economy has also experienced certain adverse effects due to the recent global financial crisis. The
Chinese government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of
these measures benefit the overall Chinese economy, but may also have a negative effect on us. For example, our operating results
and financial condition may be adversely affected by government control over capital investments or changes in tax regulations
that are applicable to us, and by government policies or guidance aimed at curtailing the perceived over-capacity of certain industry
sectors, such as pharmaceutical companies. The Chinese government has implemented certain measures, including interest rate increases,
to control the pace of economic growth. These measures may cause decreased economic activity in China, which could in turn reduce
the demand for our products and materially and adversely affect our operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Chinese economy has
been transitioning from a planned economy to a more market-oriented economy. Although in recent years the Chinese government has
implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive
assets and the establishment of sound corporate governance in business enterprises, a substantial portion of the productive assets
in China is still owned by the Chinese government. The continued control of these assets and other aspects of the national economy
by the Chinese government could materially and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Chinese government
also exercises significant control over Chinese economic growth through the allocation of resources, controlling payment of foreign
currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any adverse change in the
economic conditions or government policies in China could have a material and adverse effect on overall economic growth and the
level of investments in health industries in China, which in turn could lead to a reduction in demand for our products and consequently
have a material and adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The PRC legal system has inherent uncertainties
that could limit the legal protections available to us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The PRC legal system is
a civil law system based on written statutes. Unlike common law systems, it is a system in which decided legal cases have little
precedential value. In the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing
commercial matters. The overall effect of legislation enacted over the past 20 years has significantly enhanced the protections
afforded to foreign-invested enterprises in China. However, these laws, regulations and legal requirements are relatively recent
and are evolving rapidly, and their interpretation and enforcement involve uncertainties. These uncertainties could limit the legal
protections available to foreign investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The practical effect of
the PRC legal system on our business operations in China can be viewed from two separate but intertwined considerations. First,
as a matter of substantive law, the Foreign Invested Enterprise laws provide significant protection from government interference.
In addition, these laws guarantee the full benefit of corporate articles and contracts to Foreign Invested Enterprise participants.
These laws, however, do impose standards concerning corporate formation and governance that are not qualitatively different from
the corporation laws found in the United States. Similarly, PRC accounting laws mandate accounting practices that may not be consistent
with the U.S. generally accepted accounting principles. PRC accounting laws require that an annual &ldquo;statutory audit&rdquo;
be performed in accordance with PRC accounting standards and that the account books of a foreign invested enterprise be maintained
in accordance with PRC accounting laws. Article 14 of the PRC Wholly Foreign-Owned Enterprise Law requires a wholly foreign-owned
enterprise to submit certain periodic fiscal reports and statements to designated financial and tax authorities. If a foreign-invested
enterprise refuses to keep account books in China, the financial and tax authorities may impose a fine on it, and the industry
and commerce administration authority may order it to suspend operations or may revoke its business license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Second, while the enforcement
of substantive rights may be less clear than United States procedures, foreign invested enterprises and wholly foreign-owned enterprises
are PRC registered companies that enjoy the same status as other PRC registered companies in business-to-business dispute resolutions.
The PRC legal infrastructure, however, is significantly different in operation from its United States counterpart, and may present
a significant impediment to the operation of a foreign invested enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>PRC economic reform policies or nationalization
could result in a total investment loss in our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since 1979, the PRC government
has been in the process of reforming its economic policies. Because many reforms are unprecedented or experimental, they are expected
to be refined and improved over time. Other political, economic and social factors, such as political changes, changes in the economic
growth rates, unemployment or inflation, or in the disparities in per capita wealth between regions within China, could lead to
further readjustment of the reform measures. This refinement and readjustment process may negatively affect our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although the PRC government
owns the majority of productive assets in China, in the past several years the government has implemented economic reform measures
that emphasize decentralization and encourage private economic activity. Because these economic reform measures may be inconsistent
or ineffectual, there are no assurances that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">We will be able to capitalize on economic reforms;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: justify">The PRC government will continue its pursuit of economic reform policies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; text-align: justify">The economic policies, even if pursued, will be successful;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&middot;</TD>
    <TD STYLE="text-align: justify">Economic policies will not be significantly altered from time to time; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; text-align: justify">Business operations in China will not become subject to the risk of nationalization.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Over the last few years,
China&rsquo;s economy has registered high growth rates. Recently, there have been indications that rates of inflation have increased.
In response, the Chinese government recently has taken measures to curb this excessively expansive economy. These measures have
included restrictions on the availability of domestic credit, reducing the purchasing capability of some of its customers, and
limited recentralization of the approval process for purchases of certain foreign products. These austere measures alone may not
succeed in slowing down the economy&rsquo;s excessive expansion or control inflation, and may result in severe dislocations in
the Chinese economy. The PRC government may adopt additional measures to further combat inflation, including the establishment
of freezes or restraints on certain projects or markets. These measures may adversely affect our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that the reforms to China&rsquo;s economic system will continue or that we will not be adversely affected by changes in China&rsquo;s
political, economic, and social conditions and by changes in policies of the PRC government, such as changes in laws and regulations,
measures which may be introduced to control inflation, changes in the rate or method of taxation, imposition of additional restrictions
on currency conversion and remittance abroad, and reduction in tariff protection and other import restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>You may experience difficulties in effecting
service of legal process, enforcing foreign judgments or bringing original actions in the PRC against our company or our management
based on U.S. or other foreign laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our operating subsidiary,
Helpson, is incorporated under the laws of the PRC and substantially all of our assets are located in the PRC. In addition, substantially
all of our directors, executive officers and managers reside within the PRC, and substantially all of the assets of these persons
are located within the PRC. As a result, it may not be possible to effect service of process within the United States or elsewhere
outside the PRC upon certain of our directors, executive officers or managers, including with respect to matters arising under
U.S. federal securities laws or applicable state securities laws. Moreover, the PRC does not have treaties providing for the reciprocal
recognition and enforcement of judgments of courts with the United States, the United Kingdom, Japan or many other countries. As
a result, recognition and enforcement in the PRC of judgments of a court in the United States and any of the other jurisdictions
mentioned above in relation to any matter may be difficult or impossible. Furthermore, an original action may be brought in the
PRC against us, our directors, executive officers or managers only if the actions are not required to be arbitrated by PRC law
and Helpson&rsquo;s articles of association, and only if the facts alleged in the complaint give rise to a cause of action under
PRC law. In connection with any such original action, a PRC court may impose civil liability, including monetary damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Because we receive substantially all
of our revenue in Renminbi, which currently is not a freely convertible currency, and the PRC government controls the currency
conversion and the fluctuation of the Renminbi, we are subject to changes in the PRC&rsquo;s political and economic decisions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We receive substantially
all of our revenues in Renminbi, which currently is not a freely-convertible currency. The PRC government may, at its discretion,
restrict access in the future to foreign currencies for current account transactions. Any future restrictions on currency exchanges
may limit our ability to use revenue generated in Renminbi to fund any future business activities outside China or to make dividend
or other payments in U.S. dollars. Although the Chinese government introduced regulations in 1996 to allow greater convertibility
of the Renminbi for current account transactions, significant restrictions still remain, including primarily the restriction that
foreign-invested enterprises may only buy, sell or remit foreign currencies, after providing valid commercial documents, at those
banks authorized to conduct foreign exchange business. In addition, conversion of Renminbi for capital account items, including
direct investment and loans, is subject to governmental approval in China, and companies are required to open and maintain separate
foreign exchange accounts for capital account items.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We cannot be certain that the Chinese
regulatory authorities will not impose more stringent restrictions on the convertibility of the Renminbi, especially with respect
to foreign exchange transactions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Fluctuation in the value
of the Renminbi may have a material and adverse effect on your investment. The change in value of the Renminbi against the U.S.
dollar is affected by, among other things, changes in PRC&rsquo;s political and economic conditions. From 1995 until July 2005,
the People&rsquo;s Bank of China intervened in the foreign exchange market to maintain an exchange rate of approximately Renminbi8.3
per U.S. dollar. On July 21, 2005, the PRC government changed this policy and began allowing modest appreciation of the Renminbi
versus the U.S. dollar. Under the new policy, the Renminbi was permitted to fluctuate within a narrow and managed band against
a basket of certain foreign currencies. This change in policy caused the Renminbi to appreciate approximately 21.5% against the
U.S. dollar over the following three years. As a consequence, the Renminbi has fluctuated sharply since July 2008 against other
freely traded currencies, in tandem with the U.S. dollar. It is difficult to predict how long the current situation may last and
when and how it may change again. There remains significant international pressure on the PRC government to adopt a substantial
liberalization of its currency policy, which could result in a further and more significant appreciation in the value of the Renminbi
against the U.S. dollar. Significant revaluation of the Renminbi may have a material and adverse effect on your investment. For
example, to the extent that we need to convert U.S. dollars we receive from securities offering into Renminbi for our operations,
appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from
the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends
on our common stock or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative
effect on the U.S. dollar amount available to us. In August 2015, the PRC Government devalued its currency by approximately 3%,
represented the largest yuan depreciation for 20 years. Concerns remain that China&rsquo;s slowing economy, and in particular its
exports, will need a stimulus that can only come from further cuts in the exchange rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, appreciation
or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar
terms without giving effect to any underlying change in our business or results of operations. The income statements of our operations
are translated into U.S. dollars at the average exchange rates in each applicable period. To the extent the U.S. dollar strengthens
against foreign currencies, the translation of these foreign currencies denominated transactions results in reduced revenue, operating
expenses and net income for our international operations. Similarly, to the extent the U.S. dollar weakens against foreign currencies,
the translation of these foreign currency denominated transactions results in increased revenue, operating expenses and net income
for our international operations. We are also exposed to foreign exchange rate fluctuations as we convert the financial statements
of our foreign subsidiaries into U.S. dollars in consolidation. If there is a change in foreign currency exchange rates, the conversion
of the foreign subsidiaries&rsquo; financial statements into U.S. dollars will lead to a translation gain or loss, which is recorded
as a component of other comprehensive income. Very limited hedging transactions are available in China to reduce our exposure to
exchange rate fluctuations. To date, we have not entered into any hedging transactions. While we may enter into hedging transactions
in the future, the availability and effectiveness of these transactions may be limited, and we may not be able to successfully
hedge our exposure at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to the environmental protection
laws of the PRC that may be costly to comply with and may adversely affect our manufacturing operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our manufacturing process
may produce by-products, such as effluent, gases and noise, which are harmful to the environment. We are subject to multiple laws
governing environmental protection, such as &ldquo;The Law on Environmental Protection in the PRC&rdquo; and &ldquo;The Law on
Prevention of Effluent Pollution in the PRC,&rdquo; as well as standards set by the relevant governmental bodies determining the
classification of different wastes and proper disposal. We have properly attained a waste disposal permit for our manufacturing
facility, which details the types and concentration of effluents and gases allowed for disposal. We are responsible for the renewal
of the waste disposal permit. There is no assurance that we will obtain the renewal of the waste disposal permit when the current
permit expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">China is experiencing substantial
problems with environmental pollution. Accordingly, it is likely that the national, provincial and local governmental agencies
will adopt stricter pollution controls. There can be no assurance that future changes in environmental laws and regulations will
not impose costly compliance requirements on us or otherwise subject us to future liabilities. Our business&rsquo;s profitability
may be adversely affected if additional or modified environmental control regulations are imposed upon us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Failure to comply with PRC regulations
regarding the registration requirements for employee equity incentive plans may subject our PRC citizen employees or us to fines
and other legal or administrative sanctions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 28, 2007, the
SAFE promulgated the Application Procedure of Foreign Exchange Administration for Domestic Individuals Participating in Employee
Stock Holding Plan or Share Option Plan of Overseas-Listed Company, which were superseded by Notice from SAFE regarding Issues
related to Domestic Individual Participating Offshore Public Company Equity Incentive Plan promulgated on February 15, 2012 (&ldquo;SAFE
#7&rdquo;) or the Share Option Rule. Under the Share Option Rule, PRC citizens who are granted share options or other employee
equity incentive awards by an overseas publicly-listed company are required, through a PRC agent who may be a PRC subsidiary of
such overseas publicly-listed company, to register with the SAFE and complete certain other procedures related to the share options
or other employee equity incentive plans. We and our PRC citizen employees who are granted share options or other equity incentive
awards under our 2010 Long-Term Incentive Plan, or PRC optionees, are subject to the Share Option Rule. If we or our PRC optionees
fail to comply with these regulations, we or our PRC optionees may be subject to fines and legal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The enforcement of new labor contract
law and its implementation rules and increase in labor costs in the PRC may adversely affect our business and our profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">China adopted the PRC Employment
Contract Law, or the new Labor Contract Law, effective January 1, 2008 and the implementation rules effective September 18, 2008.
The new Labor Contract Law and its implementation rules impose more stringent obligations on employers for, among others, entering
into written employment contracts, hiring temporary employees, dismissing employees, setting compensations for dismissal and protecting
certain sick or disabled employees from dismissal and setting forth detailed requirements relating to the contents of the employment
contracts. The implementation of the new Labor Contract Law may increase our operating expenses, in particular our personnel expenses,
as the continued success of our business depends significantly on our ability to attract and retain qualified personnel. In the
event that we decide to terminate some of our employees or otherwise change our employment or labor practices, the new Labor Contract
Law may also limit our ability to effect those changes in a manner that we believe to be cost-effective or desirable, which could
adversely affect our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>PRC regulation of loans and direct investment
by offshore holding companies to PRC entities may delay or prevent us from using the proceeds we receive from a securities offering
to make loans or additional capital contributions to our PRC operating subsidiary.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In utilizing the proceeds
we receive from a securities offering, as an offshore holding company with a PRC subsidiary, we may make loans to our PRC subsidiary,
or we may make additional capital contributions to our PRC subsidiary. Any loans to our PRC subsidiary are subject to PRC regulations
and approvals. For example, loans to our PRC subsidiary Helpson, which is a foreign-invested enterprise, to finance its activities
cannot exceed statutory limits and must be registered with the State Administration of Foreign Exchange in China, or SAFE, or its
local counterpart. Loans by us to domestic PRC enterprises must be approved by the relevant government authorities and must also
be registered with the SAFE or its local counterpart. Any capital contributions to our PRC subsidiary must be approved by the Ministry
of Commerce in China or its local counterpart. On August 29, 2008, SAFE promulgated Circular 142, a notice regulating the conversion
by a foreign-invested company of foreign currency into Renminbi by restricting how the converted Renminbi may be used. The notice
requires that Renminbi converted from the foreign currency denominated capital of a foreign-invested company may only be used for
purposes within the business scope approved by the applicable governmental authority and may not be used for equity investments
within the PRC unless specifically provided for otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, SAFE strengthened
its oversight over the flow and use of Renminbi funds converted from the foreign currency-denominated capital of a foreign-invested
company. The use of such Renminbi may not be changed without approval from SAFE, and may not be used to repay Renminbi loans if
the proceeds of such loans have not yet been used. Violations of Circular 142 may result in severe penalties, including substantial
fines as set forth in the Foreign Exchange Administration Rules. We cannot assure you that
we will be able to obtain these government registrations or approvals on a timely basis, if at all, with respect to our future
loans or capital contributions to our direct or indirect subsidiaries. If we fail to receive such registrations or approvals,
our ability to use the proceeds from a securities offering and to capitalize our PRC operations may be negatively affected, which
could materially and adversely affect our liquidity and ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The 2006 M&amp;A Rule establishes more
complex procedures for some acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to
pursue growth through acquisitions in China.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 8, 2006, six
PRC regulatory agencies, namely, the Ministry of Commerce, the State Assets Supervision and Administration Commission, or SASAC,
the State Administration for Taxation, the State Administration for Industry and Commerce, the CSRC and SAFE, jointly adopted the
Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the 2006 M&amp;A Rule, which became effective
on September 8, 2006. The 2006 M&amp;A Rule establishes additional procedures and requirements that could make some acquisitions
of PRC companies by foreign entities, such as our company, more time-consuming and complex, including requirements in some instances
that the approval of the Ministry of Commerce shall be required for transactions involving the shares of an offshore listed company
being used as the acquisition consideration by foreign entities, including Sino-foreign joint ventures. In the future, we may grow
our business in part by acquiring complementary businesses. Complying with the requirements of the 2006 M&amp;A Rule to complete
such transactions could be time-consuming, and any required approval processes, including obtaining approval from the Ministry
of Commerce, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business
or maintain our market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our China-sourced income is subject to
PRC withholding tax under the new Enterprise Income Tax Law of the PRC, and we may be subject to PRC enterprise income tax at the
rate of 25% when more detailed rules or precedents are promulgated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a Nevada holding
company with substantially all of our operations conducted through our operating subsidiary in China. Under the new PRC Enterprise
Income Tax Law, or the new EIT Law, and its implementation rules, both of which became effective on January 1, 2008, China-sourced
income of foreign enterprises, such as dividends paid by a PRC subsidiary to its overseas parent, is generally subject to a 10%
withholding tax. The new EIT Law, however, also provides that enterprises established outside China whose &ldquo;de facto management
bodies&rdquo; are located in China are considered &ldquo;tax resident enterprises&rdquo; and will generally be subject to the uniform
25% enterprise income tax rate as to their global income. Under the implementation rules, &ldquo;de facto management bodies&rdquo;
are defined as the bodies that have, in substance, overall management control over such aspects as the production and business,
personnel, accounts and properties of an enterprise. In April 2009, the PRC tax authority promulgated the Notice on Determination
of Tax Resident Enterprises of Chinese-controlled Offshore Incorporated Enterprises in accordance with Their De Facto Management
Bodies, or Circular 82, to clarify the criteria for determining whether the &ldquo;de facto management bodies&rdquo; are located
within the PRC for enterprises incorporated overseas with controlling shareholders being PRC enterprises. As all of the our operational
management is currently based in the PRC, and we expect them to continue to be located in China, our company may be deemed a PRC
resident enterprise and therefore subject to the PRC enterprise income tax at a rate of 25% on our worldwide income, which excludes
the dividends received directly from another PRC resident enterprise. Due to the lack of clear guidance on the criteria pursuant
to which the PRC tax authorities will determine our tax residency under the new EIT Law, it remains unclear whether the PRC tax
authorities will treat us as a PRC resident enterprise. Therefore, we are unable to confirm whether we are subject to the tax applicable
to resident enterprises or non-resident enterprises under the new EIT Law. Furthermore, in connection with the new EIT Law and
Tax Implementation Regulations, the Ministry of Finance and State Administration of Taxation jointly issued, on April 30, 2009,
the Notice on Issues Concerning Process of Enterprise Income Tax in Enterprise Restructuring Business, or Circular 59, which became
effective retrospectively on January 1, 2008. It is uncertain to us as to how it will be implemented and the respective tax base
and the tax exposure cannot be determined reliably at this stage. In case we are required to pay the income tax on capital gains
by the relevant PRC tax authorities, our financial conditions and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Dividends payable by us to our foreign
investors and gain on the sale of our shares may become subject to taxes under PRC tax laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the new EIT law and
its implementation rules, to the extent that we are considered a &ldquo;resident enterprise&rdquo; which is &ldquo;domiciled&rdquo;
in China, PRC income tax at the rate of 10% is applicable to dividends payable by us to investors that are &ldquo;non-resident
enterprises&rdquo; so long as such &ldquo;non-resident enterprise&rdquo; investors do not have an establishment or place of business
in China or, despite the existence of such establishment or place of business in China, the relevant income is not effectively
connected with such establishment or place of business in China. Similarly, any gain realized on the transfer of our shares by
such investors is also subject to a 10% PRC income tax if such gain is regarded as income derived from sources within China and
we are considered a &ldquo;resident enterprise&rdquo; which is domiciled in China for tax purposes. Additionally, there is a possibility
that the relevant PRC tax authorities may take the view that our purpose is that of a holding company, and the capital gain derived
by our overseas stockholders would be deemed China-sourced income, in which case such capital gain may be subject to PRC withholding
tax at the rate of up to 10%. If we are required under the new EIT law to withhold PRC income tax on our dividends payable to our
foreign stockholders who are &ldquo;non-resident enterprises&rdquo;, or if you are required to pay PRC income tax on the transfer
of our shares under the circumstances mentioned above, the value of your investment in our shares may be materially and adversely
affected. It is unclear whether, if we are considered a PRC &ldquo;resident enterprise,&rdquo; holders of our shares would be able
to claim the benefit of income tax treaties or agreements entered into between China and other countries or areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The strengthened scrutiny over acquisition
transactions by the PRC tax authorities may have a negative impact on our acquisition strategy.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
new EIT Law, the Ministry of Finance and State Administration of Taxation jointly issued, on April 30, 2009, the Notice on Issues
Concerning Process of Enterprise Income Tax in Enterprise Restructuring Business, or Circular 59. On December 10, 2009, the State
Administration of Taxation issued the Notice on Strengthening the Management on Enterprise Income Tax for Non-resident Enterprises
Equity Transfer, or Circular 698. Both Circular 59 and Circular 698 became effective retrospectively on January 1, 2008. By promulgating
and implementing these circulars, the PRC tax authorities have strengthened their scrutiny over the direct or indirect transfer
of equity interest in a PRC resident enterprise by a non-resident enterprise. For example, Circular 698 specifies that the PRC
State Administration of Taxation is entitled to redefine the nature of an equity transfer where offshore vehicles are interposed
by abusing corporate structures for tax-avoidance purposes and without reasonable commercial intention. We may pursue acquisitions
as one of our growth strategies, and may conduct acquisitions involving complex corporate structures. We cannot be assured that
the PRC tax authorities will not, at their discretion, adjust the capital gains thus causing us to incur additional acquisition
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The slowing economic growth in China
may assert a negative impact on our operation and financial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">According to several articles
published by the Wall Street Journal, CNN, and BBC News in January 2016, after experiencing rapid growth for more than a decade,
China's economy has been hit by shrinking foreign and domestic demand, weak investment, factory overcapacity and oversupply in
the property market, and has experienced a painful slowdown in the last two years. As the government tried to shift the growth
engine away from manufacturing and debt-fueled investment toward the services sector and consumer spending, the outlook of the
Chinese economy is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the next two to three
years, China&rsquo;s growth performance could deteriorate because of the overhang of its real estate bubble, massive manufacturing
overcapacity, and the lack of new growth engines. A Chinese government-run think tank expected China's economy to grow by 6.5%
this year from 6.3% in 2016, according to Reuters on January 2, 2017 published by Fortune online. Industrial output could grow
5.9% this year, down from an estimated 6.1% in 2016, it said. If China&rsquo;s economy is further slowing down, it may negatively
affect our business operation and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The market price for our common stock
may be volatile which could results in a complete loss of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The market price for our
common stock is likely to be highly volatile and subject to wide fluctuations in response to factors including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; text-align: justify">actual or anticipated fluctuations in our quarterly operating results;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; text-align: justify">announcements of new products by us or our competitors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; text-align: justify">changes in financial estimates by securities analysts;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; text-align: justify">conditions in the pharmaceutical market;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 6%; text-align: center">&middot;</TD>
    <TD STYLE="width: 94%; text-align: justify">changes in the economic performance or market valuations of other companies involved in pharmaceutical production;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 6%; text-align: center">&middot;</TD>
    <TD STYLE="width: 94%; text-align: justify">announcements by our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; text-align: justify">economic, regulatory and political developments;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; text-align: justify">additions or departures of key personnel, or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: center">&middot;</TD>
    <TD STYLE="width: 93%; text-align: justify">potential litigation.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the securities
markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance
of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may issue additional shares of our
capital stock to raise additional cash for working capital; if we issue additional shares of our capital stock, our stockholders
will experience dilution in their respective percentage ownership in the company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may issue additional
shares of our capital stock to raise additional cash for working capital. There is no anti-dilution protection or preemptive rights
in connection with our common stock. Thus, the percentage ownership of existing holders of common stock may be diluted in their
respective percentage ownership in us if we issue additional shares of our capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A large portion of our common stock is
controlled by a small number of stockholders and as a result, these stockholders are able to influence and ultimately control the
outcome of stockholder votes on various matters.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A large portion of our
common stock is held by a small number of stockholders. For instance, Heung Mei Tsui, a member of our Board of Directors, holds
21.4% and Zhilin Li, our Chief Executive Officer, holds 23.1% of our common stock, respectively, as of the date hereof. As a result,
these two stockholders are able to significantly influence the outcome of stockholder votes on various matters, including the election
of directors and other corporate transactions including business combinations. In addition, the occurrence of sales of a large
number of shares of our common stock, or the perception that these sales could occur, may affect our stock price and could impair
our ability to obtain capital through an offering of equity securities. Furthermore, the current ratios of ownership of our common
stock reduce the public float and liquidity of our common stock which can in turn affect the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are likely to remain subject to &ldquo;penny
stock&rdquo; regulations and as a consequence there are additional sales practice requirements and additional warnings issued by
the SEC.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If at any time we have
net tangible assets of $5,000,000 or less and the trading price of our common stock is below $5.00 per share, the open-market trading
of our common stock will be subject to the &ldquo;penny stock&rdquo; rules of the SEC. The &ldquo;penny stock&rdquo; rules impose
additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited
investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their
spouse). For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase
of securities and have received the purchaser&rsquo;s written consent to the
transaction before the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the broker-dealer must
deliver, before the transaction, a disclosure schedule prescribed by the SEC relating to the penny stock market. The broker-dealer
also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations
for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited market in penny
stocks. These additional burdens imposed on broker-dealers may restrict the ability of broker-dealers to sell the common stock
and may affect a stockholder&rsquo;s ability to resell the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that our common stock will qualify for exemption from the &ldquo;penny stock&rdquo; rules. In any event, even if our common stock
is exempt from such rules, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to
restrict any person from participating in a distribution of a &ldquo;penny stock&rdquo; if the SEC finds that such a restriction
would be in the public interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stockholders should be
aware that, according to SEC Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud
and abuse. Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related
to the promoter or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading
press releases; (iii) boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced
sales persons; (iv) excessive and undisclosed bid-ask differential and markups by selling broker-dealers; and (v) the wholesale
dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with
the resulting inevitable collapse of those prices and with consequent investor losses. Our management is aware of the abuses that
have occurred historically in the penny stock market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are responsible for the indemnification
of our officers and directors under certain circumstances which could result in substantial expenditures, which we may be unable
to recoup.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our bylaws provide for
the indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney&rsquo;s fees
and other expenses incurred by them in any litigation to which they become a party arising from their association with or activities
on behalf of us. This indemnification policy could result in substantial expenditures, which we may be unable to recoup.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have identified material weaknesses
in our internal control over financial reporting, which could affect our ability to ensure timely and reliable financial reports,
affect the ability of our auditors to attest to the effectiveness of our internal controls should we become an accelerated filer
in the future, and weaken investor confidence in our financial reporting.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As directed by Section
404 of the Sarbanes-Oxley Act of 2002, the SEC adopted rules requiring public companies in their annual reports to include a report
of management on the reporting company's disclosure controls and procedures and internal controls over financial reporting. We
became subject to this requirement commencing with our fiscal year ended December 31, 2007 and a report of our management is included
under Item 9A. &ldquo;Controls and Procedures&rdquo; of this Annual Report on Form 10-K. As set forth in such report, our management
has concluded that our internal controls over financial reporting were not effective as of December 31, 2016, and there existed
a material weakness in our internal control over financial reporting as of December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">We believe we are taking
appropriate actions to remediate such material weakness; however, such measures may not be sufficient to address the material weaknesses
identified or ensure that our controls and procedures are effective. We may also discover other material weaknesses in the future.
Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in the implementation
of such controls, could cause us to fail to meet our periodic reporting obligations or result in material misstatements in our
financial statements and affect the ability of our auditors to attest to the effectiveness of our internal control over financing
reporting to the extent we become an accelerated filer in the future. In addition, substantial costs and resources may be required
to rectify any internal control deficiencies. If we cannot produce reliable financial reports, investors could lose confidence
in our reported financial information, the market price of our common stock could decline significantly, and our business and financial
condition could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We do not anticipate paying cash dividends
on our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should not rely on
an investment our common stock to provide dividend income, as we have not paid any cash dividends on our common stock and do not
plan to pay any in the foreseeable future. Accordingly, investors must rely on sales of their common stock after price appreciation,
which may never occur, as the only way to realize any return on their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Restrictions on the Use of Rule 144 by
Shell Companies or Former Shell Companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Historically, the SEC has
taken the position that Rule 144 under the Securities Act, as amended, is not available for the resale of securities initially
issued by companies that are, or previously were, blank check companies like us, to their promoters or affiliates despite technical
compliance with the requirements of Rule 144. The SEC has codified and expanded this position in its amendments effective on February
15, 2008 and applies it to securities acquired both before and after that date by prohibiting the use of Rule 144 for resale of
securities issued by shell companies (other than business transaction related shell companies) or issuers that have been at any
time previously a shell company. The SEC has provided an important exception to this prohibition, however, if the following conditions
are met: the issuer of the securities that was formerly a shell company has ceased to be a shell company; the issuer of the securities
is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; the issuer of the securities has filed all
Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that
the issuer was required to file such reports and materials), other than Form 8-K reports; and at least one year has elapsed from
the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell
company. As such, due to the fact that we had been a shell company prior to October 2005, holders of &quot;restricted securities&quot;
within the meaning of Rule 144, when reselling their shares pursuant to Rule 144, shall be subject to the conditions set forth
herein.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 1B. UNRESOLVED STAFF
COMMENTS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
are not required to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 2. PROPERTIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no private land
ownership in the PRC. All land is either owned by the government of the PRC on behalf of all Chinese citizens or collectively owned
by farmers. However, land use rights may be allocated by the PRC State Land Administration Bureau or its authorized branches. Helpson
was granted land use rights by the PRC government for approximately 22,936 square meters of land located on Plot C09-2 in the Haikou
Bonded Zone, Hainan Province, PRC in 2003. These land use rights will expire on September 10, 2063.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Helpson owns two production
facilities in Haikou, Hainan Province, PRC, one of which has a construction area of 663.94 square meters and is located at the
6th floor of Standard Plant Building B, Jinpan Industrial Development Zone. The other factory, located on Plot C09-2 in the Haikou
Bonded Zone, has a two buildings with production area of 20,282.42 square meters with a certificate number HK477872, and 6,593,20
square meters with a certificate number HK122889 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, Helpson rents
offices located on the second floor of the Jiahai Building owned by Hainan Zhongfu Foreign Export Personnel Service Center (the
&ldquo;Center&rdquo;) as its principal executive offices. Monthly rent at this facility is RMB 5,580 (approximately $843). The
original term of the lease was 3 years, from December 1, 2010 to November 30, 2013. On December 31, 2011, this lease was superseded
by a new lease, for a term of nine years, for office spaces on the second floor and the entire third floor at a monthly rent of
RMB 20,000 (approximately $2,941), with a 5% increase every two years from the fourth year until the end of the term. The aggregate
area of the office spaces Helpson rents is 1,686 square meters, or 16,812 square feet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that all our
properties have been adequately maintained, are generally in good condition, and are suitable and adequate for our business. However,
we are anticipate a possible need for expansion and additional space as our production increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Mortgaged Property</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Helpson entered into a
line of credit with Bank of China in October 2013, which was renewed in November 2014 and November 2015. This line of credit is
payable in two equal installments of RMB 15,000,000 ($2.31 million) payable on September 22, 2016 and October 20, 2016.&nbsp;&nbsp;In
order to secure the line of credit, Helpson mortgaged its land use rights and buildings. To provide an additional security, our
Chief Executive Officer and Chairman of our Board of Directors personally guaranteed the new line of credit. This line of credit
has been fully paid off upon the due date and the associated mortgage was lifted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Helpson entered into an
eight-year construction loan facility on September 21, 2013. The total loan facility amount is RMB80,000,000 (approximately $13
million), which had been fully utilized through May 7, 2014. We&rsquo;ve accumulatively repaid the principle of RMB11 million (approximately
$1.6 million) of the construction loans per the payback schedule as of December 31, 2016. The proceeds of the loan were used for
and are collateralized by the construction of the Company&rsquo;s new production facility and the included production line equipment
and machinery. Upon the Company&rsquo;s receipt of the ownership certificate over the new factory, the mortgage has been formally
placed on the new facility in the second quarter of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The loans referred to above
are set forth in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 19%; border: Black 1pt solid; padding-left: 1.5pt; text-align: center"><B>Total Amount of the Line of Credit</B></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><B>Lending Institution</B></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><B>Contract Period</B></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><B>Interest Rate</B></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 1.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Properties under</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Mortgage</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RMB 80 million<BR>
(Approximately $12.3million)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Bank of China</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">July 11, 2013</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">to July 10, 2021</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">The interest rate is 5.73%, based upon 110% of the PRC government&rsquo;s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates.&nbsp;&nbsp;On July 10, 2015, the interest rate was adjusted to 5.94%. &nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Helpson&rsquo;s new factory: 20,282.42 square meters&nbsp;&nbsp;(Certificate #: HK477872) and the <FONT STYLE="background-color: white">production line equipment and machinery in the new factory</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 3. LEGAL PROCEEDINGS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, we may
become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject
to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
However, we are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate,
a material adverse effect on our business, financial condition or operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 4. MINE SAFETY DISCLOSURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 5. MARKET FOR REGISTRANT&rsquo;S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our shares began trading
on the NYSE MKT (Formerly known as NYSE Amex) on September 30, 2009 under the symbol &ldquo;CPHI&rdquo;. Prior to September 30,
2009, our shares traded on the OTC Bulletin Board under the symbol &ldquo;CPHI.OB.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table, based
upon Yahoo Finance, contains information about the range of high and low sales prices for our common stock for each full quarterly
period during the fiscal years ending December 31, 2016 and 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">High</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">Low</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Fiscal 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: justify">First Quarter</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">Fiscal 2015</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: justify">First Quarter</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.56</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.27</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 27, 2017, there
were approximately 137 shareholders of record of our common stock and an indeterminate number of beneficial holders who held our
common stock in street name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The transfer agent and
registrar for our common stock is Securities Transfer Corporation, 2591 Dallas Parkway, Suite 102, Frisco, Texas 75034. Their telephone
number is (469) 633-0101.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.6pt 0 0; text-align: justify"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.6pt 0 0; text-align: justify; text-indent: 0.5in">We have never
paid or declared any dividend on our common stock and we do not anticipate paying cash dividends in the foreseeable future. As
a result of our holding company structure, we would rely entirely on dividend payments from our subsidiaries, Onny Investment Ltd.
and Hainan Helpson Medial &amp; Biotechnology Co., Ltd., for our cash flow to pay dividends on our common stock. The PRC government
imposes controls on the conversion of Renminbi into foreign currencies and the remittance of currencies out of the PRC, which may
also affect our ability to pay cash dividends in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Securities Authorized for Issuance under
Equity Compensation Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD COLSPAN="4" STYLE="text-align: center"><B>Equity Compensation Plan Information</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 31%; border-bottom: black 1.5pt solid; text-align: center"><B>Plan category</B></TD>
    <TD STYLE="width: 21%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number of </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>securities to be </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>issued upon </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>exercise of </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>outstanding </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>options, warrants </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and rights</B></P></TD>
    <TD STYLE="width: 20%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Weighted-average </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>exercise price of </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>outstanding </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>options, warrants </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and rights</B></P></TD>
    <TD STYLE="width: 28%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number of securities </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>remaining available for </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>future issuance under </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>equity compensation </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>plans (excluding </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>securities reflected </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>in column (a))</B></P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">(a)</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">(b)</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">(c)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Equity compensation plans not approved by security holders</TD>
    <TD STYLE="text-align: center">-</TD>
    <TD STYLE="text-align: center">-</TD>
    <TD STYLE="text-align: center">-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Equity compensation plans approved by security holders</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">-</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">-</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">3,825,000</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Totals</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">-</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">-</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center">3,825,000</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 6. SELECTED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a &quot;smaller reporting
company&quot; as defined in Item 10 of Regulation S-K, we are not required to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 7. MANAGEMENT&rsquo;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The statements contained in this report
with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements.
Forward-looking statements can be identified by the use of forward-looking terminology, such as &quot;anticipate&quot;, &quot;believe&quot;,
&quot;expect&quot;, &quot;plan&quot;, &quot;intend&quot;, &quot;seek&quot;, &quot;estimate&quot;, &quot;project&quot;, &quot;could&quot;,
&quot;may&quot; or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties.
Management wishes to caution the readers of the forward-looking statements that any such statements that are contained in this
report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors,
including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting
our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report including
in &ldquo;Risk Factors&rdquo; in Item 1A and some of which are discussed in our other filings with the Securities and Exchange
Commission. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement
of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ
from the assumptions underlying the statements that have been made regarding anticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">These risk factors should be considered
in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue.
All written and oral forward looking statements made in connection with this report that are attributable to our company or persons
acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution
investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&rsquo;
expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances
after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 24pt 0 12pt">Business Overview &amp; Recent Developments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In November 2014, we received a Good
Manufacturing Practices (&ldquo;GMP&rdquo;) certificate issued by the China Food and Drug Administration (&ldquo;CFDA&rdquo;) for
dried powder and liquid injectable product lines produced at our new manufacturing facility, and since then we have restarted production
of products with those formulations after a suspension of production from year end 2013 due to our inability to meet a GMP upgrade
deadline. GMP compliance timing issues also caused us to miss certain drug bids (generally with terms of around two years) in several
Chinese provinces prior to November 2014. These missed bids negatively impacted our previously-established market share in those
provinces, and reduced our overall sales in 2015 and 2016. Nevertheless, we continue to concentrate on enhancing the fundamentals
of our business. In January and December 2015, we completed upgrades to our manufacturing facilities and received new GMP certificates
for our tablet and capsule product lines and for the cephalosporin product lines at our old factories. Upgrades to our oral solution
product lines were completed ahead of the deadline, which has positioned us to better meet market demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In order to comply with requests from
the Central Committee of the Communist Party of China and State Council to use the strictest standards to monitor and regulate
food and drug production and to further rectify and standardize drug distribution, CFDA issued the &ldquo;<I>Notice of Rectification
Against Illegal Operations Regarding Drug Logistics&amp; Distribution</I>&rdquo; on May 3, 2016. Because it had become the top
priority for pharmaceutical distributors, including our distributors, to comply with this government policy, our distributors&rsquo;
time and efforts were focused on passing CFDA inspection, which delayed their ordinary promotion efforts and purchase and distribution
activities, which further negatively impacted the sales performance of our company during the second and third quarters of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Increasing our sales remains our top
priority. Through the continued implementation of sales promotion, the Company realized sales increases in the fourth quarter of
2016 compared to the previous quarter. Management will continue to vigorously promote sales by actively participating in the recent
opening of the new provincial drug tender and participation in drug exhibitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In order to support our existing products
package we remain focused on pipeline development. We have experienced delays in obtaining approval for certain products in our
pipeline because of revisions of and enhancements to CFDA approval criteria and processes. These revisions have resulted in additional
supplemental materials and trials, higher costs, and longer approval times for certain applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On March 5, 2016, the Chinese State
Council issued &quot;<I>Opinions on Carrying out Consistency Evaluations of the Quality and Efficacy of Generic Drugs</I>&quot;
(the &ldquo;Opinions&rdquo;). The Opinions define the object of evaluations and establish deadlines, determine selection criteria
for reference drugs, call for a rational selection of evaluation methods, and identify pharmaceutical manufacturers as the principle
generic drug consistency evaluation, and sets forth corresponding incentives. Subsequently, the CFDA issued &ldquo;<I>Comments
from the General Office of the State Council on the Consistency Evaluations of the Efficacy and Quality of Generic Drug&rdquo;</I>
in May 2016, in order to further elaborate on assessment processes and related technical rules. Consistency evaluations apply to
the majority of our current existing marketed and pipeline products. Complying with consistency evaluations will become our core
task in the near future and will have a significant impact on our operations as well as our industrial structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Due to the detailed implementation rules
of consistency evaluations that are still being introduced, our decision making has been impacted by those uncertainties, and we
suspended the development of our pipeline products in 2016. The following list sets forth the current status of our main pipeline
products:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Antibiotic Combination - We are currently in Phase II of clinical
trials, due to increased regulatory requests for clinical review.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rosuvastatin - Rosuvastatin is a generic form of Crestor, a drug
for the treatment of high blood cholesterol levels. Clinical trials for this generic drug were completed in the fourth quarter
of 2010.We have submitted an application for production approval and are supplementing consistency evaluation experiments pursuant
to the Opinions. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Heart disease drug - We developed an oral solution for the treatment
of coronary heart disease in our new product pipeline. This product comes with a patented Traditional Chinese Medicine (&ldquo;TCM&rdquo;)
formula. We have completed Phase III clinical trials and are supplementing clinical trials pursuant to the updated criteria.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Alzheimer's disease drug - We developed a drug for the treatment
of Alzheimer's disease and are supplementing consistency evaluation experiments pursuant to the Opinions.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Digestive diseases drug - We developed two drugs for the treatment
of digestive diseases and are supplementing consistency evaluation experiments pursuant to the Opinions.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 24pt 0 12pt">Market Trends</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Consumer demand for medicine is relatively
rigid and stable and is generally unaffected by seasonal business cycles. We have noticed that the growth rates of the pharmaceutical
manufacturing industry have been higher than GDP growth rates in China. According to the study <I>&ldquo;Deepening The Reform of
China's Medical and Healthcare System and Building A Value-Based Quality Service Delivery System</I>&quot; published by the World
Bank, if China maintains its existing healthcare system, total health expenditures will increase from 5.5% of GDP in 2014 to over
9% of GDP in 2035, with an average annual growth rate of 8.4%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The rapid development of the pharmaceutical
industry in China has been driven by the continuous growth of total healthcare costs, the establishment and improvement of the
universal Medicare system, increases in medical expenditures per capita, the aging population, and changes in the disease spectrum;
however, development has been negatively impacted by factors like Medicare cost controls and price pressure in drug tenders in
recent years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Chinese National
Health Commission published the &quot;<I>Communiqu&eacute; of China's Hygiene and Family Planning Development Statistics
in 2015&rdquo;</I> on July 20, 2016, which stated that the total Chinese national hygiene expenditure in 2015 was expected
to reach RMB4058.9 billion, comprised of government spending of RMB1253.3 billion (30.88%), social spending of RMB1589.1
billion (39.15%), and personal spending of RMB1216.4 billion (29.97%), according to preliminary accounting. The total cost
of healthcare per capita in 2015 was RMB2952, accounting for 6.0% of GDP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">China's State Council issued &quot;<I>Guidance
on the Pilot Comprehensive Reform of Urban Public Hospitals</I> &ldquo;in 2015, which proposed that the pilot comprehensive reform
of urban public hospitals be fully implemented and that the personal spending component of total hygiene expenditures be reduced
to 30% or lower by 2017. In order to achieve this goal, the Chinese government's ongoing investment will be essential. The Central
Committee Political Bureau of the Communist Party of China approved the &quot;Healthy China 2030 Plan&quot; in August 2016, which
proposed to reduce personal hygiene spending to approximately 28% of total healthcare expenditures by 2020, and 25%of total healthcare
expenditures by 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In order to achieve the objectives of
the above-mentioned &quot;Healthy China 2030 Plan&quot; in the context of an aging population and an improving universal Medicare
system, we believe that the hygiene spending proportion of total fiscal expenditures will increase and that net annual Medicare
expenditures will increase as well. We anticipate that the use of generic drugs as a cost-effective medical solution will be further
promoted as a way to reduce the payment pressures of Medicare. As a generic drug company we are presented with a huge domestic
market, and through further upgrades, especially in compliance with consistency evaluations, we could meet European and American
production standards, enabling us to engage overseas markets through product exports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In August 2015, the State Council promulgated
the &ldquo;<I>Opinions on therefore and Examination of the Approval System for the Reform of Drugs and Medical Devices</I>&rdquo;,
which opened the prelude to the reform of the drug examination and approval system in China, the reform of the drug registration
system, consistency evaluations of generic drugs, and enhanced drug listing licensing systems, among other reforms. The CFDA has
also subsequently introduced a number of specific measures and technical details related to various areas of the above-mentioned
reforms. These policies may change the existing competitive landscape, development methods, and operating patterns and rules of
the pharmaceutical industry and may have a significant impact on the strategic choices and future development models of Chinese
pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In addition, the Office of the State
Council issued the &quot;<I>Pilot Plan for Marketing Authorization Holders</I>&quot; on May 24, 2016, allowing eligible drug research
and development institutions and scientific researchers to become Marketing Authorization Holders (&ldquo;MAH&rdquo;) by obtaining
drug marketing authorization and drug approval numbers from the State Council. This policy uses a management model of separating
drug marketing authorization and drug production licenses, thereby allowing a MAH to produce pharmaceuticals itself or to consign
production to other pharmaceutical manufacturers. This policy not only transitions our production practices to meet European and
United States standards by separating drug approval and production qualifications, and therefore changing the existing model of
bundling drug approval numbers to pharmaceutical manufacturers in China, but also serves as a supplement to the ongoing consistency
evaluations policy. Given that a certain failure rate must be demonstrated by MAH applicants for in their consistency evaluations,
an applicant that passes the evaluations could consign production to an applicant who failed in order to optimize capacity, save
on fixed costs, and reduce capital expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In general, demand for pharmaceutical
products is still experiencing steady growth in China. The ongoing generic drug consistency evaluations and reform of China&rsquo;s
drug production registration and review policies will have major effects on the future development of our industry and may change
its business patterns. We will continue to actively adapt to state policy guidance and further evaluate market conditions for
our current existing products, pipeline products, and competition in the market in order to optimize our development strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B>Results of Operations for the Fiscal
Year Ended December 31, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Revenue decreased by 23.5% to $15.6
million for the year ended December 31, 2016, as compared to $20.4 million for the year ended December 31, 2015. This decrease
was primarily due to the focus of our distributor customers with the CFDA rectification of pharmaceutical distributors as discussed
above in the second and third quarters of 2016, despite our efforts to promote sales in an attempt to regain market share during
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Set forth below are our revenues by
product category in millions (USD) for the years ended December 31, 2016 and 2015:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Product Category</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Fiscal Year Ended December 31, </FONT></TD>
    <TD NOWRAP ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Net Change</FONT></TD>
    <TD NOWRAP ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">% Change</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 39%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">CNS Cerebral &amp; Cardio Vascular</FONT></TD>
    <TD NOWRAP STYLE="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2.72 </FONT></TD>
    <TD NOWRAP STYLE="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">3.11 </FONT></TD>
    <TD NOWRAP STYLE="width: 14%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-0.39 </FONT></TD>
    <TD NOWRAP STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-12%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Anti-Viral/ Infection &amp; Respiratory</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">10.27 </FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">13.51 </FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-3.24 </FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-24%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Digestive Diseases</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0.79 </FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0.76 </FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0.03 </FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">4%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Other</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.78 </FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2.97 </FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-1.19 </FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">-40%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The most significant revenue decrease
in terms of dollar amount was in our &ldquo;Anti-Viral/Infection &amp; Respiratory&rdquo; product category, which generated $10.3
million in sales revenue in 2016 compared to $13.5 million a year ago, a decrease of $3.2 million. This decrease was mainly due
to the sales decrease of our Cefaclor Dispersible Tablets in this category, which was a result of CFDA rectification of pharmaceutical
distributors as discussed above in middle 2016, as well as market fluctuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Sales in the &ldquo;CNS Cerebral &amp;
Cardio Vascular&rdquo; category decreased by $0.4 million to $2.7 million in 2016 compared to $3.1 million in 2015, which decrease
was mainly due to a drop in sales of Ozagrel, primarily the result volatility in market demand. Our &ldquo;Digestive Diseases&rdquo;
category generated $0.8 million of sales in both 2016 and 2015. Our &ldquo;Other&rdquo; product category sales decreased by $1.2
million to $1.8 million in 2016 from $3.0 million in 2015, mainly due to the decrease in sales of Vitamin B6,caused by market
volatility.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Product Category</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Fiscal Year Ended December 31, </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 50%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">CNS Cerebral &amp; Cardio Vascular</FONT></TD>
    <TD NOWRAP STYLE="width: 25%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">18%</FONT></TD>
    <TD NOWRAP STYLE="width: 25%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">15%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Anti-Viral/ Infection &amp; Respiratory</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">65%</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">66%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Digestive Diseases</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">5%</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">4%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Other</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">12%</FONT></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">15%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">For the year ended December 31, 2016,
revenue breakdown by product category remained close to that of the prior year. Sales of the &ldquo;Anti-Viral/Infection &amp;
Respiratory&rdquo; products category represented 65% and 66% of total sales in the year ended on December 31, 2016 and 2015, respectively.
The &ldquo;CNS Cerebral &amp; Cardio Vascular&rdquo; category represented 18% of total revenue in 2016, compared to15% in 2015.
The &ldquo;Digestive Diseases&rdquo; category represented 5% of total revenue in 2016 compared to 4% in 2015. The &ldquo;Other&rdquo;
category represented 12% and 15% of revenues in 2016 and 2015, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Cost of Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">For the year ended December 31, 2016,
our cost of revenue was $12.4 million, or 79% of total revenue, which represented a decrease of $3.4 million from $15.8 million,
or 78% of total revenue, in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Inventory Obsolescence</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In some cases, we have decreased our
sales estimates between the time when raw materials were purchased and the time when the sales are made for certain of our products.
We have also reassessed the market value of certain of our raw materials. As a result, we have determined that certain inventory
has become slow moving or obsolete. We did not recognize any inventory obsolescence expense for the year ended December 31, 2016,
while we recognized inventory obsolescence expense of $3.1 million for the year ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Gross Profit and Gross Margin</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Gross profit for the year ended December
31, 2016 was $3.2 million, compared to $1.5 million in 2015. Our gross profit margin in 2016 was 20.7% compared to 7.1% in 2015.
Without the effect of inventory obsolescence, management estimates that our gross profit would have been approximately 20.7% in
2016 and 22.5% in 2015. With the national implementation of full coverage health insurance almost completed, and the positive
effect of its expansion policy gradually diminished, and taking into account many unfavorable market factors such as Medicare
cost-control, and price pressures from drug tenders, we have experienced general decline in profit margins in recent years. Going
forward, we expect to see continued pricing pressure on most of our products. However, new products could help support overall
gross margin once they are launched.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Selling Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Our selling expenses for the year ended
December 31, 2016 were $4.0 million, a decrease of $0.3 million, compared to $4.3 million for the year ended December 31, 2015.&nbsp;Selling
expenses accounted for 25.9% of the total revenue in 2016 compared to 21.1% in 2015.&nbsp;&nbsp;The increase was mainly the result
of additional marketing, consulting and product promotional efforts in certain Chinese provinces. Because of adjustments in our
sales practices resulting from healthcare reform policies, despite the overall decrease in sales, we require additional personnel
and expenses to support our sales and the collection of accounts receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Our general and administrative
expenses for the year ended December 31, 2016 were $2.3 million, which represented an increase of $0.4 million compared to
$1.9 million in 2015. General and administrative expenses accounted for 14.6% and 9.3% of our total revenues in 2016 and
2015, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Our research and development expenses
for the year ended December 31, 2016 were $0.4 million, compared to $1.0 million in 2015. Research and development expenses accounted
for 2.4% and 4.7% of our total revenues in 2016 and 2015, respectively. The consistency evaluations discussed under the &ldquo;Business
Overview &amp; Recent Developments&rdquo; section here of is expected to have a significant impact on all generic products not
only in our pipeline, but also throughout the existing Chinese market. Because of the continuous introduction of detailed implementation
rules under this policy, our pipeline did not have any further development in 2016. But, we are still actively adapting to this
policy, and have filed reagent references with the CFDA for several key products in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Bad Debt Expenses</I></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bad debt expenses for the year ended December 31, 2016 was $1.1 million, which represented a decrease of $4.9 million
compared to $6.0 million in 2015. During 2015, we also recognized bad debt expenses of $4.1 million related to advances made
to suppliers based on our evaluations of the realization likelihood of payments. The decline in our bad debt expenses was
mainly the result of the decline in our revenues in recent years, which also led to the corresponding decline in the net
amount of accounts receivable aging over one year (according to our current accounting policy, we are required to recognize a
bad debt allowance 70% of the accounts receivable that are between 365 days to 720 days old).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In general, our normal credit or payment
terms extended to customers are for 90 days. This has not changed in recent years. Due to the peculiarity of the Chinese pharmaceutical
market environment, deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are
a normal phenomenon. Our customers are primarily pharmaceutical distributors that sell our products to mostly government-backed
hospitals. Therefore, the aging of our receivables from our customers tends to be longer-term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The amount of net accounts
receivable that were past due (or the amount of accounts receivable that were more than 90 days old) was $3.9 million and
$5.1 million as of December 31, 2016 and 2015, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The following table illustrates
our gross accounts receivable aging distribution in terms of percentage of total accounts receivable as of December 31, 2016
and 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">December 31,</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">December 31,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">1 - 90 Days</FONT></TD>
    <TD STYLE="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">8.8%</FONT></TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">4.0%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">90 - 180 Days</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2.6%</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2.2%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">180 - 360 Days</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">6.7%</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">7.9%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">360 - 720 Days</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">13.4%</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">14.6%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&gt; 720 Days</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">68.5%</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">71.3%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">100.0%</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">100.0%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Our bad debt allowance estimate is currently
10% of accounts receivable that are less than 365 days old, 70% of accounts receivable that are between 365 days and 720 days old,
and 100% of accounts receivable that are greater than 720 days old.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">We recognize bad debt expenses per
actual write-offs as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful
accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period,
and when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference.
The allowance for doubtful accounts was $15.7 million and $29.4 million as of December 31, 2016 and December 31, 2015, respectively.
The changes in the allowances for doubtful accounts during the years ended December 31, 2016 and 2015 were as follows:</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 9pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left">&nbsp;&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center">For the Fiscal Years Ended</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left">&nbsp;&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1pt solid; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left">&nbsp;&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center">2016</TD>
    <TD STYLE="font: 10.5pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify; width: 52%">Balance, Beginning of Year</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right; width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 3%">$</TD>
    <TD STYLE="text-align: right; width: 16%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29,352,806</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 3%">$</TD>
    <TD STYLE="text-align: right; width: 19%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44,347,451</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">Bad debt expense</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,086,449</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5,995,315</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">Charged to reserve</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13,519,167)</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(19,702,397)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">Foreign currency translation adjustment</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; border-bottom: black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1,255,592)</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; border-bottom: black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1,287,563)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">Balance, End of Year</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: black 2pt double; text-align: right">15,664,496</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: black 2pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29,352,806</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 24pt 0 12pt">Impairment of Intangible Assets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Our impairments for the year ended
December 31, 2016 were $4.0 million, compared to $0.1 million in 2015. As a pharmaceutical company, we have been focusing on the
development and maintenance of our intangible assets, mainly in the form of medical formulas. Because of recently implemented
government policies such as consistency evaluations, our management made certain assessments regarding the impairment of our intangible
assets as in 2016, and identified five formulas that would likely be unable to generate positive cash flow in the
foreseeable future and therefore recognized impairment loss on them accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Loss from Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Our operating loss for the year ended
December 31, 2016 was $8.2 million, compared to an operating loss of $14.3 million in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Net Interest Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Net interest expense for the year ended
December 31, 2016 was $0.7 million, compared to $1.0 million in 2015. The decrease is primarily due to overall decreased debt
levels due to repayment of the line of credit as discussed in Note 7 and the decrease in the interest incurred in conjunction
with the Construction loan facility as discussed in Note 9 to the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Income Tax Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Our income tax rate was 15% for
each of the years ended December 31, 2016 and 2015. Our income tax expense was $0.3 million and $0.06 million for the years
ended December 31, 2016 and 2015, respectively. The  expense arose as a result of certain deferred tax
liabilities recognized in prior years. We renewed our &quot;National High-Tech Enterprise&quot; status with the Chinese
government in the third quarter of 2013. With this designation, for the years ending December 31, 2014, 2015 and 2016, we
enjoy a preferential tax rate of 15%, which is notably lower than the statutory income tax rate of 25%. However, our recent
net loss results have put the Company in an unfavorable position for the potential renewal of &quot;National High-Tech
Enterprise&quot; status in 2017, and after evaluating the feasibility of such a renewal, the Company has decided not to renew
this status. As a result, our tax rate for 2017 and the foreseeable future will be 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Net Loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Net Loss for year ended December 31,
2016 was $9.2 million, compared to net loss of $15.4 million for the year ended December 31, 2015. The decrease in net loss was
mainly a result of the increase in inventory obsolescence and bad debt expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">For the year ended December 31, 2016,
loss per basic and diluted common share was $(0.21), compared to loss per basic and diluted share of $(0.35) for the year ended
December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The number of basic and diluted weighted-average
outstanding shares used to calculate loss per share was 43,579,557 for both 2016 and 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Liquidity and Capital Resources</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Our principal sources of liquidity
are cash generated from operations and short-term bank loans.&nbsp;Our cash and cash equivalents were $2.7 million,
representing 3.3% of our total assets as of December 31, 2016, as compared to $6.2 million, representing 6.4% of our total
assets as of December 31, 2015. All of the $2.7 million of cash and cash equivalents as of December 31, 2016, is considered
to be reinvested indefinitely in our Chinese subsidiary, Helpson, and are not expected to be available for payment of
dividends or for other payments to our parent company or to its shareholders. During 2016, we repaid in full the balance at
December 31, 2015 of approximately $4.6 million under our line of credit as discussed in Note 7 of the consolidated financial
statements. We entered into an eight-year construction loan facility on September 21, 2013. The total loan facility amount is
RMB80,000,000 (approximately $13 million), which had been fully utilized through May 7, 2014. We&rsquo;ve accumulatively
repaid the principle of RMB 11 million (approximately $1.6 million) of the construction loans per the payback schedule as of
December 31, 2016. The current portion of the construction loan facility is $1.4 million as of December 31, 2016. The cash
flow generated from operating activities was used to fund our daily operating expenses as well as repayment of our loan
facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Based on our current operating plan,
management believes that cash provided by operations will be sufficient to meet our working capital needs and our anticipated
capital expenditures, including expenditures for new formula acquisitions and the remaining new GMP upgrade related construction
and equipment in our existing facility for the next twelve months. However, if circumstances change and we do not follow our operating
plan as expected, we may be required to seek additional capital and/or to reduce certain discretionary spending, which could have
a material adverse effect on our ability to achieve our business objectives. Notwithstanding the foregoing, we may seek additional
financing as necessary for expansion purposes and when we believe market conditions are most advantageous, which may include debt
and/or equity financing.&nbsp;&nbsp;There can be no assurance that any additional financing will be available on acceptable terms,
if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Net cash provided by operating activities
was $2.9 million in the year ended December 31, 2016, compared to $3.4 million for 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of December 31, 2016, our accounts
receivable was $4.0 million, a decrease of $1.9 million from $5.2 million as of December 31, 2015. The decrease was mainly due
to $1.1 million of bad debt expenses recognized in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of December 31, 2016, total inventory
was $7.3 million, a decrease of $2.4 million from $9.7 million as of December 31, 2015. This decrease was mainly due to decreased
purchases of raw materials in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the year ended December 31,
2016, net cash used in investing activities was ($0.2) million, compared to ($1.9) million for the year ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Cash flow used in financing activities
was $6.0 million in the year ended December 31, 2016; there was no comparable activity during the year ended December 31, 2015.
The financing activities that occurred in 2016 were primarily related to the repayment of the line of credit facility as discussed
in Note 7 to the consolidated financial statements and scheduled payments of the construction loan facility described in the first
paragraph of this section entitled &ldquo;Liquidity and Capital Resources&rdquo; and in Note 9 to the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">According to relevant PRC laws, companies
registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax
net income, as determined under accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the
reserve account balances reach fifty percent (50%) of the companies&rsquo; registered capital prior to their remittance of funds
out of the PRC.&nbsp;&nbsp;Allocations to these reserves and funds can only be used for specific purposes and are not transferrable
to the parent company in the form of loans, advances or cash dividends.&nbsp;As of December 31, 2016 and 2015, the net assets of
Helpson were $55,062,000 and $68,240,000, respectively.&nbsp;&nbsp;Due to the restriction on dividend distribution to overseas
shareholders, the amount of Helpson&rsquo;s net assets that were designated for general and statutory capital reserves, and thus
could not be transferred to our parent company as cash dividends, were $8,145,000 and $8,145,000 (50% of registered capital) for
the fiscal years ended December 31, 2016 and 2015, respectively.&nbsp;Since the amount that Helpson must set aside for the statutory
surplus fund only accounts for 14.8% and 11.9%, respectively, of its total net assets, this reserve does not have a major impact
on our liquidity.&nbsp;&nbsp;There were no allocations to the statutory surplus reserve accounts during the year ended December
31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Chinese government also imposes
controls on the conversion of RMB into foreign currencies and the remittance of currencies out of China.&nbsp;&nbsp;Our businesses
and assets are primarily denominated in RMB.&nbsp;&nbsp;All foreign exchange transactions take place either through the People&rsquo;s
Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People&rsquo;s
Bank of China.&nbsp;Approval of foreign currency payments by the People&rsquo;s Bank of China or other regulatory institutions
requires the submission of a payment application form together with certain invoices and executed contracts.&nbsp;The currency
exchange control procedures imposed by the Chinese government authorities may restrict the ability of Helpson, our Chinese subsidiary,
to transfer its net assets to our parent company through loans, advances or cash dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of December 31, 2016, we did not
have any off-balance sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Commitments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of December 31, 2016, we were obligated
to pay laboratories and other service providers approximately $4.4 million over approximately the next four years upon completion
of various phases of contracts required to obtain CFDA production approval of our medical formulas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><I>Critical Accounting Policies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Management's discussion and analysis
of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared
in accordance with United States generally accepted accounting principles. Our financial statements reflect the selection and
application of accounting policies which require management to make significant estimates and judgments. The discussion of our
critical accounting policies contained in Note 1 to our consolidated financial statements, &ldquo;Organization and Significant
Accounting Policies&rdquo;, is incorporated herein by reference.&nbsp;</P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
are not required to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our consolidated balance
sheets, as of December 31, 2016 and 2015, and the related consolidated statements of operations and comprehensive income (loss),
stockholders&rsquo; equity and cash flows for each of the two years in the period ended December 31, 2016 and 2015, together with
the related notes and the report of our independent registered public accounting firms, are set forth on the &ldquo;F&rdquo; pages
of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH
ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">The Company disclosed its change of auditors under item
4.01 in a current report on Form 8-K filed with the SEC on December 2, 2016.<B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 9A. CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We maintain disclosure
controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information that
would be required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time period
specified in the SEC&rsquo;s rules and forms, and that such information is accumulated and communicated to our management, including
to our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required
disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As required by Rule 13a-15
under the Exchange Act, our management, including our Chief Executive Officer and interim Chief Financial Officer, evaluated the
effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2016. Based on that evaluation,
our Chief Executive Officer and interim Chief Financial Officer concluded that as of December 31, 2016, our disclosure controls
and procedures were not effective to satisfy the objectives for which they are intended due to the material weakness in our internal
control over financial reporting discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Management's Report on Internal Control
over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting
is defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company&rsquo;s
principal executive and principal financial officers, or persons performing similar functions, and effected by a company&rsquo;s
board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles
and includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of the assets of a company; (ii) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles
and that receipts and expenditures of a company are being made only in accordance with authorizations of management and directors
of a company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use
or disposition of a company&rsquo;s assets that could have a material effect on the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any system of internal
control, no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or
overridden and misstatements due to error or fraud may occur and not be detected in a timely manner. Also, because of changes in
conditions, internal control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide
only reasonable assurance with respect to financial statement preparation. In addition, the design of any system of controls is
based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because
of changes in conditions or deterioration in the degree of compliance with policies or procedures. Therefore, any current evaluation
of controls cannot and should not be projected to future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management assessed our
internal control over financial reporting as of the year ended December 31, 2016. In making this assessment, management used the
criteria set forth in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the report entitled
&quot;Internal Control-Integrated Framework.&quot; The 2013 COSO framework summarizes each of the components of a company&rsquo;s
internal control system, including (i) the control environment, (ii) risk assessment, (iii) control activities, (iv) information
and communication, and (v) monitoring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on management's assessment
using the COSO criteria, management has concluded that our internal control over financial reporting was not effective as of December
31, 2016, to allow our management, employees and consultants, in the normal course of performing their assigned functions, to prevent
or detect misstatements on a timely and reasonable basis and to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted
accounting principles (&ldquo;U.S. GAAP&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A material weakness is
a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement
of the annual or interim financial statements will not be prevented or detected. Our Chief Executive Officer and interim Chief
Financial Officer has determined there existed a material weakness in our internal control over financial reporting as of December
31, 2016, with respect to our lack of accounting financial reporting personnel knowledgeable in US GAAP. As of the date of this
report, we are undertaking steps to correct the aforementioned material weaknesses by obtaining education and training for our
personnel regarding the proper accounting under U.S. GAAP and reviewing the processes to correct the identified weaknesses. Notwithstanding
these material weaknesses, management has concluded that our consolidated financial statements included in this annual report are
fairly stated in all material respects in accordance with U.S. GAAP for each period presented herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Because we are a smaller
reporting company, this Annual Report on Form 10-K does not include an attestation report of our independent registered public
accounting firm regarding internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Changes in Internal Controls over Financial
Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no changes in
our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange
Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 9B. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS
AND CORPORATE GOVERNANCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Listed below are the names
and ages of all our directors and executive officers at March 27, 2017, along with their positions, offices and term:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 24%; border-bottom: black 1.5pt solid; text-align: justify"><B>Name</B></TD>
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid; text-align: justify"><B>Age</B></TD>
    <TD STYLE="width: 68%; border-bottom: black 1.5pt solid; text-align: justify"><B>Position</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">Zhilin Li</TD>
    <TD STYLE="text-align: justify">64</TD>
    <TD STYLE="text-align: justify">Chairman, President, Chief Executive Officer and interim Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">Heung Mei Tsui</TD>
    <TD STYLE="text-align: justify">60</TD>
    <TD STYLE="text-align: justify">Director</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">Gene Michael Bennett</TD>
    <TD STYLE="text-align: justify">69</TD>
    <TD STYLE="text-align: justify">Independent Director</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">Yingwen Zhang</TD>
    <TD STYLE="text-align: justify">72</TD>
    <TD STYLE="text-align: justify">Independent Director</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">Baowen Dong</TD>
    <TD STYLE="text-align: justify">76</TD>
    <TD STYLE="text-align: justify">Independent Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our independent
directors hold offices until our next annual meeting of the stockholders, at which a successor will be duly elected and qualified
or until his or her earlier resignation, removal from office, death or incapacity. Non-independent directors will hold office for
a term of three (3) years or when their respective successors shall have been elected and shall qualify, or upon their prior death,
resignation or removal. Directors may be re-elected for successive terms. Officers serve at the discretion of the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following sets forth
biographical information regarding the above directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Zhilin Li</I></B>
is the Chairman, President, Chief Executive Officer and interim Chief Financial Officer of our company. She has served as a director
since 2006 and as the President and Chief Executive Officer since 2005. She was a founder of Helpson, and served as Chairman and
Chief Executive Officer of Helpson from 1993 to 2005. Ms. Li was formerly the president of Haikou Bio-Engineering Institute as
well as the vice president of Sichuan Institute of Biology. She graduated from Sichuan University with a degree in biology. Her
role as one of the founders of our company and her extensive experience in bio-engineering make her well suited to serve as our
Chairman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Heung Mei Tsui</I>&nbsp;</B>has
served as a director since April 28, 2009. Previously, Ms. Tsui served as a member of our board from October 2005 to February 2008.
Ms. Tsui has been a self-employed businesswoman engaged in strategic investments and was previously engaged in the pharmaceutical
chemical raw material import/export business. Ms. Tsui graduated from Hunan Financial &amp; Economic College in 1982. Her experience
in the trading side of the business affords her unique insights into the pharmaceutical industry, and her presence on our board
of directors benefits the company greatly in the areas of strategic planning and execution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Gene Michael Bennett</I></B>
has served as our independent director since February 2008. From July 2016 through the present, Mr. Bennett has served as CEO for
Faroway Consulting in Shenzhen and CFO for 7 Senses Labs, both located in Shenzhen, Guangdong Province, China. Mr. Bennett also
served as advisor to Swiss Capital Asia, located in Hong Kong since 2013. From 2009 through 2013, Mr. Bennett served as the CEO
of the American General Business Association, located in Beijing, China. Mr. Bennett was a partner of Nexis Investment Consulting
Corporation based in Beijing from 2004-2009. He acted as a partner of ProCFO Company based in California which provided contract
chief financial officer service for firms during 2000-2004. During 1998-2000, he was a basic law, accounting and tax professor
at University of Hawaii, and an accounting, tax and audit professor at Chaminade University of Honolulu, Hawaii, USA. In addition,
he previously served as the chief financial officer and member of the board of directors of Argonaut Computers in Southern California.
Mr. Bennett worked as an accounting and audit professor at Chapman University and an accounting, tax, and audit professor at California
State University at Fullerton. He also acted as the chief financial officer and a board member of the National Automobile Club.
Mr. Bennett graduated from Michigan State University with an MBA in Finance and BA in Accounting. He obtained his CPA license from
the State of Colorado, which is currently inactive. Mr. Bennett&rsquo;s extensive background in accounting, financial management
and reporting, including SEC related reporting qualifies him to serve as an independent director of our company and the chairman
of our audit committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Yingwen Zhang</I></B>
has served as our independent director since February 2008. He also currently serves as the consultant of Shanghai Reseat Medical
Tech Co. Ltd., a medical device producer, and a director and a member of the compensation committee of Chongqing Wanli Battery
Holdings (Group) LLC (SHA:600847). He acted as Senior Consultant and Chairman of Safety Production Committee of Sinofert Holdings
Limited (HKG: 0297) of SINOCHEM Group from October 2005 to June 2009. Additionally, Mr. Zhang was appointed as the Commercial Counselor
of the China Embassy in Malaysia from March 2000 through October 2005. Prior to that, from 1988 to 2000, Mr. Zhang was appointed
as the Director-General to Sichuan Provincial Foreign Trade and Economic Cooperation Bureau (the Commercial Bureau of Sichuan Province,
China). In his early career he was a chemical engineer, and then became a senior manager for several chemical corporations in China.
From 1983 to 1988, Mr. Zhang served as the Chief Executive Officer of a large nature gas-chemical state owned enterprise (SOE)
in the PRC affiliated with the SINOPEC Group. Mr. Zhang graduated from the Chemical Engineering Department of Tianjin University
in 1967. Mr. Zhang&rsquo;s extensive knowledge in areas of government regulation and policies, his experience as director of a
China listed company, as well as his vast experience in senior management in SOE and the private sector, qualify him as an independent
director of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Baowen Dong</I></B>
has served as our independent director since February 2008. Mr. Dong participated on the expert team of the Sichuan University
from 2003 to 2008, doing teaching evaluation and assessment work in Engineering and Medical Science faculty. In the past few years,
Mr. Dong has focused on the research of China's Health Care Reform. Previously, he concentrated on biomedical and medical information
researches. Mr. Dong has had different roles in areas of teaching and research, including a dean and a professor, at Sichuan University
from 1974 to 2001. Additionally, Mr. Dong was engaged in the field of communication technology from 1966 to 1974. Mr. Dong graduated
from Xi&rsquo;an University of Science and Technology in 1966. His strong academic background in science and research brings value
to our company in respect of research and development and qualifies him to serve as a director of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are no family relationships
among our directors or executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Director or Officer Involvement in Certain
Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To our knowledge, our directors
and executive officers were not involved in any legal proceedings as described in Item 401(f) of Regulation S-K in the past ten
years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 16(a) of the Securities
Exchange Act of 1934, as amended, requires our directors, executive officers and persons who own more than 10% a registered class
of our equity securities (&ldquo;Reporting Persons&rdquo;), to file reports of ownership and changes in ownership on Forms 3, 4
and 5 with the SEC. The Reporting Persons are also required by SEC rules to furnish us with copies of Section 16(a) forms they
file. Based upon a review of the filings made on their behalf during the fiscal year ended December 31, 2016, as well as an examination
of the SEC&rsquo;s EDGAR system Form 3, 4, and 5 filings (including amendments to such forms) and our records, we believe that,
during the year ended December 31, 2016, the Reporting Persons met all applicable Section 16(a) filing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 8, 2008, we adopted
a code of business conduct and ethics for all directors and employees (including officers) within the meaning of the regulations
adopted by the SEC under Section 406 of the Sarbanes-Oxley Act of 2002. The code has been designed to deter wrongdoing and promote
(i) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and
professional relationships, (ii) full, fair, accurate, timely, and understandable disclosure in reports and documents that we file
with, or submit to, the SEC and in other public communications made by us, (iii) compliance with applicable governmental laws,
rules and regulations, (iv) the prompt internal reporting of violations of the code to an appropriate person or persons, and (v)
accountability for adherence to the code. The application of the code to the persons it applies to may only be waived by our Board
of Directors in accordance with SEC regulations and the Sarbanes-Oxley Act of 2002. A copy of the code is available on our website
at <U>www.chinapharmaholdings.com</U> or may be obtained by sending a written request to our corporate secretary at China Pharma
Holdings, Inc., Second Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 1, 2008, we
established an audit committee, which currently consists of our three independent directors: Gene Michael Bennett, Yingwen Zhang
and Baowen Dong. Mr. Bennett, the Chairman of the Audit Committee, is an &ldquo;audit committee financial expert&rdquo; as defined
in Item 401(d)(5) of Regulation S-K promulgated under the Securities Act. The audit committee carries out its responsibilities
in accordance with the terms of its Audit Committee Charter, a copy of which attached as Exhibit 99.1 to our Current Report on
Form 10-K filed on March 17, 2009, and available on our website at <U>www.chinapharmaholdings.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 11. EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Summary of Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our principal executive officer
and principal financial officer during the last two fiscal years in all capacities to our Company and our subsidiaries. No other
executive officer received compensation in excess of $100,000 during the fiscal year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="10">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SUMMARY COMPENSATION TABLE</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name and principal</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">position</P></TD>
    <TD STYLE="width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Year</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ended</P></TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Salary</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">($)</P></TD>
    <TD STYLE="width: 7%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bonus</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">($)</P></TD>
    <TD STYLE="width: 9%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Awards</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">($)</P></TD>
    <TD STYLE="width: 7%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Option</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Awards</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">($)</P></TD>
    <TD STYLE="width: 16%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Non-Equity</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Incentive Plan</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">($)</P></TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonqualified</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Earnings ($)</P></TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">($)</P></TD>
    <TD STYLE="width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">($)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Zhilin Li</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chairman, Chief</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Executive Officer,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President and interim Chief Financial</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Officer</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2016</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2015</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">225,600</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">225,600</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">-</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">-&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">-&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">-&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">-&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">16,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">16,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">241,600</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">241,600</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Zhilin Li</I></B>.
Hainan Helpson Medical &amp; Biotechnology Co., Ltd., our wholly-owned subsidiary and operating entity in the PRC (&ldquo;Helpson&rdquo;),
entered into an employment agreement with Ms. Zhilin Li, our Chairman of the Board and Chief Executive Officer, which will expire
on June 30, 2020. Upon the expiration of the original agreement, Helpson renewed the agreement with Ms. Li on the same terms as
the original agreement. Pursuant to the terms of the new employment agreement, Ms. Li agreed to continue to serve as Helpson&rsquo;s
Chief Executive Officer for a term of five years at an annual salary of RMB800,000. Helpson may adjust Ms. Li's compensation based
upon her production and operating achievement and her technical ability and working performance. Ms. Li&rsquo;s total annual cash
compensation for the fiscal year ended December 31, 2016, when aggregated with her compensation from our U.S. holding company level,
was $225,600.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Payments upon Termination or Change-in-Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>PRC Law.</I>Under the
applicable laws of the PRC, we must pay severance to all employees who are Chinese nationals and who are terminated with or without
cause, or whose employment agreement with us expires and we choose not to continue their employment. The severance benefit required
to be paid under the laws of the PRC equals the average monthly compensation paid to the terminated employee (including any bonuses
or other payments made in the 12 months prior to the employee&rsquo;s termination) multiplied by the number of years the employee
has been employed with us, plus an additional month&rsquo;s salary if 30 days&rsquo; prior notice of such termination has not been
given. However, if the average monthly compensation to be received by the terminated employee exceeds three times the average monthly
salary of the employee&rsquo;s local area, as determined and published by the local government, such average monthly compensation
shall be capped at three times the average monthly salary of the employee&rsquo;s local area. Except as described above, our executive
officer does not have any other agreement or arrangement under she may be entitled to severance payments upon termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Discussion of Summary Compensation and Grants
of Plan-based Awards Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of certain material
terms of our existing compensation plans and arrangements is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On November 12, 2010, our Board of Directors
adopted, and on December 22, 2010 our stockholders approved the 2010 Long-Term Incentive Plan (the &ldquo;2010 Incentive Plan&rdquo;),
which gave us the ability to grant stock options, restricted stock, stock appreciation rights and performance units to employees,
directors and consultants, or those who will become employees, directors and consultants of our company and/or our subsidiaries.
The 2010 Incentive Plan currently allows for equity awards of up to 4,000,000 shares of common stock. As of March 27, 2017, 175,000
shares of restricted stock outstanding, and no options were outstanding. &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth information concerning cash and non-cash compensation earned by or paid to our directors during the year ended December 31,
2016.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="8" STYLE="text-align: center; text-indent: 0.5in"><B>DIRECTOR COMPENSATION</B></TD></TR>
<TR>
    <TD STYLE="width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; vertical-align: middle">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Name</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Fees</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Earned</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">or</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Paid in</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Cash</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">($)</P></TD>
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Stock</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Awards</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">($)</P></TD>
    <TD STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Option</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Awards</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">($)</P></TD>
    <TD STYLE="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Non-Equity</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Incentive</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Plan</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Compensation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">($)</P></TD>
    <TD STYLE="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Non-Qualified</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Compensation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Earnings</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">($)</P></TD>
    <TD STYLE="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Compensation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">($)</P></TD>
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Total</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">($)</P></TD></TR>
<TR>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Heung Mei Tsui</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">16,000</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">16,000</TD></TR>
<TR>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Gene Michael Bennett</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">16,000</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">16,000</TD></TR>
<TR>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Yingwen Zhang</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">6,433</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">6,511</TD></TR>
<TR>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Baowen Dong</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">6,433</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">6,511</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our directors will also
be reimbursed for all of their out-of-pocket expenses in traveling to and attending meetings of our Board of Directors and committees
on which they serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ms. Zhilin Li, our Chairman,
President and Chief Executive Officer, was also compensated for serving on our board of directors as set forth in the Summary Compensation
Table appearing earlier in this Item 11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Engagement Letters</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 21, 2016, we
renewed the engagement letters with each of our three independent directors. Pursuant to the renewed engagement letters on the
same terms and conditions as the previous engagement for a term of one year, each of Mr. Zhang and Mr. Dong is entitled to receive
annual compensation of RMB40,000 (approximately $5,760), payable quarterly and Mr. Bennett is entitled to receive annual compensation
of $16,000, payable quarterly, and a warrant to purchase 5,000 shares of common stock at an exercise price of $0.20 per share.
As of the date of this report, no warrants have been issued to Mr. Bennett.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 9, 2015, we
also entered into a renewal engagement letter with Ms. Tsui, pursuant to which, Ms. Tsui is entitled to annual compensation of
$16,000 for serving as our director for a term of three years.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDERS MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth certain information as of March 27, 2017, with respect to the beneficial ownership of our common stock, the sole outstanding
class of our voting securities, by (i) any person or group owning more than 5% of each class of voting securities, (ii) each director,
(iii) each executive officer and (iv) all executive officers and directors as a group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 27, 2017,
an aggregate of 43,579,557 shares of our common stock were outstanding.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>Name and
        Address of Beneficial Owners(1)(2)</B></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>Amount</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>and Nature</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>of Beneficial</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>Ownership</B></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B>Percent</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B>of Class(3)</B></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.5in"><I>Directors and Executive Officers</I></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Zhilin Li</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">President, Chief
        Executive Officer,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Interim Chief
        Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">and Chairman
        of the Board</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">10,050,000</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">23.1%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Heung Mei Tsui</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">9,312,651</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">21.4%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Yingwen Zhang</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">0</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Gene Michael
        Bennett (4)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">0</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Baowen Dong</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Director</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">0</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.5in">All directors and executive officers as a group (5 persons)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: right; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: right; text-indent: -0.5in">19,362,651</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">44.5%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.5in"><I>Greater than 5% Stockholders</I></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Jian Yang</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">2,278,815</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.5in">5.2%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"></TD>
    <TD COLSPAN="7" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"></TD></TR>
<TR>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 26%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 18%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">__________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Represents less than 1%.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%">(1)</TD>
    <TD STYLE="width: 93%; text-align: justify">Pursuant to Rule 13d-3 under the Exchange Act, a person has beneficial ownership of any securities as to which such person, directly or indirectly, through any contract, arrangement, undertaking, relationship or otherwise has or shares voting power and/or investment power or as to which such person has the right to acquire such voting and/or investment power within 60 days.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%">(2)</TD>
    <TD STYLE="width: 93%; text-align: justify">Unless otherwise stated, each beneficial owner has sole power to vote and dispose of the shares and the address of such person is c/o China Pharma Holdings, Inc., 2nd Floor, No. 17 Jinpan Road, Haikou, Hainan Province, People&rsquo;s Republic of China 570216.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%">(3)</TD>
    <TD STYLE="width: 93%; text-align: justify">In determining the percentage of common stock owned by the beneficial owners, (a) the numerator is the number of shares of common stock beneficially owned by such owner, including shares the owner may acquire, within 60 days of March 27, 2017, upon the exercise of the options or warrants, if any, held by the owner; and (b) the denominator is the sum of (i) the total 43,579,557 shares of common stock outstanding as of March 27, 2016, and (ii) the number of shares underlying any options or warrants, which such owner has the right to acquire upon the exercise of such options or warrants within 60 days of March 27, 2017 (for those who have options or warrants).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%">(4)</TD>
    <TD STYLE="width: 93%; text-align: justify">Pursuant to the terms of his engagement letters, Mr. Bennett is entitled to receive warrants to purchase an aggregate of 40,000 shares of our common stock (5,000 shares in each of year between 2008 to 2016 fiscal years). As of the date of this report such warrants have not been issued.</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ms. Tsui, one of our directors,
has made various loans to the Company. The balance of such loans from Ms. Tsui remained $1,354,567 as of December 31, 2016 and
2015. The loans bear interest at a rate of 1% per annum and principal and interest were payable by December 31, 2017, pursuant
to a loans extension confirmation letter executed by the Company and Ms. Tsui. We recognized interest expense of $13,546 for the
years ended December 31, 2016 and 2015, respectively.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Independence of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The board of directors
has determined that Messrs. Gene Michael Bennett, Baowen Dong and Yingwen Zhang are &ldquo;independent directors&rdquo; as defined
in the listing standards of NYSE MKT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Audit Fees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate fees billed
by <FONT STYLE="background-color: white">B F Borgers CPA PC, </FONT>our current principal accountant, and ArshakDavtyan, Inc.,
our former principal accountant, for professional services rendered for the audit of our annual financial statements included
in our Annual Reports on Form 10-K, for the reviews of the financial statements included in our Quarterly Reports on Form 10-Q,
and for services in connection with statutory and regulatory filings or engagements were approximately $166,000 for the fiscal
year ended December 31, 2016, which included $75,000 for the re-auditing for the fiscal year ended December 31, 2015.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The aggregate fees billed by Arshak Davtyan,
Inc., our former principal accountant, for professional services rendered for the audit of our annual financial statements included
in our Annual Reports on Form 10-K, for the reviews of the financial statements included in our Quarterly Reports on Form 10-Q,
and for services in connection with statutory and regulatory filings or engagements were approximately $97,000 for the fiscal year
ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Audit-Related Fees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We did not incur any audit-related
fees during the fiscal years ended December 31, 2016 and 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Tax Fees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We did not engage our current
principal accountant or our former principal accountant to render tax services to us during the last two fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>All Other Fees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We did not engage our current
principal accountant or our former principal accountant to render services to us during the last two fiscal years, other than as
reported above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Pre-Approval Policies and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the
Sarbanes-Oxley Act of 2002, all audit and non-audit services performed by our auditors must be approved in advance by our
Audit Committee to assure that such services do not impair the auditors&rsquo; independence from us. In accordance with its
policies and procedures, the Audit Committee pre-approved the audit service performed by <FONT STYLE="background-color: white">B
F Borgers CPA PC</FONT>, for our consolidated financial statements as of and for the year ended December 31, 2016 and their
reaudit of our financial statements as of and for the year ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT
SCHEDULES&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) The following documents
are filed as part of this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following financial
statements of China Pharma Holdings, Inc. and Reports of Independent Registered Public Accounting Firms are presented in the &ldquo;F&rdquo;
pages of this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 100%; text-align: justify">Report of <FONT STYLE="background-color: white">B F Borgers CPA PC</FONT>, Independent Registered Public Accounting Firm</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">Consolidated Balance Sheets - as of December 31, 2016 and 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">Consolidated Statements of Operations and Comprehensive Loss - for the years ended December 31, 2016 and 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">Consolidated Statements of Shareholders&rsquo; Equity - for the years ended December 31, 2016 and 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">Consolidated Statements of Cash Flows - for the years ended December 31, 2016 and 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">Notes to Consolidated Financial Statements</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">See the Exhibit Index following
the signature page of this report, which Index is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="width: 50%; text-align: justify">Date: March 31, 2017</TD>
    <TD STYLE="width: 50%; text-align: justify">CHINA PHARMA HOLDINGS, INC.</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">By: /s/ Zhilin Li </TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: Zhilin Li</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: Chief Executive Officer</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">(principal executive officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 22%; text-align: justify">Signature</TD>
    <TD STYLE="width: 63%; text-align: justify">Title</TD>
    <TD STYLE="width: 15%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/<U>s/ Zhilin Li</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zhilin Li</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chairman of the Board, President, Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(principal executive officer) and interim Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(principal financial officer and principal accounting officer)</P></TD>
    <TD>March 31, 2017</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/<U>s/ Heung Mei Tsui</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Heung Mei Tsui</P></TD>
    <TD STYLE="text-align: justify">Director</TD>
    <TD STYLE="text-align: justify">March 31, 2017</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/<U>s/ Gene Michael Bennett</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Gene Michael Bennett</P></TD>
    <TD STYLE="text-align: justify">Director</TD>
    <TD STYLE="text-align: justify">March 31, 2017</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/<U>s/ Yingwen Zhang</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yingwen Zhang</P></TD>
    <TD STYLE="text-align: justify">Director</TD>
    <TD STYLE="text-align: justify">March 31, 2017</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/<U>s/ Baowen Dong</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Baowen Dong</P></TD>
    <TD STYLE="text-align: justify">Director</TD>
    <TD STYLE="text-align: justify">March 31, 2017</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit Index to Annual Report on Form 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Fiscal Year Ended December 31, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Exhibit </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>No.</B></P></TD>
    <TD COLSPAN="13">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Description</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">3.1</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on December 31, 2012).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">3.2</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on December 31, 2012).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">10.1</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">Engagement Letter dated December 9, 2015 by and between the Company and Ms. Heung Mei Tsui for Ms. Tsui serving as a director of the Company (incorporated by reference to Exhibit 10.1 to our Annual Report on Form 10-K filed on March 30, 2016).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">10.2</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">Engagement Letter dated December 9, 2015 by and between the Company and Ms. Zhilin Li for Ms. Li serving as a director of the Company&nbsp;&nbsp;(incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 30, 2016)..</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">10.3</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">Form of Independent Director Engagement Letter (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 30, 2015).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">10.4</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">Employment Agreement dated July 1, 2015 between Hainan Helpson Medical &amp; Biotechnology Co., Ltd. and Zhilin Li (incorporated by reference to Exhibit 10.1 to our Annual Report on Form 10-K filed on March 30, 2016).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">10.5*</TD>
    <TD COLSPAN="13">Loans Extension Confirmation Letter between the Company and Heung Mei Tsui confirming the extension of the loans. </TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">10.6</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">2010 Long-Term Incentive Plan of the Company (incorporated by reference to the Definitive Proxy Statement on Schedule 14A filed on November 12, 2010).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">10.7</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">Form of Restricted Stock Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.8</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD COLSPAN="13" STYLE="text-align: justify">Form of Non-Qualified Stock Option Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">14.1</TD>
    <TD COLSPAN="13" STYLE="text-align: justify">Code of Business Conduct and Ethics (incorporated by reference to the Registration Statement on Form S-1 filed on July 11, 2008).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">21.1</TD>
    <TD COLSPAN="13">Subsidiaries of the Company (incorporated by reference to our Annual Report on Form 10-K filed on March 3, 2011).</TD></TR>
<TR>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD>
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: justify">23.1*</TD>
    <TD STYLE="width: 93%; text-align: justify">Consent of <FONT STYLE="background-color: white">B F Borgers CPA PC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: justify">31.1*</TD>
    <TD STYLE="width: 92%; text-align: justify">Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">31.2*</TD>
    <TD STYLE="text-align: justify">Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">32.1*</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: justify">101*</TD>
    <TD STYLE="width: 92%; text-align: justify">Interactive data files pursuant to Rule 405 of Regulation S-T</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">*</FONT></TD><TD>Exhibits filed herewith.<BR CLEAR="ALL">
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Report of B F Borgers, CPA PC Independent Registered Public Accounting Firm</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Consolidated Balance Sheets as of December 31, 2016 and 2015</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.5in; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2016 and 2015</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.5in; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Consolidated Statements of Stockholders&rsquo; Equity for the Years Ended December 31, 2016 and 2015</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.5in; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2016 and 2015</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.5in; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Notes to Consolidated Financial Statements</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
</TABLE>
<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>To the Board of Directors and Stockholders of China Pharma Holdings,
Inc.:</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of China Pharma Holdings, Inc. (&ldquo;the Company&rdquo;) as of December 31, 2016 and 2015, and the related statements
of operations and comprehensive loss, stockholders&rsquo; equity and cash flows for the years then ended. These financial statements
are the responsibility of the Company's management.&nbsp; Our responsibility is to express an opinion on these financial statements
based on our audit.&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audit in accordance with standards
of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement.&nbsp; An audit includes examining,
on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation.&nbsp; We
believe that our audit provides a reasonable basis for our opinion.&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In our opinion, the consolidated financial statements
referred to above present fairly, in all material respects, the financial position of China Pharma Holdings, Inc. and subsidiaries,
as of December 31, 2016 and 2015, and the results of its operations and its cash flows for the years then ended, in conformity
with generally accepted accounting principles in the United States of America.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting.&nbsp; Our audits included consideration of internal
control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for
the purpose of expressing an opinion on the Company's internal control over financial reporting.&nbsp; Accordingly, we express
no such opinion.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">/s/ B F Borgers CPA PC</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0pt 0 12pt"><B>B F Borgers CPA PC</B><BR>
Lakewood, CO<BR>
March 31, 2017&nbsp;</P>


<!-- Field: Page; Sequence: 73; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: left; color: Red; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CHINA PHARMA HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CONSOLIDATED BALANCE SHEETS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: middle">December 31,</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: middle">December 31,</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left; padding-left: 12px">Cash and cash equivalents</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,665,802</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6,248,760</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,088,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Trade accounts receivable, less allowance for doubtful</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">accounts of $15,664,496 and $29,352,806, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,999,809</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,174,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Other receivables, less allowance for doubtful</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">accounts of $71,548 and $74,400, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">290,739</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Advances to suppliers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,003,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,533,354</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,310,939</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,662,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Prepaid expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">226,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">339,140</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,519,951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,248,844</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Advances for purchases of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,498,059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,030,649</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,967,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,393,257</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Intangible assets, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">534,682</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">841,075</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,520,140</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">96,513,825</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Trade accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,060,374</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,439,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139,830</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143,409</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,502,694</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,095,449</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Advances from customers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">811,232</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">595,681</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Other payables - related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,354,567</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,354,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Current portion of construction loan facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,440,154</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,540,666</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Bankers' acceptance notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,088,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Short-term notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,621,998</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,397,730</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,791,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Non-current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Construction loan facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,640,927</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,784,661</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Deferred tax liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">572,349</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">296,890</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,611,006</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,872,676</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders' Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Preferred stock, $0.001 par value; 5,000,000 shares authorized;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">no shares issued or outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Common stock, $0.001 par value; 95,000,000 shares authorized;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">43,579,557 shares and 43,579,557 shares outstanding, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,590,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,590,204</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Retained earnings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,757,374</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,939,998</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Accumulated other comprehensive income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,517,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,067,367</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Stockholders' Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,909,134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72,641,149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,520,140</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">96,513,825</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: left; color: Red; text-indent: 0.5in"></P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CHINA PHARMA HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CONSOLIDATED STATEMENTS OF OPERATIONS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">AND COMPREHENSIVE INCOME (LOSS)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">For the Year</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ended December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">Revenue</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">15,570,514</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">20,351,630</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cost of revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,352,004</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,778,243</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Inventory obsolescence</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,108,826</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,218,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,464,561</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Selling expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,036,590</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,294,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,265,851</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,896,559</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">365,969</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">961,897</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Bad debt expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,086,449</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,147,293</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Impairment loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,962,141</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">104,544</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,717,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,404,932</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Subsidy income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">343,023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,640,531</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,155,467</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14,299,840</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">119,925</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Interest expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(849,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,165,164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net other expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(718,982</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,045,239</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,874,449</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,345,079</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income tax&nbsp;expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(308,175</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(60,439</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,182,624</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,405,518</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other comprehensive income - foreign currency</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">translation adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,549,391</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,693,453</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,732,015</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(20,098,971</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Basic and diluted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.35</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Weighted average shares outstanding</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,579,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,579,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>




<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="25" STYLE="font-weight: bold; text-align: center">CHINA PHARMA HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="25" STYLE="font-weight: bold; text-align: center">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: right">Accumulated</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Other</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Total</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Paid-in</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Retained</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: right; padding-bottom: 1pt">Comprehensive</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: right; padding-bottom: 1pt">Stockholders'</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Earnings</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; font-weight: bold">Balance, December 31, 2014</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">43,579,557</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">43,580</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">23,590,204</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">49,345,516</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">19,760,820</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">92,740,120</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss for the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,405,518</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,405,518</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,693,453</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,693,453</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance, December 31, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,579,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,590,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,939,998</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,067,367</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,641,149</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss for the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,182,624</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,182,624</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,549,391</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,549,391</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Balance, December 31, 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,579,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,580</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,590,204</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,757,374</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,517,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,909,134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CHINA PHARMA HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CONSOLIDATED STATEMENTS OF CASH FLOWS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">For the Year</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ended December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Operating Activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left; padding-left: 12px">Net loss</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(9,182,624</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(15,405,518</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,078,074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,598,527</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Bad debt expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,086,449</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,147,293</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Deferred income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,439</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Provision for obsolete inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,941,007</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Impairment of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,962,141</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,544</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Changes in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Trade accounts and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,097,556</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,511,888</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Advances to suppliers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">380,779</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">843,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,734,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,157,861</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Trade accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">815,198</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">216,304</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Accrued taxes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,107</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,802</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Other payables and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377,663</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">548,455</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Advances from customers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,430,595</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 24px">Prepaid expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">94,762</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45,190</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided by Operating Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,895,708</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,350,060</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Advances for purchases of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,634,097</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Bankers acceptances redeemed for cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">423,693</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(193,404</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(685,302</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used in Investing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(193,404</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,895,706</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Payments of construction term loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,505,346</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Payments of short term notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,516,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash; </TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used in Financing Activity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,021,385</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Effect of Exchange Rate Changes on Cash</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(263,877</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(501,384</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net (Decrease) Increase in Cash and Cash Equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,582,958</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">952,970</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents at Beginning of Period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,248,760</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,295,790</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents at End of Period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,665,802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,248,760</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental Cash Flow Information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Cash paid for interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">836,011</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,151,613</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental Noncash Investing and Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts payable for purchases of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">171,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of banker's acceptances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,088,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts receivable collected with banker's acceptances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">935,265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,422,137</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Inventory purchased with banker's acceptances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">935,265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,059,028</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Advances for purchases of intangibles paid with banker's acceptances</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">391,826</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">The accompanying notes are an integral part of these consolidated
financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2016
and 2015</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 &ndash; ORGANIZATION AND SIGNIFICANT ACCOUNTING
POLICIES</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Organization and Nature of Operations
&ndash; </I></B>China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin
Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under
the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as
the Company.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">On
December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation
from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp;&nbsp;The
reincorporation merger was approved by stockholders holding the majority of the Company&rsquo;s outstanding shares of common stock
on December 21, 2012.</FONT></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Foreign Investment Industrial Catalogue<I>&nbsp;</I>(the
&ldquo;Catalogue&rdquo;) jointly issued by China&rsquo;s Ministry of Commerce and the National Development and Reform Commission
(the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different
categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment.
For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for
foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment
enterprise (the &ldquo;FIE&rdquo;) shall not have the whole or majority of its equity interests owned by a foreign owner if the
FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case
for the Company&rsquo;s business.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Helpson manufactures and markets generic
and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout
the PRC. The Company believes Helpson&rsquo;s business is not subject to any ownership restrictions prescribed under the Catalogue.
Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&rsquo;s
three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson
received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its
business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has acquired and continues
to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Consolidation and Basis of Presentation
</I></B>&ndash; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements
include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and
transactions have been eliminated in the consolidation.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Helpson&rsquo;s functional currency is
the Chinese Renminbi. Helpson&rsquo;s revenue and expenses are translated into United States dollars at the average exchange rate
for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses
from translating Helpson&rsquo;s financial statements are included in accumulated other comprehensive income, which is a component
of stockholders&rsquo; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency
of the entity that is party to the transaction are included in the results of operations.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Accounting Estimates </I>- </B>The
methodology used to prepare for the Company&rsquo;s financial statements is in conformity with the accounting principles generally
accepted in the United States of America, which requires the management of the Company (&ldquo;Management&rdquo;) to make estimates
and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities
at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore,
actual results could differ from those estimates.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cash and Cash Equivalents </I></B>&ndash;
Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term
banker&rsquo;s acceptances purchased with maturities of three months or less.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Restricted
Cash</I>&nbsp;</B>&ndash;<B>&nbsp;</B>Restricted cash includes cash that has been deposited with a bank to satisfy obligations
outstanding under banker's acceptance notes issued by the Company as discussed in Note 8.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Trade Accounts Receivable and Allowance
for Doubtful Accounts &ndash; </I></B>Trade accounts receivables are carried at the original invoiced amounts less an allowance
for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer
accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's
credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting
in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts
receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $1,086,449 and $10,147,293
for the years ended December 31, 2016 and 2015, respectively.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2016
and 2015</B></P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable that have been
fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made.
The Company charged off uncollectable trade accounts receivable balances in the amount of $13.5 million and $19.7 million against
the allowance for the years ended December 31, 2016 and 2015, respectively. It is common practice in the PRC for receivables to
extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating
the allowance for doubtful accounts.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Advances to Suppliers and Advances
from Customers</I></B> &ndash; Common practice in the PRC is to make advances to suppliers for materials and to receive advances
from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received.
Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews
a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers
were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize
bad debt expense in the period they are considered unlikely to be collected. The Company recognized bad debt expense of approximately
$0 and $4.1 million for the years ended December 31, 2016 and 2015, respectively.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Inventories</I></B> &ndash; Inventories
consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined
using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an
allocated portion of the Company&rsquo;s production overhead. The Company writes down excess and obsolete inventory to its estimated
net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process,
if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business,
less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written down
to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs
are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this
lower cost basis until sold or scrapped.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Valuation of Long-Lived Assets</I></B>
&ndash; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances
indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash
flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections
indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value
over the projected discounted cash flows estimated to be generated by the asset. For the year ended December 31, 2016 and 2015
the Company evaluated its long-lived assets and determined that impairment adjustments of $3,962,141 related to advances for intangible
assets as discussed in Note 5 and $104,544 related to certain intangible assets as discussed in Note 4 were necessary.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Property and Equipment</I></B>
&ndash; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements
are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation
relating to office equipment was included in general and administrative expenses, while all other depreciation was included in
cost of revenue.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B><I>Revenue Recognition</I></B>
&ndash; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery
of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery
does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer
acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria
specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable
until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be
reasonably assured. Management had determined that revenue deferred from 2014 was not completely collected in 2016. Thus, according
to the Company&rsquo;s trade receivable provision policy, such deferred revenue was reclassified to allowance for doubtful accounts
as of December 31, 2015.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cost of Revenues</I></B> &ndash;
Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of
products.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development</I></B>
&ndash; Research and development expenditures are recorded as expenses in the period in which they occur.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Retirement Benefit Plans</I></B>
&ndash; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans
organized by the provincial governments. The benefit plans of the government assume the retirement benefit obligations of all existing
and future retired employees of the Company. The Company contributed $261,063 and $270,488 to retirement benefit plans for the
years ended December 31, 2016 and 2015, respectively. Contributions to these plans are charged to expense as incurred.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0.3in 0 0; text-align: justify"><B><I>Advertising Costs</I></B>
&ndash; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December
31, 2016 and 2015.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Basic and Diluted Loss per Common
Share </I>- </B>Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding
during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no potential dilutive common
shares outstanding during the years ended December 31, 2016 and 2015, respectively.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Credit Risk</I></B> &ndash; The
carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation
to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit
evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances
in the aggregate have not exceeded Management's estimates.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2016
and 2015</B></P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has its cash in bank deposits
primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy
of protecting depositors&rsquo; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007,
which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws
are enacted for banks in the PRC, the Company&rsquo;s deposits may be at a higher risk of loss.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Interest Rate Risk</I></B> &ndash;
The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing
debts and viability of securing future debt instruments within the PRC.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Reclassification</I></B> &ndash;Certain
prior year balance sheet amounts have been reclassified to conform to the current year presentation. These amounts had no effect
on the reported results of operations.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU 2014-09,&nbsp;<I>&quot;Revenue
from Contracts with Customers&quot;</I>&nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a
company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services.
&nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard
will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted,
but no earlier than 2017 for calendar year-end entities.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The standard allows for two transition
methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying
the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating
the impact that this guidance will have on our financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2015, the FASB issued Accounting
Standards Update 2015-17,&nbsp;&ldquo;<I>Balance Sheet Classification of Deferred Taxes</I>,&rdquo; which is intended to simplify
the balance sheet presentation of deferred income taxes. Current accounting principles require an entity to separate deferred income
tax liabilities and assets into current and noncurrent amounts in its balance sheet. The amendments require that deferred tax liabilities
and assets be classified as noncurrent in its balance sheet. The amendments are effective for fiscal years, and interim periods
within those fiscal years, beginning after December 15, 2016. Companies may apply the new provisions either retrospectively or
on a prospective basis, and early adoption is permitted. We early adopted the amendments effective December 31, 2015 on a retrospective
basis. There was no effect on our Consolidated Balance Sheet as of December 31, 2016 or 2015.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, the FASB issued Accounting
Standards Update 2016-01,&nbsp;&ldquo;<I>Recognition and Measurement of Financial Assets and Financial Liabilities</I>.&rdquo;
The amendments require equity investments (except those accounted for under the equity method of accounting or those that result
in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate
presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the
amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial
instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December
15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value
of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at
fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on our financial
statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In February
2016, the FASB issued ASU No. 2016-02,&nbsp;<I>Leases</I>, a new standard on accounting for leases. The ASU introduces a lessee
model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor
model with those in the current accounting guidance as well as the FASB's new revenue recognition standard. However, the ASU eliminates
the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional
qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the
amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods
beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach.
Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated
financial statements and related disclosures.</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In March 2016,
the FASB issued ASU No. 2016-09,&nbsp;<I>Improvements to Employee Share-Based Payment Accounting</I>. The standard provides a new
requirement to record all of the tax effects related to share-based payments at settlement (or expiration) through the income statement.
This pronouncement is effective for annual reporting periods beginning after December 15, 2016. The Company has completed an evaluation
of the pronouncement and determined that its impact upon adoption will not be material to the Company's consolidated financial
statements and related disclosures.</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify">In June
2016, the FASB issued Accounting Standards Update 2016-13,&nbsp;<I>Financial Instruments &ndash; Credit Losses (Topic
326)</I>, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new
guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments.
It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting
model for purchased financial assets with credit deterioration since their origination.&nbsp;The pronouncement will be
effective for Public business entities that are SEC filers in fiscal years beginning after&nbsp;December 15, 2019, including
interim periods within those fiscal years. </P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify"></P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2016
and 2015</B></P>


<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify">Early application of the guidance will be permitted
for all entities for fiscal years beginning after&nbsp;December 15, 2018, including interim periods within those fiscal years.
The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements
and related disclosures.</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In August 2016,
the FASB issued ASU No. 2016-15,&nbsp;<I>Classification of Certain Cash Receipts and Cash Payments</I>. The standard addresses
the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement
is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using
a retrospective approach.&nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated
financial statements and related disclosures, but does not expect the impact to be material.</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November
2016, the FASB issued ASU 2016-18, <I>Statement of Cash Flows (Topic 230): Restricted Cash (&ldquo;ASU 2016-18&rdquo;)</I>. The
ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents
on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance
sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item
on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to
be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact
that the adoption of ASU 2016-18 may have on its consolidated financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Other
accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect
on the Company&rsquo;s financial position, result of operations or cash flows.</FONT></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 &ndash; INVENTORY</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">Inventory consisted of the following:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: middle">2016</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: middle">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 62%; text-align: left">Raw materials</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">11,562,388</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">14,699,736</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in process</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">360,550</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,530,641</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,380,109</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,453,579</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,079,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Obsolescence reserve</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,142,640</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,417,095</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 12px">Total Inventory</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,310,939</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,662,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 3 - PROPERTY AND EQUIPMENT</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">Property and equipment consisted of the following:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: middle">2016</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: middle">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 62%; text-align: left">Permit of land use</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">405,645</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">433,956</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Building</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,419,700</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,557,234</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plant, machinery and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,151,029</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,326,953</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Motor vehicle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">309,777</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">307,747</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Office equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">182,718</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">190,279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 12px">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,468,869</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,816,169</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,501,421</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,422,912</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Property and Equipment, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,967,448</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29,393,257</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2016
and 2015, depreciation expense was $2,815,167 and $3,280,618, respectively.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">Depreciation is computed on a straight-line basis over the
estimated useful lives of the assets as follows:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2016
and 2015</B></P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: center; width: 71%">Asset</TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: center; width: 27%">&nbsp;Life - years&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Permit of land use</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">40 - 70</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Building</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">20 - 49</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Plant, machinery and equipment</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">5 - 10</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Motor vehicle</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">5 - 10</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Office equipment</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">3-5</TD></TR>
</TABLE>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 4 - INTANGIBLE ASSETS</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets represent the cost
of medical formulas approved for production by the CFDA. The Company did not obtain CFDA production approval for any medical formula
during the year ended December 31, 2016 and 2015 and no costs were reclassified from advances to intangible assets in 2016 and
2015, respectively.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Approved medical formulas are amortized
from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen
years.&nbsp;&nbsp;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could
occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization
expense relating to intangible assets was $262,908 and $317,908 for the years ended December 31, 2016 and 2015, respectively, and
was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of
their amortization period.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates each approved medical
formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial
statement. The Company&rsquo;s evaluation is based on an estimated discounted net cash flow model, considering currently available
market data for the related drug and the Company&rsquo;s estimated market share. If the carrying value of the medical formula exceeds
the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value
of the medical formula, which is determined by the estimated undiscounted future net cash flows. An impairment loss of $104,544
was recognized during the year ended December 31, 2015. No impairment loss was recognized during the year ended December 31, 2016.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets consisted solely of
CFDA approved medical formulas as follows:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">Gross carrying amount</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">4,861,766</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">5,201,079</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,327,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,360,004</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net carrying amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">534,682</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">841,075</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">The estimated aggregate annual amortization expense for each
of the next five years and thereafter is as follows:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 39%">Year</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 6%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 55%">&nbsp;Amount&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">2017</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;160,947</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">2018</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;109,872</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">2019</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;57,290</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">2020</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35,412</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">2021</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35,412</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">Thereafter</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;135,749</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right">Total</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="border-top: Black 0.5pt solid; border-bottom: Black 1pt solid; text-align: right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;534,682</TD></TR>
</TABLE>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"><B></B></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 5 &ndash; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to expand the number of medicines
the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase
of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts,
the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is
completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process
for the year end December 31, 2013. These patents have not expired.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2016
and 2015</B></P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to entering into contracts with
the Company, laboratories typically are required to complete all&nbsp;research and development to determine the content of the
medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made
by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys
the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the
production approval from the CFDA.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A typical CFDA approval process for the
production of a generic medical product involves a number of steps that generally require three to five years to complete. If the
medical formula is purchased at the point when the generic medical product receives the CFDA&rsquo;s approval for a clinical study,
which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to
complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed
with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application
and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company
can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to
be received in approximately two to five years from the date&nbsp;the Company signs the medical formula contracts.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the contracts, the
laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management
monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately
under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if
the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full
amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to
another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved
medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for
purchases of intangible assets.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2016, the Company
was obligated to pay laboratories and others approximately $4,400,000 upon the completion of various phases of contracts to obtain
CFDA production approval of medical formulas.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2016, with CFDA's tightened scrutiny
procedure in connection with its review of production applications and based on the Company's monitoring and assessment process,
the Company determined five advanced payments to five independent laboratories were impaired. As a result, the Company recognized
an impairment loss for the advances made to these laboratories in the amount of $3,962,141.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 6 &ndash; RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A member of the Company&rsquo;s board
of directors had previously advanced the Company an aggregate amount of $1,354,567 as of December 31, 2016 and 2015 which are recorded
as other payables &ndash; related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate
of 1.0% per year.&nbsp;&nbsp;Total interest expense of $13,546 was recognized for each of the years ended December 31, 2016 and
2015.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 7 &ndash; NOTES PAYABLE</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2014, the Company entered
into a line of credit with a bank in the amount of RMB30,000,000 (approximately $4.5 million). Advances on the line of credit were
due one year from the date of the advance and were collateralized by certain land use rights, buildings and accounts receivable
and bear interest at an annual rate of 6.16% (based upon 110% of the PRC government's short term rate of 5.6% in November 2014).
In addition, the Company's Chief Executive Officer and Chair of the board of directors personally guaranteed the line of credit.
In November, 2015 the Company renewed its line of credit in the amount of RMB30,000,000 (approximately $4.5 million) with the same
bank. The line of credit was payable in two equal installments of RMB15,000,000 (approximately $2.25 million) payable on September
16, 2016 and October 19, 2016, respectively. The Company made the respective payments due for RMB15,000,000 according to the terms
of the agreement during 2016.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The outstanding balance due under the
revolving line of credit was RMB0 and RMB30,000,000 as of December 31, 2016 and December 31, 2015, respectively ($0 and $4,621,998
as of December 31, 2016 and 2015, respectively). The Company has no additional amounts available to it under this line of credit.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fair Value of Notes Payable</I></B>
&ndash; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying
amounts of notes payable outstanding as of December 31, 2015 approximated its fair value because of the immediate or short-term
maturity of this financial instrument and because the underlying instrument bears interest rates that approximated current market
rates.</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NOTE 8 &ndash;
BANKER'S ACCEPTANCE NOTES PAYABLE</B></P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In April 2016,
the Company entered into a Banker's Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company
can issue banker's acceptance notes (the &quot;Banker's Notes&quot;) to any third party as payment of amounts owing to that third
party. The Company is required to deposit with the bank an amount equal to the amounts represented by the Banker's Notes issued
to the third parties. The amount of these deposited balances is shown as &quot;Restricted cash&quot; on the accompanying balance
sheets as of December 31, 2016. The maximum amount that the Company can issue under this agreement is limited to the lesser of
RMB30,000,000 (approximately $4.5 million) or the amount of cash available to deposit against the Banker's Notes. In addition,
the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank. At December 31 2016 and 2015, the Company
had outstanding Banker's Acceptance Notes in the amount of $1,088,879 and $0, respectively.</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2016
and 2015</B></P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 9 &ndash; CONSTRUCTION LOAN FACILITY</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company obtained a construction loan
facility in the aggregate amount of RMB80,000,000 (approximately $13 million) from a construction loan facility dated June 21,
2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The total loan
facility is from the same bank that provided the line of credit as discussed in Note 7.&nbsp;&nbsp;The proceeds of the loan were
used for and are collateralized by the construction of the Company&rsquo;s new production facility and the included production
line equipment and machinery. During 2015, the loan bore weighted interest at 5.73%, based upon 110% of the PRC government&rsquo;s
eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for
the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest
rate was adjusted to 5.94% and on July 10, 2016 the interest rate was further adjusted to 5.39%. &nbsp;The loan requires interest
only payments for the first two years. Beginning July 11, 2015, the balance of the principal will be due in at least two (2) annual
installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment
being due July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described
above for 2015. In January 2016, the Company made a principal payment in the amount of approximately $0.3 million (RMB2,000,000)
and on July 13, 2016 the Company made a payment in the amount of approximately $1.2 million (RMB8,000,000). As of December 31,
2016, the Company had no additional amounts available to it under this facility.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Principal payments required for the next
five years as of December 31, 2016 are as follows:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 69%">Year</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 3%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 28%">Amount</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">2017</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,440,154</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">2018</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">2019</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">2020</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 0.5pt solid; border-bottom: Black 1pt solid; text-align: right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10,081,082</TD></TR>
</TABLE>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fair Value of Construction Loan
Facility</I></B> &ndash; Based on the borrowing rates currently available to the Company for bank loans with similar terms and
maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2016 and 2015 approximated its
fair value because the underlying instrument bears an interest rate that approximated current market rates.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><B>NOTE 10 &ndash; SUBSIDY INCOME</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the years
ended December 31, 2016 and 2015, the Company received cash of $0.34 million and $1.64 million related to a subsidy from the government
for the technological innovation it has achieved and the industrial upgrading related to its new GMP certified facility.&nbsp;This
has been recorded as &ldquo;Subsidy income&rdquo; in the accompanying Statement of Operations for the years ended December 31,
2016 and 2015, respectively.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 11 - INCOME TAXES</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred income tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in
income in the period that includes the enactment date.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Undistributed earnings of Helpson, the
Company&rsquo;s foreign subsidiary, since its acquisition, amounted to approximately $34.2 million as of December 31, 2016. Those
earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and,
accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form
of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign
tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability
is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits
may be available to reduce a portion of the U.S. tax liability.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Liabilities are established for uncertain
tax positions expected to be taken in income tax return when such positions are judged to meet the &ldquo;more-likely-than-not&rdquo;
threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are
included as a component of other expenses. Through December 31, 2016, the Company has not identified any uncertain tax positions
that it has taken. U.S. income tax returns for the years ended December 31, 2013 through December 31, 2016 and the Chinese income
tax return for the year ended December 31, 2016 are open for possible examination.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 16, 2007, the National People&rsquo;s
Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the
Implementation Regulations for the EIT Law which took effect on January&nbsp;1, 2008. The EIT Law and Implementation Regulations
Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify
under certain limited exceptions.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2016
and 2015</B></P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is located in a special region,
which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax
rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1,
2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status
in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for
2014 to 2016.&nbsp;The recent&nbsp;net losses have put the Company in an unfavorable position for the potential renewal of&nbsp;&quot;National
High-Tech Enterprise&quot; status in 2017. After evaluating the feasibility of the renewal, the Company has decided not to renew
this status.&nbsp;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax
rates:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 21%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 31%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 7%">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="font-weight: bold; border-bottom: black 0.5pt solid; text-align: center; width: 41%">Enterprise Income Tax Rate</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Year</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2015</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">15%</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2016</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15%</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25%</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25%</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Thereafter</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25%</TD></TR>
</TABLE>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The provision for income taxes consisted
of the following:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD></TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right"></TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; padding-bottom: 1pt">Deferred</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">308,175</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">60,439</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total income tax expense </TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">308,175</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">60,439</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"><B></B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0.3in 0 0">Following is a reconciliation of income taxes calculated
at the federal statutory rates to the provision for income taxes:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0.3in 0 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0.3in 0 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">(Benefit) tax at statutory rate of 25%</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(2,218,612</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(3,832,536</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of tax holiday</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">837,089</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,478,831</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of change in tax rate from 15% to 25%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,094,456</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other, primarily the difference in U.S. tax rates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,136</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,776,251</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,410,008</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">308,175</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">60,439</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0.3in 0 0"></P>

<P STYLE="font: 9pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The effect of the tax holiday amounted
to a change in the tax expense of $837,089 and $1,478,831 for the years ended December 31, 2016 and 2015, which was equivalent
to basic and diluted earnings per share of ($0.02) and ($0.03) per share for the years ended December 31, 2016 and 2015, respectively.
The temporary differences which give rise to the deferred income tax assets and liability are as follows:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31,
2016 and 2015</B>&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Deferred income tax assets:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">Allowance for doubtful trade receivables</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,916,124</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">4,402,921</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Allowance for doubtful other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Inventory obsolescence reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,535,660</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,262,564</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expenses not deductible in current year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,008,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">647,236</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Advances for intangible assets impairment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">793,624</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">PRC net operating loss carry forward</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,660,410</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,114,478</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">U.S. net operating loss carry forward</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,520,675</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,360,213</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total deferred income tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,452,802</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,798,572</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,452,802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,798,572</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Net deferred income tax asset</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Deferred income tax liability:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">572,349</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">296,890</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"><B></B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2016, the
Company had net operating loss carryforwards for PRC tax purposes of approximately $51.0 million which are available to
offset any future taxable income through 2021. The Company also has net operating losses for United States federal income tax
purposes of approximately $4.5 million which are available to offset future taxable income, if any, through 2036.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In assessing the realizability of deferred
tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not
be realized.&nbsp;&nbsp;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those differences become deductible or tax loss carry forwards are utilized.&nbsp;&nbsp;Management
considers projected future taxable income and tax planning strategies in making this assessment.&nbsp;&nbsp;Based upon an assessment
of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax
assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred
tax assets as of December 31, 2016 and 2015.&nbsp;&nbsp;Therefore, the Company provided for a valuation allowance against its deferred
tax assets of $21,452,802 and $12,798,572 as of December 31, 2016 and 2015, respectively.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also incurred various other
taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any
unpaid amounts are reflected on the balance sheets as accrued taxes payable.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 12 - STOCKHOLDERS' EQUITY</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue 95,000,000
shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be
issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely
by the Company&rsquo;s board of directors.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Employee Stock Options</U></B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>2010 Incentive Plan</I></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 12, 2010, the Company&rsquo;s
Board of Directors adopted the Company&rsquo;s 2010 Incentive Plan (the &ldquo;Plan&rdquo;), which was then approved by stockholders
on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights
and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants
of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock.
Through December 31, 2016, there were 175,000 shares of restricted stock granted and outstanding under the Plan.&nbsp; No options
were outstanding as of December 31, 2016 under the Plan.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">There were no securities issued from the Plan during each
of the year ended December 31, 2016 and 2015.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized no compensation
expense related to the awards of common shares and the grants and modifications of stock options during each of the years ended
December 31, 2016 and 2015.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2016
and 2015</B></P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option award is
estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility
of the Company&rsquo;s common stock prices. The Company uses historical data to estimate employee termination rates. The expected
term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified
method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected
term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect
at the time of grant.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2016, there was no
remaining unrecognized compensation expense related to stock options or restricted stock grants.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 13 &ndash; COMMITMENTS AND CONTINGENCIES</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Economic environment </I>- </B>Substantially
all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant
risks not typically associated with companies operating in the United States of America. These risks include, among others, the
political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations
may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies
with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods
of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company&rsquo;s
operations.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, all of the Company's revenue
is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of
the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of
the PRC government.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 14 &ndash; CONCENTRATIONS</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December 31, 2016,
no customer accounted for more than 10.0% of sales and one supplier accounted for 21.1% of raw material purchases, one customer
accounted for 46.3% of accounts receivable, and three different products accounted for 49.0%, 14.0% and 11.0% of revenue.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December 31, 2015,
no customer accounted for more than 10% of sales and one supplier accounted for 27.0% of raw material purchases, one customer accounted
for 28.0% of accounts receivable, and three different products accounted for 49.0%, 15.0% and 14.0% of revenue.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; font-size: 8pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !4&%I;G0N3D54('8U+C P /_; $, $PT.$ X,
M$Q /$!44$Q8<+AX<&AH<.2DK(BY#.T=&0CM!0$I4:UI*3V500$%=?EYE;G)W
M>7=(68.,@G2+:W5W<__; $,!%!45'!@<-QX>-W--04US<W-S<W-S<W-S<W-S
M<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<__  !$( -P
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M>0CY< ?J37,0QJS#.37HFFV\=K91QQ+@$;B>Y)[U$W9%P6I__]D_
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>ex105.htm
<DESCRIPTION>EX 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 14pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loans
Extension Confirmation Letter</B></FONT></P>

<P STYLE="font: 14pt SimSun; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 28.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the &ldquo;Company&rdquo;), the principal and accumulated
interest totaled USD1,354,567 and USD71,303.91 respectively as of December 31, 2016. Due to the fact the Company temporarily did
not have enough balance in its oversea account to repay the loans, both Ms. Tsui and the Company agreed to extend the loans to
December 31, 2017, by which date the Company shall repay the principal and accumulated interest.</FONT></P>

<P STYLE="font: 14pt SimSun; margin: 0; text-align: justify; text-indent: 28.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in"></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"></TD>
    <TD STYLE="width: 55%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Creditor&#65306;/s/
    Heung Mei Tsui</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debtor<FONT STYLE="line-height: 200%">&#65306;China
                                         Pharma Holdings, Inc.</FONT></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 44pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 200%">By:
                                         Zhilin Li</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex231.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference
in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 31,
2017 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the years
ended December 31, 2016 and 2015 appearing in this Annual Report on Form 10-K of China Pharma Holdings, Inc. for the year ended
December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>/s/ </B></FONT><FONT STYLE="background-color: white">B
F Borgers CPA PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">B F Borgers CPA PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lakewood, CO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>ex311.htm
<DESCRIPTION>EX31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Zhilin Li certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">3.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">c) Evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures
as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">d) Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">5.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">a) all significant deficiencies and material weaknesses
in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">b) any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant's internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Zhilin Li </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(principal executive officer)</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>ex312.htm
<DESCRIPTION>EX31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 31.2</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Zhilin Li, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">3.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">c) Evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures
as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">d) Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">5.</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">a) all significant deficiencies and material weaknesses
in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt">b) any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant's internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Zhilin Li </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: Interim Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(principal financial officer and principal accounting officer)</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>ex321.htm
<DESCRIPTION>EX32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The undersigned hereby certifies, in her capacity as principal executive
officer of China Pharma Holdings, Inc. (the &ldquo;Company&rdquo;), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(1) The Company&rsquo;s Annual Report on Form 10-K for the fiscal
year ended December 31, 2016 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(2) The information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dated: March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Zhilin Li </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(principal executive officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Zhilin Li </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: Interim Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(principal financial officer and principal accounting officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This certification accompanies each Report pursuant to &sect; 906
of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed
by the Company for purposes of &sect;18 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A signed original of this written statement required by Section
906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request.</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>cphi-20161231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<xbrl xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric' xmlns='http://www.xbrl.org/2003/instance' xmlns:us-gaap='http://fasb.org/us-gaap/2016-01-31' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:dei='http://xbrl.sec.gov/dei/2014-01-31' xmlns:fil='http://www.chinapharmaholdings.com/20161231' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:num='http://www.xbrl.org/dtr/type/numeric' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrli='http://www.xbrl.org/2003/instance'>
	<link:schemaRef xlink:type='simple' xlink:href='cphi-20161231.xsd' />
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent decimals='INF' contextRef='E16' unitRef='USD'>15664496</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent decimals='INF' contextRef='E15' unitRef='USD'>29352806</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<fil:AllowanceForDoubtfulAccountsOnOtherReceivables decimals='INF' contextRef='E16' unitRef='USD'>71548</fil:AllowanceForDoubtfulAccountsOnOtherReceivables>
	<fil:AllowanceForDoubtfulAccountsOnOtherReceivables decimals='INF' contextRef='E15' unitRef='USD'>74400</fil:AllowanceForDoubtfulAccountsOnOtherReceivables>
	<us-gaap:PreferredStockParOrStatedValuePerShare decimals='INF' contextRef='E16' unitRef='UsdPerShare'>0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare decimals='INF' contextRef='E15' unitRef='UsdPerShare'>0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized decimals='INF' contextRef='E16' unitRef='Shares'>5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized decimals='INF' contextRef='E15' unitRef='Shares'>5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued decimals='INF' contextRef='E16' unitRef='Shares'>0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued decimals='INF' contextRef='E15' unitRef='Shares'>0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding decimals='INF' contextRef='E16' unitRef='Shares'>0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding decimals='INF' contextRef='E15' unitRef='Shares'>0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare decimals='INF' contextRef='E16' unitRef='UsdPerShare'>0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare decimals='INF' contextRef='E15' unitRef='UsdPerShare'>0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized decimals='INF' contextRef='E16' unitRef='Shares'>95000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized decimals='INF' contextRef='E15' unitRef='Shares'>95000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued decimals='INF' contextRef='E16' unitRef='Shares'>43579557</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued decimals='INF' contextRef='E15' unitRef='Shares'>43579557</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding decimals='INF' contextRef='E16' unitRef='Shares'>43579557</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding decimals='INF' contextRef='E15' unitRef='Shares'>43579557</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:Revenues decimals='INF' contextRef='Y16' unitRef='USD'>15570514</us-gaap:Revenues>
	<us-gaap:Revenues decimals='INF' contextRef='Y15' unitRef='USD'>20351630</us-gaap:Revenues>
	<us-gaap:CostOfRevenue decimals='INF' contextRef='Y16' unitRef='USD'>12352004</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue decimals='INF' contextRef='Y15' unitRef='USD'>15778243</us-gaap:CostOfRevenue>
	<us-gaap:InventoryWriteDown decimals='INF' contextRef='Y16' unitRef='USD'>0</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown decimals='INF' contextRef='Y15' unitRef='USD'>3108826</us-gaap:InventoryWriteDown>
	<us-gaap:GrossProfit decimals='INF' contextRef='Y16' unitRef='USD'>3218510</us-gaap:GrossProfit>
	<us-gaap:GrossProfit decimals='INF' contextRef='Y15' unitRef='USD'>1464561</us-gaap:GrossProfit>
	<us-gaap:SellingExpense decimals='INF' contextRef='Y16' unitRef='USD'>4036590</us-gaap:SellingExpense>
	<us-gaap:SellingExpense decimals='INF' contextRef='Y15' unitRef='USD'>4294639</us-gaap:SellingExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='Y16' unitRef='USD'>2265851</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='Y15' unitRef='USD'>1896559</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='Y16' unitRef='USD'>365969</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='Y15' unitRef='USD'>961897</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='Y16' unitRef='USD'>11717000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='Y15' unitRef='USD'>17404932</us-gaap:OperatingExpenses>
	<fil:SubsidyIncome decimals='INF' contextRef='Y16' unitRef='USD'>343023</fil:SubsidyIncome>
	<fil:SubsidyIncome decimals='INF' contextRef='Y15' unitRef='USD'>1640531</fil:SubsidyIncome>
	<us-gaap:OperatingIncomeLoss decimals='INF' contextRef='Y16' unitRef='USD'>-8155467</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss decimals='INF' contextRef='Y15' unitRef='USD'>-14299840</us-gaap:OperatingIncomeLoss>
	<us-gaap:InvestmentIncomeInterest decimals='INF' contextRef='Y16' unitRef='USD'>130575</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest decimals='INF' contextRef='Y15' unitRef='USD'>119925</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InterestExpense decimals='INF' contextRef='Y16' unitRef='USD'>-849557</us-gaap:InterestExpense>
	<us-gaap:InterestExpense decimals='INF' contextRef='Y15' unitRef='USD'>-1165164</us-gaap:InterestExpense>
	<us-gaap:OtherExpenses decimals='INF' contextRef='Y16' unitRef='USD'>-718982</us-gaap:OtherExpenses>
	<us-gaap:OtherExpenses decimals='INF' contextRef='Y15' unitRef='USD'>-1045239</us-gaap:OtherExpenses>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals='INF' contextRef='Y16' unitRef='USD'>-8874449</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals='INF' contextRef='Y15' unitRef='USD'>-15345079</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax decimals='INF' contextRef='Y16' unitRef='USD'>-4549391</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax decimals='INF' contextRef='Y15' unitRef='USD'>-4693453</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax decimals='INF' contextRef='Y16' unitRef='USD'>-13732015</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax decimals='INF' contextRef='Y15' unitRef='USD'>-20098971</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:EarningsPerShareBasicAndDiluted decimals='INF' contextRef='Y16' unitRef='UsdPerShare'>-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted decimals='INF' contextRef='Y15' unitRef='UsdPerShare'>-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted decimals='INF' contextRef='Y16' unitRef='Shares'>43579557</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted decimals='INF' contextRef='Y15' unitRef='Shares'>43579557</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='Y16' unitRef='USD'>-9182624</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='Y15' unitRef='USD'>-15405518</us-gaap:NetIncomeLoss>
	<us-gaap:DepreciationDepletionAndAmortization decimals='INF' contextRef='Y16' unitRef='USD'>3078074</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization decimals='INF' contextRef='Y15' unitRef='USD'>3598527</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:ProvisionForDoubtfulAccounts decimals='INF' contextRef='Y16' unitRef='USD'>1086449</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts decimals='INF' contextRef='Y15' unitRef='USD'>10147293</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:IncreaseDecreaseInIncomeTaxes decimals='INF' contextRef='Y16' unitRef='USD'>308175</us-gaap:IncreaseDecreaseInIncomeTaxes>
	<us-gaap:IncreaseDecreaseInIncomeTaxes decimals='INF' contextRef='Y15' unitRef='USD'>60439</us-gaap:IncreaseDecreaseInIncomeTaxes>
	<fil:ProvisionForObsoleteInventory decimals='INF' contextRef='Y16' unitRef='USD'>0</fil:ProvisionForObsoleteInventory>
	<fil:ProvisionForObsoleteInventory decimals='INF' contextRef='Y15' unitRef='USD'>1941007</fil:ProvisionForObsoleteInventory>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill decimals='INF' contextRef='Y16' unitRef='USD'>3962141</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill decimals='INF' contextRef='Y15' unitRef='USD'>104544</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables decimals='INF' contextRef='Y16' unitRef='USD'>-1097556</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables decimals='INF' contextRef='Y15' unitRef='USD'>-2511888</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInDepositOtherAssets decimals='INF' contextRef='Y16' unitRef='USD'>380779</us-gaap:IncreaseDecreaseInDepositOtherAssets>
	<us-gaap:IncreaseDecreaseInDepositOtherAssets decimals='INF' contextRef='Y15' unitRef='USD'>843639</us-gaap:IncreaseDecreaseInDepositOtherAssets>
	<us-gaap:IncreaseDecreaseInInventories decimals='INF' contextRef='Y16' unitRef='USD'>2734612</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories decimals='INF' contextRef='Y15' unitRef='USD'>5157861</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInAccountsPayableTrade decimals='INF' contextRef='Y16' unitRef='USD'>815198</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
	<us-gaap:IncreaseDecreaseInAccountsPayableTrade decimals='INF' contextRef='Y15' unitRef='USD'>216304</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
	<us-gaap:IncreaseDecreaseInAccruedTaxesPayable decimals='INF' contextRef='Y16' unitRef='USD'>72107</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedTaxesPayable decimals='INF' contextRef='Y15' unitRef='USD'>34802</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities decimals='INF' contextRef='Y16' unitRef='USD'>377663</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities decimals='INF' contextRef='Y15' unitRef='USD'>548455</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInCustomerAdvances decimals='INF' contextRef='Y16' unitRef='USD'>265928</us-gaap:IncreaseDecreaseInCustomerAdvances>
	<us-gaap:IncreaseDecreaseInCustomerAdvances decimals='INF' contextRef='Y15' unitRef='USD'>-1430595</us-gaap:IncreaseDecreaseInCustomerAdvances>
	<us-gaap:IncreaseDecreaseInPrepaidExpense decimals='INF' contextRef='Y16' unitRef='USD'>94762</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense decimals='INF' contextRef='Y15' unitRef='USD'>45190</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities decimals='INF' contextRef='Y16' unitRef='USD'>2895708</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities decimals='INF' contextRef='Y15' unitRef='USD'>3350060</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:PaymentsToAcquireIntangibleAssets decimals='INF' contextRef='Y16' unitRef='USD'>0</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets decimals='INF' contextRef='Y15' unitRef='USD'>-1634097</us-gaap:PaymentsToAcquireIntangibleAssets>
	<fil:BankersAcceptancesRedeemedForCash decimals='INF' contextRef='Y16' unitRef='USD'>0</fil:BankersAcceptancesRedeemedForCash>
	<fil:BankersAcceptancesRedeemedForCash decimals='INF' contextRef='Y15' unitRef='USD'>423693</fil:BankersAcceptancesRedeemedForCash>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals='INF' contextRef='Y16' unitRef='USD'>-193404</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals='INF' contextRef='Y15' unitRef='USD'>-685302</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities decimals='INF' contextRef='Y16' unitRef='USD'>-193404</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities decimals='INF' contextRef='Y15' unitRef='USD'>-1895706</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:ProceedsFromConstructionLoansPayable decimals='INF' contextRef='Y16' unitRef='USD'>-1505346</us-gaap:ProceedsFromConstructionLoansPayable>
	<us-gaap:ProceedsFromConstructionLoansPayable decimals='INF' contextRef='Y15' unitRef='USD'>0</us-gaap:ProceedsFromConstructionLoansPayable>
	<us-gaap:ProceedsFromShortTermDebt decimals='INF' contextRef='Y16' unitRef='USD'>-4516039</us-gaap:ProceedsFromShortTermDebt>
	<us-gaap:ProceedsFromShortTermDebt decimals='INF' contextRef='Y15' unitRef='USD'>0</us-gaap:ProceedsFromShortTermDebt>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities decimals='INF' contextRef='Y16' unitRef='USD'>-6021385</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities decimals='INF' contextRef='Y15' unitRef='USD'>0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents decimals='INF' contextRef='Y16' unitRef='USD'>-263877</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents decimals='INF' contextRef='Y15' unitRef='USD'>-501384</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease decimals='INF' contextRef='Y16' unitRef='USD'>-3582958</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease decimals='INF' contextRef='Y15' unitRef='USD'>952970</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<fil:CashAndCashEquivalentsAtBeginningOfPeriod decimals='INF' contextRef='Y16' unitRef='USD'>6248760</fil:CashAndCashEquivalentsAtBeginningOfPeriod>
	<fil:CashAndCashEquivalentsAtBeginningOfPeriod decimals='INF' contextRef='Y15' unitRef='USD'>5295790</fil:CashAndCashEquivalentsAtBeginningOfPeriod>
	<fil:CashAndCashEquivalentsAtEndOfPeriod decimals='INF' contextRef='Y16' unitRef='USD'>2665802</fil:CashAndCashEquivalentsAtEndOfPeriod>
	<fil:CashAndCashEquivalentsAtEndOfPeriod decimals='INF' contextRef='Y15' unitRef='USD'>6248760</fil:CashAndCashEquivalentsAtEndOfPeriod>
	<us-gaap:InterestPaid decimals='INF' contextRef='Y16' unitRef='USD'>836011</us-gaap:InterestPaid>
	<us-gaap:InterestPaid decimals='INF' contextRef='Y15' unitRef='USD'>1151613</us-gaap:InterestPaid>
	<fil:AccountsPayableForPurchasesOfPropertyAndEquipment decimals='INF' contextRef='Y16' unitRef='USD'>0</fil:AccountsPayableForPurchasesOfPropertyAndEquipment>
	<fil:AccountsPayableForPurchasesOfPropertyAndEquipment decimals='INF' contextRef='Y15' unitRef='USD'>171245</fil:AccountsPayableForPurchasesOfPropertyAndEquipment>
	<fil:IssuanceOfBankerSAcceptances decimals='INF' contextRef='Y16' unitRef='USD'>1088879</fil:IssuanceOfBankerSAcceptances>
	<fil:IssuanceOfBankerSAcceptances decimals='INF' contextRef='Y15' unitRef='USD'>0</fil:IssuanceOfBankerSAcceptances>
	<fil:AccountsReceivableCollectedWithBankerSAcceptances decimals='INF' contextRef='Y16' unitRef='USD'>935265</fil:AccountsReceivableCollectedWithBankerSAcceptances>
	<fil:AccountsReceivableCollectedWithBankerSAcceptances decimals='INF' contextRef='Y15' unitRef='USD'>2422137</fil:AccountsReceivableCollectedWithBankerSAcceptances>
	<fil:InventoryPurchasedWithBankerSAcceptances decimals='INF' contextRef='Y16' unitRef='USD'>935265</fil:InventoryPurchasedWithBankerSAcceptances>
	<fil:InventoryPurchasedWithBankerSAcceptances decimals='INF' contextRef='Y15' unitRef='USD'>2059028</fil:InventoryPurchasedWithBankerSAcceptances>
	<fil:AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances decimals='INF' contextRef='Y16' unitRef='USD'>0</fil:AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances>
	<fil:AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances decimals='INF' contextRef='Y15' unitRef='USD'>391826</fil:AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances>
	<us-gaap:Cash decimals='INF' contextRef='E16' unitRef='USD'>2665802</us-gaap:Cash>
	<us-gaap:Cash decimals='INF' contextRef='E15' unitRef='USD'>6248760</us-gaap:Cash>
	<us-gaap:RestrictedCashAndCashEquivalents decimals='INF' contextRef='E16' unitRef='USD'>1088879</us-gaap:RestrictedCashAndCashEquivalents>
	<us-gaap:RestrictedCashAndCashEquivalents decimals='INF' contextRef='E15' unitRef='USD'>0</us-gaap:RestrictedCashAndCashEquivalents>
	<fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts decimals='INF' contextRef='E16' unitRef='USD'>3999809</fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts>
	<fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts decimals='INF' contextRef='E15' unitRef='USD'>5174101</fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts>
	<us-gaap:AccountsAndOtherReceivablesNetCurrent decimals='INF' contextRef='E16' unitRef='USD'>224373</us-gaap:AccountsAndOtherReceivablesNetCurrent>
	<us-gaap:AccountsAndOtherReceivablesNetCurrent decimals='INF' contextRef='E15' unitRef='USD'>290739</us-gaap:AccountsAndOtherReceivablesNetCurrent>
	<fil:AdvancesToSuppliers decimals='INF' contextRef='E16' unitRef='USD'>2003792</fil:AdvancesToSuppliers>
	<fil:AdvancesToSuppliers decimals='INF' contextRef='E15' unitRef='USD'>2533354</fil:AdvancesToSuppliers>
	<us-gaap:InventoryNet decimals='INF' contextRef='E16' unitRef='USD'>7310939</us-gaap:InventoryNet>
	<us-gaap:InventoryNet decimals='INF' contextRef='E15' unitRef='USD'>9662750</us-gaap:InventoryNet>
	<us-gaap:PrepaidExpenseCurrent decimals='INF' contextRef='E16' unitRef='USD'>226357</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent decimals='INF' contextRef='E15' unitRef='USD'>339140</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:AssetsCurrent decimals='INF' contextRef='E16' unitRef='USD'>17519951</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent decimals='INF' contextRef='E15' unitRef='USD'>24248844</us-gaap:AssetsCurrent>
	<fil:AdvancesForPurchasesOfIntangibleAssets decimals='INF' contextRef='E16' unitRef='USD'>35498059</fil:AdvancesForPurchasesOfIntangibleAssets>
	<fil:AdvancesForPurchasesOfIntangibleAssets decimals='INF' contextRef='E15' unitRef='USD'>42030649</fil:AdvancesForPurchasesOfIntangibleAssets>
	<us-gaap:PropertyPlantAndEquipmentNet decimals='INF' contextRef='E16' unitRef='USD'>24967448</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet decimals='INF' contextRef='E15' unitRef='USD'>29393257</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:Assets decimals='INF' contextRef='E16' unitRef='USD'>78520140</us-gaap:Assets>
	<us-gaap:Assets decimals='INF' contextRef='E15' unitRef='USD'>96513825</us-gaap:Assets>
	<us-gaap:AccountsPayableTradeCurrent decimals='INF' contextRef='E16' unitRef='USD'>3060374</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccountsPayableTradeCurrent decimals='INF' contextRef='E15' unitRef='USD'>2439355</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccruedLiabilitiesCurrent decimals='INF' contextRef='E16' unitRef='USD'>139830</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent decimals='INF' contextRef='E15' unitRef='USD'>143409</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableOtherCurrent decimals='INF' contextRef='E16' unitRef='USD'>2502694</us-gaap:AccountsPayableOtherCurrent>
	<us-gaap:AccountsPayableOtherCurrent decimals='INF' contextRef='E15' unitRef='USD'>2095449</us-gaap:AccountsPayableOtherCurrent>
	<us-gaap:CustomerAdvancesCurrent decimals='INF' contextRef='E16' unitRef='USD'>811232</us-gaap:CustomerAdvancesCurrent>
	<us-gaap:CustomerAdvancesCurrent decimals='INF' contextRef='E15' unitRef='USD'>595681</us-gaap:CustomerAdvancesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent decimals='INF' contextRef='E16' unitRef='USD'>1354567</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent decimals='INF' contextRef='E15' unitRef='USD'>1354567</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:LongTermConstructionLoanCurrent decimals='INF' contextRef='E16' unitRef='USD'>1440154</us-gaap:LongTermConstructionLoanCurrent>
	<us-gaap:LongTermConstructionLoanCurrent decimals='INF' contextRef='E15' unitRef='USD'>1540666</us-gaap:LongTermConstructionLoanCurrent>
	<fil:BankersAcceptanceNotesPayable decimals='INF' contextRef='E16' unitRef='USD'>1088879</fil:BankersAcceptanceNotesPayable>
	<fil:BankersAcceptanceNotesPayable decimals='INF' contextRef='E15' unitRef='USD'>0</fil:BankersAcceptanceNotesPayable>
	<us-gaap:NotesPayableCurrent decimals='INF' contextRef='E16' unitRef='USD'>0</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent decimals='INF' contextRef='E15' unitRef='USD'>4621998</us-gaap:NotesPayableCurrent>
	<us-gaap:LiabilitiesCurrent decimals='INF' contextRef='E16' unitRef='USD'>10397730</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent decimals='INF' contextRef='E15' unitRef='USD'>12791125</us-gaap:LiabilitiesCurrent>
	<us-gaap:LongtermConstructionLoanCurrentAndNoncurrent decimals='INF' contextRef='E16' unitRef='USD'>8640927</us-gaap:LongtermConstructionLoanCurrentAndNoncurrent>
	<us-gaap:LongtermConstructionLoanCurrentAndNoncurrent decimals='INF' contextRef='E15' unitRef='USD'>10784661</us-gaap:LongtermConstructionLoanCurrentAndNoncurrent>
	<us-gaap:DeferredTaxLiabilities decimals='INF' contextRef='E16' unitRef='USD'>572349</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities decimals='INF' contextRef='E15' unitRef='USD'>296890</us-gaap:DeferredTaxLiabilities>
	<us-gaap:Liabilities decimals='INF' contextRef='E16' unitRef='USD'>19611006</us-gaap:Liabilities>
	<us-gaap:Liabilities decimals='INF' contextRef='E15' unitRef='USD'>23872676</us-gaap:Liabilities>
	<us-gaap:PreferredStockValue decimals='INF' contextRef='E16' unitRef='USD'>0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue decimals='INF' contextRef='E15' unitRef='USD'>0</us-gaap:PreferredStockValue>
	<us-gaap:CommonStockValue decimals='INF' contextRef='E16' unitRef='USD'>43580</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue decimals='INF' contextRef='E15' unitRef='USD'>43580</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapital decimals='INF' contextRef='E16' unitRef='USD'>23590204</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital decimals='INF' contextRef='E15' unitRef='USD'>23590204</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit decimals='INF' contextRef='E16' unitRef='USD'>24757374</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit decimals='INF' contextRef='E15' unitRef='USD'>33939998</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss decimals='INF' contextRef='E16' unitRef='USD'>10517976</us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss>
	<us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss decimals='INF' contextRef='E15' unitRef='USD'>15067367</us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss>
	<us-gaap:StockholdersEquity decimals='INF' contextRef='E16' unitRef='USD'>58909134</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity decimals='INF' contextRef='E15' unitRef='USD'>72641149</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity decimals='INF' contextRef='E16' unitRef='USD'>78520140</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity decimals='INF' contextRef='E15' unitRef='USD'>96513825</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 1 &amp;#150; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Organization and Nature of Operations &amp;#150; &lt;/i&gt;&lt;/b&gt;China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&apos;s Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;font style=&apos;background:white&apos;&gt;On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&amp;nbsp;&amp;nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&amp;#146;s outstanding shares of common stock on December 21, 2012.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Foreign Investment Industrial Catalogue&lt;i&gt;&amp;nbsp;&lt;/i&gt;(the &amp;#147;Catalogue&amp;#148;) jointly issued by China&amp;#146;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &amp;#147;FIE&amp;#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&amp;#146;s business.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&amp;#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&amp;#146;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Consolidation and Basis of Presentation &lt;/i&gt;&lt;/b&gt;&amp;#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Helpson&amp;#146;s functional currency is the Chinese Renminbi. Helpson&amp;#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&amp;#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&amp;#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Accounting Estimates &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;The methodology used to prepare for the Company&amp;#146;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&amp;#147;Management&amp;#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents &lt;/i&gt;&lt;/b&gt;&amp;#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&amp;#146;s acceptances purchased with maturities of three months or less.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&amp;#150;&lt;b&gt;&amp;nbsp;&lt;/b&gt;Restricted cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker&apos;s acceptance notes issued by the Company as discussed in Note 8.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts &amp;#150; &lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company&apos;s customer base. The Company reviews a customer&apos;s credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $1,086,449 and $10,147,293 for the years ended December 31, 2016 and 2015, respectively.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectable trade accounts receivable balances in the amount of $13.5 million and $19.7 million against the allowance for the years ended December 31, 2016 and 2015, respectively. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Advances to Suppliers and Advances from Customers&lt;/i&gt;&lt;/b&gt; &amp;#150; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&apos;s credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company recognized bad debt expense of approximately $0 and $4.1 million for the years ended December 31, 2016 and 2015, respectively.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt; &amp;#150; Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated portion of the Company&amp;#146;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this lower cost basis until sold or scrapped.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Valuation of Long-Lived Assets&lt;/i&gt;&lt;/b&gt; &amp;#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. For the year ended December 31, 2016 and 2015 the Company evaluated its long-lived assets and determined that impairment adjustments of $3,962,141 related to advances for intangible assets as discussed in Note 5 and $104,544 related to certain intangible assets as discussed in Note 4 were necessary.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt; &amp;#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:115%;margin:0in 0in 10pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font style=&apos;line-height:115%&apos;&gt;Revenue Recognition&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font style=&apos;line-height:115%&apos;&gt; &amp;#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be reasonably assured. Management had determined that revenue deferred from 2014 was not completely collected in 2016. Thus, according to the Company&amp;#146;s trade receivable provision policy, such deferred revenue was reclassified to allowance for doubtful accounts as of December 31, 2015.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Cost of Revenues&lt;/i&gt;&lt;/b&gt; &amp;#150; Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt; &amp;#150; Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Retirement Benefit Plans&lt;/i&gt;&lt;/b&gt; &amp;#150; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by the provincial governments. The benefit plans of the government assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $261,063 and $270,488 to retirement benefit plans for the years ended December 31, 2016 and 2015, respectively. Contributions to these plans are charged to expense as incurred.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.3in 0pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Advertising Costs&lt;/i&gt;&lt;/b&gt; &amp;#150; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2016 and 2015.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Common Share &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;There were no potential dilutive common shares outstanding during the years ended December 31, 2016 and 2015, respectively.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt; &amp;#150; The carrying amount of accounts receivable included in the balance sheet represents the Company&apos;s exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer&apos;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management&apos;s estimates.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&amp;#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&amp;nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&amp;#146;s deposits may be at a higher risk of loss.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Interest Rate Risk&lt;/i&gt;&lt;/b&gt; &amp;#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Reclassification&lt;/i&gt;&lt;/b&gt; &amp;#150;Certain prior year balance sheet amounts have been reclassified to conform to the current year presentation. These amounts had no effect on the reported results of operations.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In May 2014, the FASB issued ASU 2014-09,&amp;nbsp;&lt;i&gt;&quot;Revenue from Contracts with Customers&quot;&lt;/i&gt;&amp;nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. &amp;nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In November 2015, the FASB issued Accounting Standards Update 2015-17,&amp;nbsp;&amp;#147;&lt;i&gt;Balance Sheet Classification of Deferred Taxes&lt;/i&gt;,&amp;#148; which is intended to simplify the balance sheet presentation of deferred income taxes. Current accounting principles require an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in its balance sheet. The amendments require that deferred tax liabilities and assets be classified as noncurrent in its balance sheet. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Companies may apply the new provisions either retrospectively or on a prospective basis, and early adoption is permitted. We early adopted the amendments effective December 31, 2015 on a retrospective basis. There was no effect on our Consolidated Balance Sheet as of December 31, 2016 or 2015.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In January 2016, the FASB issued Accounting Standards Update 2016-01,&amp;nbsp;&amp;#147;&lt;i&gt;Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;.&amp;#148; The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on our financial statements.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;In February 2016, the FASB issued ASU No. 2016-02,&amp;nbsp;&lt;i&gt;Leases&lt;/i&gt;, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB&apos;s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;In March 2016, the FASB issued ASU No. 2016-09,&amp;nbsp;&lt;i&gt;Improvements to Employee Share-Based Payment Accounting&lt;/i&gt;. The standard provides a new requirement to record all of the tax effects related to share-based payments at settlement (or expiration) through the income statement. This pronouncement is effective for annual reporting periods beginning after December 15, 2016. The Company has completed an evaluation of the pronouncement and determined that its impact upon adoption will not be material to the Company&apos;s consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;In June 2016, the FASB issued Accounting Standards Update 2016-13,&amp;nbsp;&lt;i&gt;Financial Instruments &amp;#150; Credit Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration since their origination.&amp;nbsp;The pronouncement will be effective for Public business entities that are SEC filers in fiscal years beginning after&amp;nbsp;December 15, 2019, including interim periods within those fiscal years. &lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;&amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;Early application of the guidance will be permitted for all entities for fiscal years beginning after&amp;nbsp;December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;In August 2016, the FASB issued ASU No. 2016-15,&amp;nbsp;&lt;i&gt;Classification of Certain Cash Receipts and Cash Payments&lt;/i&gt;. The standard addresses the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective approach.&amp;nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures, but does not expect the impact to be material.&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white&apos;&gt;In November 2016, the FASB issued ASU 2016-18, &lt;i&gt;Statement of Cash Flows (Topic 230): Restricted Cash (&amp;#147;ASU 2016-18&amp;#148;)&lt;/i&gt;. The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-18 may have on its consolidated financial statements.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;font style=&apos;background:white&apos;&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&amp;#146;s financial position, result of operations or cash flows.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 2 &amp;#150; INVENTORY&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Inventory consisted of the following:&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;62%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:62%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Raw materials&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;13%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;11,562,388&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;13%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;14,699,736&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Work in process&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;360,550&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Finished goods&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,530,641&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;3,380,109&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;13,453,579&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;18,079,845&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Obsolescence reserve&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(6,142,640&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(8,417,095&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:9pt;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total Inventory&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;7,310,939&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;9,662,750&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Property and equipment consisted of the following:&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;62%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:62%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;13%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:13%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;405,645&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;13%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:13%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;433,956&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;9,419,700&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;10,557,234&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;26,151,029&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;27,326,953&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;309,777&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;307,747&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;182,718&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;190,279&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:9pt;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;36,468,869&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;38,816,169&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(11,501,421&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(9,422,912&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Property and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;24,967,448&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;29,393,257&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;For the years ended December 31, 2016 and 2015, depreciation expense was $2,815,167 and $3,280,618, respectively.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;71%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;Asset&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;2%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:2%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;27%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:27%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;Life - years&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;40 - 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;20 - 49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;3-5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 4 - INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Intangible assets represent the cost of medical formulas approved for production by the CFDA. The Company did not obtain CFDA production approval for any medical formula during the year ended December 31, 2016 and 2015 and no costs were reclassified from advances to intangible assets in 2016 and 2015, respectively.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.&amp;nbsp;&amp;nbsp;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $262,908 and $317,908 for the years ended December 31, 2016 and 2015, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company&amp;#146;s evaluation is based on an estimated discounted net cash flow model, considering currently available market data for the related drug and the Company&amp;#146;s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated undiscounted future net cash flows. An impairment loss of $104,544 was recognized during the year ended December 31, 2015. No impairment loss was recognized during the year ended December 31, 2016.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Intangible assets consisted solely of CFDA approved medical formulas as follows:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Gross carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;4,861,766&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;5,201,079&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(4,327,084&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(4,360,004&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Net carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;534,682&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;841,075&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;39%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:39%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;6%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:6%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:55%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;Amount&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;160,947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2018&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;109,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2019&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;57,290&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2020&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;35,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2021&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;35,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;Thereafter&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;135,749&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:black 1pt solid;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;534,682&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<fil:AdvancesForPurchasesOfIntangibleAssetsTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 5 &amp;#150; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In order to expand the number of medicines the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process for the year end December 31, 2013. These patents have not expired.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Prior to entering into contracts with the Company, laboratories typically are required to complete all&amp;nbsp;research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA&amp;#146;s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to be received in approximately two to five years from the date&amp;nbsp;the Company signs the medical formula contracts.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;As of December 31, 2016, the Company was obligated to pay laboratories and others approximately $4,400,000 upon the completion of various phases of contracts to obtain CFDA production approval of medical formulas.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;During 2016, with CFDA&apos;s tightened scrutiny procedure in connection with its review of production applications and based on the Company&apos;s monitoring and assessment process, the Company determined five advanced payments to five independent laboratories were impaired. As a result, the Company recognized an impairment loss for the advances made to these laboratories in the amount of $3,962,141.&lt;/p&gt;</fil:AdvancesForPurchasesOfIntangibleAssetsTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 6 &amp;#150; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;A member of the Company&amp;#146;s board of directors had previously advanced the Company an aggregate amount of $1,354,567 as of December 31, 2016 and 2015 which are recorded as other payables &amp;#150; related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.&amp;nbsp;&amp;nbsp;Total interest expense of $13,546 was recognized for each of the years ended December 31, 2016 and 2015.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 7 &amp;#150; NOTES PAYABLE&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In November 2014, the Company entered into a line of credit with a bank in the amount of RMB30,000,000 (approximately $4.5 million). Advances on the line of credit were due one year from the date of the advance and were collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.16% (based upon 110% of the PRC government&apos;s short term rate of 5.6% in November 2014). In addition, the Company&apos;s Chief Executive Officer and Chair of the board of directors personally guaranteed the line of credit. In November, 2015 the Company renewed its line of credit in the amount of RMB30,000,000 (approximately $4.5 million) with the same bank. The line of credit was payable in two equal installments of RMB15,000,000 (approximately $2.25 million) payable on September 16, 2016 and October 19, 2016, respectively. The Company made the respective payments due for RMB15,000,000 according to the terms of the agreement during 2016.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The outstanding balance due under the revolving line of credit was RMB0 and RMB30,000,000 as of December 31, 2016 and December 31, 2015, respectively ($0 and $4,621,998 as of December 31, 2016 and 2015, respectively). The Company has no additional amounts available to it under this line of credit.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Fair Value of Notes Payable&lt;/i&gt;&lt;/b&gt; &amp;#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable outstanding as of December 31, 2015 approximated its fair value because of the immediate or short-term maturity of this financial instrument and because the underlying instrument bears interest rates that approximated current market rates.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:LongTermDebtTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 9 &amp;#150; CONSTRUCTION LOAN FACILITY&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company obtained a construction loan facility in the aggregate amount of RMB80,000,000 (approximately $13 million) from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The total loan facility is from the same bank that provided the line of credit as discussed in Note 7.&amp;nbsp;&amp;nbsp;The proceeds of the loan were used for and are collateralized by the construction of the Company&amp;#146;s new production facility and the included production line equipment and machinery. During 2015, the loan bore weighted interest at 5.73%, based upon 110% of the PRC government&amp;#146;s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest rate was adjusted to 5.94% and on July 10, 2016 the interest rate was further adjusted to 5.39%. &amp;nbsp;The loan requires interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal will be due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described above for 2015. In January 2016, the Company made a principal payment in the amount of approximately $0.3 million (RMB2,000,000) and on July 13, 2016 the Company made a payment in the amount of approximately $1.2 million (RMB8,000,000). As of December 31, 2016, the Company had no additional amounts available to it under this facility.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Principal payments required for the next five years as of December 31, 2016 are as follows:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;69%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:69%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;28%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:28%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;1,440,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2018&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2,160,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2019&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2,160,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2020&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2,160,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2021&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2,160,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:black 1pt solid;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;10,081,082&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Fair Value of Construction Loan Facility&lt;/i&gt;&lt;/b&gt; &amp;#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2016 and 2015 approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&amp;nbsp;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
	<fil:SubsidyIncomeDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;background:white;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 10 &amp;#150; SUBSIDY INCOME&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;background:white;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt&apos;&gt;During the years ended December 31, 2016 and 2015, the Company received cash of $0.34 million and $1.64 million related to a subsidy from the government for the technological innovation it has achieved and the industrial upgrading related to its new GMP certified facility.&amp;nbsp;This has been recorded as &amp;#147;Subsidy income&amp;#148; in the accompanying Statement of Operations for the years ended December 31, 2016 and 2015, respectively.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;</fil:SubsidyIncomeDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 11 - INCOME TAXES&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Undistributed earnings of Helpson, the Company&amp;#146;s foreign subsidiary, since its acquisition, amounted to approximately $34.2 million as of December 31, 2016. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Liabilities are established for uncertain tax positions expected to be taken in income tax return when such positions are judged to meet the &amp;#147;more-likely-than-not&amp;#148; threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2016, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2013 through December 31, 2016 and the Chinese income tax return for the year ended December 31, 2016 are open for possible examination.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;On March 16, 2007, the National People&amp;#146;s Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&amp;nbsp;1, 2008. The EIT Law and Implementation Regulations Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for 2014 to 2016.&amp;nbsp;The recent&amp;nbsp;net losses have put the Company in an unfavorable position for the potential renewal of&amp;nbsp;&quot;National High-Tech Enterprise&quot; status in 2017. After evaluating the feasibility of the renewal, the Company has decided not to renew this status.&amp;nbsp;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt;  &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:21%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;31%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:31%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:7%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; rowspan=&quot;2&quot; width=&quot;41%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:41%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Enterprise Income Tax Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;2016&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;2018&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Thereafter&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The provision for income taxes consisted of the following:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt;  &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;7&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Current&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Deferred&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;308,175&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;60,439&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total income tax expense &lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;308,175&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;60,439&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.3in 0pt 0in&apos;&gt;Following is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes:&lt;/p&gt; &lt;p style=&apos;margin:0in 0.3in 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt;  &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;7&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;(Benefit) tax at statutory rate of 25%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(2,218,612&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(3,832,536&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Effect of tax holiday&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;837,089&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,478,831&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Effect of change in tax rate from 15% to 25%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(8,094,456&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Other, primarily the difference in U.S. tax rates&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;7,903&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;4,136&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;9,776,251&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2,410,008&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;308,175&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;60,439&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The effect of the tax holiday amounted to a change in the tax expense of $837,089 and $1,478,831 for the years ended December 31, 2016 and 2015, which was equivalent to basic and diluted earnings per share of ($0.02) and ($0.03) per share for the years ended December 31, 2016 and 2015, respectively. The temporary differences which give rise to the deferred income tax assets and liability are as follows:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt;  &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;7&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Deferred income tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Allowance for doubtful trade receivables&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;3,916,124&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;4,402,921&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Allowance for doubtful other receivables&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;17,959&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;11,160&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Inventory obsolescence reserve&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,535,660&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,262,564&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Expenses not deductible in current year&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,008,350&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;647,236&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Advances for intangible assets impairment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;793,624&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;PRC net operating loss carry forward&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;12,660,410&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;5,114,478&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;U.S. net operating loss carry forward&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,520,675&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,360,213&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;21,452,802&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;12,798,572&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(21,452,802&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(12,798,572&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:9pt;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Net deferred income tax asset&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Deferred income tax liability:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Intangible assets&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;572,349&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;296,890&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;As of December 31, 2016, the Company had net operating loss carryforwards for PRC tax purposes of approximately $51.0 million which are available to offset any future taxable income through 2021. The Company also has net operating losses for United States federal income tax purposes of approximately $4.5 million which are available to offset future taxable income, if any, through 2036.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&amp;nbsp;&amp;nbsp;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&amp;nbsp;&amp;nbsp;Management considers projected future taxable income and tax planning strategies in making this assessment.&amp;nbsp;&amp;nbsp;Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December 31, 2016 and 2015.&amp;nbsp;&amp;nbsp;Therefore, the Company provided for a valuation allowance against its deferred tax assets of $21,452,802 and $12,798,572 as of December 31, 2016 and 2015, respectively.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 12 - STOCKHOLDERS&apos; EQUITY&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&amp;#146;s board of directors.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;u&gt;Employee Stock Options&lt;/u&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;i&gt;2010 Incentive Plan&lt;/i&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;On November 12, 2010, the Company&amp;#146;s Board of Directors adopted the Company&amp;#146;s 2010 Incentive Plan (the &amp;#147;Plan&amp;#148;), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through December 31, 2016, there were 175,000 shares of restricted stock granted and outstanding under the Plan.&amp;nbsp; No options were outstanding as of December 31, 2016 under the Plan.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;There were no securities issued from the Plan during each of the year ended December 31, 2016 and 2015.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the years ended December 31, 2016 and 2015.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company&amp;#146;s common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;As of December 31, 2016, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 13 &amp;#150; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Economic environment &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;Substantially all of the Company&apos;s operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company&apos;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company&amp;#146;s operations.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In addition, all of the Company&apos;s revenue is denominated in the PRC&apos;s currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;NOTE 14 &amp;#150; CONCENTRATIONS&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;For the year ended December 31, 2016, no customer accounted for more than 10.0% of sales and one supplier accounted for 21.1% of raw material purchases, one customer accounted for 46.3% of accounts receivable, and three different products accounted for 49.0%, 14.0% and 11.0% of revenue.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;For the year ended December 31, 2015, no customer accounted for more than 10% of sales and one supplier accounted for 27.0% of raw material purchases, one customer accounted for 28.0% of accounts receivable, and three different products accounted for 49.0%, 15.0% and 14.0% of revenue.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<fil:BankerSAcceptanceNotesPayableTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;&lt;b&gt;NOTE 8 &amp;#150; BANKER&apos;S ACCEPTANCE NOTES PAYABLE&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;background:white;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;In April 2016, the Company entered into a Banker&apos;s Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker&apos;s acceptance notes (the &quot;Banker&apos;s Notes&quot;) to any third party as payment of amounts owing to that third party. The Company is required to deposit with the bank an amount equal to the amounts represented by the Banker&apos;s Notes issued to the third parties. The amount of these deposited balances is shown as &quot;Restricted cash&quot; on the accompanying balance sheets as of December 31, 2016. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately $4.5 million) or the amount of cash available to deposit against the Banker&apos;s Notes. In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank. At December 31 2016 and 2015, the Company had outstanding Banker&apos;s Acceptance Notes in the amount of $1,088,879 and $0, respectively.&lt;/p&gt;</fil:BankerSAcceptanceNotesPayableTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Inventory consisted of the following:&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;62%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:62%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Raw materials&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;13%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;11,562,388&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;13%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;14,699,736&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Work in process&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;360,550&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Finished goods&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,530,641&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;3,380,109&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;13,453,579&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;18,079,845&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Obsolescence reserve&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(6,142,640&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(8,417,095&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:9pt;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total Inventory&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;7,310,939&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;9,662,750&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Property and equipment consisted of the following:&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;62%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:62%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;13%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;405,645&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;13%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;433,956&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;9,868,491&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;10,557,234&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;25,700,825&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;27,325,440&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;249,122&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;242,860&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;244,786&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;256,679&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:9pt;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;36,468,869&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;38,816,169&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(11,501,421&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(9,422,912&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Property and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;24,967,448&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;29,393,257&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<fil:UsefulLivesOfTheAssetsTableTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;71%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;Asset&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;2%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:2%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;27%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:27%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;Life - years&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;40 - 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;20 - 49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;3-5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:UsefulLivesOfTheAssetsTableTextBlock>
	<fil:IntangibleAssetsMedicalFormulasTablesTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Intangible assets consisted solely of CFDA approved medical formulas as follows:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Gross carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;4,861,766&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;5,201,079&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(4,327,084&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(4,360,004&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Net carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;534,682&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;841,075&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:IntangibleAssetsMedicalFormulasTablesTextBlock>
	<fil:IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;39%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:39%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;6%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:6%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:55%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;Amount&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;160,947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2018&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;109,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2019&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;57,290&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2020&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;35,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2021&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;35,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;Thereafter&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;135,749&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:black 1pt solid;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;534,682&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock>
	<us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Principal payments required for the next five years as of December 31, 2016 are as follows:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;69%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:69%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;28%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:28%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;1,440,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2018&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2,160,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2019&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2,160,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2020&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2,160,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;2021&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2,160,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:black 1pt solid;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;10,081,082&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
	<fil:ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:21%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;31%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:31%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:7%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; rowspan=&quot;2&quot; width=&quot;41%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:41%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Enterprise Income Tax Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;2016&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;2018&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Thereafter&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</fil:ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The provision for income taxes consisted of the following:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;7&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Current&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Deferred&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;308,175&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;60,439&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total income tax expense &lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;308,175&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;60,439&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0.3in 0pt 0in&apos;&gt;Following is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes:&lt;/p&gt; &lt;p style=&apos;margin:0in 0.3in 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;7&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;(Benefit) tax at statutory rate of 25%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(2,218,612&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(3,832,536&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Effect of tax holiday&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;837,089&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,478,831&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Effect of change in tax rate from 15% to 25%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(8,094,456&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Other, primarily the difference in U.S. tax rates&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;7,903&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;4,136&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;9,776,251&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;2,410,008&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;308,175&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;60,439&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The temporary differences which give rise to the deferred income tax assets and liability are as follows:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;7&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Deferred income tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Allowance for doubtful trade receivables&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;3,916,124&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;4,402,921&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Allowance for doubtful other receivables&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;17,959&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;11,160&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Inventory obsolescence reserve&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,535,660&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,262,564&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Expenses not deductible in current year&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,008,350&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;647,236&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Advances for intangible assets impairment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;793,624&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;PRC net operating loss carry forward&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;12,660,410&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;5,114,478&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;U.S. net operating loss carry forward&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,520,675&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;1,360,213&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;21,452,802&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;12,798,572&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(21,452,802&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;(12,798,572&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:9pt;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Net deferred income tax asset&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Deferred income tax liability:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;Intangible assets&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;572,349&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;296,890&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In May 2014, the FASB issued ASU 2014-09,&amp;nbsp;&lt;i&gt;&quot;Revenue from Contracts with Customers&quot;&lt;/i&gt;&amp;nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. &amp;nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In November 2015, the FASB issued Accounting Standards Update 2015-17,&amp;nbsp;&amp;#147;&lt;i&gt;Balance Sheet Classification of Deferred Taxes&lt;/i&gt;,&amp;#148; which is intended to simplify the balance sheet presentation of deferred income taxes. Current accounting principles require an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in its balance sheet. The amendments require that deferred tax liabilities and assets be classified as noncurrent in its balance sheet. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Companies may apply the new provisions either retrospectively or on a prospective basis, and early adoption is permitted. We early adopted the amendments effective December 31, 2015 on a retrospective basis. There was no effect on our Consolidated Balance Sheet as of December 31, 2016 or 2015.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;In January 2016, the FASB issued Accounting Standards Update 2016-01,&amp;nbsp;&amp;#147;&lt;i&gt;Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;.&amp;#148; The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on our financial statements.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;In February 2016, the FASB issued ASU No. 2016-02,&amp;nbsp;&lt;i&gt;Leases&lt;/i&gt;, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB&apos;s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style=&apos;background:white;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;In March 2016, the FASB issued ASU No. 2016-09,&amp;nbsp;&lt;i&gt;Improvements to Employee Share-Based Payment Accounting&lt;/i&gt;. The standard provides a new requirement to record all of the tax effects related to share-based payments at settlement (or expiration) through the income statement. This pronouncement is effective for annual reporting periods beginning after December 15, 2016. The Company has completed an evaluation of the pronouncement and determined that its impact upon adoption will not be material to the Company&apos;s consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style=&apos;background:white;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;In June 2016, the FASB issued Accounting Standards Update 2016-13,&amp;nbsp;&lt;i&gt;Financial Instruments &amp;#150; Credit Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration since their origination.&amp;nbsp;The pronouncement will be effective for Public business entities that are SEC filers in fiscal years beginning after&amp;nbsp;December 15, 2019, including interim periods within those fiscal years. &lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;&amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;Early application of the guidance will be permitted for all entities for fiscal years beginning after&amp;nbsp;December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style=&apos;background:white;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;In August 2016, the FASB issued ASU No. 2016-15,&amp;nbsp;&lt;i&gt;Classification of Certain Cash Receipts and Cash Payments&lt;/i&gt;. The standard addresses the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective approach.&amp;nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures, but does not expect the impact to be material.&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;In November 2016, the FASB issued ASU 2016-18, &lt;i&gt;Statement of Cash Flows (Topic 230): Restricted Cash (&amp;#147;ASU 2016-18&amp;#148;)&lt;/i&gt;. The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-18 may have on its consolidated financial statements.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;font style=&apos;background:white&apos;&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&amp;#146;s financial position, result of operations or cash flows.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Reclassification&lt;/i&gt;&lt;/b&gt; &amp;#150;Certain prior year balance sheet amounts have been reclassified to conform to the current year presentation. These amounts had no effect on the reported results of operations.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<fil:InterestRateRiskPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Interest Rate Risk&lt;/i&gt;&lt;/b&gt; &amp;#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/p&gt;</fil:InterestRateRiskPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt; &amp;#150; The carrying amount of accounts receivable included in the balance sheet represents the Company&apos;s exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer&apos;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management&apos;s estimates.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&amp;#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&amp;nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&amp;#146;s deposits may be at a higher risk of loss.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Common Share &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;There were no potential dilutive common shares outstanding during the years ended December 31, 2016 and 2015, respectively.&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:AdvertisingCostsPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0.3in 0pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Advertising Costs&lt;/i&gt;&lt;/b&gt; &amp;#150; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2016 and 2015.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
	<us-gaap:PostemploymentBenefitPlansPolicy contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Retirement Benefit Plans&lt;/i&gt;&lt;/b&gt; &amp;#150; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by the provincial governments. The benefit plans of the government assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $261,063 and $270,488 to retirement benefit plans for the years ended December 31, 2016 and 2015, respectively. Contributions to these plans are charged to expense as incurred.&lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt; &amp;#150; Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Cost of Revenues&lt;/i&gt;&lt;/b&gt; &amp;#150; Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:115%;margin:0in 0in 10pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font style=&apos;line-height:115%&apos;&gt;Revenue Recognition&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font style=&apos;line-height:115%&apos;&gt; &amp;#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be reasonably assured. Management had determined that revenue deferred from 2014 was not completely collected in 2016. Thus, according to the Company&amp;#146;s trade receivable provision policy, such deferred revenue was reclassified to allowance for doubtful accounts as of December 31, 2015.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt; &amp;#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Valuation of Long-Lived Assets&lt;/i&gt;&lt;/b&gt; &amp;#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. For the year ended December 31, 2016 and 2015 the Company evaluated its long-lived assets and determined that impairment adjustments of $3,962,141 related to advances for intangible assets as discussed in Note 5 and $104,544 related to certain intangible assets as discussed in Note 4 were necessary.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt; &amp;#150; Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated portion of the Company&amp;#146;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this lower cost basis until sold or scrapped.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
	<fil:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Advances to Suppliers and Advances from Customers&lt;/i&gt;&lt;/b&gt; &amp;#150; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&apos;s credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company recognized bad debt expense of approximately $0 and $4.1 million for the years ended December 31, 2016 and 2015, respectively.&lt;/p&gt;</fil:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts &amp;#150; &lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company&apos;s customer base. The Company reviews a customer&apos;s credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $1,086,449 and $10,147,293 for the years ended December 31, 2016 and 2015, respectively.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectable trade accounts receivable balances in the amount of $13.5 million and $19.7 million against the allowance for the years ended December 31, 2016 and 2015, respectively. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents &lt;/i&gt;&lt;/b&gt;&amp;#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&amp;#146;s acceptances purchased with maturities of three months or less.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:UseOfEstimates contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Accounting Estimates &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;The methodology used to prepare for the Company&amp;#146;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&amp;#147;Management&amp;#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:UseOfEstimates>
	<us-gaap:ConsolidationPolicyTextBlock contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Consolidation and Basis of Presentation &lt;/i&gt;&lt;/b&gt;&amp;#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Helpson&amp;#146;s functional currency is the Chinese Renminbi. Helpson&amp;#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&amp;#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&amp;#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:NatureOfOperations contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;Organization and Nature of Operations &amp;#150; &lt;/i&gt;&lt;/b&gt;China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&apos;s Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&lt;font style=&apos;background:white&apos;&gt;On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&amp;nbsp;&amp;nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&amp;#146;s outstanding shares of common stock on December 21, 2012.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Foreign Investment Industrial Catalogue&lt;i&gt;&amp;nbsp;&lt;/i&gt;(the &amp;#147;Catalogue&amp;#148;) jointly issued by China&amp;#146;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &amp;#147;FIE&amp;#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&amp;#146;s business.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&amp;#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&amp;#146;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:NatureOfOperations>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef='Y16'>&lt;!--egx--&gt;&lt;p style=&apos;background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt&apos;&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&amp;#150;&lt;b&gt;&amp;nbsp;&lt;/b&gt;Restricted cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker&apos;s acceptance notes issued by the Company as discussed in Note 8.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited decimals='INF' contextRef='E16' unitRef='Pure'>1.0000</fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited>
	<fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1 decimals='INF' contextRef='E16' unitRef='Pure'>1.0000</fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1>
	<fil:PercetageOfAcquiredByOnnyInHelpson decimals='INF' contextRef='E16' unitRef='Pure'>1.0000</fil:PercetageOfAcquiredByOnnyInHelpson>
	<fil:BadDebtExpense decimals='INF' contextRef='Y16' unitRef='USD'>1086449</fil:BadDebtExpense>
	<fil:BadDebtExpense decimals='INF' contextRef='Y15' unitRef='USD'>10147293</fil:BadDebtExpense>
	<fil:UncollectableTradeAccountsReceivable decimals='INF' contextRef='Y16' unitRef='USD'>13500000</fil:UncollectableTradeAccountsReceivable>
	<fil:UncollectableTradeAccountsReceivable decimals='INF' contextRef='Y15' unitRef='USD'>19700000</fil:UncollectableTradeAccountsReceivable>
	<fil:CompanyRecognizedBadDebtExpense decimals='INF' contextRef='Y16' unitRef='USD'>0</fil:CompanyRecognizedBadDebtExpense>
	<fil:CompanyRecognizedBadDebtExpense decimals='INF' contextRef='Y15' unitRef='USD'>4100000</fil:CompanyRecognizedBadDebtExpense>
	<fil:ImpairmentAdjustmentsRelatedToAdvances decimals='INF' contextRef='Y16' unitRef='USD'>3962141</fil:ImpairmentAdjustmentsRelatedToAdvances>
	<fil:ImpairmentAdjustmentsRelatedToAdvances decimals='INF' contextRef='Y15' unitRef='USD'>104544</fil:ImpairmentAdjustmentsRelatedToAdvances>
	<fil:RetirementBenefitPlans decimals='INF' contextRef='Y16' unitRef='USD'>261063</fil:RetirementBenefitPlans>
	<fil:RetirementBenefitPlans decimals='INF' contextRef='Y15' unitRef='USD'>270488</fil:RetirementBenefitPlans>
	<us-gaap:InventoryRawMaterials decimals='INF' contextRef='E16' unitRef='USD'>11562388</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryRawMaterials decimals='INF' contextRef='E15' unitRef='USD'>14699736</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryWorkInProcess decimals='INF' contextRef='E16' unitRef='USD'>360550</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryFinishedGoods decimals='INF' contextRef='E16' unitRef='USD'>1530641</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods decimals='INF' contextRef='E15' unitRef='USD'>3380109</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross decimals='INF' contextRef='E16' unitRef='USD'>13453579</us-gaap:InventoryGross>
	<us-gaap:InventoryGross decimals='INF' contextRef='E15' unitRef='USD'>18079845</us-gaap:InventoryGross>
	<us-gaap:InventoryValuationReserves decimals='INF' contextRef='E16' unitRef='USD'>-6142640</us-gaap:InventoryValuationReserves>
	<us-gaap:InventoryValuationReserves decimals='INF' contextRef='E15' unitRef='USD'>-8417095</us-gaap:InventoryValuationReserves>
	<fil:TotalInventory decimals='INF' contextRef='E16' unitRef='USD'>7310939</fil:TotalInventory>
	<fil:TotalInventory decimals='INF' contextRef='E15' unitRef='USD'>9662750</fil:TotalInventory>
	<fil:PermitOfLandUseMinimumLife decimals='INF' contextRef='E16' unitRef='Pure'>40</fil:PermitOfLandUseMinimumLife>
	<fil:PermitOfLandUseMaximumLife decimals='INF' contextRef='E16' unitRef='Pure'>70</fil:PermitOfLandUseMaximumLife>
	<fil:BuildingMinimumLife decimals='INF' contextRef='E16' unitRef='Pure'>20</fil:BuildingMinimumLife>
	<fil:BuildingMaximumLife decimals='INF' contextRef='E16' unitRef='Pure'>49</fil:BuildingMaximumLife>
	<fil:PlantMachineryAndEquipmentMinimumLife decimals='INF' contextRef='E16' unitRef='Pure'>5</fil:PlantMachineryAndEquipmentMinimumLife>
	<fil:PlantMachineryAndEquipmentMaximumLife decimals='INF' contextRef='E16' unitRef='Pure'>10</fil:PlantMachineryAndEquipmentMaximumLife>
	<fil:MotorVehicleMinimumLife decimals='INF' contextRef='E16' unitRef='Pure'>5</fil:MotorVehicleMinimumLife>
	<fil:MotorVehicleMaximumLife decimals='INF' contextRef='E16' unitRef='Pure'>10</fil:MotorVehicleMaximumLife>
	<fil:OfficeEquipmentMinimumLife decimals='INF' contextRef='E16' unitRef='Pure'>3</fil:OfficeEquipmentMinimumLife>
	<fil:OfficeEquipmentMaximumLife decimals='INF' contextRef='E16' unitRef='Pure'>5</fil:OfficeEquipmentMaximumLife>
	<fil:GrossCarryingAmount decimals='INF' contextRef='E16' unitRef='USD'>4861766</fil:GrossCarryingAmount>
	<fil:GrossCarryingAmount decimals='INF' contextRef='E15' unitRef='USD'>5201079</fil:GrossCarryingAmount>
	<fil:AccumulatedAmortization decimals='INF' contextRef='E16' unitRef='USD'>-4327084</fil:AccumulatedAmortization>
	<fil:AccumulatedAmortization decimals='INF' contextRef='E15' unitRef='USD'>-4360004</fil:AccumulatedAmortization>
	<fil:NetCarryingAmount decimals='INF' contextRef='E16' unitRef='USD'>534682</fil:NetCarryingAmount>
	<fil:NetCarryingAmount decimals='INF' contextRef='E15' unitRef='USD'>841075</fil:NetCarryingAmount>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo decimals='INF' contextRef='E16' unitRef='USD'>160947</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo decimals='INF' contextRef='E16' unitRef='USD'>109872</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree decimals='INF' contextRef='E16' unitRef='USD'>57290</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour decimals='INF' contextRef='E16' unitRef='USD'>35412</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive decimals='INF' contextRef='E16' unitRef='USD'>35412</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive decimals='INF' contextRef='E16' unitRef='USD'>135749</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
	<fil:EstimatedAggregateAnnualAmortizationExpenseThereafter decimals='INF' contextRef='E16' unitRef='USD'>534682</fil:EstimatedAggregateAnnualAmortizationExpenseThereafter>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived decimals='INF' contextRef='Y16' unitRef='USD'>3962141</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived decimals='INF' contextRef='Y15' unitRef='USD'>104544</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:LandAndLandImprovements decimals='INF' contextRef='E16' unitRef='USD'>405645</us-gaap:LandAndLandImprovements>
	<us-gaap:LandAndLandImprovements decimals='INF' contextRef='E15' unitRef='USD'>433956</us-gaap:LandAndLandImprovements>
	<us-gaap:BuildingsAndImprovementsGross decimals='INF' contextRef='E16' unitRef='USD'>9868491</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BuildingsAndImprovementsGross decimals='INF' contextRef='E15' unitRef='USD'>10557234</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:MachineryAndEquipmentGross decimals='INF' contextRef='E16' unitRef='USD'>25700825</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MachineryAndEquipmentGross decimals='INF' contextRef='E15' unitRef='USD'>27325440</us-gaap:MachineryAndEquipmentGross>
	<fil:MotorVehicleGross decimals='INF' contextRef='E16' unitRef='USD'>249122</fil:MotorVehicleGross>
	<fil:MotorVehicleGross decimals='INF' contextRef='E15' unitRef='USD'>242860</fil:MotorVehicleGross>
	<fil:OfficeEquipment1 decimals='INF' contextRef='E16' unitRef='USD'>244786</fil:OfficeEquipment1>
	<fil:OfficeEquipment1 decimals='INF' contextRef='E15' unitRef='USD'>256679</fil:OfficeEquipment1>
	<us-gaap:PropertyPlantAndEquipmentGross decimals='INF' contextRef='E16' unitRef='USD'>36468869</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross decimals='INF' contextRef='E15' unitRef='USD'>38816169</us-gaap:PropertyPlantAndEquipmentGross>
	<fil:LessAccumulatedDepreciation decimals='INF' contextRef='E16' unitRef='USD'>-11501421</fil:LessAccumulatedDepreciation>
	<fil:LessAccumulatedDepreciation decimals='INF' contextRef='E15' unitRef='USD'>-9422912</fil:LessAccumulatedDepreciation>
	<fil:PropertyAndEquipmentNet decimals='INF' contextRef='E16' unitRef='USD'>24967448</fil:PropertyAndEquipmentNet>
	<fil:PropertyAndEquipmentNet decimals='INF' contextRef='E15' unitRef='USD'>29393257</fil:PropertyAndEquipmentNet>
	<fil:CompanyWasObligatedToPayLaboratoriesAndOthers decimals='INF' contextRef='E16' unitRef='USD'>4400000</fil:CompanyWasObligatedToPayLaboratoriesAndOthers>
	<fil:ImpairmentLossForTheAdvancesMadeToTheseLaboratories decimals='INF' contextRef='E16' unitRef='USD'>3962141</fil:ImpairmentLossForTheAdvancesMadeToTheseLaboratories>
	<fil:AdvancesOwingToBoardOfDirectors decimals='INF' contextRef='E16' unitRef='USD'>1354567</fil:AdvancesOwingToBoardOfDirectors>
	<fil:AdvancesOwingToBoardOfDirectors decimals='INF' contextRef='E15' unitRef='USD'>1354567</fil:AdvancesOwingToBoardOfDirectors>
	<fil:InterestRateOnAdvancesFromMemberOfBOD decimals='INF' contextRef='E16' unitRef='Pure'>0.0100</fil:InterestRateOnAdvancesFromMemberOfBOD>
	<fil:InterestRateOnAdvancesFromMemberOfBOD decimals='INF' contextRef='E15' unitRef='Pure'>0.0100</fil:InterestRateOnAdvancesFromMemberOfBOD>
	<fil:TotalInterestExpense decimals='INF' contextRef='E16' unitRef='USD'>13546</fil:TotalInterestExpense>
	<fil:TotalInterestExpense decimals='INF' contextRef='E15' unitRef='USD'>13546</fil:TotalInterestExpense>
	<fil:RevolvingLineOfCreditWithABankRmb decimals='INF' contextRef='I141130' unitRef='USD'>30000000</fil:RevolvingLineOfCreditWithABankRmb>
	<fil:AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56 decimals='INF' contextRef='I141130' unitRef='Pure'>0.0616</fil:AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56>
	<fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000 decimals='INF' contextRef='E16' unitRef='USD'>0</fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000>
	<fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000 decimals='INF' contextRef='E15' unitRef='USD'>4621998</fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000>
	<fil:CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount decimals='INF' contextRef='E16' unitRef='USD'>1088879</fil:CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount>
	<fil:CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount decimals='INF' contextRef='E15' unitRef='USD'>0</fil:CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount>
	<fil:TotalLoanFacilityAmountRmb80000000 decimals='INF' contextRef='E16' unitRef='USD'>13000000</fil:TotalLoanFacilityAmountRmb80000000>
	<fil:LoanInterestForAnEightYearTerm decimals='INF' contextRef='E16' unitRef='Pure'>0.0721</fil:LoanInterestForAnEightYearTerm>
	<fil:InterestRateWasAdjustedTo decimals='INF' contextRef='I150710' unitRef='Pure'>0.0594</fil:InterestRateWasAdjustedTo>
	<fil:PrincipalPayments2017 decimals='INF' contextRef='E16' unitRef='USD'>1440154</fil:PrincipalPayments2017>
	<fil:PrincipalPayments2018 decimals='INF' contextRef='E16' unitRef='USD'>2160232</fil:PrincipalPayments2018>
	<fil:PrincipalPayments2019 decimals='INF' contextRef='E16' unitRef='USD'>2160232</fil:PrincipalPayments2019>
	<fil:PrincipalPayments2020 decimals='INF' contextRef='E16' unitRef='USD'>2160232</fil:PrincipalPayments2020>
	<fil:PrincipalPayments2021 decimals='INF' contextRef='E16' unitRef='USD'>2160232</fil:PrincipalPayments2021>
	<fil:TotalPrincipalPaymentsDue decimals='INF' contextRef='E16' unitRef='USD'>10081082</fil:TotalPrincipalPaymentsDue>
	<fil:ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1 decimals='INF' contextRef='Y16' unitRef='USD'>3400000</fil:ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1>
	<fil:ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1 decimals='INF' contextRef='Y15' unitRef='USD'>16400000</fil:ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1>
	<fil:EnterpriseIncomeTaxRate2015 decimals='INF' contextRef='E16' unitRef='Pure'>0.1500</fil:EnterpriseIncomeTaxRate2015>
	<fil:EnterpriseIncomeTaxRate2016 decimals='INF' contextRef='E16' unitRef='Pure'>0.1500</fil:EnterpriseIncomeTaxRate2016>
	<fil:EnterpriseIncomeTaxRate2017 decimals='INF' contextRef='E16' unitRef='Pure'>0.2500</fil:EnterpriseIncomeTaxRate2017>
	<fil:EnterpriseIncomeTaxRate2018 decimals='INF' contextRef='E16' unitRef='Pure'>0.2500</fil:EnterpriseIncomeTaxRate2018>
	<fil:EnterpriseIncomeTaxRateThereafter decimals='INF' contextRef='E16' unitRef='Pure'>0.2500</fil:EnterpriseIncomeTaxRateThereafter>
	<us-gaap:CurrentIncomeTaxExpenseBenefit decimals='INF' contextRef='Y16' unitRef='USD'>0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit decimals='INF' contextRef='Y16' unitRef='USD'>308175</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit decimals='INF' contextRef='Y15' unitRef='USD'>60439</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit decimals='INF' contextRef='Y16' unitRef='USD'>308175</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit decimals='INF' contextRef='Y15' unitRef='USD'>60439</us-gaap:IncomeTaxExpenseBenefit>
	<fil:AmortizationExpensesRelatingToIntangibleAssets decimals='INF' contextRef='Y16' unitRef='USD'>262908</fil:AmortizationExpensesRelatingToIntangibleAssets>
	<fil:AmortizationExpensesRelatingToIntangibleAssets decimals='INF' contextRef='Y15' unitRef='USD'>317908</fil:AmortizationExpensesRelatingToIntangibleAssets>
	<fil:ImpairmentLoss1 decimals='INF' contextRef='Y16' unitRef='USD'>0</fil:ImpairmentLoss1>
	<fil:ImpairmentLoss1 decimals='INF' contextRef='Y15' unitRef='USD'>104544</fil:ImpairmentLoss1>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill decimals='INF' contextRef='E16' unitRef='USD'>534682</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill decimals='INF' contextRef='E15' unitRef='USD'>841075</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts decimals='INF' contextRef='E16' unitRef='USD'>3916124</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts decimals='INF' contextRef='E15' unitRef='USD'>4402921</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
	<fil:AllowanceForDoubtfulOtherReceivables decimals='INF' contextRef='E16' unitRef='USD'>17959</fil:AllowanceForDoubtfulOtherReceivables>
	<fil:AllowanceForDoubtfulOtherReceivables decimals='INF' contextRef='E15' unitRef='USD'>11160</fil:AllowanceForDoubtfulOtherReceivables>
	<us-gaap:DeferredTaxAssetsInventory decimals='INF' contextRef='E16' unitRef='USD'>1535660</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsInventory decimals='INF' contextRef='E15' unitRef='USD'>1262564</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther decimals='INF' contextRef='E16' unitRef='USD'>1008350</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther decimals='INF' contextRef='E15' unitRef='USD'>647236</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
	<fil:AdvancesForIntangibleAssetsImpairment1 decimals='INF' contextRef='E16' unitRef='USD'>793624</fil:AdvancesForIntangibleAssetsImpairment1>
	<fil:PrcNetOperatingLossCarryForward decimals='INF' contextRef='E16' unitRef='USD'>12660410</fil:PrcNetOperatingLossCarryForward>
	<fil:PrcNetOperatingLossCarryForward decimals='INF' contextRef='E15' unitRef='USD'>5114478</fil:PrcNetOperatingLossCarryForward>
	<us-gaap:OperatingLossCarryforwards decimals='INF' contextRef='E16' unitRef='USD'>1520675</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards decimals='INF' contextRef='E15' unitRef='USD'>1360213</us-gaap:OperatingLossCarryforwards>
	<fil:TotalDeferredIncomeTaxAssets decimals='INF' contextRef='E16' unitRef='USD'>21452802</fil:TotalDeferredIncomeTaxAssets>
	<fil:TotalDeferredIncomeTaxAssets decimals='INF' contextRef='E15' unitRef='USD'>12798572</fil:TotalDeferredIncomeTaxAssets>
	<us-gaap:DeferredTaxAssetsValuationAllowance decimals='INF' contextRef='E16' unitRef='USD'>-21452802</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance decimals='INF' contextRef='E15' unitRef='USD'>-12798572</us-gaap:DeferredTaxAssetsValuationAllowance>
	<fil:NetDeferredIncomeTaxAsset1 decimals='INF' contextRef='E15' unitRef='USD'>0</fil:NetDeferredIncomeTaxAsset1>
	<fil:IntangibleAssets1 decimals='INF' contextRef='E16' unitRef='USD'>572349</fil:IntangibleAssets1>
	<fil:IntangibleAssets1 decimals='INF' contextRef='E15' unitRef='USD'>296890</fil:IntangibleAssets1>
	<fil:ChangeInTheTaxExpense decimals='INF' contextRef='Y16' unitRef='USD'>837087</fil:ChangeInTheTaxExpense>
	<fil:ChangeInTheTaxExpense decimals='INF' contextRef='Y15' unitRef='USD'>1478831</fil:ChangeInTheTaxExpense>
	<fil:BasicAndDilutedEarningsPerShare decimals='INF' contextRef='Y16' unitRef='UsdPerShare'>-0.02</fil:BasicAndDilutedEarningsPerShare>
	<fil:BasicAndDilutedEarningsPerShare decimals='INF' contextRef='Y15' unitRef='UsdPerShare'>-0.03</fil:BasicAndDilutedEarningsPerShare>
	<fil:NetOperatingLossCarryforwardsForPrcTaxPurposes decimals='INF' contextRef='Y16' unitRef='USD'>51000000</fil:NetOperatingLossCarryforwardsForPrcTaxPurposes>
	<fil:NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes decimals='INF' contextRef='Y16' unitRef='USD'>4500000</fil:NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes>
	<fil:ValuationAllowanceAgainstItsDeferredTax decimals='INF' contextRef='Y16' unitRef='USD'>21452802</fil:ValuationAllowanceAgainstItsDeferredTax>
	<fil:ValuationAllowanceAgainstItsDeferredTax decimals='INF' contextRef='Y15' unitRef='USD'>12798572</fil:ValuationAllowanceAgainstItsDeferredTax>
	<fil:CommonSharesAuthorized decimals='INF' contextRef='E16' unitRef='Shares'>95000000</fil:CommonSharesAuthorized>
	<fil:PreferredSharesAuthorized decimals='INF' contextRef='E16' unitRef='Shares'>5000000</fil:PreferredSharesAuthorized>
	<fil:CommonSharesParValue decimals='INF' contextRef='E16' unitRef='UsdPerShare'>0.001</fil:CommonSharesParValue>
	<fil:PreferredSharesParValue decimals='INF' contextRef='E16' unitRef='UsdPerShare'>0.001</fil:PreferredSharesParValue>
	<fil:NumberOfCommonShares decimals='INF' contextRef='I101112' unitRef='Shares'>4000000</fil:NumberOfCommonShares>
	<fil:SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan decimals='INF' contextRef='E16' unitRef='Shares'>175000</fil:SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan>
	<fil:NoCustomerAccountedForMoreThanPercentageOfSales decimals='INF' contextRef='Y16' unitRef='Pure'>0.1000</fil:NoCustomerAccountedForMoreThanPercentageOfSales>
	<fil:NoCustomerAccountedForMoreThanPercentageOfSales decimals='INF' contextRef='Y15' unitRef='Pure'>0.1000</fil:NoCustomerAccountedForMoreThanPercentageOfSales>
	<fil:OneSupplierAccountedForPercentageOfRawMaterialPurchases decimals='INF' contextRef='Y16' unitRef='Pure'>0.2110</fil:OneSupplierAccountedForPercentageOfRawMaterialPurchases>
	<fil:OneSupplierAccountedForPercentageOfRawMaterialPurchases decimals='INF' contextRef='Y15' unitRef='Pure'>0.2700</fil:OneSupplierAccountedForPercentageOfRawMaterialPurchases>
	<fil:OneCustomerAccountedForPercentageOfAccountsReceivable decimals='INF' contextRef='Y16' unitRef='Pure'>0.4630</fil:OneCustomerAccountedForPercentageOfAccountsReceivable>
	<fil:OneCustomerAccountedForPercentageOfAccountsReceivable decimals='INF' contextRef='Y15' unitRef='Pure'>0.2800</fil:OneCustomerAccountedForPercentageOfAccountsReceivable>
	<fil:PercentageOfProductFirstAccountedForRevenue decimals='INF' contextRef='Y16' unitRef='Pure'>0.4900</fil:PercentageOfProductFirstAccountedForRevenue>
	<fil:PercentageOfProductFirstAccountedForRevenue decimals='INF' contextRef='Y15' unitRef='Pure'>0.4900</fil:PercentageOfProductFirstAccountedForRevenue>
	<fil:PercentageOfProductSecondAccountedForRevenue decimals='INF' contextRef='Y16' unitRef='Pure'>0.1400</fil:PercentageOfProductSecondAccountedForRevenue>
	<fil:PercentageOfProductSecondAccountedForRevenue decimals='INF' contextRef='Y15' unitRef='Pure'>0.1500</fil:PercentageOfProductSecondAccountedForRevenue>
	<fil:PercentageOfThirdProductAccountedForRevenue decimals='INF' contextRef='Y16' unitRef='Pure'>0.1100</fil:PercentageOfThirdProductAccountedForRevenue>
	<fil:PercentageOfThirdProductAccountedForRevenue decimals='INF' contextRef='Y15' unitRef='Pure'>0.1400</fil:PercentageOfThirdProductAccountedForRevenue>
	<us-gaap:SharesOutstanding decimals='INF' contextRef='E14_StEqComps-CapUnits' unitRef='Shares'>43579557</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding decimals='INF' contextRef='E14_StEqComps-CommonStock' unitRef='Shares'>43580</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding decimals='INF' contextRef='E14_StEqComps-AddPaidInCap' unitRef='Shares'>23590204</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding decimals='INF' contextRef='E14_StEqComps-RetainedEarnings' unitRef='Shares'>49345516</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding decimals='INF' contextRef='E14_StEqComps-AccumulatedOtherComprIncome' unitRef='Shares'>19760820</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding decimals='INF' contextRef='E14_StEqComps-StockholdersEqTotal' unitRef='Shares'>92740120</us-gaap:SharesOutstanding>
	<fil:NetLossForTheYear decimals='INF' contextRef='Y15_StEqComps-RetainedEarnings' unitRef='USD'>-15405518</fil:NetLossForTheYear>
	<fil:NetLossForTheYear decimals='INF' contextRef='Y15_StEqComps-StockholdersEqTotal' unitRef='USD'>-15405518</fil:NetLossForTheYear>
	<fil:ForeignCurrencyTranslationAdjustment decimals='INF' contextRef='Y15_StEqComps-AccumulatedOtherComprIncome' unitRef='USD'>-4693453</fil:ForeignCurrencyTranslationAdjustment>
	<fil:ForeignCurrencyTranslationAdjustment decimals='INF' contextRef='Y15_StEqComps-StockholdersEqTotal' unitRef='USD'>-4693453</fil:ForeignCurrencyTranslationAdjustment>
	<fil:Balance decimals='INF' contextRef='E15_StEqComps-CapUnits' unitRef='Shares'>43579557</fil:Balance>
	<fil:Balance decimals='INF' contextRef='E15_StEqComps-CommonStock' unitRef='Shares'>43580</fil:Balance>
	<fil:Balance decimals='INF' contextRef='E15_StEqComps-AddPaidInCap' unitRef='Shares'>23590204</fil:Balance>
	<fil:Balance decimals='INF' contextRef='E15_StEqComps-RetainedEarnings' unitRef='Shares'>33939998</fil:Balance>
	<fil:Balance decimals='INF' contextRef='E15_StEqComps-AccumulatedOtherComprIncome' unitRef='Shares'>15067367</fil:Balance>
	<fil:Balance decimals='INF' contextRef='E15_StEqComps-StockholdersEqTotal' unitRef='Shares'>72641149</fil:Balance>
	<fil:NetLossForTheYear1 decimals='INF' contextRef='Y16_StEqComps-RetainedEarnings' unitRef='USD'>-9182624</fil:NetLossForTheYear1>
	<fil:NetLossForTheYear1 decimals='INF' contextRef='Y16_StEqComps-StockholdersEqTotal' unitRef='USD'>-9182624</fil:NetLossForTheYear1>
	<fil:ForeignCurrencyTranslationAdjustment1 decimals='INF' contextRef='Y16_StEqComps-AccumulatedOtherComprIncome' unitRef='USD'>-4549391</fil:ForeignCurrencyTranslationAdjustment1>
	<fil:ForeignCurrencyTranslationAdjustment1 decimals='INF' contextRef='Y16_StEqComps-StockholdersEqTotal' unitRef='USD'>-4549391</fil:ForeignCurrencyTranslationAdjustment1>
	<fil:Balance1 decimals='INF' contextRef='E16_StEqComps-CapUnits' unitRef='Shares'>43579557</fil:Balance1>
	<fil:Balance1 decimals='INF' contextRef='E16_StEqComps-CommonStock' unitRef='Shares'>43580</fil:Balance1>
	<fil:Balance1 decimals='INF' contextRef='E16_StEqComps-AddPaidInCap' unitRef='Shares'>23590204</fil:Balance1>
	<fil:Balance1 decimals='INF' contextRef='E16_StEqComps-RetainedEarnings' unitRef='Shares'>24757374</fil:Balance1>
	<fil:Balance1 decimals='INF' contextRef='E16_StEqComps-AccumulatedOtherComprIncome' unitRef='Shares'>10517976</fil:Balance1>
	<fil:Balance1 decimals='INF' contextRef='E16_StEqComps-StockholdersEqTotal' unitRef='Shares'>58909134</fil:Balance1>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate decimals='INF' contextRef='Y16' unitRef='USD'>-2218612</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate decimals='INF' contextRef='Y15' unitRef='USD'>-3832536</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationTaxHolidays decimals='INF' contextRef='Y16' unitRef='USD'>837089</us-gaap:IncomeTaxReconciliationTaxHolidays>
	<us-gaap:IncomeTaxReconciliationTaxHolidays decimals='INF' contextRef='Y15' unitRef='USD'>1478831</us-gaap:IncomeTaxReconciliationTaxHolidays>
	<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential decimals='INF' contextRef='Y16' unitRef='USD'>-8094456</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate decimals='INF' contextRef='Y16' unitRef='USD'>7903</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate decimals='INF' contextRef='Y15' unitRef='USD'>4136</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance decimals='INF' contextRef='Y16' unitRef='USD'>9776251</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance decimals='INF' contextRef='Y15' unitRef='USD'>2410008</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<fil:IncomeTaxExpense decimals='INF' contextRef='Y16' unitRef='USD'>308175</fil:IncomeTaxExpense>
	<fil:IncomeTaxExpense decimals='INF' contextRef='Y15' unitRef='USD'>60439</fil:IncomeTaxExpense>
	<dei:DocumentType contextRef='Y16'>10-K</dei:DocumentType>
	<dei:DocumentPeriodEndDate contextRef='Y16'>2016-12-31</dei:DocumentPeriodEndDate>
	<dei:AmendmentFlag contextRef='Y16'>false</dei:AmendmentFlag>
	<dei:EntityRegistrantName contextRef='Y16'>CHINA PHARMA HOLDINGS, INC.</dei:EntityRegistrantName>
	<dei:EntityCentralIndexKey contextRef='Y16'>0001106644</dei:EntityCentralIndexKey>
	<dei:TradingSymbol contextRef='Y16'>cphi</dei:TradingSymbol>
	<dei:CurrentFiscalYearEndDate contextRef='Y16'>--12-31</dei:CurrentFiscalYearEndDate>
	<dei:EntityCommonStockSharesOutstanding decimals='INF' contextRef='I170329' unitRef='Shares'>43579557</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityPublicFloat decimals='INF' contextRef='E15Q2' unitRef='USD'>0</dei:EntityPublicFloat>
	<dei:EntityFilerCategory contextRef='Y16'>Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityCurrentReportingStatus contextRef='Y16'>Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityVoluntaryFilers contextRef='Y16'>No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef='Y16'>No</dei:EntityWellKnownSeasonedIssuer>
	<dei:DocumentFiscalYearFocus contextRef='Y16'>2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentFiscalPeriodFocus contextRef='Y16'>FY</dei:DocumentFiscalPeriodFocus>
	<context id='Y16'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<startDate>2016-01-01</startDate>
			<endDate>2016-12-31</endDate>
		</period>
	</context>
	<context id='I170329'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2017-03-29</instant>
		</period>
	</context>
	<context id='E15Q2'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2015-06-30</instant>
		</period>
	</context>
	<context id='E16'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2016-12-31</instant>
		</period>
	</context>
	<context id='E15'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2015-12-31</instant>
		</period>
	</context>
	<context id='Y15'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<startDate>2015-01-01</startDate>
			<endDate>2015-12-31</endDate>
		</period>
	</context>
	<context id='I141130'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2014-11-30</instant>
		</period>
	</context>
	<context id='I150710'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2015-07-10</instant>
		</period>
	</context>
	<context id='I101112'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2010-11-12</instant>
		</period>
	</context>
	<context id='Y16_StEqComps-RetainedEarnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2016-01-01</startDate>
			<endDate>2016-12-31</endDate>
		</period>
	</context>
	<context id='Y16_StEqComps-AccumulatedOtherComprIncome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2016-01-01</startDate>
			<endDate>2016-12-31</endDate>
		</period>
	</context>
	<context id='Y16_StEqComps-StockholdersEqTotal'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:StockholdersEquityTotalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2016-01-01</startDate>
			<endDate>2016-12-31</endDate>
		</period>
	</context>
	<context id='E16_StEqComps-CapUnits'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CapitalUnitsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2016-12-31</instant>
		</period>
	</context>
	<context id='E16_StEqComps-CommonStock'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2016-12-31</instant>
		</period>
	</context>
	<context id='E16_StEqComps-AddPaidInCap'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2016-12-31</instant>
		</period>
	</context>
	<context id='E16_StEqComps-RetainedEarnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2016-12-31</instant>
		</period>
	</context>
	<context id='E16_StEqComps-AccumulatedOtherComprIncome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2016-12-31</instant>
		</period>
	</context>
	<context id='E16_StEqComps-StockholdersEqTotal'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:StockholdersEquityTotalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2016-12-31</instant>
		</period>
	</context>
	<context id='E14_StEqComps-CapUnits'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CapitalUnitsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2014-12-31</instant>
		</period>
	</context>
	<context id='E14_StEqComps-CommonStock'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2014-12-31</instant>
		</period>
	</context>
	<context id='E14_StEqComps-AddPaidInCap'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2014-12-31</instant>
		</period>
	</context>
	<context id='E14_StEqComps-RetainedEarnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2014-12-31</instant>
		</period>
	</context>
	<context id='E14_StEqComps-AccumulatedOtherComprIncome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2014-12-31</instant>
		</period>
	</context>
	<context id='E14_StEqComps-StockholdersEqTotal'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:StockholdersEquityTotalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2014-12-31</instant>
		</period>
	</context>
	<context id='Y15_StEqComps-RetainedEarnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2015-01-01</startDate>
			<endDate>2015-12-31</endDate>
		</period>
	</context>
	<context id='Y15_StEqComps-AccumulatedOtherComprIncome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2015-01-01</startDate>
			<endDate>2015-12-31</endDate>
		</period>
	</context>
	<context id='Y15_StEqComps-StockholdersEqTotal'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:StockholdersEquityTotalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2015-01-01</startDate>
			<endDate>2015-12-31</endDate>
		</period>
	</context>
	<context id='E15_StEqComps-CapUnits'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CapitalUnitsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2015-12-31</instant>
		</period>
	</context>
	<context id='E15_StEqComps-CommonStock'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2015-12-31</instant>
		</period>
	</context>
	<context id='E15_StEqComps-AddPaidInCap'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2015-12-31</instant>
		</period>
	</context>
	<context id='E15_StEqComps-RetainedEarnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2015-12-31</instant>
		</period>
	</context>
	<context id='E15_StEqComps-AccumulatedOtherComprIncome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2015-12-31</instant>
		</period>
	</context>
	<context id='E15_StEqComps-StockholdersEqTotal'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:StockholdersEquityTotalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2015-12-31</instant>
		</period>
	</context>
	<unit id='USD'>
		<measure>iso4217:USD</measure>
	</unit>
	<unit id='Shares'>
		<measure>shares</measure>
	</unit>
	<unit id='UsdPerShare'>
		<divide>
			<unitNumerator>
				<measure>iso4217:USD</measure>
			</unitNumerator>
			<unitDenominator>
				<measure>shares</measure>
			</unitDenominator>
		</divide>
	</unit>
	<unit id='Pure'>
		<measure>pure</measure>
	</unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cphi-20161231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<schema xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2016-01-31' xmlns:fil='http://www.chinapharmaholdings.com/20161231' xmlns:dei='http://xbrl.sec.gov/dei/2014-01-31' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:num='http://www.xbrl.org/dtr/type/numeric' targetNamespace='http://www.chinapharmaholdings.com/20161231' xmlns:link='http://www.xbrl.org/2003/linkbase' elementFormDefault='qualified' xmlns:xbrli='http://www.xbrl.org/2003/instance' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails" id="idr_BANKERSACCEPTANCENOTESPAYABLEDetails">
				<link:definition>000400 - Statement - BANKER&apos;S ACCEPTANCE NOTES PAYABLE (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES" id="idr_DisclosureACCOUNTINGPOLICIESPOLICIES">
				<link:definition>000210 - Disclosure - ACCOUNTING POLICIES (POLICIES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETS" id="idr_DisclosureINTANGIBLEASSETS">
				<link:definition>000100 - Disclosure - INTANGIBLE ASSETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureNOTESPAYABLE" id="idr_DisclosureNOTESPAYABLE">
				<link:definition>000130 - Disclosure - NOTES PAYABLE</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_INVENTORYDETAILS" id="idr_INVENTORYDETAILS">
				<link:definition>000290 - Statement - INVENTORY (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETSTABLES" id="idr_DisclosureINTANGIBLEASSETSTABLES">
				<link:definition>000240 - Disclosure - INTANGIBLE ASSETS (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" id="idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
				<link:definition>000050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_RELATEDPARTYTRANSACTIONSDetails" id="idr_RELATEDPARTYTRANSACTIONSDetails">
				<link:definition>000380 - Statement - RELATED PARTY TRANSACTIONS (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXES" id="idr_DisclosureINCOMETAXES">
				<link:definition>000170 - Disclosure - INCOME TAXES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" id="idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS">
				<link:definition>000110 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS" id="idr_CAPITALSTOCKTRANSACTIONSDETAILS">
				<link:definition>000500 - Statement - CAPITAL STOCK TRANSACTIONS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS" id="idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS">
				<link:definition>000480 - Statement - DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS" id="idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS">
				<link:definition>000300 - Statement - PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES" id="idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES">
				<link:definition>000250 - Disclosure - SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONCENTRATIONS" id="idr_DisclosureCONCENTRATIONS">
				<link:definition>000200 - Disclosure - CONCENTRATIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
				<link:definition>000060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES" id="idr_DisclosurePROPERTYANDEQUIPMENTTABLES">
				<link:definition>000230 - Disclosure - PROPERTY AND EQUIPMENT (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_RECONCILIATIONOFINCOMETAXESCALCULATEDATSTATUTORYRATESDETAILS" id="idr_RECONCILIATIONOFINCOMETAXESCALCULATEDATSTATUTORYRATESDETAILS">
				<link:definition>000470 - Statement - RECONCILIATION OF INCOME TAXES CALCULATED AT STATUTORY RATES (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" id="idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
				<link:definition>000280 - Statement - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES -Narrative(Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_INCOMETAXESNARRATIVEDETAILS" id="idr_INCOMETAXESNARRATIVEDETAILS">
				<link:definition>000481 - Statement - INCOME TAXES NARRATIVE (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORY" id="idr_DisclosureINVENTORY">
				<link:definition>000080 - Disclosure - INVENTORY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSUBSIDYINCOME" id="idr_DisclosureSUBSIDYINCOME">
				<link:definition>000160 - Disclosure - SUBSIDY INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORYTABLES" id="idr_DisclosureINVENTORYTABLES">
				<link:definition>000220 - Disclosure - INVENTORY (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONSTRUCTIONLOANFACILITY" id="idr_DisclosureCONSTRUCTIONLOANFACILITY">
				<link:definition>000150 - Disclosure - CONSTRUCTION LOAN FACILITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" id="idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
				<link:definition>000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETS" id="idr_CONSOLIDATEDBALANCESHEETS">
				<link:definition>000020 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" id="idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
				<link:definition>000270 - Statement - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENT" id="idr_DisclosurePROPERTYANDEQUIPMENT">
				<link:definition>000090 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_IntangibleAssetsAmortizationExpensesDetails" id="idr_IntangibleAssetsAmortizationExpensesDetails">
				<link:definition>000350 - Statement - Intangible assets amortization expenses (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSTOCKHOLDERSEQUITY" id="idr_DisclosureSTOCKHOLDERSEQUITY">
				<link:definition>000180 - Disclosure - STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS" id="idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS">
				<link:definition>000370 - Statement - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS" id="idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS">
				<link:definition>000030 - Statement - CONSOLIDATED BALANCE SHEETS PARENTHETICALS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE" id="idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE">
				<link:definition>000140 - Disclosure - BANKER&apos;S ACCEPTANCE NOTES PAYABLE</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXESTABLES" id="idr_DisclosureINCOMETAXESTABLES">
				<link:definition>000260 - Disclosure - INCOME TAXES (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDAGGREGATEANNUALAMORTIZATIONEXPENSEDETAILS" id="idr_ESTIMATEDAGGREGATEANNUALAMORTIZATIONEXPENSEDETAILS">
				<link:definition>000360 - Statement - ESTIMATED AGGREGATE ANNUAL AMORTIZATION EXPENSE (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_NOTESPAYABLESDETAILS" id="idr_NOTESPAYABLESDETAILS">
				<link:definition>000390 - Statement - NOTES PAYABLES (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS" id="idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS">
				<link:definition>000340 - Statement - INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS" id="idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS">
				<link:definition>000320 - Statement - ESTIMATED USEFUL LIVES OF THE ASSETS AS FOLLOWS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" id="idr_DisclosureCOMMITMENTSANDCONTINGENCIES">
				<link:definition>000190 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_PROVISIONFORINCOMETAXESDETAILS" id="idr_PROVISIONFORINCOMETAXESDETAILS">
				<link:definition>000460 - Statement - PROVISION FOR INCOME TAXES (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" id="idr_DisclosureRELATEDPARTYTRANSACTIONS">
				<link:definition>000120 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS" id="idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS">
				<link:definition>000420 - Statement - PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" id="idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
				<link:definition>000070 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSTRUCTIONLOANFACILITYDETAILS" id="idr_CONSTRUCTIONLOANFACILITYDETAILS">
				<link:definition>000410 - Statement - CONSTRUCTION LOAN FACILITY (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_SUBSIDYINCOMEDetails" id="idr_SUBSIDYINCOMEDetails">
				<link:definition>000440 - Statement - SUBSIDY INCOME (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ENTERPRISEINCOMETAXRATESDETAILS" id="idr_ENTERPRISEINCOMETAXRATESDETAILS">
				<link:definition>000450 - Statement - ENTERPRISE INCOME TAX RATES (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONCENTRATIONSDETAILS" id="idr_CONCENTRATIONSDETAILS">
				<link:definition>000510 - Statement - CONCENTRATIONS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/numeric'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/non-numeric'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import namespace='http://fasb.org/us-gaap/2016-01-31' schemaLocation='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd' />
	<import namespace='http://xbrl.sec.gov/dei/2014-01-31' schemaLocation='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DocumentAndEntityInformationAbstract' name='DocumentAndEntityInformationAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AdvancesToSuppliers' name='AdvancesToSuppliers' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' name='AllowanceForDoubtfulAccountsOnOtherReceivables' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_InventoryPurchasedWithBankerSAcceptances' name='InventoryPurchasedWithBankerSAcceptances' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_AccountsReceivableCollectedWithBankerSAcceptances' name='AccountsReceivableCollectedWithBankerSAcceptances' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_AccountsPayableForPurchasesOfPropertyAndEquipment' name='AccountsPayableForPurchasesOfPropertyAndEquipment' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' name='AdvancesForPurchasesOfIntangibleAssetsAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' name='AdvancesForPurchasesOfIntangibleAssetsTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NotesPayable1Abstract' name='NotesPayable1Abstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_InventoryTablesAbstract' name='InventoryTablesAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PropertyAndEquipmentTablesAbstract' name='PropertyAndEquipmentTablesAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_UsefulLivesOfTheAssetsTableTextBlock' name='UsefulLivesOfTheAssetsTableTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsTablesAbstract' name='IntangibleAssetsTablesAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' name='IntangibleAssetsMedicalFormulasTablesTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IncomeTaxesTablesAbstract' name='IncomeTaxesTablesAbstract' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PercetageOfAcquiredByOnnyInHelpson' name='PercetageOfAcquiredByOnnyInHelpson' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_MotorVehicleGross' name='MotorVehicleGross' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PropertyAndEquipmentNet' name='PropertyAndEquipmentNet' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_OfficeEquipmentMaximumLife' name='OfficeEquipmentMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_MotorVehicleMaximumLife' name='MotorVehicleMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_BuildingMaximumLife' name='BuildingMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PermitOfLandUseMaximumLife' name='PermitOfLandUseMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_OfficeEquipmentMinimumLife' name='OfficeEquipmentMinimumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_MotorVehicleMinimumLife' name='MotorVehicleMinimumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_BuildingMinimumLife' name='BuildingMinimumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PermitOfLandUseMinimumLife' name='PermitOfLandUseMinimumLife' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_GrossCarryingAmount' name='GrossCarryingAmount' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_NetCarryingAmount' name='NetCarryingAmount' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_CommonSharesAuthorized' name='CommonSharesAuthorized' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PreferredSharesAuthorized' name='PreferredSharesAuthorized' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_NumberOfCommonShares' name='NumberOfCommonShares' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_InterestRateOnAdvancesFromMemberOfBOD' name='InterestRateOnAdvancesFromMemberOfBOD' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' name='OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' name='PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CashAndCashEquivalentsAtBeginningOfPeriod' name='CashAndCashEquivalentsAtBeginningOfPeriod' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CashAndCashEquivalentsAtEndOfPeriod' name='CashAndCashEquivalentsAtEndOfPeriod' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DebtAbstract' name='DebtAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AdvancesForPurchasesOfIntangibleAssets' name='AdvancesForPurchasesOfIntangibleAssets' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' name='PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' name='AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ConstructionLoanFacilityDetailsAbstract' name='ConstructionLoanFacilityDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommitmentAndContingenciesAbstract' name='CommitmentAndContingenciesAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock' name='AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfLongTermDebtInstrumentsAbstract' name='ScheduleOfLongTermDebtInstrumentsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_OfficeEquipment1' name='OfficeEquipment1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2017' name='PrincipalPayments2017' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2018' name='PrincipalPayments2018' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' name='SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalInventory' name='TotalInventory' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PlantMachineryAndEquipmentMaximumLife' name='PlantMachineryAndEquipmentMaximumLife' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_RevolvingLineOfCreditWithABankRmb' name='RevolvingLineOfCreditWithABankRmb' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_PrincipalPayments2019' name='PrincipalPayments2019' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_TotalPrincipalPaymentsDue' name='TotalPrincipalPaymentsDue' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ConcentrationsDetailsAbstract' name='ConcentrationsDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_LessAccumulatedDepreciation' name='LessAccumulatedDepreciation' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AccumulatedAmortization' name='AccumulatedAmortization' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_LoanInterestForAnEightYearTerm' name='LoanInterestForAnEightYearTerm' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalLoanFacilityAmountRmb80000000' name='TotalLoanFacilityAmountRmb80000000' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' name='PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' name='IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PlantMachineryAndEquipmentMinimumLife' name='PlantMachineryAndEquipmentMinimumLife' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_SubsidyIncome' name='SubsidyIncome' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_BankersAcceptancesRedeemedForCash' name='BankersAcceptancesRedeemedForCash' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' name='AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_InterestRateWasAdjustedTo' name='InterestRateWasAdjustedTo' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SubsidyIncomeDetailsAbstract' name='SubsidyIncomeDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' name='OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_Balance' name='Balance' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_Balance1' name='Balance1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_NetLossForTheYear' name='NetLossForTheYear' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_NetLossForTheYear1' name='NetLossForTheYear1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_ForeignCurrencyTranslationAdjustment' name='ForeignCurrencyTranslationAdjustment' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_ForeignCurrencyTranslationAdjustment1' name='ForeignCurrencyTranslationAdjustment1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' name='AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AccountingPoliciesAbstract1' name='AccountingPoliciesAbstract1' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' name='AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_BadDebtExpense' name='BadDebtExpense' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_UncollectableTradeAccountsReceivable' name='UncollectableTradeAccountsReceivable' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_InventoryDetailsAbstract' name='InventoryDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' name='PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' name='EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' name='EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_EstimatedAggregateAnnualAmortizationExpenseThereafter' name='EstimatedAggregateAnnualAmortizationExpenseThereafter' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_CompanyWasObligatedToPayLaboratoriesAndOthers' name='CompanyWasObligatedToPayLaboratoriesAndOthers' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' name='IntangibleAssetsAmortizationExpensesDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_AmortizationExpensesRelatingToIntangibleAssets' name='AmortizationExpensesRelatingToIntangibleAssets' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RelatedPartyTransactionsDetailsAbstract' name='RelatedPartyTransactionsDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_TotalInterestExpense' name='TotalInterestExpense' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_AdvancesOwingToBoardOfDirectors' name='AdvancesOwingToBoardOfDirectors' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NotesPayablesDetailsAbstract' name='NotesPayablesDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2020' name='PrincipalPayments2020' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2021' name='PrincipalPayments2021' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_EnterpriseIncomeTaxRatesDetailsAbstract' name='EnterpriseIncomeTaxRatesDetailsAbstract' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRate2015' name='EnterpriseIncomeTaxRate2015' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRate2016' name='EnterpriseIncomeTaxRate2016' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRate2017' name='EnterpriseIncomeTaxRate2017' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRate2018' name='EnterpriseIncomeTaxRate2018' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRateThereafter' name='EnterpriseIncomeTaxRateThereafter' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ProvisionForIncomeTaxesDetailsAbstract' name='ProvisionForIncomeTaxesDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' name='ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_IncomeTaxExpense' name='IncomeTaxExpense' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DeferredIncomeTaxAssetsAbstract' name='DeferredIncomeTaxAssetsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AllowanceForDoubtfulOtherReceivables' name='AllowanceForDoubtfulOtherReceivables' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrcNetOperatingLossCarryForward' name='PrcNetOperatingLossCarryForward' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DeferredIncomeTaxLiabilityAbstract' name='DeferredIncomeTaxLiabilityAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CapitalStockTransactionsAbstract' name='CapitalStockTransactionsAbstract' />
	<element nillable='true' type='num:perShareItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_CommonSharesParValue' name='CommonSharesParValue' />
	<element nillable='true' type='num:perShareItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PreferredSharesParValue' name='PreferredSharesParValue' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_EmployeeStockOptions2010IncentivePlanAbstract' name='EmployeeStockOptions2010IncentivePlanAbstract' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NoCustomerAccountedForMoreThanPercentageOfSales' name='NoCustomerAccountedForMoreThanPercentageOfSales' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' name='OneSupplierAccountedForPercentageOfRawMaterialPurchases' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OneCustomerAccountedForPercentageOfAccountsReceivable' name='OneCustomerAccountedForPercentageOfAccountsReceivable' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PercentageOfProductFirstAccountedForRevenue' name='PercentageOfProductFirstAccountedForRevenue' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PercentageOfProductSecondAccountedForRevenue' name='PercentageOfProductSecondAccountedForRevenue' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PercentageOfThirdProductAccountedForRevenue' name='PercentageOfThirdProductAccountedForRevenue' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SubsidyIncomeAbstract' name='SubsidyIncomeAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SubsidyIncomeDisclosureTextBlock' name='SubsidyIncomeDisclosureTextBlock' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_InterestRateRiskPolicyTextBlock' name='InterestRateRiskPolicyTextBlock' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' name='ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock' name='IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts' name='TradeAccountsReceivableLessAllowanceForDoubtfulAccounts' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_BankersAcceptanceNotesPayable' name='BankersAcceptanceNotesPayable' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_ProvisionForObsoleteInventory' name='ProvisionForObsoleteInventory' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_IssuanceOfBankerSAcceptances' name='IssuanceOfBankerSAcceptances' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BankerSAcceptanceNotesPayableAbstract' name='BankerSAcceptanceNotesPayableAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BankerSAcceptanceNotesPayableTextBlock' name='BankerSAcceptanceNotesPayableTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' name='OrganizationAndSignificantAccountingPoliciesDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract' name='AdvancesToSuppliersAndAdvancesFromCustomersAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CompanyRecognizedBadDebtExpense' name='CompanyRecognizedBadDebtExpense' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ValuationOfLongLivedAssetsAbstract' name='ValuationOfLongLivedAssetsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_ImpairmentAdjustmentsRelatedToAdvances' name='ImpairmentAdjustmentsRelatedToAdvances' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RetirementBenefitPlansAbstract' name='RetirementBenefitPlansAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_RetirementBenefitPlans' name='RetirementBenefitPlans' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories' name='ImpairmentLossForTheAdvancesMadeToTheseLaboratories' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BankerSAcceptanceNotesPayableDetailsAbstract' name='BankerSAcceptanceNotesPayableDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount' name='CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1' name='ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_ImpairmentLoss1' name='ImpairmentLoss1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AdvancesForIntangibleAssetsImpairment1' name='AdvancesForIntangibleAssetsImpairment1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalDeferredIncomeTaxAssets' name='TotalDeferredIncomeTaxAssets' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_IntangibleAssets1' name='IntangibleAssets1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_NetDeferredIncomeTaxAsset1' name='NetDeferredIncomeTaxAsset1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IncomeTaxesNarrativeDetailsAbstract' name='IncomeTaxesNarrativeDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_ChangeInTheTaxExpense' name='ChangeInTheTaxExpense' />
	<element nillable='true' type='num:perShareItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BasicAndDilutedEarningsPerShare' name='BasicAndDilutedEarningsPerShare' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes' name='NetOperatingLossCarryforwardsForPrcTaxPurposes' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes' name='NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_ValuationAllowanceAgainstItsDeferredTax' name='ValuationAllowanceAgainstItsDeferredTax' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ChangesInStockholdersEquityAbstract' name='ChangesInStockholdersEquityAbstract' />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cphi-20161231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20161231"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDBALANCESHEETS"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssets' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_Revenues' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfRevenue' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown' xlink:label='us-gaap_InventoryWriteDown'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_InventoryWriteDown' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInCustomerAdvances' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInDepositOtherAssets' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:label='us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInIncomeTaxes' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization' xlink:label='us-gaap_DepreciationDepletionAndAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DepreciationDepletionAndAmortization' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='8.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_NetIncomeLoss' use='optional' order='9.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='10.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:label='us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidExpense' use='optional' order='11.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ProvisionForObsoleteInventory' xlink:label='fil_ProvisionForObsoleteInventory'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='fil_ProvisionForObsoleteInventory' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' use='optional' order='13.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayableTrade' use='optional' order='14.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cphi-20161231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20161231"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDBALANCESHEETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalUnitsMember' xlink:label='us-gaap_CapitalUnitsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CapitalUnitsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityTotalMember' xlink:label='us-gaap_StockholdersEquityTotalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_StockholdersEquityTotalMember' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_Balance' xlink:label='fil_Balance'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Balance' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_Balance1' xlink:label='fil_Balance1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Balance1' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetLossForTheYear' xlink:label='fil_NetLossForTheYear'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetLossForTheYear' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ForeignCurrencyTranslationAdjustment' xlink:label='fil_ForeignCurrencyTranslationAdjustment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForeignCurrencyTranslationAdjustment' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetLossForTheYear1' xlink:label='fil_NetLossForTheYear1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetLossForTheYear1' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ForeignCurrencyTranslationAdjustment1' xlink:label='fil_ForeignCurrencyTranslationAdjustment1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForeignCurrencyTranslationAdjustment1' use='optional' order='7.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORY" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINVENTORY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORY"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINTANGIBLEASSETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureNOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureNOTESPAYABLE"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureNOTESPAYABLE"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONSTRUCTIONLOANFACILITY" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureCONSTRUCTIONLOANFACILITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONSTRUCTIONLOANFACILITY"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSUBSIDYINCOME" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureSUBSIDYINCOME"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSUBSIDYINCOME"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINCOMETAXES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONCENTRATIONS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureCONCENTRATIONS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONCENTRATIONS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureACCOUNTINGPOLICIESPOLICIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORYTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINVENTORYTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORYTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosurePROPERTYANDEQUIPMENTTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETSTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINTANGIBLEASSETSTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETSTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXESTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINCOMETAXESTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXESTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_INVENTORYDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_INVENTORYDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_INVENTORYDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_IntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_IntangibleAssetsAmortizationExpensesDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_IntangibleAssetsAmortizationExpensesDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDAGGREGATEANNUALAMORTIZATIONEXPENSEDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ESTIMATEDAGGREGATEANNUALAMORTIZATIONEXPENSEDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDAGGREGATEANNUALAMORTIZATIONEXPENSEDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_RELATEDPARTYTRANSACTIONSDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_RELATEDPARTYTRANSACTIONSDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_NOTESPAYABLESDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_NOTESPAYABLESDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_NOTESPAYABLESDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_BANKERSACCEPTANCENOTESPAYABLEDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSTRUCTIONLOANFACILITYDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSTRUCTIONLOANFACILITYDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSTRUCTIONLOANFACILITYDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_SUBSIDYINCOMEDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_SUBSIDYINCOMEDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_SUBSIDYINCOMEDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ENTERPRISEINCOMETAXRATESDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ENTERPRISEINCOMETAXRATESDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ENTERPRISEINCOMETAXRATESDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_PROVISIONFORINCOMETAXESDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_PROVISIONFORINCOMETAXESDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_PROVISIONFORINCOMETAXESDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_RECONCILIATIONOFINCOMETAXESCALCULATEDATSTATUTORYRATESDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_RECONCILIATIONOFINCOMETAXESCALCULATEDATSTATUTORYRATESDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_RECONCILIATIONOFINCOMETAXESCALCULATEDATSTATUTORYRATESDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_INCOMETAXESNARRATIVEDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_INCOMETAXESNARRATIVEDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_INCOMETAXESNARRATIVEDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CAPITALSTOCKTRANSACTIONSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONCENTRATIONSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONCENTRATIONSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONCENTRATIONSDETAILS"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cphi-20161231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20161231"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:label='fil_OneCustomerAccountedForPercentageOfAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>One customer accounted for percentage of accounts receivable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>One customer accounted for percentage of accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:to='lab_fil_OneCustomerAccountedForPercentageOfAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:label='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Reconciliation of income taxes calculated at the federal statutory rates:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:to='lab_fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_GrossCarryingAmount' xlink:label='fil_GrossCarryingAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross carrying amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Gross carrying amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrossCarryingAmount' xlink:to='lab_fil_GrossCarryingAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:label='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets CFDA approved medical formulas details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:to='lab_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BadDebtExpense' xlink:label='fil_BadDebtExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Bad debt expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BadDebtExpense' xlink:to='lab_fil_BadDebtExpense'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:label='fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Useful lives of the assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure of useful lives of the assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:to='lab_fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock' xlink:label='fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>A reconciliation of total interest cost incurred to interest expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure for reconciliation of total interest cost incurred to interest expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock' xlink:to='lab_fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock' xlink:label='us-gaap_InventoryPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryPolicyTextBlock' xlink:to='lab_us-gaap_InventoryPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:label='fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:to='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:label='us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:to='lab_us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization' xlink:label='us-gaap_DepreciationDepletionAndAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DepreciationDepletionAndAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation and amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DepreciationDepletionAndAmortization' xlink:to='lab_us-gaap_DepreciationDepletionAndAmortization'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock Amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Table]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract' xlink:label='us-gaap_LiabilitiesNoncurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesNoncurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Non-current Liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesNoncurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent' xlink:label='us-gaap_NotesPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NotesPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Short-term notes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NotesPayableCurrent' xlink:to='lab_us-gaap_NotesPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankersAcceptanceNotesPayable' xlink:label='fil_BankersAcceptanceNotesPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers&apos; acceptance notes payable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesPayable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers&apos; acceptance notes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesPayable' xlink:to='lab_fil_BankersAcceptanceNotesPayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CommonSharesParValue' xlink:label='fil_CommonSharesParValue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesParValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common shares par value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesParValue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Face amount or stated value per share of common stock.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonSharesParValue' xlink:to='lab_fil_CommonSharesParValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1' xlink:label='fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Received cash related to a subsidy from the government for the technological innovation</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1' xlink:to='lab_fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NotesPayablesDetailsAbstract' xlink:label='fil_NotesPayablesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NotesPayablesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>NOTES PAYABLES DETAILS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NotesPayablesDetailsAbstract' xlink:to='lab_fil_NotesPayablesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PlantMachineryAndEquipmentMaximumLife' xlink:label='fil_PlantMachineryAndEquipmentMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PlantMachineryAndEquipmentMaximumLife' xlink:to='lab_fil_PlantMachineryAndEquipmentMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_MotorVehicleGross' xlink:label='fil_MotorVehicleGross'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleGross' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of motor vehicle gross as on the date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleGross' xlink:to='lab_fil_MotorVehicleGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:to='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' xlink:label='us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Temporary differences which give rise to the deferred income tax assets and liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of Revenues</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NatureOfOperations' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Organization and Nature of Operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NatureOfOperations' xlink:to='lab_us-gaap_NatureOfOperations'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock' xlink:label='us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INCOME TAXES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxDisclosureTextBlock' xlink:to='lab_us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SubsidyIncomeAbstract' xlink:label='fil_SubsidyIncomeAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SubsidyIncomeAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SUBSIDY INCOME:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SubsidyIncomeAbstract' xlink:to='lab_fil_SubsidyIncomeAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:label='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:to='lab_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract' xlink:label='us-gaap_EarningsPerShareAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loss per share:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='lab_us-gaap_EarningsPerShareAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses' xlink:label='us-gaap_OtherExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net other expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherExpenses' xlink:to='lab_us-gaap_OtherExpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ChangeInTheTaxExpense' xlink:label='fil_ChangeInTheTaxExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangeInTheTaxExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Change in the Tax expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangeInTheTaxExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Change in the Tax expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ChangeInTheTaxExpense' xlink:to='lab_fil_ChangeInTheTaxExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards' xlink:label='us-gaap_OperatingLossCarryforwards'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLossCarryforwards' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>U.S. net operating loss carry forward</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLossCarryforwards' xlink:to='lab_us-gaap_OperatingLossCarryforwards'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory' xlink:label='us-gaap_DeferredTaxAssetsInventory'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxAssetsInventory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory obsolescence reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxAssetsInventory' xlink:to='lab_us-gaap_DeferredTaxAssetsInventory'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxHolidays' xlink:label='us-gaap_IncomeTaxReconciliationTaxHolidays'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxReconciliationTaxHolidays' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of tax holiday</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxReconciliationTaxHolidays' xlink:to='lab_us-gaap_IncomeTaxReconciliationTaxHolidays'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRate2018' xlink:label='fil_EnterpriseIncomeTaxRate2018'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2018' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rate 2018</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2018' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rate 2018</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRate2018' xlink:to='lab_fil_EnterpriseIncomeTaxRate2018'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_LoanInterestForAnEightYearTerm' xlink:label='fil_LoanInterestForAnEightYearTerm'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LoanInterestForAnEightYearTerm' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loan interest for an eight-year term</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LoanInterestForAnEightYearTerm' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Loan interest for an eight-year term</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LoanInterestForAnEightYearTerm' xlink:to='lab_fil_LoanInterestForAnEightYearTerm'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated aggregate annual amortization expense Thereafter</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated aggregate annual amortization expense for 2021</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:label='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets amortization expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:to='lab_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_MotorVehicleMinimumLife' xlink:label='fil_MotorVehicleMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleMinimumLife' xlink:to='lab_fil_MotorVehicleMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandAndLandImprovements' xlink:label='us-gaap_LandAndLandImprovements'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LandAndLandImprovements' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LandAndLandImprovements' xlink:to='lab_us-gaap_LandAndLandImprovements'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_RetirementBenefitPlans' xlink:label='fil_RetirementBenefitPlans'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RetirementBenefitPlans' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retirement Benefit Plans {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RetirementBenefitPlans' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Retirement Benefit Plans</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RetirementBenefitPlans' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Retirement Benefit Plans</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RetirementBenefitPlans' xlink:to='lab_fil_RetirementBenefitPlans'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:label='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock' xlink:label='fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets estimated aggregate annual amortization expense for each of the next five years and thereafter</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabluar disclosure of Intangible Assets estimated aggregate annual amortization expense for each of the next five years and thereafter</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock' xlink:to='lab_fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_UseOfEstimates' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounting Estimates</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_UseOfEstimates' xlink:to='lab_us-gaap_UseOfEstimates'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NotesPayable1Abstract' xlink:label='fil_NotesPayable1Abstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NotesPayable1Abstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>NOTES PAYABLES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NotesPayable1Abstract' xlink:to='lab_fil_NotesPayable1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract' xlink:label='us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RelatedPartyTransactionsAbstract' xlink:to='lab_us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:label='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchases of intangibles paid with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The fair value of advances for purchases of intangibles paid with banker&apos;s acceptances under non cash investing and financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:to='lab_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income - foreign currency translation adjustment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract' xlink:label='us-gaap_RevenuesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenuesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenuesAbstract' xlink:to='lab_us-gaap_RevenuesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockValue' xlink:to='lab_us-gaap_PreferredStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NumberOfCommonShares' xlink:label='fil_NumberOfCommonShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of common shares permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfCommonShares' xlink:to='lab_fil_NumberOfCommonShares'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrcNetOperatingLossCarryForward' xlink:label='fil_PrcNetOperatingLossCarryForward'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrcNetOperatingLossCarryForward' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PRC net operating loss carry forward</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrcNetOperatingLossCarryForward' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrcNetOperatingLossCarryForward' xlink:to='lab_fil_PrcNetOperatingLossCarryForward'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts' xlink:label='us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful trade receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts' xlink:to='lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential' xlink:label='us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of change in tax rate from 15% to 25%</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential' xlink:to='lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2018' xlink:label='fil_PrincipalPayments2018'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2018' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2018</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2018' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2018' xlink:to='lab_fil_PrincipalPayments2018'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:label='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual interest rate based upon 110% of PRC government&apos;s current short term rate of 5.6%</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual interest rate based upon 110% of PRC government&apos;s current short term rate of 5.6%</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:to='lab_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_RelatedPartyTransactionsDetailsAbstract' xlink:label='fil_RelatedPartyTransactionsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RelatedPartyTransactionsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS DETAILS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RelatedPartyTransactionsDetailsAbstract' xlink:to='lab_fil_RelatedPartyTransactionsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:label='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated useful lives of the assets as follows:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='lab_fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryValuationReserves' xlink:label='us-gaap_InventoryValuationReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryValuationReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obsolescence reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryValuationReserves' xlink:to='lab_us-gaap_InventoryValuationReserves'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Recent Accounting Pronouncements</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk' xlink:label='us-gaap_ConcentrationRiskCreditRisk'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskCreditRisk' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Credit Risk</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConcentrationRiskCreditRisk' xlink:to='lab_us-gaap_ConcentrationRiskCreditRisk'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankerSAcceptanceNotesPayableTextBlock' xlink:label='fil_BankerSAcceptanceNotesPayableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BANKER&apos;S ACCEPTANCE NOTES PAYABLE {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>BANKER&apos;S ACCEPTANCE NOTES PAYABLE</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The entire disclosure is about the bankers&apos; acceptance notes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankerSAcceptanceNotesPayableTextBlock' xlink:to='lab_fil_BankerSAcceptanceNotesPayableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>PROPERTY AND EQUIPMENT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:label='fil_AccountsPayableForPurchasesOfPropertyAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable for purchases of property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:to='lab_fil_AccountsPayableForPurchasesOfPropertyAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Impairment of intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:to='lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ChangesInStockholdersEquityAbstract' xlink:label='fil_ChangesInStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangesInStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CHANGES IN STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ChangesInStockholdersEquityAbstract' xlink:to='lab_fil_ChangesInStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, shares authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesAuthorized' xlink:to='lab_us-gaap_PreferredStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermConstructionLoanCurrent' xlink:label='us-gaap_LongTermConstructionLoanCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermConstructionLoanCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current portion of construction loan facility</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongTermConstructionLoanCurrent' xlink:to='lab_us-gaap_LongTermConstructionLoanCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>TOTAL ASSETS</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>TOTAL ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component [Domain]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ConcentrationsDetailsAbstract' xlink:label='fil_ConcentrationsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConcentrationsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Concentrations Details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConcentrationsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company made payments as per Construction agreement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='lab_fil_ConcentrationsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssets1' xlink:label='fil_IntangibleAssets1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssets1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets;</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssets1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Intangible assets1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssets1' xlink:to='lab_fil_IntangibleAssets1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRate2015' xlink:label='fil_EnterpriseIncomeTaxRate2015'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2015' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rate 2015</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2015' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rate 2015</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRate2015' xlink:to='lab_fil_EnterpriseIncomeTaxRate2015'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:label='fil_CompanyWasObligatedToPayLaboratoriesAndOthers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company was obligated to pay laboratories and others</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company was obligated to pay laboratories and others</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:to='lab_fil_CompanyWasObligatedToPayLaboratoriesAndOthers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BuildingMaximumLife' xlink:label='fil_BuildingMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BuildingMaximumLife' xlink:to='lab_fil_BuildingMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingsAndImprovementsGross' xlink:label='us-gaap_BuildingsAndImprovementsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_BuildingsAndImprovementsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_BuildingsAndImprovementsGross' xlink:to='lab_us-gaap_BuildingsAndImprovementsGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ValuationOfLongLivedAssetsAbstract' xlink:label='fil_ValuationOfLongLivedAssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValuationOfLongLivedAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation of Long-Lived Assets {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValuationOfLongLivedAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Valuation of Long-Lived Assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValuationOfLongLivedAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company recognized bad debt expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ValuationOfLongLivedAssetsAbstract' xlink:to='lab_fil_ValuationOfLongLivedAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock' xlink:label='us-gaap_AdvertisingCostsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdvertisingCostsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advertising Costs</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdvertisingCostsPolicyTextBlock' xlink:to='lab_us-gaap_AdvertisingCostsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:label='us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>CONCENTRATIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:to='lab_us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The entire disclosure of advances for purchases of intangible assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromShortTermDebt' xlink:label='us-gaap_ProceedsFromShortTermDebt'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromShortTermDebt' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payments of short term notes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromShortTermDebt' xlink:to='lab_us-gaap_ProceedsFromShortTermDebt'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetLossForTheYear1' xlink:label='fil_NetLossForTheYear1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLossForTheYear1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss for the year {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLossForTheYear1' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Net loss for the year</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLossForTheYear1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetLossForTheYear1' xlink:to='lab_fil_NetLossForTheYear1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown' xlink:label='us-gaap_InventoryWriteDown'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWriteDown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory obsolescence</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWriteDown' xlink:to='lab_us-gaap_InventoryWriteDown'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:label='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful accounts on trade accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:to='lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchases of intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>AdvancesForPurchasesOfIntangibleAssets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssets' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Cash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Cash' xlink:to='lab_us-gaap_Cash'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DocumentAndEntityInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document and Entity Information</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='lab_fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated aggregate annual amortization expense for 2018</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:label='fil_AmortizationExpensesRelatingToIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization expenses relating to intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:to='lab_fil_AmortizationExpensesRelatingToIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetCarryingAmount' xlink:label='fil_NetCarryingAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net carrying amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net carrying amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetCarryingAmount' xlink:to='lab_fil_NetCarryingAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PlantMachineryAndEquipmentMinimumLife' xlink:label='fil_PlantMachineryAndEquipmentMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Plant, machinery and equipment minimum life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PlantMachineryAndEquipmentMinimumLife' xlink:to='lab_fil_PlantMachineryAndEquipmentMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_UncollectableTradeAccountsReceivable' xlink:label='fil_UncollectableTradeAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_UncollectableTradeAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Uncollectable trade accounts receivable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_UncollectableTradeAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of valuation allowance for receivables due a company that are expected to be uncollectible.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_UncollectableTradeAccountsReceivable' xlink:to='lab_fil_UncollectableTradeAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' xlink:label='us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:label='fil_ScheduleOfLongTermDebtInstrumentsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Construction Loan Facility:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:to='lab_fil_ScheduleOfLongTermDebtInstrumentsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsTablesAbstract' xlink:label='fil_IntangibleAssetsTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='lab_fil_IntangibleAssetsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment consists</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory consists</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:to='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued taxes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ProvisionForObsoleteInventory' xlink:label='fil_ProvisionForObsoleteInventory'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ProvisionForObsoleteInventory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for obsolete inventory</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ProvisionForObsoleteInventory' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Provision for obsolete inventory</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ProvisionForObsoleteInventory' xlink:to='lab_fil_ProvisionForObsoleteInventory'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated Other Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalUnitsMember' xlink:label='us-gaap_CapitalUnitsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CapitalUnitsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock Shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CapitalUnitsMember' xlink:to='lab_us-gaap_CapitalUnitsMember'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IncomeTaxExpense' xlink:label='fil_IncomeTaxExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income tax expense;</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxExpense' xlink:to='lab_fil_IncomeTaxExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingExpense' xlink:to='lab_us-gaap_SellingExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfRevenue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfRevenue' xlink:to='lab_us-gaap_CostOfRevenue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Current Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PreferredSharesParValue' xlink:label='fil_PreferredSharesParValue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesParValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred shares par value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesParValue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PreferredSharesParValue' xlink:to='lab_fil_PreferredSharesParValue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2020' xlink:label='fil_PrincipalPayments2020'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2020' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2020</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2020' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2020' xlink:to='lab_fil_PrincipalPayments2020'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_RevolvingLineOfCreditWithABankRmb' xlink:label='fil_RevolvingLineOfCreditWithABankRmb'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RevolvingLineOfCreditWithABankRmb' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revolving line of credit with a bank (RMB)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RevolvingLineOfCreditWithABankRmb' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank&apos;s commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RevolvingLineOfCreditWithABankRmb' xlink:to='lab_fil_RevolvingLineOfCreditWithABankRmb'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:label='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated aggregate annual amortization expense details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:to='lab_fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ImpairmentLoss1' xlink:label='fil_ImpairmentLoss1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ImpairmentLoss1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Impairment loss;</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ImpairmentLoss1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>ImpairmentLoss1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ImpairmentLoss1' xlink:to='lab_fil_ImpairmentLoss1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PropertyAndEquipmentNet' xlink:label='fil_PropertyAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and Equipment, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentNet' xlink:to='lab_fil_PropertyAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross' xlink:label='us-gaap_InventoryGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryGross' xlink:to='lab_us-gaap_InventoryGross'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription' xlink:label='us-gaap_PriorPeriodReclassificationAdjustmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Reclassification</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PriorPeriodReclassificationAdjustmentDescription' xlink:to='lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PostemploymentBenefitPlansPolicy' xlink:label='us-gaap_PostemploymentBenefitPlansPolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PostemploymentBenefitPlansPolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retirement Benefit Plans</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PostemploymentBenefitPlansPolicy' xlink:to='lab_us-gaap_PostemploymentBenefitPlansPolicy'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:label='us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research and Development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SubsidyIncomeDisclosureTextBlock' xlink:label='fil_SubsidyIncomeDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SubsidyIncomeDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SUBSIDY INCOME</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SubsidyIncomeDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The entirte disclosure is about the subsidy from the government received by the Company for the technological innovation achieved.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SubsidyIncomeDisclosureTextBlock' xlink:to='lab_fil_SubsidyIncomeDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtBeginningOfPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents at Beginning of Period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:to='lab_fil_CashAndCashEquivalentsAtBeginningOfPeriod'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConstructionLoansPayable' xlink:label='us-gaap_ProceedsFromConstructionLoansPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromConstructionLoansPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payments of construction term loan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromConstructionLoansPayable' xlink:to='lab_us-gaap_ProceedsFromConstructionLoansPayable'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_Balance' xlink:label='fil_Balance'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Balance' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Balance.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Balance' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Balance.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Balance' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Balance.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Balance' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of shares issued which are neither cancelled nor held in the treasury.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Balance' xlink:to='lab_fil_Balance'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetIncomeLoss' xlink:to='lab_us-gaap_NetIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities' xlink:label='us-gaap_DeferredTaxLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilities' xlink:to='lab_us-gaap_DeferredTaxLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:label='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>One supplier accounted for percentage of raw material purchases</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>One supplier accounted for percentage of raw material purchases</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:to='lab_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BasicAndDilutedEarningsPerShare' xlink:label='fil_BasicAndDilutedEarningsPerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BasicAndDilutedEarningsPerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic and diluted earnings per share</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BasicAndDilutedEarningsPerShare' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Basic and diluted earnings per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BasicAndDilutedEarningsPerShare' xlink:to='lab_fil_BasicAndDilutedEarningsPerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Change in valuation allowance</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' xlink:to='lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRateThereafter' xlink:label='fil_EnterpriseIncomeTaxRateThereafter'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRateThereafter' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rate Thereafter</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRateThereafter' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rate Thereafter</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRateThereafter' xlink:to='lab_fil_EnterpriseIncomeTaxRateThereafter'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalLoanFacilityAmountRmb80000000' xlink:label='fil_TotalLoanFacilityAmountRmb80000000'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLoanFacilityAmountRmb80000000' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total loan facility amount (RMB 80,000,000)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLoanFacilityAmountRmb80000000' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total loan facility amount (RMB 80,000,000)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLoanFacilityAmountRmb80000000' xlink:to='lab_fil_TotalLoanFacilityAmountRmb80000000'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ConstructionLoanFacilityDetailsAbstract' xlink:label='fil_ConstructionLoanFacilityDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConstructionLoanFacilityDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Construction loan facility details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConstructionLoanFacilityDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>ConstructionLoanFacilityDetailsAbstract [Abstract]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='lab_fil_ConstructionLoanFacilityDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:label='fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Impairment loss for the advances made to these laboratories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Impairment loss for the advances made to these laboratories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:to='lab_fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BuildingMinimumLife' xlink:label='fil_BuildingMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BuildingMinimumLife' xlink:to='lab_fil_BuildingMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods' xlink:label='us-gaap_InventoryFinishedGoods'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoods' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoods' xlink:to='lab_us-gaap_InventoryFinishedGoods'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Work in process</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:label='us-gaap_ScheduleOfDebtInstrumentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Principal payments required for the next five years as of December 31, 2015</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:to='lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InventoryTablesAbstract' xlink:label='fil_InventoryTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY (TABLES)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryTablesAbstract' xlink:to='lab_fil_InventoryTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and Equipment, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AccountingPoliciesAbstract1' xlink:label='fil_AccountingPoliciesAbstract1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountingPoliciesAbstract1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounting Policies:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='lab_fil_AccountingPoliciesAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash used in Financing Activity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net Cash used in Financing Activity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Financing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Investing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Provided by Operating Activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityTotalMember' xlink:label='us-gaap_StockholdersEquityTotalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityTotalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Stockholders&apos; Equity {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityTotalMember' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Total Stockholders&apos; Equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityTotalMember' xlink:to='lab_us-gaap_StockholdersEquityTotalMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestExpense' xlink:to='lab_us-gaap_InterestExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract' xlink:label='us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherIncomeAndExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income (expense):</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='lab_us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>General and administrative expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_GeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, shares issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesIssued' xlink:to='lab_us-gaap_PreferredStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; Equity:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:label='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Construction loan facility</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:to='lab_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts' xlink:label='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts receivable, less allowance for doubtful accounts of $15,664,496 and $29,352,806, respectively</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Trade accounts receivable, less allowance for doubtful accounts of $15,664,496 and $29,352,806, respectively, as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts' xlink:to='lab_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:label='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares of restricted stock granted and outstanding under the 2010 Incentive Plan</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>shares of restricted stock granted and outstanding under the 2010 Incentive Plan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:to='lab_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_DeferredIncomeTaxLiabilityAbstract' xlink:label='fil_DeferredIncomeTaxLiabilityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DeferredIncomeTaxLiabilityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income tax liability:</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DeferredIncomeTaxLiabilityAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DeferredIncomeTaxLiabilityAbstract' xlink:to='lab_fil_DeferredIncomeTaxLiabilityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InterestRateWasAdjustedTo' xlink:label='fil_InterestRateWasAdjustedTo'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateWasAdjustedTo' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest rate was adjusted to</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateWasAdjustedTo' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Interest rate was adjusted to</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InterestRateWasAdjustedTo' xlink:to='lab_fil_InterestRateWasAdjustedTo'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount' xlink:label='fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company had outstanding Banker&apos;s Acceptance Notes in the amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company had outstanding Banker&apos;s Acceptance Notes in the amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount' xlink:to='lab_fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalInterestExpense' xlink:label='fil_TotalInterestExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInterestExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total interest expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInterestExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the cost of borrowed funds accounted for as interest expense for debt.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalInterestExpense' xlink:to='lab_fil_TotalInterestExpense'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:label='fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest rate on advances from Member of BOD</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Interest rate on advances from Member of BOD</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:to='lab_fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:label='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='lab_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IncomeTaxesTablesAbstract' xlink:label='fil_IncomeTaxesTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='lab_fil_IncomeTaxesTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Trade accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to suppliers {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Advances to suppliers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Balance</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Balance</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Balance</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapital' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapital' xlink:to='lab_us-gaap_AdditionalPaidInCapital'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:label='fil_NoCustomerAccountedForMoreThanPercentageOfSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>No customer accounted for more than percentage of sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>No customer accounted for more than percentage of sales</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:to='lab_fil_NoCustomerAccountedForMoreThanPercentageOfSales'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetDeferredIncomeTaxAsset1' xlink:label='fil_NetDeferredIncomeTaxAsset1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetDeferredIncomeTaxAsset1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net deferred income tax asset;</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetDeferredIncomeTaxAsset1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net deferred income tax asset;</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetDeferredIncomeTaxAsset1' xlink:to='lab_fil_NetDeferredIncomeTaxAsset1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate' xlink:label='us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other, primarily the difference in U.S. tax rates</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate' xlink:to='lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRate2016' xlink:label='fil_EnterpriseIncomeTaxRate2016'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2016' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rate 2016</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2016' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rate 2016</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRate2016' xlink:to='lab_fil_EnterpriseIncomeTaxRate2016'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PermitOfLandUseMaximumLife' xlink:label='fil_PermitOfLandUseMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PermitOfLandUseMaximumLife' xlink:to='lab_fil_PermitOfLandUseMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_LessAccumulatedDepreciation' xlink:label='fil_LessAccumulatedDepreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LessAccumulatedDepreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Less: accumulated depreciation</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LessAccumulatedDepreciation' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of accumulated depreciation pertaining to real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LessAccumulatedDepreciation' xlink:to='lab_fil_LessAccumulatedDepreciation'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ImpairmentAdjustmentsRelatedToAdvances' xlink:label='fil_ImpairmentAdjustmentsRelatedToAdvances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ImpairmentAdjustmentsRelatedToAdvances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Impairment adjustments related to advances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ImpairmentAdjustmentsRelatedToAdvances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Impairment adjustments related to advances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ImpairmentAdjustmentsRelatedToAdvances' xlink:to='lab_fil_ImpairmentAdjustmentsRelatedToAdvances'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp; Biotechnology Co., Ltd.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:to='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' xlink:label='us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Restricted Cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' xlink:to='lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock' xlink:label='us-gaap_DebtDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DebtDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>NOTES PAYABLES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DebtDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>NOTES PAYABLES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DebtDisclosureTextBlock' xlink:to='lab_us-gaap_DebtDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:label='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net (Decrease) Increase in Cash and Cash Equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:to='lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of Exchange Rate Changes on Cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Operating Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ForeignCurrencyTranslationAdjustment' xlink:label='fil_ForeignCurrencyTranslationAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyTranslationAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyTranslationAdjustment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ForeignCurrencyTranslationAdjustment' xlink:to='lab_fil_ForeignCurrencyTranslationAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Revenues' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Revenues' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Revenues' xlink:to='lab_us-gaap_Revenues'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, par value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to suppliers</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Carrying amount as of the balance sheet date of advances to suppliers.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesToSuppliers' xlink:to='lab_fil_AdvancesToSuppliers'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfProductFirstAccountedForRevenue' xlink:label='fil_PercentageOfProductFirstAccountedForRevenue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfProductFirstAccountedForRevenue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of product first accounted for revenue.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfProductFirstAccountedForRevenue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of product first accounted for revenue.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfProductFirstAccountedForRevenue' xlink:to='lab_fil_PercentageOfProductFirstAccountedForRevenue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CommonSharesAuthorized' xlink:label='fil_CommonSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common shares authorized</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of common shares permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonSharesAuthorized' xlink:to='lab_fil_CommonSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes' xlink:label='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net operating losses for United States federal income tax purposes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net operating losses for United States federal income tax purposes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes' xlink:to='lab_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_DeferredIncomeTaxAssetsAbstract' xlink:label='fil_DeferredIncomeTaxAssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DeferredIncomeTaxAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income tax assets:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='lab_fil_DeferredIncomeTaxAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:label='fil_BankerSAcceptanceNotesPayableDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BANKER&apos;S ACCEPTANCE NOTES PAYABLE Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:to='lab_fil_BankerSAcceptanceNotesPayableDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OfficeEquipment1' xlink:label='fil_OfficeEquipment1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipment1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipment1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipment1' xlink:to='lab_fil_OfficeEquipment1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InventoryDetailsAbstract' xlink:label='fil_InventoryDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory Details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>NetLoss1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryDetailsAbstract' xlink:to='lab_fil_InventoryDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:label='fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets Medical Formulas</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabluar disclosure of Intangible Assets Medical Formulas</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:to='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:to='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IssuanceOfBankerSAcceptances' xlink:label='fil_IssuanceOfBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IssuanceOfBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Issuance of banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IssuanceOfBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Issuance of banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IssuanceOfBankerSAcceptances' xlink:to='lab_fil_IssuanceOfBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:label='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Supplemental Noncash Investing and Financing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SupplementalCashFlowInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Supplemental Cash Flow Information:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='lab_us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances from customers {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Advances from customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:to='lab_us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SubsidyIncome' xlink:label='fil_SubsidyIncome'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SubsidyIncome' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Subsidy income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SubsidyIncome' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Subsidy income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SubsidyIncome' xlink:to='lab_fil_SubsidyIncome'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research and development expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableTradeCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableTradeCurrent' xlink:to='lab_us-gaap_AccountsPayableTradeCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:label='fil_EmployeeStockOptions2010IncentivePlanAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Employee Stock Options 2010 Incentive Plan</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:to='lab_fil_EmployeeStockOptions2010IncentivePlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForIntangibleAssetsImpairment1' xlink:label='fil_AdvancesForIntangibleAssetsImpairment1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForIntangibleAssetsImpairment1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for intangible assets impairment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForIntangibleAssetsImpairment1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>AdvancesForIntangibleAssetsImpairment1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForIntangibleAssetsImpairment1' xlink:to='lab_fil_AdvancesForIntangibleAssetsImpairment1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' xlink:label='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(Benefit) tax at statutory rate of 25%</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' xlink:to='lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total income tax expense.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2021' xlink:label='fil_PrincipalPayments2021'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2021' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2021</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2021' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2021' xlink:to='lab_fil_PrincipalPayments2021'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2019' xlink:label='fil_PrincipalPayments2019'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2019' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2019</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2019' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Principal amount paid by the company in 2019</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2019' xlink:to='lab_fil_PrincipalPayments2019'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EstimatedAggregateAnnualAmortizationExpenseThereafter' xlink:label='fil_EstimatedAggregateAnnualAmortizationExpenseThereafter'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EstimatedAggregateAnnualAmortizationExpenseThereafter' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated aggregate annual amortization expense total</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EstimatedAggregateAnnualAmortizationExpenseThereafter' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EstimatedAggregateAnnualAmortizationExpenseThereafter' xlink:to='lab_fil_EstimatedAggregateAnnualAmortizationExpenseThereafter'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OfficeEquipmentMaximumLife' xlink:label='fil_OfficeEquipmentMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipmentMaximumLife' xlink:to='lab_fil_OfficeEquipmentMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross' xlink:label='us-gaap_MachineryAndEquipmentGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_MachineryAndEquipmentGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_MachineryAndEquipmentGross' xlink:to='lab_us-gaap_MachineryAndEquipmentGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InterestRateRiskPolicyTextBlock' xlink:label='fil_InterestRateRiskPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateRiskPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest Rate Risk</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateRiskPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Disclosure for accounting policy on interest rate risk</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InterestRateRiskPolicyTextBlock' xlink:to='lab_fil_InterestRateRiskPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:to='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtTextBlock' xlink:label='us-gaap_LongTermDebtTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermDebtTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONSTRUCTION LOAN FACILITY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermDebtTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>CONSTRUCTION LOAN FACILITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongTermDebtTextBlock' xlink:to='lab_us-gaap_LongTermDebtTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>RELATED PARTY TRANSACTIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:to='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract' xlink:label='us-gaap_InventoryDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='lab_us-gaap_InventoryDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtEndOfPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents at End of Period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:to='lab_fil_CashAndCashEquivalentsAtEndOfPeriod'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Purchases of property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchases of intangible assets {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Advances for purchases of intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquireIntangibleAssets' xlink:to='lab_us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventory</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_Balance1' xlink:label='fil_Balance1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Balance1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Balance {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Balance1' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Balance</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Balance1' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Balance</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Balance1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of shares issued which are neither cancelled nor held in the treasury.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Balance1' xlink:to='lab_fil_Balance1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loss before income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expenses:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>TOTAL LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetOperatingLossCarryforwardsForPrcTaxPurposes' xlink:label='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net operating loss carryforwards for PRC tax purposes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net operating loss carryforwards for PRC tax purposes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes' xlink:to='lab_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxAssetsValuationAllowance' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation allowance</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxAssetsValuationAllowance' xlink:to='lab_us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:label='fil_ProvisionForIncomeTaxesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:to='lab_fil_ProvisionForIncomeTaxesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:label='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal payments required for the next five years are as follows:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='lab_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PermitOfLandUseMinimumLife' xlink:label='fil_PermitOfLandUseMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PermitOfLandUseMinimumLife' xlink:to='lab_fil_PermitOfLandUseMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PropertyAndEquipmentTablesAbstract' xlink:label='fil_PropertyAndEquipmentTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='lab_fil_PropertyAndEquipmentTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:label='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to Suppliers and Advances from Customers</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Disclosure for accounting policy of advances to Suppliers and Advances from Customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:to='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CommitmentAndContingenciesAbstract' xlink:label='fil_CommitmentAndContingenciesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommitmentAndContingenciesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommitmentAndContingenciesAbstract' xlink:to='lab_fil_CommitmentAndContingenciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract' xlink:label='us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentAbstract' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InventoryPurchasedWithBankerSAcceptances' xlink:label='fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryPurchasedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory purchased with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryPurchasedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Inventory purchased with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryPurchasedWithBankerSAcceptances' xlink:to='lab_fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Used in Investing Activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted' xlink:label='us-gaap_EarningsPerShareBasicAndDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasicAndDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic and diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasicAndDiluted' xlink:to='lab_us-gaap_EarningsPerShareBasicAndDiluted'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest' xlink:label='us-gaap_InvestmentIncomeInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InvestmentIncomeInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InvestmentIncomeInterest' xlink:to='lab_us-gaap_InvestmentIncomeInterest'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:label='us-gaap_StockTransactionsParentheticalDisclosuresAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Parentheticals</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='lab_us-gaap_StockTransactionsParentheticalDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DueToRelatedPartiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables - related parties</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DueToRelatedPartiesCurrent' xlink:to='lab_us-gaap_DueToRelatedPartiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:label='us-gaap_AccountsAndOtherReceivablesNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other receivables, less allowance for doubtful accounts of $71,548 and $74,400, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:to='lab_us-gaap_AccountsAndOtherReceivablesNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Voluntary Filers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfThirdProductAccountedForRevenue' xlink:label='fil_PercentageOfThirdProductAccountedForRevenue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfThirdProductAccountedForRevenue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of third product accounted for revenue.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfThirdProductAccountedForRevenue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of third product accounted for revenue.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfThirdProductAccountedForRevenue' xlink:to='lab_fil_PercentageOfThirdProductAccountedForRevenue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CapitalStockTransactionsAbstract' xlink:label='fil_CapitalStockTransactionsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CapitalStockTransactionsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Capital stock transactions:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='lab_fil_CapitalStockTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SubsidyIncomeDetailsAbstract' xlink:label='fil_SubsidyIncomeDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SubsidyIncomeDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SUBSIDY INCOME DETAILS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SubsidyIncomeDetailsAbstract' xlink:to='lab_fil_SubsidyIncomeDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:label='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Outstanding balance due under revolving line of credit (RMB 30,000,000)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Outstanding balance due under revolving line of credit (RMB 30,000,000)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:to='lab_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesOwingToBoardOfDirectors' xlink:label='fil_AdvancesOwingToBoardOfDirectors'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesOwingToBoardOfDirectors' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances owing to board of directors</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesOwingToBoardOfDirectors' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Advances owing to board of directors</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesOwingToBoardOfDirectors' xlink:to='lab_fil_AdvancesOwingToBoardOfDirectors'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated aggregate annual amortization expense for 2019</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalInventory' xlink:label='fil_TotalInventory'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInventory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Inventory</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInventory' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalInventory' xlink:to='lab_fil_TotalInventory'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract' xlink:label='fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to Suppliers and Advances from Customers {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Advances to Suppliers and Advances from Customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract' xlink:to='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercetageOfAcquiredByOnnyInHelpson' xlink:label='fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercetageOfAcquiredByOnnyInHelpson' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percetage of acquired by Onny in Helpson</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercetageOfAcquiredByOnnyInHelpson' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percetage of acquired by Onny in Helpson</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercetageOfAcquiredByOnnyInHelpson' xlink:to='lab_fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables and accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in assets and liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, shares issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Stockholders&apos; Equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:label='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:to='lab_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableOtherCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableOtherCurrent' xlink:to='lab_us-gaap_AccountsPayableOtherCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents' xlink:label='us-gaap_RestrictedCashAndCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RestrictedCashAndCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Restricted cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RestrictedCashAndCashEquivalents' xlink:to='lab_us-gaap_RestrictedCashAndCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IncomeTaxesNarrativeDetailsAbstract' xlink:label='fil_IncomeTaxesNarrativeDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesNarrativeDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES NARRATIVE DETAILS</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesNarrativeDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>ImpairmentLoss1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxesNarrativeDetailsAbstract' xlink:to='lab_fil_IncomeTaxesNarrativeDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther' xlink:label='us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Expenses not deductible in current year</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther' xlink:to='lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRate2017' xlink:label='fil_EnterpriseIncomeTaxRate2017'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2017' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rate 2017</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2017' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rate 2017</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRate2017' xlink:to='lab_fil_EnterpriseIncomeTaxRate2017'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:label='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchase of intangible assets details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract [Abstract]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:to='lab_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AccumulatedAmortization' xlink:label='fil_AccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accumulated amortization on long-term land leases capitalized as part of real property.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccumulatedAmortization' xlink:to='lab_fil_AccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OfficeEquipmentMinimumLife' xlink:label='fil_OfficeEquipmentMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipmentMinimumLife' xlink:to='lab_fil_OfficeEquipmentMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_RetirementBenefitPlansAbstract' xlink:label='fil_RetirementBenefitPlansAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RetirementBenefitPlansAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retirement Benefit Plans {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RetirementBenefitPlansAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Retirement Benefit Plans</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RetirementBenefitPlansAbstract' xlink:to='lab_fil_RetirementBenefitPlansAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock' xlink:label='us-gaap_ReceivablesPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ReceivablesPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade Accounts Receivable and Allowance for Doubtful Accounts, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ReceivablesPolicyTextBlock' xlink:to='lab_us-gaap_ReceivablesPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract' xlink:label='us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RisksAndUncertaintiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RisksAndUncertaintiesAbstract' xlink:to='lab_us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ForeignCurrencyTranslationAdjustment1' xlink:label='fil_ForeignCurrencyTranslationAdjustment1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyTranslationAdjustment1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyTranslationAdjustment1' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyTranslationAdjustment1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ForeignCurrencyTranslationAdjustment1' xlink:to='lab_fil_ForeignCurrencyTranslationAdjustment1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:label='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted average shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:to='lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesOutstanding' xlink:to='lab_us-gaap_PreferredStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:label='fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful accounts on other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:to='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Current Assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total Current Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Assets:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfProductSecondAccountedForRevenue' xlink:label='fil_PercentageOfProductSecondAccountedForRevenue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfProductSecondAccountedForRevenue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of product second accounted for revenue.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfProductSecondAccountedForRevenue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of product second accounted for revenue.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfProductSecondAccountedForRevenue' xlink:to='lab_fil_PercentageOfProductSecondAccountedForRevenue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PreferredSharesAuthorized' xlink:label='fil_PreferredSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred shares authorized</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PreferredSharesAuthorized' xlink:to='lab_fil_PreferredSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ValuationAllowanceAgainstItsDeferredTax' xlink:label='fil_ValuationAllowanceAgainstItsDeferredTax'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValuationAllowanceAgainstItsDeferredTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation allowance against its deferred tax</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValuationAllowanceAgainstItsDeferredTax' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Valuation allowance against its deferred tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ValuationAllowanceAgainstItsDeferredTax' xlink:to='lab_fil_ValuationAllowanceAgainstItsDeferredTax'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AllowanceForDoubtfulOtherReceivables' xlink:label='fil_AllowanceForDoubtfulOtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AllowanceForDoubtfulOtherReceivables' xlink:to='lab_fil_AllowanceForDoubtfulOtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:label='us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2017' xlink:label='fil_PrincipalPayments2017'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2017' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2017</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2017' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2017' xlink:to='lab_fil_PrincipalPayments2017'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated aggregate annual amortization expense for 2020</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated aggregate annual amortization expense for 2017</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:label='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment consisted of the following details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='lab_fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation of Long-Lived Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:to='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract' xlink:label='us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxDisclosureAbstract' xlink:to='lab_us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankerSAcceptanceNotesPayableAbstract' xlink:label='fil_BankerSAcceptanceNotesPayableAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BANKER&apos;S ACCEPTANCE NOTES PAYABLE</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankerSAcceptanceNotesPayableAbstract' xlink:to='lab_fil_BankerSAcceptanceNotesPayableAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:label='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:to='lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INVENTORY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankersAcceptancesRedeemedForCash' xlink:label='fil_BankersAcceptancesRedeemedForCash'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptancesRedeemedForCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptances redeemed for cash</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptancesRedeemedForCash' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptances redeemed for cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptancesRedeemedForCash' xlink:to='lab_fil_BankersAcceptancesRedeemedForCash'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:label='us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Prepaid expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loss from operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, shares authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CustomerAdvancesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances from customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CustomerAdvancesCurrent' xlink:to='lab_us-gaap_CustomerAdvancesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent' xlink:label='us-gaap_PrepaidExpenseCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PrepaidExpenseCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PrepaidExpenseCurrent' xlink:to='lab_us-gaap_PrepaidExpenseCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalDeferredIncomeTaxAssets' xlink:label='fil_TotalDeferredIncomeTaxAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalDeferredIncomeTaxAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total deferred income tax assets;</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalDeferredIncomeTaxAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total deferred income tax assets;</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalDeferredIncomeTaxAssets' xlink:to='lab_fil_TotalDeferredIncomeTaxAssets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:label='fil_EnterpriseIncomeTaxRatesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise income tax rates details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Received cash subsidy from the government for the enterprises that suffered losses from the typhoon to resume production</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='lab_fil_EnterpriseIncomeTaxRatesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalPrincipalPaymentsDue' xlink:label='fil_TotalPrincipalPaymentsDue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalPrincipalPaymentsDue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total principal payments due</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalPrincipalPaymentsDue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total Principal amount due by the company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalPrincipalPaymentsDue' xlink:to='lab_fil_TotalPrincipalPaymentsDue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_MotorVehicleMaximumLife' xlink:label='fil_MotorVehicleMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleMaximumLife' xlink:to='lab_fil_MotorVehicleMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross' xlink:label='us-gaap_PropertyPlantAndEquipmentGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment Gross Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentGross' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CompanyRecognizedBadDebtExpense' xlink:label='fil_CompanyRecognizedBadDebtExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyRecognizedBadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company recognized bad debt expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyRecognizedBadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company recognized bad debt expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyRecognizedBadDebtExpense' xlink:to='lab_fil_CompanyRecognizedBadDebtExpense'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:label='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Enterprise Income Tax Rates</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure is about the Enterprise Income Tax Rates under the current tax law in the PRC, the Company is and will be subject to.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:to='lab_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerSharePolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic and Diluted (Loss) Earnings per Common Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerSharePolicyTextBlock' xlink:to='lab_us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock' xlink:label='us-gaap_ConsolidationPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConsolidationPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Consolidation and Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConsolidationPolicyTextBlock' xlink:to='lab_us-gaap_ConsolidationPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract' xlink:label='us-gaap_EquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityAbstract' xlink:to='lab_us-gaap_EquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_DebtAbstract' xlink:label='fil_DebtAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DebtAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONSTRUCTION LOAN FACILITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DebtAbstract' xlink:to='lab_fil_DebtAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetLossForTheYear' xlink:label='fil_NetLossForTheYear'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLossForTheYear' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss for the year</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLossForTheYear' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetLossForTheYear' xlink:to='lab_fil_NetLossForTheYear'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsFinitelived'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Impairment loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ImpairmentOfIntangibleAssetsFinitelived' xlink:to='lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, par value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cphi-20161231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20161231"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_TradingSymbol' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='16.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDBALANCESHEETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Cash' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents' xlink:label='us-gaap_RestrictedCashAndCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_RestrictedCashAndCashEquivalents' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts' xlink:label='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:label='us-gaap_AccountsAndOtherReceivablesNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsAndOtherReceivablesNetCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_AdvancesToSuppliers' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent' xlink:label='us-gaap_PrepaidExpenseCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_PrepaidExpenseCurrent' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AssetsCurrent' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssets' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Assets' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_AccountsPayableTradeCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_AccountsPayableOtherCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_CustomerAdvancesCurrent' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_DueToRelatedPartiesCurrent' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermConstructionLoanCurrent' xlink:label='us-gaap_LongTermConstructionLoanCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LongTermConstructionLoanCurrent' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankersAcceptanceNotesPayable' xlink:label='fil_BankersAcceptanceNotesPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='fil_BankersAcceptanceNotesPayable' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent' xlink:label='us-gaap_NotesPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_NotesPayableCurrent' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract' xlink:label='us-gaap_LiabilitiesNoncurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_LiabilitiesNoncurrentAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:label='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities' xlink:label='us-gaap_DeferredTaxLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_DeferredTaxLiabilities' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_PreferredStockValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AdditionalPaidInCapital' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:label='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='5.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:label='us-gaap_StockTransactionsParentheticalDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:label='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:label='fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockParOrStatedValuePerShare' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockSharesAuthorized' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockSharesIssued' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockSharesOutstanding' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='10.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract' xlink:label='us-gaap_RevenuesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_Revenues' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_CostOfRevenue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown' xlink:label='us-gaap_InventoryWriteDown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_InventoryWriteDown' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_SellingExpense' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_GeneralAndAdministrativeExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsFinitelived'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ImpairmentOfIntangibleAssetsFinitelived' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SubsidyIncome' xlink:label='fil_SubsidyIncome'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='fil_SubsidyIncome' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract' xlink:label='us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_OtherIncomeAndExpensesAbstract' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest' xlink:label='us-gaap_InvestmentIncomeInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_InvestmentIncomeInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_InterestExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses' xlink:label='us-gaap_OtherExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_OtherExpenses' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IncomeTaxExpense' xlink:label='fil_IncomeTaxExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='fil_IncomeTaxExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_NetIncomeLoss' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossNetOfTax' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract' xlink:label='us-gaap_EarningsPerShareAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_EarningsPerShareAbstract' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted' xlink:label='us-gaap_EarningsPerShareBasicAndDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_EarningsPerShareBasicAndDiluted' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:label='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ChangesInStockholdersEquityAbstract' xlink:label='fil_ChangesInStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ChangesInStockholdersEquityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalUnitsMember' xlink:label='us-gaap_CapitalUnitsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CapitalUnitsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityTotalMember' xlink:label='us-gaap_StockholdersEquityTotalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_StockholdersEquityTotalMember' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_Balance' xlink:label='fil_Balance'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Balance' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_Balance1' xlink:label='fil_Balance1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Balance1' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetLossForTheYear' xlink:label='fil_NetLossForTheYear'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetLossForTheYear' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ForeignCurrencyTranslationAdjustment' xlink:label='fil_ForeignCurrencyTranslationAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForeignCurrencyTranslationAdjustment' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_Balance' xlink:label='fil_Balance_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Balance_1' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetLossForTheYear1' xlink:label='fil_NetLossForTheYear1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetLossForTheYear1' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ForeignCurrencyTranslationAdjustment1' xlink:label='fil_ForeignCurrencyTranslationAdjustment1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForeignCurrencyTranslationAdjustment1' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_Balance1' xlink:label='fil_Balance1_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Balance1_1' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_NetIncomeLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization' xlink:label='us-gaap_DepreciationDepletionAndAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_DepreciationDepletionAndAmortization' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:label='us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_IncreaseDecreaseInIncomeTaxes' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ProvisionForObsoleteInventory' xlink:label='fil_ProvisionForObsoleteInventory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='fil_ProvisionForObsoleteInventory' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInDepositOtherAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayableTrade' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInCustomerAdvances' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:label='us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidExpense' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankersAcceptancesRedeemedForCash' xlink:label='fil_BankersAcceptancesRedeemedForCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='fil_BankersAcceptancesRedeemedForCash' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConstructionLoansPayable' xlink:label='us-gaap_ProceedsFromConstructionLoansPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromConstructionLoansPayable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromShortTermDebt' xlink:label='us-gaap_ProceedsFromShortTermDebt'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromShortTermDebt' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:label='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtBeginningOfPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='fil_CashAndCashEquivalentsAtBeginningOfPeriod' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtEndOfPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='fil_CashAndCashEquivalentsAtEndOfPeriod' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_SupplementalCashFlowInformationAbstract' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:label='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:label='fil_AccountsPayableForPurchasesOfPropertyAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AccountsPayableForPurchasesOfPropertyAndEquipment' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IssuanceOfBankerSAcceptances' xlink:label='fil_IssuanceOfBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_IssuanceOfBankerSAcceptances' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:label='fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AccountsReceivableCollectedWithBankerSAcceptances' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InventoryPurchasedWithBankerSAcceptances' xlink:label='fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_InventoryPurchasedWithBankerSAcceptances' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:label='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' use='optional' order='5.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:label='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORY" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINVENTORY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract' xlink:label='us-gaap_InventoryDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENT">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract' xlink:label='us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PropertyPlantAndEquipmentAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINTANGIBLEASSETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:label='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract' xlink:label='us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RelatedPartyTransactionsAbstract' xlink:to='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureNOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureNOTESPAYABLE"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureNOTESPAYABLE">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NotesPayable1Abstract' xlink:label='fil_NotesPayable1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock' xlink:label='us-gaap_DebtDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayable1Abstract' xlink:to='us-gaap_DebtDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankerSAcceptanceNotesPayableAbstract' xlink:label='fil_BankerSAcceptanceNotesPayableAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankerSAcceptanceNotesPayableTextBlock' xlink:label='fil_BankerSAcceptanceNotesPayableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BankerSAcceptanceNotesPayableAbstract' xlink:to='fil_BankerSAcceptanceNotesPayableTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONSTRUCTIONLOANFACILITY" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureCONSTRUCTIONLOANFACILITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONSTRUCTIONLOANFACILITY">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_DebtAbstract' xlink:label='fil_DebtAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtTextBlock' xlink:label='us-gaap_LongTermDebtTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DebtAbstract' xlink:to='us-gaap_LongTermDebtTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSUBSIDYINCOME" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureSUBSIDYINCOME"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSUBSIDYINCOME">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SubsidyIncomeAbstract' xlink:label='fil_SubsidyIncomeAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SubsidyIncomeDisclosureTextBlock' xlink:label='fil_SubsidyIncomeDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_SubsidyIncomeAbstract' xlink:to='fil_SubsidyIncomeDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINCOMETAXES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXES">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract' xlink:label='us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock' xlink:label='us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeTaxDisclosureAbstract' xlink:to='us-gaap_IncomeTaxDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract' xlink:label='us-gaap_EquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EquityAbstract' xlink:to='us-gaap_StockholdersEquityNoteDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CommitmentAndContingenciesAbstract' xlink:label='fil_CommitmentAndContingenciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CommitmentAndContingenciesAbstract' xlink:to='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONCENTRATIONS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureCONCENTRATIONS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONCENTRATIONS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract' xlink:label='us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:label='us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RisksAndUncertaintiesAbstract' xlink:to='us-gaap_ConcentrationRiskDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureACCOUNTINGPOLICIESPOLICIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AccountingPoliciesAbstract1' xlink:label='fil_AccountingPoliciesAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_NatureOfOperations' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock' xlink:label='us-gaap_ConsolidationPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ConsolidationPolicyTextBlock' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_UseOfEstimates' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' xlink:label='us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_CashAndCashEquivalentsPolicyTextBlock' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock' xlink:label='us-gaap_ReceivablesPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ReceivablesPolicyTextBlock' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:label='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock' xlink:label='us-gaap_InventoryPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_InventoryPolicyTextBlock' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:label='us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ResearchAndDevelopmentExpensePolicy' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PostemploymentBenefitPlansPolicy' xlink:label='us-gaap_PostemploymentBenefitPlansPolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_PostemploymentBenefitPlansPolicy' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock' xlink:label='us-gaap_AdvertisingCostsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_AdvertisingCostsPolicyTextBlock' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_EarningsPerSharePolicyTextBlock' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk' xlink:label='us-gaap_ConcentrationRiskCreditRisk'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ConcentrationRiskCreditRisk' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InterestRateRiskPolicyTextBlock' xlink:label='fil_InterestRateRiskPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='fil_InterestRateRiskPolicyTextBlock' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription' xlink:label='us-gaap_PriorPeriodReclassificationAdjustmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_PriorPeriodReclassificationAdjustmentDescription' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='20.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORYTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINVENTORYTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORYTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InventoryTablesAbstract' xlink:label='fil_InventoryTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryTablesAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosurePROPERTYANDEQUIPMENTTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PropertyAndEquipmentTablesAbstract' xlink:label='fil_PropertyAndEquipmentTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock' xlink:label='fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:label='fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='fil_UsefulLivesOfTheAssetsTableTextBlock' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETSTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINTANGIBLEASSETSTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETSTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsTablesAbstract' xlink:label='fil_IntangibleAssetsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:label='fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock' xlink:label='fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:label='fil_ScheduleOfLongTermDebtInstrumentsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:label='us-gaap_ScheduleOfDebtInstrumentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:to='us-gaap_ScheduleOfDebtInstrumentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXESTABLES" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DisclosureINCOMETAXESTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXESTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IncomeTaxesTablesAbstract' xlink:label='fil_IncomeTaxesTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:label='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:label='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' xlink:label='us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' xlink:label='us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:label='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercetageOfAcquiredByOnnyInHelpson' xlink:label='fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_PercetageOfAcquiredByOnnyInHelpson' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:label='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BadDebtExpense' xlink:label='fil_BadDebtExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_BadDebtExpense' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_UncollectableTradeAccountsReceivable' xlink:label='fil_UncollectableTradeAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_UncollectableTradeAccountsReceivable' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract' xlink:label='fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CompanyRecognizedBadDebtExpense' xlink:label='fil_CompanyRecognizedBadDebtExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract' xlink:to='fil_CompanyRecognizedBadDebtExpense' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ValuationOfLongLivedAssetsAbstract' xlink:label='fil_ValuationOfLongLivedAssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_ValuationOfLongLivedAssetsAbstract' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ImpairmentAdjustmentsRelatedToAdvances' xlink:label='fil_ImpairmentAdjustmentsRelatedToAdvances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ValuationOfLongLivedAssetsAbstract' xlink:to='fil_ImpairmentAdjustmentsRelatedToAdvances' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_RetirementBenefitPlansAbstract' xlink:label='fil_RetirementBenefitPlansAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_RetirementBenefitPlansAbstract' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_RetirementBenefitPlans' xlink:label='fil_RetirementBenefitPlans'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RetirementBenefitPlansAbstract' xlink:to='fil_RetirementBenefitPlans' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_INVENTORYDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_INVENTORYDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_INVENTORYDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InventoryDetailsAbstract' xlink:label='fil_InventoryDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods' xlink:label='us-gaap_InventoryFinishedGoods'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryFinishedGoods' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross' xlink:label='us-gaap_InventoryGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryGross' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryValuationReserves' xlink:label='us-gaap_InventoryValuationReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryValuationReserves' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalInventory' xlink:label='fil_TotalInventory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='fil_TotalInventory' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:label='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandAndLandImprovements' xlink:label='us-gaap_LandAndLandImprovements'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='us-gaap_LandAndLandImprovements' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingsAndImprovementsGross' xlink:label='us-gaap_BuildingsAndImprovementsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='us-gaap_BuildingsAndImprovementsGross' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross' xlink:label='us-gaap_MachineryAndEquipmentGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='us-gaap_MachineryAndEquipmentGross' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_MotorVehicleGross' xlink:label='fil_MotorVehicleGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='fil_MotorVehicleGross' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OfficeEquipment1' xlink:label='fil_OfficeEquipment1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='fil_OfficeEquipment1' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross' xlink:label='us-gaap_PropertyPlantAndEquipmentGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='us-gaap_PropertyPlantAndEquipmentGross' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_LessAccumulatedDepreciation' xlink:label='fil_LessAccumulatedDepreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='fil_LessAccumulatedDepreciation' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PropertyAndEquipmentNet' xlink:label='fil_PropertyAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='fil_PropertyAndEquipmentNet' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:label='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PermitOfLandUseMinimumLife' xlink:label='fil_PermitOfLandUseMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_PermitOfLandUseMinimumLife' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PermitOfLandUseMaximumLife' xlink:label='fil_PermitOfLandUseMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_PermitOfLandUseMaximumLife' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BuildingMinimumLife' xlink:label='fil_BuildingMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_BuildingMinimumLife' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BuildingMaximumLife' xlink:label='fil_BuildingMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_BuildingMaximumLife' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PlantMachineryAndEquipmentMinimumLife' xlink:label='fil_PlantMachineryAndEquipmentMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_PlantMachineryAndEquipmentMinimumLife' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PlantMachineryAndEquipmentMaximumLife' xlink:label='fil_PlantMachineryAndEquipmentMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_PlantMachineryAndEquipmentMaximumLife' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_MotorVehicleMinimumLife' xlink:label='fil_MotorVehicleMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_MotorVehicleMinimumLife' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_MotorVehicleMaximumLife' xlink:label='fil_MotorVehicleMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_MotorVehicleMaximumLife' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OfficeEquipmentMinimumLife' xlink:label='fil_OfficeEquipmentMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_OfficeEquipmentMinimumLife' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OfficeEquipmentMaximumLife' xlink:label='fil_OfficeEquipmentMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_OfficeEquipmentMaximumLife' use='optional' order='10.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:label='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_GrossCarryingAmount' xlink:label='fil_GrossCarryingAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:to='fil_GrossCarryingAmount' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AccumulatedAmortization' xlink:label='fil_AccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:to='fil_AccumulatedAmortization' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetCarryingAmount' xlink:label='fil_NetCarryingAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:to='fil_NetCarryingAmount' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_IntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_IntangibleAssetsAmortizationExpensesDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_IntangibleAssetsAmortizationExpensesDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:label='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:label='fil_AmortizationExpensesRelatingToIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:to='fil_AmortizationExpensesRelatingToIntangibleAssets' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ImpairmentLoss1' xlink:label='fil_ImpairmentLoss1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:to='fil_ImpairmentLoss1' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDAGGREGATEANNUALAMORTIZATIONEXPENSEDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ESTIMATEDAGGREGATEANNUALAMORTIZATIONEXPENSEDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDAGGREGATEANNUALAMORTIZATIONEXPENSEDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:label='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EstimatedAggregateAnnualAmortizationExpenseThereafter' xlink:label='fil_EstimatedAggregateAnnualAmortizationExpenseThereafter'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract' xlink:to='fil_EstimatedAggregateAnnualAmortizationExpenseThereafter' use='optional' order='7.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:label='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:label='fil_CompanyWasObligatedToPayLaboratoriesAndOthers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:to='fil_CompanyWasObligatedToPayLaboratoriesAndOthers' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:label='fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:to='fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_RELATEDPARTYTRANSACTIONSDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_RELATEDPARTYTRANSACTIONSDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_RelatedPartyTransactionsDetailsAbstract' xlink:label='fil_RelatedPartyTransactionsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesOwingToBoardOfDirectors' xlink:label='fil_AdvancesOwingToBoardOfDirectors'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionsDetailsAbstract' xlink:to='fil_AdvancesOwingToBoardOfDirectors' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:label='fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionsDetailsAbstract' xlink:to='fil_InterestRateOnAdvancesFromMemberOfBOD' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalInterestExpense' xlink:label='fil_TotalInterestExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionsDetailsAbstract' xlink:to='fil_TotalInterestExpense' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_NOTESPAYABLESDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_NOTESPAYABLESDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_NOTESPAYABLESDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NotesPayablesDetailsAbstract' xlink:label='fil_NotesPayablesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_RevolvingLineOfCreditWithABankRmb' xlink:label='fil_RevolvingLineOfCreditWithABankRmb'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayablesDetailsAbstract' xlink:to='fil_RevolvingLineOfCreditWithABankRmb' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:label='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayablesDetailsAbstract' xlink:to='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:label='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayablesDetailsAbstract' xlink:to='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_BANKERSACCEPTANCENOTESPAYABLEDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:label='fil_BankerSAcceptanceNotesPayableDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount' xlink:label='fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:to='fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONSTRUCTIONLOANFACILITYDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONSTRUCTIONLOANFACILITYDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONSTRUCTIONLOANFACILITYDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ConstructionLoanFacilityDetailsAbstract' xlink:label='fil_ConstructionLoanFacilityDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalLoanFacilityAmountRmb80000000' xlink:label='fil_TotalLoanFacilityAmountRmb80000000'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_TotalLoanFacilityAmountRmb80000000' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_LoanInterestForAnEightYearTerm' xlink:label='fil_LoanInterestForAnEightYearTerm'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_LoanInterestForAnEightYearTerm' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_InterestRateWasAdjustedTo' xlink:label='fil_InterestRateWasAdjustedTo'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_InterestRateWasAdjustedTo' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:label='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2017' xlink:label='fil_PrincipalPayments2017'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2017' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2018' xlink:label='fil_PrincipalPayments2018'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2018' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2019' xlink:label='fil_PrincipalPayments2019'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2019' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2020' xlink:label='fil_PrincipalPayments2020'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2020' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrincipalPayments2021' xlink:label='fil_PrincipalPayments2021'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2021' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalPrincipalPaymentsDue' xlink:label='fil_TotalPrincipalPaymentsDue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_TotalPrincipalPaymentsDue' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_SUBSIDYINCOMEDetails" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_SUBSIDYINCOMEDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_SUBSIDYINCOMEDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SubsidyIncomeDetailsAbstract' xlink:label='fil_SubsidyIncomeDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1' xlink:label='fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_SubsidyIncomeDetailsAbstract' xlink:to='fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_ENTERPRISEINCOMETAXRATESDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_ENTERPRISEINCOMETAXRATESDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_ENTERPRISEINCOMETAXRATESDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:label='fil_EnterpriseIncomeTaxRatesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRate2015' xlink:label='fil_EnterpriseIncomeTaxRate2015'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='fil_EnterpriseIncomeTaxRate2015' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRate2016' xlink:label='fil_EnterpriseIncomeTaxRate2016'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='fil_EnterpriseIncomeTaxRate2016' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRate2017' xlink:label='fil_EnterpriseIncomeTaxRate2017'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='fil_EnterpriseIncomeTaxRate2017' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRate2018' xlink:label='fil_EnterpriseIncomeTaxRate2018'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='fil_EnterpriseIncomeTaxRate2018' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EnterpriseIncomeTaxRateThereafter' xlink:label='fil_EnterpriseIncomeTaxRateThereafter'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='fil_EnterpriseIncomeTaxRateThereafter' use='optional' order='5.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_PROVISIONFORINCOMETAXESDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_PROVISIONFORINCOMETAXESDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_PROVISIONFORINCOMETAXESDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:label='fil_ProvisionForIncomeTaxesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:label='us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:to='us-gaap_CurrentIncomeTaxExpenseBenefit' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_RECONCILIATIONOFINCOMETAXESCALCULATEDATSTATUTORYRATESDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_RECONCILIATIONOFINCOMETAXESCALCULATEDATSTATUTORYRATESDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_RECONCILIATIONOFINCOMETAXESCALCULATEDATSTATUTORYRATESDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:label='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' xlink:label='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:to='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxHolidays' xlink:label='us-gaap_IncomeTaxReconciliationTaxHolidays'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:to='us-gaap_IncomeTaxReconciliationTaxHolidays' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential' xlink:label='us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:to='us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate' xlink:label='us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:to='us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:to='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IncomeTaxExpense' xlink:label='fil_IncomeTaxExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract' xlink:to='fil_IncomeTaxExpense' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_DeferredIncomeTaxAssetsAbstract' xlink:label='fil_DeferredIncomeTaxAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts' xlink:label='us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AllowanceForDoubtfulOtherReceivables' xlink:label='fil_AllowanceForDoubtfulOtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='fil_AllowanceForDoubtfulOtherReceivables' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory' xlink:label='us-gaap_DeferredTaxAssetsInventory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='us-gaap_DeferredTaxAssetsInventory' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther' xlink:label='us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_AdvancesForIntangibleAssetsImpairment1' xlink:label='fil_AdvancesForIntangibleAssetsImpairment1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='fil_AdvancesForIntangibleAssetsImpairment1' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PrcNetOperatingLossCarryForward' xlink:label='fil_PrcNetOperatingLossCarryForward'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='fil_PrcNetOperatingLossCarryForward' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards' xlink:label='us-gaap_OperatingLossCarryforwards'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='us-gaap_OperatingLossCarryforwards' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_TotalDeferredIncomeTaxAssets' xlink:label='fil_TotalDeferredIncomeTaxAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='fil_TotalDeferredIncomeTaxAssets' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='us-gaap_DeferredTaxAssetsValuationAllowance' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetDeferredIncomeTaxAsset1' xlink:label='fil_NetDeferredIncomeTaxAsset1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='fil_NetDeferredIncomeTaxAsset1' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_DeferredIncomeTaxLiabilityAbstract' xlink:label='fil_DeferredIncomeTaxLiabilityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='fil_DeferredIncomeTaxLiabilityAbstract' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IntangibleAssets1' xlink:label='fil_IntangibleAssets1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='fil_IntangibleAssets1' use='optional' order='12.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_INCOMETAXESNARRATIVEDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_INCOMETAXESNARRATIVEDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_INCOMETAXESNARRATIVEDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_IncomeTaxesNarrativeDetailsAbstract' xlink:label='fil_IncomeTaxesNarrativeDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ChangeInTheTaxExpense' xlink:label='fil_ChangeInTheTaxExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesNarrativeDetailsAbstract' xlink:to='fil_ChangeInTheTaxExpense' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_BasicAndDilutedEarningsPerShare' xlink:label='fil_BasicAndDilutedEarningsPerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesNarrativeDetailsAbstract' xlink:to='fil_BasicAndDilutedEarningsPerShare' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetOperatingLossCarryforwardsForPrcTaxPurposes' xlink:label='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesNarrativeDetailsAbstract' xlink:to='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes' xlink:label='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesNarrativeDetailsAbstract' xlink:to='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ValuationAllowanceAgainstItsDeferredTax' xlink:label='fil_ValuationAllowanceAgainstItsDeferredTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesNarrativeDetailsAbstract' xlink:to='fil_ValuationAllowanceAgainstItsDeferredTax' use='optional' order='5.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CAPITALSTOCKTRANSACTIONSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CapitalStockTransactionsAbstract' xlink:label='fil_CapitalStockTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CommonSharesAuthorized' xlink:label='fil_CommonSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_CommonSharesAuthorized' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PreferredSharesAuthorized' xlink:label='fil_PreferredSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_PreferredSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_CommonSharesParValue' xlink:label='fil_CommonSharesParValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_CommonSharesParValue' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PreferredSharesParValue' xlink:label='fil_PreferredSharesParValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_PreferredSharesParValue' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:label='fil_EmployeeStockOptions2010IncentivePlanAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_EmployeeStockOptions2010IncentivePlanAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NumberOfCommonShares' xlink:label='fil_NumberOfCommonShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_NumberOfCommonShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:label='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' use='optional' order='7.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20161231/role/idr_CONCENTRATIONSDETAILS" xlink:type="simple" xlink:href="cphi-20161231.xsd#idr_CONCENTRATIONSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20161231/role/idr_CONCENTRATIONSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_ConcentrationsDetailsAbstract' xlink:label='fil_ConcentrationsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:label='fil_NoCustomerAccountedForMoreThanPercentageOfSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_NoCustomerAccountedForMoreThanPercentageOfSales' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:label='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:label='fil_OneCustomerAccountedForPercentageOfAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_OneCustomerAccountedForPercentageOfAccountsReceivable' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfProductFirstAccountedForRevenue' xlink:label='fil_PercentageOfProductFirstAccountedForRevenue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_PercentageOfProductFirstAccountedForRevenue' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfProductSecondAccountedForRevenue' xlink:label='fil_PercentageOfProductSecondAccountedForRevenue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_PercentageOfProductSecondAccountedForRevenue' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20161231.xsd#fil_PercentageOfThirdProductAccountedForRevenue' xlink:label='fil_PercentageOfThirdProductAccountedForRevenue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_PercentageOfThirdProductAccountedForRevenue' use='optional' order='6.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817676928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHINA PHARMA HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Entity Trading Symbol</a></td>
<td class="text">cphi<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001106644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818119376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,665,802<span></span>
</td>
<td class="nump">$ 6,248,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">1,088,879<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts', window );">Trade accounts receivable, less allowance for doubtful accounts of $15,664,496 and $29,352,806, respectively</a></td>
<td class="nump">3,999,809<span></span>
</td>
<td class="nump">5,174,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables, less allowance for doubtful accounts of $71,548 and $74,400, respectively</a></td>
<td class="nump">224,373<span></span>
</td>
<td class="nump">290,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesToSuppliers', window );">Advances to suppliers</a></td>
<td class="nump">2,003,792<span></span>
</td>
<td class="nump">2,533,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,310,939<span></span>
</td>
<td class="nump">9,662,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">226,357<span></span>
</td>
<td class="nump">339,140<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">17,519,951<span></span>
</td>
<td class="nump">24,248,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssets', window );">Advances for purchases of intangible assets</a></td>
<td class="nump">35,498,059<span></span>
</td>
<td class="nump">42,030,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">24,967,448<span></span>
</td>
<td class="nump">29,393,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">534,682<span></span>
</td>
<td class="nump">841,075<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">78,520,140<span></span>
</td>
<td class="nump">96,513,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">3,060,374<span></span>
</td>
<td class="nump">2,439,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">139,830<span></span>
</td>
<td class="nump">143,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="nump">2,502,694<span></span>
</td>
<td class="nump">2,095,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerAdvancesCurrent', window );">Advances from customers</a></td>
<td class="nump">811,232<span></span>
</td>
<td class="nump">595,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Other payables - related parties</a></td>
<td class="nump">1,354,567<span></span>
</td>
<td class="nump">1,354,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermConstructionLoanCurrent', window );">Current portion of construction loan facility</a></td>
<td class="nump">1,440,154<span></span>
</td>
<td class="nump">1,540,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesPayable', window );">Bankers' acceptance notes payable</a></td>
<td class="nump">1,088,879<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Short-term notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,621,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">10,397,730<span></span>
</td>
<td class="nump">12,791,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent', window );">Construction loan facility</a></td>
<td class="nump">8,640,927<span></span>
</td>
<td class="nump">10,784,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">572,349<span></span>
</td>
<td class="nump">296,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">19,611,006<span></span>
</td>
<td class="nump">23,872,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively</a></td>
<td class="nump">43,580<span></span>
</td>
<td class="nump">43,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">23,590,204<span></span>
</td>
<td class="nump">23,590,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">24,757,374<span></span>
</td>
<td class="nump">33,939,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss', window );">Accumulated other comprehensive income</a></td>
<td class="nump">10,517,976<span></span>
</td>
<td class="nump">15,067,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">58,909,134<span></span>
</td>
<td class="nump">72,641,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 78,520,140<span></span>
</td>
<td class="nump">$ 96,513,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AdvancesForPurchasesOfIntangibleAssets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers' acceptance notes payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Trade accounts receivable, less allowance for doubtful accounts of $15,664,496 and $29,352,806, respectively, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerAdvancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of prepayments received from customers for goods or services to be provided in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerAdvancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermConstructionLoanCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermConstructionLoanCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current and noncurrent portions of a long-term real estate loan with an initial maturity beyond one year or beyond the normal operating cycle, if longer, to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConstructionLoanCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated other comprehensive Income or Loss at the balance sheet date before fresh-start adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=34712771&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818215520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS PARENTHETICALS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract', window );"><strong>Parentheticals</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts on trade accounts receivable</a></td>
<td class="nump">$ 15,664,496<span></span>
</td>
<td class="nump">$ 29,352,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AllowanceForDoubtfulAccountsOnOtherReceivables', window );">Allowance for doubtful accounts on other receivables</a></td>
<td class="nump">$ 71,548<span></span>
</td>
<td class="nump">$ 74,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AllowanceForDoubtfulAccountsOnOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AllowanceForDoubtfulAccountsOnOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockTransactionsParentheticalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817985888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 15,570,514<span></span>
</td>
<td class="nump">$ 20,351,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">12,352,004<span></span>
</td>
<td class="nump">15,778,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory obsolescence</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,108,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,218,510<span></span>
</td>
<td class="nump">1,464,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">4,036,590<span></span>
</td>
<td class="nump">4,294,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,265,851<span></span>
</td>
<td class="nump">1,896,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">365,969<span></span>
</td>
<td class="nump">961,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">1,086,449<span></span>
</td>
<td class="nump">10,147,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss</a></td>
<td class="nump">3,962,141<span></span>
</td>
<td class="nump">104,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">11,717,000<span></span>
</td>
<td class="nump">17,404,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SubsidyIncome', window );">Subsidy income</a></td>
<td class="nump">343,023<span></span>
</td>
<td class="nump">1,640,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,155,467)<span></span>
</td>
<td class="num">(14,299,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">130,575<span></span>
</td>
<td class="nump">119,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(849,557)<span></span>
</td>
<td class="num">(1,165,164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Net other expense</a></td>
<td class="num">(718,982)<span></span>
</td>
<td class="num">(1,045,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(8,874,449)<span></span>
</td>
<td class="num">(15,345,079)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxExpense', window );">Income tax expense;</a></td>
<td class="nump">308,175<span></span>
</td>
<td class="nump">60,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,182,624)<span></span>
</td>
<td class="num">(15,405,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income - foreign currency translation adjustment</a></td>
<td class="num">(4,549,391)<span></span>
</td>
<td class="num">(4,693,453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (13,732,015)<span></span>
</td>
<td class="num">$ (20,098,971)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SubsidyIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidy income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SubsidyIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817988560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock Shares</div></th>
<th class="th"><div>Common Stock Amount</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Total Stockholders' Equity</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,580<span></span>
</td>
<td class="nump">23,590,204<span></span>
</td>
<td class="nump">49,345,516<span></span>
</td>
<td class="nump">19,760,820<span></span>
</td>
<td class="nump">92,740,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetLossForTheYear', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,405,518)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,405,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,693,453)<span></span>
</td>
<td class="num">$ (4,693,453)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Balance', window );">Balance. at Dec. 31, 2015</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,580<span></span>
</td>
<td class="nump">23,590,204<span></span>
</td>
<td class="nump">33,939,998<span></span>
</td>
<td class="nump">15,067,367<span></span>
</td>
<td class="nump">72,641,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetLossForTheYear1', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,182,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,182,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ForeignCurrencyTranslationAdjustment1', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,549,391)<span></span>
</td>
<td class="num">$ (4,549,391)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Balance1', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,580<span></span>
</td>
<td class="nump">23,590,204<span></span>
</td>
<td class="nump">24,757,374<span></span>
</td>
<td class="nump">10,517,976<span></span>
</td>
<td class="nump">58,909,134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Balance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_Balance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Balance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_Balance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ForeignCurrencyTranslationAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ForeignCurrencyTranslationAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetLossForTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetLossForTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetLossForTheYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetLossForTheYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CapitalUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CapitalUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_StockholdersEquityTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_StockholdersEquityTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817545552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,182,624)<span></span>
</td>
<td class="num">$ (15,405,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,078,074<span></span>
</td>
<td class="nump">3,598,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">1,086,449<span></span>
</td>
<td class="nump">10,147,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">308,175<span></span>
</td>
<td class="nump">60,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProvisionForObsoleteInventory', window );">Provision for obsolete inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,941,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">3,962,141<span></span>
</td>
<td class="nump">104,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade accounts and other receivables</a></td>
<td class="num">(1,097,556)<span></span>
</td>
<td class="num">(2,511,888)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Advances to suppliers</a></td>
<td class="nump">380,779<span></span>
</td>
<td class="nump">843,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">2,734,612<span></span>
</td>
<td class="nump">5,157,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="nump">815,198<span></span>
</td>
<td class="nump">216,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Accrued taxes payable</a></td>
<td class="nump">72,107<span></span>
</td>
<td class="nump">34,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other payables and accrued expenses</a></td>
<td class="nump">377,663<span></span>
</td>
<td class="nump">548,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCustomerAdvances', window );">Advances from customers</a></td>
<td class="nump">265,928<span></span>
</td>
<td class="num">(1,430,595)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">94,762<span></span>
</td>
<td class="nump">45,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">2,895,708<span></span>
</td>
<td class="nump">3,350,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Advances for purchases of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,634,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptancesRedeemedForCash', window );">Bankers acceptances redeemed for cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">423,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(193,404)<span></span>
</td>
<td class="num">(685,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(193,404)<span></span>
</td>
<td class="num">(1,895,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConstructionLoansPayable', window );">Payments of construction term loan</a></td>
<td class="num">(1,505,346)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Payments of short term notes payable</a></td>
<td class="num">(4,516,039)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash used in Financing Activity</a></td>
<td class="num">(6,021,385)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of Exchange Rate Changes on Cash</a></td>
<td class="num">(263,877)<span></span>
</td>
<td class="num">(501,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (Decrease) Increase in Cash and Cash Equivalents</a></td>
<td class="num">(3,582,958)<span></span>
</td>
<td class="nump">952,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashAndCashEquivalentsAtBeginningOfPeriod', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">6,248,760<span></span>
</td>
<td class="nump">5,295,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashAndCashEquivalentsAtEndOfPeriod', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">2,665,802<span></span>
</td>
<td class="nump">6,248,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">836,011<span></span>
</td>
<td class="nump">1,151,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountsPayableForPurchasesOfPropertyAndEquipment', window );">Accounts payable for purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">171,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IssuanceOfBankerSAcceptances', window );">Issuance of banker's acceptances</a></td>
<td class="nump">1,088,879<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountsReceivableCollectedWithBankerSAcceptances', window );">Accounts receivable collected with banker's acceptances</a></td>
<td class="nump">935,265<span></span>
</td>
<td class="nump">2,422,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryPurchasedWithBankerSAcceptances', window );">Inventory purchased with banker's acceptances</a></td>
<td class="nump">935,265<span></span>
</td>
<td class="nump">2,059,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances', window );">Advances for purchases of intangibles paid with banker's acceptances</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 391,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountsPayableForPurchasesOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable collected with banker's acceptances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccountsPayableForPurchasesOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountsReceivableCollectedWithBankerSAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable collected with banker's acceptances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccountsReceivableCollectedWithBankerSAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of advances for purchases of intangibles paid with banker's acceptances under non cash investing and financing activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptancesRedeemedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptances redeemed for cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptancesRedeemedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashAndCashEquivalentsAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashAndCashEquivalentsAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashAndCashEquivalentsAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashAndCashEquivalentsAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryPurchasedWithBankerSAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory purchased with banker's acceptances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryPurchasedWithBankerSAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IssuanceOfBankerSAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of banker's acceptances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IssuanceOfBankerSAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProvisionForObsoleteInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision for obsolete inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ProvisionForObsoleteInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCustomerAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCustomerAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConstructionLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings to finance the cost of construction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConstructionLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808778944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1', window );"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'><b>NOTE 1 &#150; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Organization and Nature of Operations &#150; </i></b>China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><font style='background:white'>On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp;&nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&#146;s outstanding shares of common stock on December 21, 2012.</font></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Foreign Investment Industrial Catalogue<i>&nbsp;</i>(the &#147;Catalogue&#148;) jointly issued by China&#146;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &#147;FIE&#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&#146;s business.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&#146;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Consolidation and Basis of Presentation </i></b>&#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Helpson&#146;s functional currency is the Chinese Renminbi. Helpson&#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Accounting Estimates </i></b><b>- </b>The methodology used to prepare for the Company&#146;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&#147;Management&#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Cash and Cash Equivalents </i></b>&#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#146;s acceptances purchased with maturities of three months or less.</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'><b><i>Restricted Cash</i></b><b>&nbsp;</b>&#150;<b>&nbsp;</b>Restricted cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker's acceptance notes issued by the Company as discussed in Note 8.</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Trade Accounts Receivable and Allowance for Doubtful Accounts &#150; </i></b>Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $1,086,449 and $10,147,293 for the years ended December 31, 2016 and 2015, respectively.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectable trade accounts receivable balances in the amount of $13.5 million and $19.7 million against the allowance for the years ended December 31, 2016 and 2015, respectively. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Advances to Suppliers and Advances from Customers</i></b> &#150; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company recognized bad debt expense of approximately $0 and $4.1 million for the years ended December 31, 2016 and 2015, respectively.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Inventories</i></b> &#150; Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated portion of the Company&#146;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this lower cost basis until sold or scrapped.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Valuation of Long-Lived Assets</i></b> &#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. For the year ended December 31, 2016 and 2015 the Company evaluated its long-lived assets and determined that impairment adjustments of $3,962,141 related to advances for intangible assets as discussed in Note 5 and $104,544 related to certain intangible assets as discussed in Note 4 were necessary.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Property and Equipment</i></b> &#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;line-height:115%;margin:0in 0in 10pt'><b><i><font style='line-height:115%'>Revenue Recognition</font></i></b><font style='line-height:115%'> &#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be reasonably assured. Management had determined that revenue deferred from 2014 was not completely collected in 2016. Thus, according to the Company&#146;s trade receivable provision policy, such deferred revenue was reclassified to allowance for doubtful accounts as of December 31, 2015.</font></p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Cost of Revenues</i></b> &#150; Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Research and Development</i></b> &#150; Research and development expenditures are recorded as expenses in the period in which they occur.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Retirement Benefit Plans</i></b> &#150; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by the provincial governments. The benefit plans of the government assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $261,063 and $270,488 to retirement benefit plans for the years ended December 31, 2016 and 2015, respectively. Contributions to these plans are charged to expense as incurred.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0.3in 0pt 0in'><b><i>Advertising Costs</i></b> &#150; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2016 and 2015.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Basic and Diluted Loss per Common Share </i></b><b>- </b>Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.</p> <p style='text-align:justify;margin:0in 0in 0pt'>There were no potential dilutive common shares outstanding during the years ended December 31, 2016 and 2015, respectively.&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Credit Risk</i></b> &#150; The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&#146;s deposits may be at a higher risk of loss.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Interest Rate Risk</i></b> &#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Reclassification</i></b> &#150;Certain prior year balance sheet amounts have been reclassified to conform to the current year presentation. These amounts had no effect on the reported results of operations.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Recent Accounting Pronouncements</i></b></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In May 2014, the FASB issued ASU 2014-09,&nbsp;<i>"Revenue from Contracts with Customers"</i>&nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. &nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In November 2015, the FASB issued Accounting Standards Update 2015-17,&nbsp;&#147;<i>Balance Sheet Classification of Deferred Taxes</i>,&#148; which is intended to simplify the balance sheet presentation of deferred income taxes. Current accounting principles require an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in its balance sheet. The amendments require that deferred tax liabilities and assets be classified as noncurrent in its balance sheet. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Companies may apply the new provisions either retrospectively or on a prospective basis, and early adoption is permitted. We early adopted the amendments effective December 31, 2015 on a retrospective basis. There was no effect on our Consolidated Balance Sheet as of December 31, 2016 or 2015.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In January 2016, the FASB issued Accounting Standards Update 2016-01,&nbsp;&#147;<i>Recognition and Measurement of Financial Assets and Financial Liabilities</i>.&#148; The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on our financial statements.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'>In February 2016, the FASB issued ASU No. 2016-02,&nbsp;<i>Leases</i>, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB's new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures.</p> <p style='line-height:10.25pt;margin:0in 0in 0pt;background:white'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'>In March 2016, the FASB issued ASU No. 2016-09,&nbsp;<i>Improvements to Employee Share-Based Payment Accounting</i>. The standard provides a new requirement to record all of the tax effects related to share-based payments at settlement (or expiration) through the income statement. This pronouncement is effective for annual reporting periods beginning after December 15, 2016. The Company has completed an evaluation of the pronouncement and determined that its impact upon adoption will not be material to the Company's consolidated financial statements and related disclosures.</p> <p style='line-height:10.25pt;margin:0in 0in 0pt;background:white'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'>In June 2016, the FASB issued Accounting Standards Update 2016-13,&nbsp;<i>Financial Instruments &#150; Credit Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration since their origination.&nbsp;The pronouncement will be effective for Public business entities that are SEC filers in fiscal years beginning after&nbsp;December 15, 2019, including interim periods within those fiscal years. </p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'>&nbsp;&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'>Early application of the guidance will be permitted for all entities for fiscal years beginning after&nbsp;December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and related disclosures.</p> <p style='line-height:10.25pt;margin:0in 0in 0pt;background:white'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'>In August 2016, the FASB issued ASU No. 2016-15,&nbsp;<i>Classification of Certain Cash Receipts and Cash Payments</i>. The standard addresses the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective approach.&nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures, but does not expect the impact to be material.</p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:0in 0in 0pt;background:white'>In November 2016, the FASB issued ASU 2016-18, <i>Statement of Cash Flows (Topic 230): Restricted Cash (&#147;ASU 2016-18&#148;)</i>. The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-18 may have on its consolidated financial statements.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><font style='background:white'>Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&#146;s financial position, result of operations or cash flows.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749776064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'><b>NOTE 2 &#150; INVENTORY</b></p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='margin:0in 0in 0pt'>Inventory consisted of the following:</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr> <td valign="bottom" width="62%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:62%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Raw materials</p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="13%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>11,562,388</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="13%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>14,699,736</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Work in process</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>360,550</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Finished goods</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,530,641</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>3,380,109</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>13,453,579</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>18,079,845</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Obsolescence reserve</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(6,142,640</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(8,417,095</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:9pt;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'><b>Total Inventory</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>7,310,939</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>9,662,750</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table> <p style='margin:0in 0in 0pt'>&nbsp;<b>&nbsp;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6741036720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'><b>NOTE 3 - PROPERTY AND EQUIPMENT</b></p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='margin:0in 0in 0pt'>Property and equipment consisted of the following:</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" colspan="3" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr> <td valign="bottom" width="62%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:62%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Permit of land use</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:13%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>405,645</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:13%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>433,956</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Building</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>9,419,700</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>10,557,234</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Plant, machinery and equipment</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>26,151,029</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>27,326,953</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Motor vehicle</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>309,777</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>307,747</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Office equipment</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>182,718</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>190,279</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:9pt;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Total</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>36,468,869</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>38,816,169</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Less: accumulated depreciation</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(11,501,421</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(9,422,912</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Property and Equipment, net</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>24,967,448</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>29,393,257</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>For the years ended December 31, 2016 and 2015, depreciation expense was $2,815,167 and $3,280,618, respectively.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='margin:0in 0in 0pt'>Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" width="71%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>Asset</p></td> <td valign="bottom" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:2%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="27%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:27%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;Life - years&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Permit of land use</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>40 - 70</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Building</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>20 - 49</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Plant, machinery and equipment</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>5 - 10</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Motor vehicle</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>5 - 10</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Office equipment</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>3-5</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620205216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b>NOTE 4 - INTANGIBLE ASSETS</b></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Intangible assets represent the cost of medical formulas approved for production by the CFDA. The Company did not obtain CFDA production approval for any medical formula during the year ended December 31, 2016 and 2015 and no costs were reclassified from advances to intangible assets in 2016 and 2015, respectively.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.&nbsp;&nbsp;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $262,908 and $317,908 for the years ended December 31, 2016 and 2015, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company&#146;s evaluation is based on an estimated discounted net cash flow model, considering currently available market data for the related drug and the Company&#146;s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated undiscounted future net cash flows. An impairment loss of $104,544 was recognized during the year ended December 31, 2015. No impairment loss was recognized during the year ended December 31, 2016.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Intangible assets consisted solely of CFDA approved medical formulas as follows:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr align="left"> <td valign="bottom" width="56%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Gross carrying amount</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>4,861,766</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>5,201,079</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Accumulated amortization</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(4,327,084</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(4,360,004</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Net carrying amount</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>534,682</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>841,075</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table> <p style='margin:0in 0in 0pt'>&nbsp;&nbsp;</p> <p style='margin:0in 0in 0pt'>The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" width="39%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:39%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Year</b></p></td> <td valign="bottom" width="6%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:6%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="55%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:55%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>&nbsp;Amount&nbsp;</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2017</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;160,947</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2018</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;109,872</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2019</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;57,290</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2020</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35,412</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2021</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35,412</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>Thereafter</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;135,749</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'><b>Total</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:black 1pt solid;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;534,682</p></td></tr></table> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808762336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract', window );"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock', window );">ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'><b>NOTE 5 &#150; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</b></p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In order to expand the number of medicines the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process for the year end December 31, 2013. These patents have not expired.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Prior to entering into contracts with the Company, laboratories typically are required to complete all&nbsp;research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA&#146;s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to be received in approximately two to five years from the date&nbsp;the Company signs the medical formula contracts.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>As of December 31, 2016, the Company was obligated to pay laboratories and others approximately $4,400,000 upon the completion of various phases of contracts to obtain CFDA production approval of medical formulas.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>During 2016, with CFDA's tightened scrutiny procedure in connection with its review of production applications and based on the Company's monitoring and assessment process, the Company determined five advanced payments to five independent laboratories were impaired. As a result, the Company recognized an impairment loss for the advances made to these laboratories in the amount of $3,962,141.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of advances for purchases of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618875792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b>NOTE 6 &#150; RELATED PARTY TRANSACTIONS</b></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p>A member of the Company&#146;s board of directors had previously advanced the Company an aggregate amount of $1,354,567 as of December 31, 2016 and 2015 which are recorded as other payables &#150; related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.&nbsp;&nbsp;Total interest expense of $13,546 was recognized for each of the years ended December 31, 2016 and 2015.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808740720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotesPayable1Abstract', window );"><strong>NOTES PAYABLES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLES</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b>NOTE 7 &#150; NOTES PAYABLE</b></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In November 2014, the Company entered into a line of credit with a bank in the amount of RMB30,000,000 (approximately $4.5 million). Advances on the line of credit were due one year from the date of the advance and were collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.16% (based upon 110% of the PRC government's short term rate of 5.6% in November 2014). In addition, the Company's Chief Executive Officer and Chair of the board of directors personally guaranteed the line of credit. In November, 2015 the Company renewed its line of credit in the amount of RMB30,000,000 (approximately $4.5 million) with the same bank. The line of credit was payable in two equal installments of RMB15,000,000 (approximately $2.25 million) payable on September 16, 2016 and October 19, 2016, respectively. The Company made the respective payments due for RMB15,000,000 according to the terms of the agreement during 2016.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The outstanding balance due under the revolving line of credit was RMB0 and RMB30,000,000 as of December 31, 2016 and December 31, 2015, respectively ($0 and $4,621,998 as of December 31, 2016 and 2015, respectively). The Company has no additional amounts available to it under this line of credit.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Fair Value of Notes Payable</i></b> &#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable outstanding as of December 31, 2015 approximated its fair value because of the immediate or short-term maturity of this financial instrument and because the underlying instrument bears interest rates that approximated current market rates.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NotesPayable1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NotesPayable1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618875792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BANKER'S ACCEPTANCE NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankerSAcceptanceNotesPayableAbstract', window );"><strong>BANKER'S ACCEPTANCE NOTES PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankerSAcceptanceNotesPayableTextBlock', window );">BANKER'S ACCEPTANCE NOTES PAYABLE</a></td>
<td class="text"><!--egx--><p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'><b>NOTE 8 &#150; BANKER'S ACCEPTANCE NOTES PAYABLE</b></p> <p style='background:white;margin:0in 0in 0pt;line-height:10.25pt'>&nbsp;</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>In April 2016, the Company entered into a Banker's Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker's acceptance notes (the "Banker's Notes") to any third party as payment of amounts owing to that third party. The Company is required to deposit with the bank an amount equal to the amounts represented by the Banker's Notes issued to the third parties. The amount of these deposited balances is shown as "Restricted cash" on the accompanying balance sheets as of December 31, 2016. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately $4.5 million) or the amount of cash available to deposit against the Banker's Notes. In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank. At December 31 2016 and 2015, the Company had outstanding Banker's Acceptance Notes in the amount of $1,088,879 and $0, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankerSAcceptanceNotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankerSAcceptanceNotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankerSAcceptanceNotesPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure is about the bankers' acceptance notes payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankerSAcceptanceNotesPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749819856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSTRUCTION LOAN FACILITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DebtAbstract', window );"><strong>CONSTRUCTION LOAN FACILITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONSTRUCTION LOAN FACILITY</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b>NOTE 9 &#150; CONSTRUCTION LOAN FACILITY</b></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company obtained a construction loan facility in the aggregate amount of RMB80,000,000 (approximately $13 million) from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The total loan facility is from the same bank that provided the line of credit as discussed in Note 7.&nbsp;&nbsp;The proceeds of the loan were used for and are collateralized by the construction of the Company&#146;s new production facility and the included production line equipment and machinery. During 2015, the loan bore weighted interest at 5.73%, based upon 110% of the PRC government&#146;s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest rate was adjusted to 5.94% and on July 10, 2016 the interest rate was further adjusted to 5.39%. &nbsp;The loan requires interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal will be due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described above for 2015. In January 2016, the Company made a principal payment in the amount of approximately $0.3 million (RMB2,000,000) and on July 13, 2016 the Company made a payment in the amount of approximately $1.2 million (RMB8,000,000). As of December 31, 2016, the Company had no additional amounts available to it under this facility.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Principal payments required for the next five years as of December 31, 2016 are as follows:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" width="69%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:69%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Year</b></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="28%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:28%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Amount</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2017</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,440,154</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2018</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2019</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2020</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2021</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:black 1pt solid;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10,081,082</p></td></tr></table> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Fair Value of Construction Loan Facility</i></b> &#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2016 and 2015 approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749857424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSIDY INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SubsidyIncomeAbstract', window );"><strong>SUBSIDY INCOME:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SubsidyIncomeDisclosureTextBlock', window );">SUBSIDY INCOME</a></td>
<td class="text"><!--egx--><p style='background:white;margin:0in 0in 0pt'><b>NOTE 10 &#150; SUBSIDY INCOME</b></p> <p style='background:white;margin:0in 0in 0pt'>&nbsp;</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt'>During the years ended December 31, 2016 and 2015, the Company received cash of $0.34 million and $1.64 million related to a subsidy from the government for the technological innovation it has achieved and the industrial upgrading related to its new GMP certified facility.&nbsp;This has been recorded as &#147;Subsidy income&#148; in the accompanying Statement of Operations for the years ended December 31, 2016 and 2015, respectively.</p> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SubsidyIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SubsidyIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SubsidyIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entirte disclosure is about the subsidy from the government received by the Company for the technological innovation achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SubsidyIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808799312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'><b>NOTE 11 - INCOME TAXES</b></p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Undistributed earnings of Helpson, the Company&#146;s foreign subsidiary, since its acquisition, amounted to approximately $34.2 million as of December 31, 2016. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Liabilities are established for uncertain tax positions expected to be taken in income tax return when such positions are judged to meet the &#147;more-likely-than-not&#148; threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2016, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2013 through December 31, 2016 and the Chinese income tax return for the year ended December 31, 2016 are open for possible examination.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>On March 16, 2007, the National People&#146;s Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&nbsp;1, 2008. The EIT Law and Implementation Regulations Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for 2014 to 2016.&nbsp;The recent&nbsp;net losses have put the Company in an unfavorable position for the potential renewal of&nbsp;"National High-Tech Enterprise" status in 2017. After evaluating the feasibility of the renewal, the Company has decided not to renew this status.&nbsp;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'>  <tr align="left"> <td valign="bottom" width="21%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:21%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="31%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:31%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="7%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:7%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" rowspan="2" width="41%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:41%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Enterprise Income Tax Rate</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Year</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>2015</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>15%</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>2016</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>15%</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>2017</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>25%</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>2018</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>25%</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Thereafter</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>25%</p></td></tr></table> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The provision for income taxes consisted of the following:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'>  <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="7" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Year Ended December 31,</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Current</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" width="56%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Deferred</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>308,175</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>60,439</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Total income tax expense </b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>308,175</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>60,439</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='margin:0in 0.3in 0pt 0in'>Following is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes:</p> <p style='margin:0in 0.3in 0pt 0in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'>  <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="7" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Years Ended December 31,</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr align="left"> <td valign="bottom" width="56%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>(Benefit) tax at statutory rate of 25%</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(2,218,612</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(3,832,536</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Effect of tax holiday</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>837,089</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,478,831</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Effect of change in tax rate from 15% to 25%</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(8,094,456</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Other, primarily the difference in U.S. tax rates</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>7,903</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>4,136</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Change in valuation allowance</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>9,776,251</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2,410,008</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Income tax expense</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>308,175</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>60,439</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The effect of the tax holiday amounted to a change in the tax expense of $837,089 and $1,478,831 for the years ended December 31, 2016 and 2015, which was equivalent to basic and diluted earnings per share of ($0.02) and ($0.03) per share for the years ended December 31, 2016 and 2015, respectively. The temporary differences which give rise to the deferred income tax assets and liability are as follows:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'>  <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="7" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Deferred income tax assets:</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" width="56%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Allowance for doubtful trade receivables</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>3,916,124</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>4,402,921</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Allowance for doubtful other receivables</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>17,959</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>11,160</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Inventory obsolescence reserve</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,535,660</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,262,564</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Expenses not deductible in current year</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,008,350</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>647,236</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Advances for intangible assets impairment</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>793,624</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>PRC net operating loss carry forward</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>12,660,410</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>5,114,478</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>U.S. net operating loss carry forward</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,520,675</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,360,213</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Total deferred income tax assets</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>21,452,802</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>12,798,572</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Valuation allowance</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(21,452,802</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(12,798,572</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:9pt;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Net deferred income tax asset</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Deferred income tax liability:</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Intangible assets</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>572,349</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>296,890</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>As of December 31, 2016, the Company had net operating loss carryforwards for PRC tax purposes of approximately $51.0 million which are available to offset any future taxable income through 2021. The Company also has net operating losses for United States federal income tax purposes of approximately $4.5 million which are available to offset future taxable income, if any, through 2036.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&nbsp;&nbsp;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&nbsp;&nbsp;Management considers projected future taxable income and tax planning strategies in making this assessment.&nbsp;&nbsp;Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December 31, 2016 and 2015.&nbsp;&nbsp;Therefore, the Company provided for a valuation allowance against its deferred tax assets of $21,452,802 and $12,798,572 as of December 31, 2016 and 2015, respectively.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808627872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'><b>NOTE 12 - STOCKHOLDERS' EQUITY</b></p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&#146;s board of directors.</p> <p style='text-align:justify;margin:0in 0in 0pt'><b>&nbsp;</b></p> <p style='text-align:justify;margin:0in 0in 0pt'><b><u>Employee Stock Options</u></b></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><i>2010 Incentive Plan</i></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>On November 12, 2010, the Company&#146;s Board of Directors adopted the Company&#146;s 2010 Incentive Plan (the &#147;Plan&#148;), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through December 31, 2016, there were 175,000 shares of restricted stock granted and outstanding under the Plan.&nbsp; No options were outstanding as of December 31, 2016 under the Plan.</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='margin:0in 0in 0pt'>There were no securities issued from the Plan during each of the year ended December 31, 2016 and 2015.&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the years ended December 31, 2016 and 2015.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company&#146;s common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>As of December 31, 2016, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808761648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b>NOTE 13 &#150; COMMITMENTS AND CONTINGENCIES</b></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Economic environment </i></b><b>- </b>Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company&#146;s operations.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommitmentAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommitmentAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6624598288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>CONCENTRATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b>NOTE 14 &#150; CONCENTRATIONS</b></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>For the year ended December 31, 2016, no customer accounted for more than 10.0% of sales and one supplier accounted for 21.1% of raw material purchases, one customer accounted for 46.3% of accounts receivable, and three different products accounted for 49.0%, 14.0% and 11.0% of revenue.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>For the year ended December 31, 2015, no customer accounted for more than 10% of sales and one supplier accounted for 27.0% of raw material purchases, one customer accounted for 28.0% of accounts receivable, and three different products accounted for 49.0%, 15.0% and 14.0% of revenue.&nbsp;</p> <p style='margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6327-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817765744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTING POLICIES (POLICIES)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountingPoliciesAbstract1', window );"><strong>Accounting Policies:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Organization and Nature of Operations &#150; </i></b>China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><font style='background:white'>On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp;&nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&#146;s outstanding shares of common stock on December 21, 2012.</font></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Foreign Investment Industrial Catalogue<i>&nbsp;</i>(the &#147;Catalogue&#148;) jointly issued by China&#146;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &#147;FIE&#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&#146;s business.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&#146;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation and Basis of Presentation</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Consolidation and Basis of Presentation </i></b>&#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Helpson&#146;s functional currency is the Chinese Renminbi. Helpson&#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Accounting Estimates </i></b><b>- </b>The methodology used to prepare for the Company&#146;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&#147;Management&#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.</p> <p style='margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><!--egx--><p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'><b><i>Restricted Cash</i></b><b>&nbsp;</b>&#150;<b>&nbsp;</b>Restricted cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker's acceptance notes issued by the Company as discussed in Note 8.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><b><i>Cash and Cash Equivalents </i></b>&#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#146;s acceptances purchased with maturities of three months or less.</p> <p style='margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts, Policy</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Trade Accounts Receivable and Allowance for Doubtful Accounts &#150; </i></b>Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $1,086,449 and $10,147,293 for the years ended December 31, 2016 and 2015, respectively.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectable trade accounts receivable balances in the amount of $13.5 million and $19.7 million against the allowance for the years ended December 31, 2016 and 2015, respectively. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock', window );">Advances to Suppliers and Advances from Customers</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Advances to Suppliers and Advances from Customers</i></b> &#150; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company recognized bad debt expense of approximately $0 and $4.1 million for the years ended December 31, 2016 and 2015, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Inventories</i></b> &#150; Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated portion of the Company&#146;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this lower cost basis until sold or scrapped.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Valuation of Long-Lived Assets</i></b> &#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. For the year ended December 31, 2016 and 2015 the Company evaluated its long-lived assets and determined that impairment adjustments of $3,962,141 related to advances for intangible assets as discussed in Note 5 and $104,544 related to certain intangible assets as discussed in Note 4 were necessary.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Policy</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Property and Equipment</i></b> &#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:115%;margin:0in 0in 10pt'><b><i><font style='line-height:115%'>Revenue Recognition</font></i></b><font style='line-height:115%'> &#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be reasonably assured. Management had determined that revenue deferred from 2014 was not completely collected in 2016. Thus, according to the Company&#146;s trade receivable provision policy, such deferred revenue was reclassified to allowance for doubtful accounts as of December 31, 2015.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Cost of Revenues</i></b> &#150; Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.</p> <p style='margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Research and Development</i></b> &#150; Research and development expenditures are recorded as expenses in the period in which they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitPlansPolicy', window );">Retirement Benefit Plans</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Retirement Benefit Plans</i></b> &#150; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by the provincial governments. The benefit plans of the government assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $261,063 and $270,488 to retirement benefit plans for the years ended December 31, 2016 and 2015, respectively. Contributions to these plans are charged to expense as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0.3in 0pt 0in'><b><i>Advertising Costs</i></b> &#150; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2016 and 2015.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted (Loss) Earnings per Common Share</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Basic and Diluted Loss per Common Share </i></b><b>- </b>Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.</p> <p style='text-align:justify;margin:0in 0in 0pt'>There were no potential dilutive common shares outstanding during the years ended December 31, 2016 and 2015, respectively.&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Credit Risk</i></b> &#150; The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&#146;s deposits may be at a higher risk of loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InterestRateRiskPolicyTextBlock', window );">Interest Rate Risk</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Interest Rate Risk</i></b> &#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Reclassification</i></b> &#150;Certain prior year balance sheet amounts have been reclassified to conform to the current year presentation. These amounts had no effect on the reported results of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'><b><i>Recent Accounting Pronouncements</i></b></p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In May 2014, the FASB issued ASU 2014-09,&nbsp;<i>"Revenue from Contracts with Customers"</i>&nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. &nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In November 2015, the FASB issued Accounting Standards Update 2015-17,&nbsp;&#147;<i>Balance Sheet Classification of Deferred Taxes</i>,&#148; which is intended to simplify the balance sheet presentation of deferred income taxes. Current accounting principles require an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in its balance sheet. The amendments require that deferred tax liabilities and assets be classified as noncurrent in its balance sheet. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Companies may apply the new provisions either retrospectively or on a prospective basis, and early adoption is permitted. We early adopted the amendments effective December 31, 2015 on a retrospective basis. There was no effect on our Consolidated Balance Sheet as of December 31, 2016 or 2015.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>In January 2016, the FASB issued Accounting Standards Update 2016-01,&nbsp;&#147;<i>Recognition and Measurement of Financial Assets and Financial Liabilities</i>.&#148; The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on our financial statements.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>In February 2016, the FASB issued ASU No. 2016-02,&nbsp;<i>Leases</i>, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB's new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures.</p> <p style='background:white;margin:0in 0in 0pt;line-height:10.25pt'>&nbsp;</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>In March 2016, the FASB issued ASU No. 2016-09,&nbsp;<i>Improvements to Employee Share-Based Payment Accounting</i>. The standard provides a new requirement to record all of the tax effects related to share-based payments at settlement (or expiration) through the income statement. This pronouncement is effective for annual reporting periods beginning after December 15, 2016. The Company has completed an evaluation of the pronouncement and determined that its impact upon adoption will not be material to the Company's consolidated financial statements and related disclosures.</p> <p style='background:white;margin:0in 0in 0pt;line-height:10.25pt'>&nbsp;</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>In June 2016, the FASB issued Accounting Standards Update 2016-13,&nbsp;<i>Financial Instruments &#150; Credit Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration since their origination.&nbsp;The pronouncement will be effective for Public business entities that are SEC filers in fiscal years beginning after&nbsp;December 15, 2019, including interim periods within those fiscal years. </p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>&nbsp;</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>&nbsp;&nbsp;</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>Early application of the guidance will be permitted for all entities for fiscal years beginning after&nbsp;December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and related disclosures.</p> <p style='background:white;margin:0in 0in 0pt;line-height:10.25pt'>&nbsp;</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>In August 2016, the FASB issued ASU No. 2016-15,&nbsp;<i>Classification of Certain Cash Receipts and Cash Payments</i>. The standard addresses the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective approach.&nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures, but does not expect the impact to be material.</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>&nbsp;</p> <p style='background:white;text-align:justify;margin:0in 0in 0pt;line-height:10.25pt'>In November 2016, the FASB issued ASU 2016-18, <i>Statement of Cash Flows (Topic 230): Restricted Cash (&#147;ASU 2016-18&#148;)</i>. The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-18 may have on its consolidated financial statements.</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'><font style='background:white'>Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&#146;s financial position, result of operations or cash flows.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountingPoliciesAbstract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccountingPoliciesAbstract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for accounting policy of advances to Suppliers and Advances from Customers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InterestRateRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for accounting policy on interest rate risk</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InterestRateRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054294&amp;loc=d3e8384-108330<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68072981&amp;loc=d3e8275-108329<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6410195&amp;loc=d3e80090-111668<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the accounting policy for determining revenue earned from providing cargo and freight related services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808639840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (TABLES)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryTablesAbstract', window );"><strong>INVENTORY (TABLES)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'>Inventory consisted of the following:</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr> <td valign="bottom" width="62%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:62%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Raw materials</p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="13%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>11,562,388</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="13%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>14,699,736</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Work in process</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>360,550</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Finished goods</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,530,641</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>3,380,109</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>13,453,579</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>18,079,845</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Obsolescence reserve</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(6,142,640</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(8,417,095</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:9pt;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'><b>Total Inventory</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>7,310,939</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>9,662,750</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808799312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (TABLES)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentTablesAbstract', window );"><strong>PROPERTY AND EQUIPMENT (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment consists</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'>Property and equipment consisted of the following:</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr> <td valign="bottom" width="62%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:62%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Permit of land use</p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="13%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>405,645</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="13%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:13%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>433,956</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Building</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>9,868,491</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>10,557,234</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Plant, machinery and equipment</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>25,700,825</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>27,325,440</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Motor vehicle</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>249,122</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>242,860</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Office equipment</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>244,786</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>256,679</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:9pt;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'><b>Total</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>36,468,869</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>38,816,169</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Less: accumulated depreciation</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(11,501,421</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(9,422,912</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'><b>Property and Equipment, net</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>24,967,448</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>29,393,257</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UsefulLivesOfTheAssetsTableTextBlock', window );">Useful lives of the assets</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'>Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" width="71%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:71%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>Asset</p></td> <td valign="bottom" width="2%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:2%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="27%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:27%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;Life - years&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>Permit of land use</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>40 - 70</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>Building</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>20 - 49</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>Plant, machinery and equipment</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>5 - 10</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>Motor vehicle</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>5 - 10</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>Office equipment</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>3-5</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UsefulLivesOfTheAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_UsefulLivesOfTheAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808826304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (TABLES)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsTablesAbstract', window );"><strong>Intangible Assets (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsMedicalFormulasTablesTextBlock', window );">Intangible Assets Medical Formulas</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'>Intangible assets consisted solely of CFDA approved medical formulas as follows:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Gross carrying amount</p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>4,861,766</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>5,201,079</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Accumulated amortization</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(4,327,084</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(4,360,004</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>Net carrying amount</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>534,682</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>841,075</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock', window );">Intangible Assets estimated aggregate annual amortization expense for each of the next five years and thereafter</a></td>
<td class="text"><!--egx--><p style='margin:0in 0in 0pt'>The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:</p> <p style='margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" width="39%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:39%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Year</b></p></td> <td valign="bottom" width="6%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:6%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="55%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:55%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>&nbsp;Amount&nbsp;</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2017</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;160,947</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2018</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;109,872</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2019</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;57,290</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2020</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35,412</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2021</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35,412</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>Thereafter</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;135,749</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'><b>Total</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:black 1pt solid;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;534,682</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabluar disclosure of Intangible Assets estimated aggregate annual amortization expense for each of the next five years and thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsEstimatedAggregateAnnualAmortizationExpenseForEachOfTheNextFiveYearsAndThereafterTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsMedicalFormulasTablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabluar disclosure of Intangible Assets Medical Formulas</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsMedicalFormulasTablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6619393488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfLongTermDebtInstrumentsAbstract', window );"><strong>Schedule of Construction Loan Facility:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Principal payments required for the next five years as of December 31, 2015</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'>Principal payments required for the next five years as of December 31, 2016 are as follows:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" width="69%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:69%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Year</b></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="28%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:28%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Amount</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2017</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,440,154</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2018</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2019</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2020</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>2021</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,160,232</p></td></tr> <tr align="left"> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:black 1pt solid;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10,081,082</p></td></tr></table> <p align="center" style='text-align:center;margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfLongTermDebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfLongTermDebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816564016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (TABLES)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxesTablesAbstract', window );"><strong>INCOME TAXES (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock', window );">Schedule of Enterprise Income Tax Rates</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'>Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" width="21%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:21%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="31%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:31%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" width="7%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:7%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" rowspan="2" width="41%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:41%;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Enterprise Income Tax Rate</b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Year</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>&nbsp;</b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>2015</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>15%</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>2016</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>15%</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>2017</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>25%</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>2018</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>25%</p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>Thereafter</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'>25%</p></td></tr></table> <p style='margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for income taxes</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'>The provision for income taxes consisted of the following:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="7" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Year Ended December 31,</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" colspan="3" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Current</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" width="56%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Deferred</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>308,175</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>60,439</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Total income tax expense </b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>308,175</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>60,439</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes</a></td>
<td class="text"><!--egx--><p style='margin:0in 0.3in 0pt 0in'>Following is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes:</p> <p style='margin:0in 0.3in 0pt 0in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="7" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Years Ended December 31,</b></p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>(Benefit) tax at statutory rate of 25%</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(2,218,612</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(3,832,536</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Effect of tax holiday</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>837,089</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,478,831</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Effect of change in tax rate from 15% to 25%</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(8,094,456</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Other, primarily the difference in U.S. tax rates</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>7,903</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>4,136</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Change in valuation allowance</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>9,776,251</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>2,410,008</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Income tax expense</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>308,175</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>60,439</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Temporary differences which give rise to the deferred income tax assets and liability</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0in 0in 0pt'>The temporary differences which give rise to the deferred income tax assets and liability are as follows:</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <p style='text-align:justify;margin:0in 0in 0pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="7" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>December 31,</b></p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" colspan="3" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>2015</b></p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Deferred income tax assets:</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'><b>&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>&nbsp;</b></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:56%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Allowance for doubtful trade receivables</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>3,916,124</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="8%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:8%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>4,402,921</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Allowance for doubtful other receivables</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>17,959</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>11,160</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Inventory obsolescence reserve</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,535,660</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,262,564</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Expenses not deductible in current year</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,008,350</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>647,236</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Advances for intangible assets impairment</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>793,624</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>PRC net operating loss carry forward</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>12,660,410</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>5,114,478</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>U.S. net operating loss carry forward</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,520,675</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>1,360,213</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Total deferred income tax assets</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>21,452,802</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>12,798,572</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Valuation allowance</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(21,452,802</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>(12,798,572</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:9pt;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Net deferred income tax asset</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&#151;&nbsp;&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'><b>Deferred income tax liability:</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>Intangible assets</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>572,349</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>$</p></td> <td valign="bottom" style='border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>296,890</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1pt;padding-left:0in;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure is about the Enterprise Income Tax Rates under the current tax law in the PRC, the Company is and will be subject to.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749798800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract', window );"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited', window );">Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1', window );">Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp; Biotechnology Co., Ltd.</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercetageOfAcquiredByOnnyInHelpson', window );">Percetage of acquired by Onny in Helpson</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercetageOfAcquiredByOnnyInHelpson">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percetage of acquired by Onny in Helpson</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercetageOfAcquiredByOnnyInHelpson</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6644328096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES -Narrative(Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract', window );"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BadDebtExpense', window );">Bad debt expense</a></td>
<td class="nump">$ 1,086,449<span></span>
</td>
<td class="nump">$ 10,147,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UncollectableTradeAccountsReceivable', window );">Uncollectable trade accounts receivable</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">19,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract', window );"><strong>Advances to Suppliers and Advances from Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyRecognizedBadDebtExpense', window );">Company recognized bad debt expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ValuationOfLongLivedAssetsAbstract', window );"><strong>Valuation of Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ImpairmentAdjustmentsRelatedToAdvances', window );">Impairment adjustments related to advances</a></td>
<td class="nump">3,962,141<span></span>
</td>
<td class="nump">104,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RetirementBenefitPlansAbstract', window );"><strong>Retirement Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RetirementBenefitPlans', window );">Retirement Benefit Plans</a></td>
<td class="nump">$ 261,063<span></span>
</td>
<td class="nump">$ 270,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesToSuppliersAndAdvancesFromCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyRecognizedBadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company recognized bad debt expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyRecognizedBadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ImpairmentAdjustmentsRelatedToAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment adjustments related to advances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ImpairmentAdjustmentsRelatedToAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RetirementBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retirement Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RetirementBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RetirementBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RetirementBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UncollectableTradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_UncollectableTradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ValuationOfLongLivedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company recognized bad debt expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ValuationOfLongLivedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754365184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryDetailsAbstract', window );"><strong>Inventory Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 11,562,388<span></span>
</td>
<td class="nump">$ 14,699,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">360,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,530,641<span></span>
</td>
<td class="nump">3,380,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory gross</a></td>
<td class="nump">13,453,579<span></span>
</td>
<td class="nump">18,079,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence reserve</a></td>
<td class="num">(6,142,640)<span></span>
</td>
<td class="num">(8,417,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalInventory', window );">Total Inventory</a></td>
<td class="nump">$ 7,310,939<span></span>
</td>
<td class="nump">$ 9,662,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NetLoss1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817677504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract', window );"><strong>Property and equipment consisted of the following details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandAndLandImprovements', window );">Permit of land use</a></td>
<td class="nump">$ 405,645<span></span>
</td>
<td class="nump">$ 433,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building</a></td>
<td class="nump">9,868,491<span></span>
</td>
<td class="nump">10,557,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Plant, machinery and equipment</a></td>
<td class="nump">25,700,825<span></span>
</td>
<td class="nump">27,325,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleGross', window );">Motor vehicle</a></td>
<td class="nump">249,122<span></span>
</td>
<td class="nump">242,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipment1', window );">Office equipment</a></td>
<td class="nump">244,786<span></span>
</td>
<td class="nump">256,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment Gross Total</a></td>
<td class="nump">36,468,869<span></span>
</td>
<td class="nump">38,816,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LessAccumulatedDepreciation', window );">Less: accumulated depreciation</a></td>
<td class="num">(11,501,421)<span></span>
</td>
<td class="num">(9,422,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">$ 24,967,448<span></span>
</td>
<td class="nump">$ 29,393,257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LessAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation pertaining to real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LessAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of motor vehicle gross as on the date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MotorVehicleGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OfficeEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandAndLandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated deprecation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandAndLandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817765600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ESTIMATED USEFUL LIVES OF THE ASSETS AS FOLLOWS (DETAILS)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract', window );"><strong>Estimated useful lives of the assets as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PermitOfLandUseMinimumLife', window );">Permit of land use minimum life</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PermitOfLandUseMaximumLife', window );">Permit of land use maximum life</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BuildingMinimumLife', window );">Building minimum life</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BuildingMaximumLife', window );">Building maximum life</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlantMachineryAndEquipmentMinimumLife', window );">Plant, machinery and equipment minimum life</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlantMachineryAndEquipmentMaximumLife', window );">Plant, machinery and equipment maximum life</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleMinimumLife', window );">Motor vehicle minimum life</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleMaximumLife', window );">Motor vehicle maximum life</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipmentMinimumLife', window );">Office equipment minimum life</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipmentMaximumLife', window );">Office equipment maximum life</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BuildingMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BuildingMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BuildingMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BuildingMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MotorVehicleMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MotorVehicleMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipmentMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OfficeEquipmentMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipmentMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OfficeEquipmentMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PermitOfLandUseMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PermitOfLandUseMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PermitOfLandUseMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PermitOfLandUseMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlantMachineryAndEquipmentMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PlantMachineryAndEquipmentMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlantMachineryAndEquipmentMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Plant, machinery and equipment minimum life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PlantMachineryAndEquipmentMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620199840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract', window );"><strong>Intangible assets CFDA approved medical formulas details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="nump">$ 4,861,766<span></span>
</td>
<td class="nump">$ 5,201,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(4,327,084)<span></span>
</td>
<td class="num">(4,360,004)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetCarryingAmount', window );">Net carrying amount</a></td>
<td class="nump">$ 534,682<span></span>
</td>
<td class="nump">$ 841,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization on long-term land leases capitalized as part of real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrossCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_GrossCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net carrying amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809317520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets amortization expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract', window );"><strong>Intangible assets amortization expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmortizationExpensesRelatingToIntangibleAssets', window );">Amortization expenses relating to intangible assets</a></td>
<td class="nump">$ 262,908<span></span>
</td>
<td class="nump">$ 317,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ImpairmentLoss1', window );">Impairment loss;</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 104,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmortizationExpensesRelatingToIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AmortizationExpensesRelatingToIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ImpairmentLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ImpairmentLoss1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ImpairmentLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsAmortizationExpensesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6735342880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ESTIMATED AGGREGATE ANNUAL AMORTIZATION EXPENSE (DETAILS)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract', window );"><strong>Estimated aggregate annual amortization expense details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">Estimated aggregate annual amortization expense for 2017</a></td>
<td class="nump">$ 160,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate annual amortization expense for 2018</a></td>
<td class="nump">109,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate annual amortization expense for 2019</a></td>
<td class="nump">57,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate annual amortization expense for 2020</a></td>
<td class="nump">35,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">Estimated aggregate annual amortization expense for 2021</a></td>
<td class="nump">35,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Estimated aggregate annual amortization expense Thereafter</a></td>
<td class="nump">135,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EstimatedAggregateAnnualAmortizationExpenseThereafter', window );">Estimated aggregate annual amortization expense total</a></td>
<td class="nump">$ 534,682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EstimatedAggregateAnnualAmortizationExpenseDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EstimatedAggregateAnnualAmortizationExpenseThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EstimatedAggregateAnnualAmortizationExpenseThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749799344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract', window );"><strong>Advances for purchase of intangible assets details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyWasObligatedToPayLaboratoriesAndOthers', window );">Company was obligated to pay laboratories and others</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories', window );">Impairment loss for the advances made to these laboratories</a></td>
<td class="nump">$ 3,962,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyWasObligatedToPayLaboratoriesAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company was obligated to pay laboratories and others</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyWasObligatedToPayLaboratoriesAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment loss for the advances made to these laboratories</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ImpairmentLossForTheAdvancesMadeToTheseLaboratories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808630304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RelatedPartyTransactionsDetailsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS DETAILS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesOwingToBoardOfDirectors', window );">Advances owing to board of directors</a></td>
<td class="nump">$ 1,354,567<span></span>
</td>
<td class="nump">$ 1,354,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InterestRateOnAdvancesFromMemberOfBOD', window );">Interest rate on advances from Member of BOD</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalInterestExpense', window );">Total interest expense</a></td>
<td class="nump">$ 13,546<span></span>
</td>
<td class="nump">$ 13,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesOwingToBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances owing to board of directors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesOwingToBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InterestRateOnAdvancesFromMemberOfBOD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate on advances from Member of BOD</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InterestRateOnAdvancesFromMemberOfBOD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RelatedPartyTransactionsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RelatedPartyTransactionsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807822128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTES PAYABLES (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Nov. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotesPayablesDetailsAbstract', window );"><strong>NOTES PAYABLES DETAILS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RevolvingLineOfCreditWithABankRmb', window );">Revolving line of credit with a bank (RMB)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56', window );">Annual interest rate based upon 110% of PRC government's current short term rate of 5.6%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000', window );">Outstanding balance due under revolving line of credit (RMB 30,000,000)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,621,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual interest rate based upon 110% of PRC government's current short term rate of 5.6%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NotesPayablesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NotesPayablesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Outstanding balance due under revolving line of credit (RMB 30,000,000)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RevolvingLineOfCreditWithABankRmb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RevolvingLineOfCreditWithABankRmb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620133776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BANKER'S ACCEPTANCE NOTES PAYABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankerSAcceptanceNotesPayableDetailsAbstract', window );"><strong>BANKER'S ACCEPTANCE NOTES PAYABLE Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount', window );">Company had outstanding Banker's Acceptance Notes in the amount</a></td>
<td class="nump">$ 1,088,879<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankerSAcceptanceNotesPayableDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankerSAcceptanceNotesPayableDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company had outstanding Banker's Acceptance Notes in the amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyHadOutstandingBankerSAcceptanceNotesInTheAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807695840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSTRUCTION LOAN FACILITY (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jul. 10, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConstructionLoanFacilityDetailsAbstract', window );"><strong>Construction loan facility details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLoanFacilityAmountRmb80000000', window );">Total loan facility amount (RMB 80,000,000)</a></td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LoanInterestForAnEightYearTerm', window );">Loan interest for an eight-year term</a></td>
<td class="nump">7.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InterestRateWasAdjustedTo', window );">Interest rate was adjusted to</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.94%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConstructionLoanFacilityDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ConstructionLoanFacilityDetailsAbstract [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ConstructionLoanFacilityDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InterestRateWasAdjustedTo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate was adjusted to</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InterestRateWasAdjustedTo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LoanInterestForAnEightYearTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan interest for an eight-year term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LoanInterestForAnEightYearTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLoanFacilityAmountRmb80000000">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loan facility amount (RMB 80,000,000)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalLoanFacilityAmountRmb80000000</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6733330640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract', window );"><strong>Principal payments required for the next five years are as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2017', window );">Principal Payments 2017</a></td>
<td class="nump">$ 1,440,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2018', window );">Principal Payments 2018</a></td>
<td class="nump">2,160,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2019', window );">Principal Payments 2019</a></td>
<td class="nump">2,160,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2020', window );">Principal Payments 2020</a></td>
<td class="nump">2,160,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2021', window );">Principal Payments 2021</a></td>
<td class="nump">2,160,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalPrincipalPaymentsDue', window );">Total principal payments due</a></td>
<td class="nump">$ 10,081,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2018">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2018</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount paid by the company in 2019</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalPrincipalPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Principal amount due by the company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalPrincipalPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618527776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSIDY INCOME (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SubsidyIncomeDetailsAbstract', window );"><strong>SUBSIDY INCOME DETAILS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1', window );">Received cash related to a subsidy from the government for the technological innovation</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 16,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ReceivedCashRelatedToASubsidyFromTheGovernmentForTheTechnologicalInnovation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SubsidyIncomeDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SubsidyIncomeDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618654144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ENTERPRISE INCOME TAX RATES (DETAILS)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRatesDetailsAbstract', window );"><strong>Enterprise income tax rates details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRate2015', window );">Enterprise Income Tax Rate 2015</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRate2016', window );">Enterprise Income Tax Rate 2016</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRate2017', window );">Enterprise Income Tax Rate 2017</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRate2018', window );">Enterprise Income Tax Rate 2018</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRateThereafter', window );">Enterprise Income Tax Rate Thereafter</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRate2015">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rate 2015</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRate2015</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRate2016">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rate 2016</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRate2016</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRate2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rate 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRate2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRate2018">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rate 2018</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRate2018</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRateThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rate Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRateThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRatesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Received cash subsidy from the government for the enterprises that suffered losses from the typhoon to resume production</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRatesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6624691248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROVISION FOR INCOME TAXES (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProvisionForIncomeTaxesDetailsAbstract', window );"><strong>Provision for income taxes details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">308,175<span></span>
</td>
<td class="nump">$ 60,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense.</a></td>
<td class="nump">$ 308,175<span></span>
</td>
<td class="nump">$ 60,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProvisionForIncomeTaxesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ProvisionForIncomeTaxesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749809968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECONCILIATION OF INCOME TAXES CALCULATED AT STATUTORY RATES (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract', window );"><strong>Reconciliation of income taxes calculated at the federal statutory rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">(Benefit) tax at statutory rate of 25%</a></td>
<td class="num">$ (2,218,612)<span></span>
</td>
<td class="num">$ (3,832,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxHolidays', window );">Effect of tax holiday</a></td>
<td class="nump">837,089<span></span>
</td>
<td class="nump">1,478,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Effect of change in tax rate from 15% to 25%</a></td>
<td class="num">(8,094,456)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Other, primarily the difference in U.S. tax rates</a></td>
<td class="nump">7,903<span></span>
</td>
<td class="nump">4,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">9,776,251<span></span>
</td>
<td class="nump">2,410,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxExpense', window );">Income tax expense;</a></td>
<td class="nump">$ 308,175<span></span>
</td>
<td class="nump">$ 60,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ReconciliationOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxHolidays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxHolidays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761578768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DeferredIncomeTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful trade receivables</a></td>
<td class="nump">$ 3,916,124<span></span>
</td>
<td class="nump">$ 4,402,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AllowanceForDoubtfulOtherReceivables', window );">Allowance for doubtful other receivables</a></td>
<td class="nump">17,959<span></span>
</td>
<td class="nump">11,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory obsolescence reserve</a></td>
<td class="nump">1,535,660<span></span>
</td>
<td class="nump">1,262,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Expenses not deductible in current year</a></td>
<td class="nump">1,008,350<span></span>
</td>
<td class="nump">647,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForIntangibleAssetsImpairment1', window );">Advances for intangible assets impairment</a></td>
<td class="nump">793,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrcNetOperatingLossCarryForward', window );">PRC net operating loss carry forward</a></td>
<td class="nump">12,660,410<span></span>
</td>
<td class="nump">5,114,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">U.S. net operating loss carry forward</a></td>
<td class="nump">1,520,675<span></span>
</td>
<td class="nump">1,360,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalDeferredIncomeTaxAssets', window );">Total deferred income tax assets;</a></td>
<td class="nump">21,452,802<span></span>
</td>
<td class="nump">12,798,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21,452,802)<span></span>
</td>
<td class="num">(12,798,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetDeferredIncomeTaxAsset1', window );">Net deferred income tax asset;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DeferredIncomeTaxLiabilityAbstract', window );"><strong>Deferred income tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssets1', window );">Intangible assets;</a></td>
<td class="nump">$ 572,349<span></span>
</td>
<td class="nump">$ 296,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForIntangibleAssetsImpairment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AdvancesForIntangibleAssetsImpairment1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForIntangibleAssetsImpairment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AllowanceForDoubtfulOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AllowanceForDoubtfulOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DeferredIncomeTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DeferredIncomeTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DeferredIncomeTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DeferredIncomeTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetDeferredIncomeTaxAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net deferred income tax asset;</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetDeferredIncomeTaxAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrcNetOperatingLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrcNetOperatingLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalDeferredIncomeTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total deferred income tax assets;</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalDeferredIncomeTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6734129744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES NARRATIVE (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxesNarrativeDetailsAbstract', window );"><strong>INCOME TAXES NARRATIVE DETAILS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ChangeInTheTaxExpense', window );">Change in the Tax expense</a></td>
<td class="nump">$ 837,087<span></span>
</td>
<td class="nump">$ 1,478,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BasicAndDilutedEarningsPerShare', window );">Basic and diluted earnings per share</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes', window );">Net operating loss carryforwards for PRC tax purposes</a></td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes', window );">Net operating losses for United States federal income tax purposes</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ValuationAllowanceAgainstItsDeferredTax', window );">Valuation allowance against its deferred tax</a></td>
<td class="nump">$ 21,452,802<span></span>
</td>
<td class="nump">$ 12,798,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BasicAndDilutedEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and diluted earnings per share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BasicAndDilutedEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ChangeInTheTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the Tax expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ChangeInTheTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxesNarrativeDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ImpairmentLoss1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxesNarrativeDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards for PRC tax purposes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetOperatingLossCarryforwardsForPrcTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating losses for United States federal income tax purposes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ValuationAllowanceAgainstItsDeferredTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance against its deferred tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ValuationAllowanceAgainstItsDeferredTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808014880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CAPITAL STOCK TRANSACTIONS (DETAILS) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Nov. 12, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CapitalStockTransactionsAbstract', window );"><strong>Capital stock transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonSharesAuthorized', window );">Common shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PreferredSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonSharesParValue', window );">Common shares par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PreferredSharesParValue', window );">Preferred shares par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EmployeeStockOptions2010IncentivePlanAbstract', window );"><strong>Employee Stock Options 2010 Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfCommonShares', window );">Number of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan', window );">Shares of restricted stock granted and outstanding under the 2010 Incentive Plan</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CapitalStockTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CapitalStockTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommonSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommonSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EmployeeStockOptions2010IncentivePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EmployeeStockOptions2010IncentivePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PreferredSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PreferredSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PreferredSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PreferredSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares of restricted stock granted and outstanding under the 2010 Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808099120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS (DETAILS)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConcentrationsDetailsAbstract', window );"><strong>Concentrations Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NoCustomerAccountedForMoreThanPercentageOfSales', window );">No customer accounted for more than percentage of sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases', window );">One supplier accounted for percentage of raw material purchases</a></td>
<td class="nump">21.10%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OneCustomerAccountedForPercentageOfAccountsReceivable', window );">One customer accounted for percentage of accounts receivable</a></td>
<td class="nump">46.30%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfProductFirstAccountedForRevenue', window );">Percentage of product first accounted for revenue.</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfProductSecondAccountedForRevenue', window );">Percentage of product second accounted for revenue.</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfThirdProductAccountedForRevenue', window );">Percentage of third product accounted for revenue.</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConcentrationsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company made payments as per Construction agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ConcentrationsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NoCustomerAccountedForMoreThanPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No customer accounted for more than percentage of sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NoCustomerAccountedForMoreThanPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OneCustomerAccountedForPercentageOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One customer accounted for percentage of accounts receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OneCustomerAccountedForPercentageOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One supplier accounted for percentage of raw material purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfProductFirstAccountedForRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of product first accounted for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercentageOfProductFirstAccountedForRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfProductSecondAccountedForRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of product second accounted for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercentageOfProductSecondAccountedForRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfThirdProductAccountedForRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of third product accounted for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercentageOfThirdProductAccountedForRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M<SGZO3QT]6D\UIY?S]:7_P-02P,$%     @ Q()_2FA5WT6U 0  T@,  !@
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M+W=O<FMS:&5E=',O<VAE970X+GAM;'U3VV[;, S]%4$?4#E*VA6!;:#I,'3
M!@0=MCXK-GU!=?$D.>[^?I3LN&[G]442*9[#0XI*!V.?70/@R8N2VF6T\;[;
M,^:*!I1P5Z8#C3>5L4IX-&W-7&=!E!&D).-)<L.4:#7-T^@[VCPUO9>MAJ,E
MKE=*V#\'D&;(Z(9>'(]MW?C@8'G:B1I^@/_9'2U:;&8I6P7:M483"U5&[S;[
MPR[$QX!?+0QN<2:ADI,QS\'X6F8T"8) 0N$#@\#M#/<@92!"&;\G3CJG#,#E
M^<+^)=:.M9R$@WLCG]K2-QF]I:2$2O32/YKA :9ZKBF9BO\&9Y 8'I1@CL)(
M%U=2],X;-;&@%"5>QKW5<1^FFPML'< G )\!MQ' QD11^6?A19Y:,Q []KX3
MX8DW>XZ]*8(SMB+>H7B'WG.^N4Y2=@Y$4\QAC.'+F#F"(?N<@J^E./!_X'P=
MOEU5N(WP[7\4OB'8K1+L(L'NPQ+78MX7R18]56#K.$V.%*;7<9(7WGE@[WA\
MD]?P<=J_"UNWVI&3\?BRL?^5,1Y02G*%(]3@!YL-"94/QT]XMN.8C88WW?2#
MV/R-\[]02P,$%     @ Q()_2C'/;L6S 0  T@,  !@   !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q]4V&/U" 0_2N$'W#LTCV];-HFMV>,)IILSNA]9MMI
M2PZ8"G1[_GN!]FK5ZA=@AGEOW@Q#/J)]=AV )R]:&5?0SOO^R)BK.M#"W6 /
M)MPT:+7PP;0M<[T%42>05HSO=F^8%M+0,D^^LRUS'+R2!LZ6N$%K87^<0.%8
MT#U]=3S*MO/1P<J\%RU\ ?^U/]M@L86EEAJ,DVB(A::@]_OCZ1#C4\ W":-;
MG4FLY(+X'(V/=4%W41 HJ'QD$&&[P@,H%8F"C.\S)UU21N#Z_,K^/M4>:KD(
M!P^HGF3MNX+>45)#(P;E'W'\ ',]MY3,Q7^"*Z@0'I6$'!4JEU92#<ZCGEF"
M%"U>IEV:M(_3#<]FV#: SP"^ .Y2'C8E2LK?"2_*W.)([-3[7L0GWA]YZ$T5
MG:D5Z2Z(=\%[+?>W/&?72#3'G*88OHY9(EA@7U+PK10G_A><;\.S3859@F?_
M4/@;P6&3X) (#O\M<2LF^R,)6_54@VW3-#E2X6#2)*^\R\#>\_0FO\*G:?\L
M;"N-(Q?TX653_QM$#T'*[B:,4!<^V&(H:'P\O@UG.XW99'CLYQ_$EF]<_@10
M2P,$%     @ Q()_2ICEK$6S 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3 N>&UL?5-M;]L@$/XKB!]0$N)L461;:CI-J[1)4:>MGXE]ME%Y<0''
MW;\?8.JYG;<OP!WW//?<<>2C-D^V W#H10IE"]PYUQ\)L54'DMD;W8/R-XTV
MDCEOFI;8W@"K(T@*0C>;#T0RKG"91]_9E+D>G. *S@;904IF?IU Z+' 6_SJ
M>.!MYX*#E'G/6O@.[D=_-MXB,TO-)2C+M4(&F@+?;H^G+,3'@)\<1KLXHU#)
M1>NG8-S7!=X$02"@<H&!^>T*=R!$(/(RGA,GGE,&X/+\ROXYUNYKN3 +=UH\
M\MIU!3Y@5$/#!N$>]/@%4CU[C%+Q7^$*PH<')3Y'I86-*ZH&Z[1,+%Z*9"_3
MSE7<QW1S2+!U $T .@,.,0^9$D7EGYAC96[TB,S4^YZ%)]X>J>]-%9RQ%?'.
MB[?>>RVW^RPGUT"48DY3#%W&S!'$L\\IZ%J*$_T+3M?ANU6%NPC?_4/A&X)L
ME2"+!-E_2UR+V;]+0A8]E6#:.$T657I0<9(7WGE@;VE\DS_AT[1_8Z;ERJ*+
M=OYE8_\;K1UX*9L;/T*=_V"S(:!QX?C1G\TT9I/A=)]^$)F_<?D;4$L#!!0
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ML?\UH@,O97/C1ZCU'VPV)-0N'._\V8QC-AH.N^D'L?D;%^]02P,$%     @
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M/]AB*&A"/+[!LYO&;#*"[><?Q)9O7/X$4$L#!!0    ( ,2"?TH9#_=LM $
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MH [Q>,2S&\=L-(+MIA_$YF]<_ 102P,$%     @ Q()_2M?V<G.U 0  T@,
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MO/5G,XW99#C=IQ]$YF]<_@)02P,$%     @ Q()_2GR3P:&R 0  T@,  !D
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M*^N>3[CD6BD+3DIRX[2T;HH70T!M_?;.[?7TEB?#JGX>4[+\*XI_4$L#!!0
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M<A)J&<LUFX; M!%TF ><MTS9_#]02P,$%     @ Q()_2B#ZL$ [ @  B@8
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M[:OA>1P&1O;CRP^FWT_U!U!+ P04    " #$@G]*S3)5@70"  #8!P  &0
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M['51F[T+4^GG_=AKQH6SW=1'BVLS7_T%4$L#!!0    ( ,2"?TK*=8G8&0(
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MY\)=0Q<HWO8O#!J>N>P?4$L#!!0    ( ,2"?THDF'3\!@(  ,H%   9
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M+Z$YH- H,[W7<S']BE.@^.!N&3Q?=>4'4$L#!!0    ( ,2"?TH>]QR\LP$
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M79C>^[F9K]E<.#VF%T269]S\!5!+ P04    " #$@G]*?AHO)<D!  !\!
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M[Q%ILAXA72TB]?STJHBG=8%L52#S MF5P,>;4PB8C<>(@,DB]]P4<X^+-S?
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M22S C8* %*2/IW<4,PDHF(#V"=*[!-0K8]#P7E,/FAQS3%*OF%"7IHCD!,-
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M-'NQ5@5T)"=+6;R]K]?J]0:>E0#^M0\^BHY7!UJ&_T7*HL_?9P#$\!_!XB/
M4/TU1(FP$$!*<;5HE**T<J[>P<G:+:]ST?,ZG0O]*Y"?_5=C <=XT"+$\P!
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M^7-F[] ,E$#">CPB,,"XY6*!_^#R%@"[!%:-,8)EO EC!,TOL/\@8>:+K#2
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M[NY_0:PX 6*O=CYBA+*"H$L.)RO]0_J=K)X'W4_EU@4WE 7EDCOJQ-VR1X;
M7^YQV.%X:LXA"*ART\%D.OQ"[VH^3@:WCW?B;O@ST*\\0^DHZT_D:4[RL[0&
M>J6W\/C!B2U@.K[BA=>23VDN'_UR-=?.QD-CYHT.C'3$2WEPS4>Z'IBUZ/4\
M-$FIY8$Q+:?IH6'MQ@=&MEVMY+OL/P#O^!E0[<O@!D3''2#5^,OC77]R&D\M
M:QQ'_*$5#,+I]G1<.7!Z.ZW[X+:+\_BZ70[$5)P@)T\<RMJ,<SZ2>3(!T=*1
M#\A-5&L_5G.1_J=/X\$G^ CB8?0(9]S_<C^>*M5A\+>'P6@RJ.8B8-+4M#E3
M 8;!*WVS%8CPVF%D)>*+WVF<R]]IG-[O,TZS_CN-T_C><::5COG7CI2Y)&G_
MYF=\410EVE@\/(ZO/_<G+/ < :(J-.V[7EUGGU*91"NP3[^"\8K7UH]0Y6N>
M\;84TNK'M4]@3 =Z2PA6 E _;&I7SJK,-V0'693ODUQ87]@7 B-<W=]89IC+
M"%..3SELA<U0?"_\%%$UBI^ B?&3:>TCPU7 9USYY+#QCCB5^[ @J]Z/,X'E
M>('0>EY;.54JGMDNST./=UM:PL&WE"O?4<:-B/Q556M/QU\$/@%)CP]28:Q]
MYZNGUG '@FS'<>LO^TU-/^)GK[3Z;5'WWJ:.YSYEJ)8.Y;+Z4"C I]',_2)I
MN<]%K=FPD*9(UZ4W'\N-Z0E(VR0=CJZ'#Z!MP%%R.9XQ6J9CX$G(YM&4&0W^
M-A6W8-R(7P?],6#!>&#8-3]5\_K?%"XL>FJKA]3I<"[-PMW,4AS<S2R]P-G,
M%OON9I949\2QWENDU]DMOWSQ?;P3:+7\HEX5DS1?ROO=GL&SU([1=# &% .]
M-8^BBG%_.CAD#E<'*2L5TNK0I8O8L1"-+=,.#])]77,+(YN_84Y;T:UN7JW[
MH>4XG"#+1((N1K-/<B]5Q5BK]#.6AK9]PF[Q*E6B'+:R/+#C 5:< G;/!A&I
MG<9>P"J^?F1EJC\5DVE_^DA.QQ*V'5#%?J<PI\6S3@M86F?MBE!6-SH>GK0T
MCM=&)JV#/A2<M(Y_<#L8HU0Q&('RD8UN!)SJU<F2_$"8SM+I3HS:G=C/"M95
M.Y%=T3KK^$X+U!VTH0Y%Z6Q6<#Q*9X483HG/N8FZ.C1GN4$<03F7QZAR1&O
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MX"G!_4R1M50YJ+%,A <HC1D45HZB967_6M:!#6HMN3%R2DHIB-,P9/2&H<V
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MR#CE)R&L^5H+X%KX7@L 6_AB"R!;^&8+0%OX:@M@6_AN"X!;^'(+H%OX=@O
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M<F]P<R]A<' N>&UL4$L! A0#%     @ Q()_2A9 P,[M    *P(  !$
M         ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ Q()_
M2IE<G",0!@  G"<  !,              ( !M0(  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #$@G]*D$6DPJ@"    "@  &
M@ 'V"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ Q()_
M2M;QXO:H!   Q14  !@              ( !U L  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( ,2"?TJ]NX*8< (  -8(   8
M      "  ;(0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #$@G]*/"PWUR$$  !-$0  &               @ %8$P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ Q()_2L4%6S[( @  1@H  !@
M             ( !KQ<  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( ,2"?TH\&(>S_P0  &<7   8              "  :T:  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #$@G]*:%7?1;4!  #2
M P  &               @ 'B'P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ Q()_2M?DF6JQ 0  T@,  !@              ( !S2$
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,2"?THQSV[%
MLP$  -(#   8              "  ;0C  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #$@G]*F.6L1;,!  #2 P  &0
M@ &=)0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,2"
M?TK76L^/M $  -(#   9              "  8<G  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ Q()_2O'X*H&U 0  T@,  !D
M         ( !<BD  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #$@G]*TS#?4;0!  #2 P  &0              @ %>*P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,2"?TJ7 K_^M $  -(#
M   9              "  4DM  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ Q()_2AD/]VRT 0  T@,  !D              ( !-"\
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #$@G]*U_9R
M<[4!  #2 P  &0              @ $?,0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( ,2"?TI\D\&AL@$  -(#   9
M  "  0LS  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MQ()_2EU!MQ"S 0  T@,  !D              ( !]#0  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #$@G]*>:PF3[,!  #2 P  &0
M            @ '>-@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( ,2"?TJZ/(K,LP$  -(#   9              "  <@X  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ Q()_2@VEJWNY @
M? L  !D              ( !LCH  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #$@G]*;OYC(;8!  #2 P  &0              @ &B
M/0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,2"?TH3
MRF3TQ0$  #<$   9              "  8\_  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ Q()_2BF,",?! 0  -P0  !D
M     ( !BT$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M" #$@G]*[44TN;,!  #2 P  &0              @ &#0P  >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,2"?TJSB>KWW $   $%   9
M              "  6U%  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!
M A0#%     @ Q()_2N+:K6BP 0  (@0  !D              ( !@$<  'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #$@G]*D>?2#68"
M  !Q!P  &0              @ %G20  >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;%!+ 0(4 Q0    ( ,2"?TH@^K! .P(  (H&   9              "
M 01,  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ Q()_
M2LTR58%T @  V <  !D              ( !=DX  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #$@G]*RG6)V!D"  #A!@  &0
M        @ $A40  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( ,2"?TH=LM#K[P$  /H$   9              "  7%3  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ Q()_2J/Q=]GX 0  \@0
M !D              ( !EU4  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #$@G]*))AT_ 8"  #*!0  &0              @ '&5P
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,2"?TI>:] T
MLP$  ,<#   9              "  0-:  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ Q()_2MGOCN_9 0  [@0  !D
M ( ![5L  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #$
M@G]*)1$5\-X!  #V!   &0              @ ']70  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,2"?TH>]QR\LP$  -(#   9
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M970T,BYX;6Q02P$"% ,4    " #$@G]*I' YAP4"  !8!0  &0
M    @ $W:@  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M ,2"?TJ' VZ(80(   \'   9              "  7-L  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ Q()_2EEZ@*VP @  ?@D  !D
M             ( !"V\  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #$@G]*19#:JSL"  !<!@  &0              @ 'R<0  >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,2"?TJA\8:B P(
M /L%   9              "  61T  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ Q()_2HOXC$@P @  #P<  !D              ( !
MGG8  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #$@G]*
M1M<7?&<T   :XP  %               @ $%>0  >&PO<VAA<F5D4W1R:6YG
M<RYX;6Q02P$"% ,4    " #$@G]*WKLIVS@"  #;"0  #0
M@ &>K0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,2"?THSS5026@0  %4?
M   /              "  0&P  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #$@G]*:]=\*\\!  !U'0  &@              @ &(M   >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #$@G]*&7O2#L$!  !V'0
M$P              @ &/M@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
...0 Y ($/  "!N      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>33</ContextCount>
  <ElementCount>263</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>6</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - CONSOLIDATED BALANCE SHEETS PARENTHETICALS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS PARENTHETICALS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETS</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS</Role>
      <ShortName>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureNOTESPAYABLE</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - BANKER'S ACCEPTANCE NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE</Role>
      <ShortName>BANKER'S ACCEPTANCE NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - CONSTRUCTION LOAN FACILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONSTRUCTIONLOANFACILITY</Role>
      <ShortName>CONSTRUCTION LOAN FACILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - SUBSIDY INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSUBSIDYINCOME</Role>
      <ShortName>SUBSIDY INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSTOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureCONCENTRATIONS</Role>
      <ShortName>CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - ACCOUNTING POLICIES (POLICIES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES</Role>
      <ShortName>ACCOUNTING POLICIES (POLICIES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - INVENTORY (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINVENTORYTABLES</Role>
      <ShortName>INVENTORY (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - PROPERTY AND EQUIPMENT (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES</Role>
      <ShortName>PROPERTY AND EQUIPMENT (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - INTANGIBLE ASSETS (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINTANGIBLEASSETSTABLES</Role>
      <ShortName>INTANGIBLE ASSETS (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES</Role>
      <ShortName>SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - INCOME TAXES (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureINCOMETAXESTABLES</Role>
      <ShortName>INCOME TAXES (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000270 - Statement - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/20161231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000280 - Statement - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES -Narrative(Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES -Narrative(Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000290 - Statement - INVENTORY (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_INVENTORYDETAILS</Role>
      <ShortName>INVENTORY (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000300 - Statement - PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS</Role>
      <ShortName>PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000320 - Statement - ESTIMATED USEFUL LIVES OF THE ASSETS AS FOLLOWS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS</Role>
      <ShortName>ESTIMATED USEFUL LIVES OF THE ASSETS AS FOLLOWS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000340 - Statement - INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS</Role>
      <ShortName>INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000350 - Statement - Intangible assets amortization expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_IntangibleAssetsAmortizationExpensesDetails</Role>
      <ShortName>Intangible assets amortization expenses (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000360 - Statement - ESTIMATED AGGREGATE ANNUAL AMORTIZATION EXPENSE (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_ESTIMATEDAGGREGATEANNUALAMORTIZATIONEXPENSEDETAILS</Role>
      <ShortName>ESTIMATED AGGREGATE ANNUAL AMORTIZATION EXPENSE (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000370 - Statement - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS</Role>
      <ShortName>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000380 - Statement - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000390 - Statement - NOTES PAYABLES (DETAILS)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_NOTESPAYABLESDETAILS</Role>
      <ShortName>NOTES PAYABLES (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000400 - Statement - BANKER'S ACCEPTANCE NOTES PAYABLE (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails</Role>
      <ShortName>BANKER'S ACCEPTANCE NOTES PAYABLE (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000410 - Statement - CONSTRUCTION LOAN FACILITY (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_CONSTRUCTIONLOANFACILITYDETAILS</Role>
      <ShortName>CONSTRUCTION LOAN FACILITY (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000420 - Statement - PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS</Role>
      <ShortName>PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000440 - Statement - SUBSIDY INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_SUBSIDYINCOMEDetails</Role>
      <ShortName>SUBSIDY INCOME (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000450 - Statement - ENTERPRISE INCOME TAX RATES (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_ENTERPRISEINCOMETAXRATESDETAILS</Role>
      <ShortName>ENTERPRISE INCOME TAX RATES (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000460 - Statement - PROVISION FOR INCOME TAXES (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_PROVISIONFORINCOMETAXESDETAILS</Role>
      <ShortName>PROVISION FOR INCOME TAXES (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000470 - Statement - RECONCILIATION OF INCOME TAXES CALCULATED AT STATUTORY RATES (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_RECONCILIATIONOFINCOMETAXESCALCULATEDATSTATUTORYRATESDETAILS</Role>
      <ShortName>RECONCILIATION OF INCOME TAXES CALCULATED AT STATUTORY RATES (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000480 - Statement - DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS</Role>
      <ShortName>DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000481 - Statement - INCOME TAXES NARRATIVE (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_INCOMETAXESNARRATIVEDETAILS</Role>
      <ShortName>INCOME TAXES NARRATIVE (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>000500 - Statement - CAPITAL STOCK TRANSACTIONS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS</Role>
      <ShortName>CAPITAL STOCK TRANSACTIONS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cphi-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>000510 - Statement - CONCENTRATIONS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20161231/role/idr_CONCENTRATIONSDETAILS</Role>
      <ShortName>CONCENTRATIONS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cphi-20161231.xml</File>
    <File>cphi-20161231.xsd</File>
    <File>cphi-20161231_cal.xml</File>
    <File>cphi-20161231_def.xml</File>
    <File>cphi-20161231_lab.xml</File>
    <File>cphi-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001010549-17-000112-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001010549-17-000112-xbrl.zip
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M!4X^[9.MZZ*O+(ZWE7O8$Z3N>#P>M865.K#+)Z6X9%MVV+/:UJ,IEO.Q)0L
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MT '?>+1SCX\W:.WN>#A43=IV<_)X(]89CD&1]G?N$!@\V<S@X*GA4>S#%/H
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MNU-AWG+S8-5,J-%JCL@.S2Z([;C??<NP:E_O^3#\%B9A9-RQF>?X%98E>+V
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M*R6@%:I6J%JA-E"A]DUP<<WVP?<<:,;=50G4,436E*HCQTK!7#6)XJ5#"TW
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M19A>,0%A@#%RZ6]*<*9>A/M!X"[30KYE?&*@AV@O2!5$P2?24Y,;"L!&CK>
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M9FEYZI'1ZP1HF(M"6A<+%HDSW6IULUTFH'"$:2MW['FS9QD?\V/4#PFC>LZ
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MJ<P5^V%+G=$ <;D(C&]4M9:?\V\/^1R>V^)PRB4+02FI]O,$5ID1UJC#V
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M+0/!2MA\$49VM%3226)!]2T\9T0> "(J5+KB9BBUUKL=QRR)J0_?LR>>[R4
M-- &0YY2P<P'RE<^34'0JEK5%3)W5&]%W?5&"EOIDF"Z0N;>_DS5)<%T5<SF
ML;]6'+J6X(LK#ET54W/RJ^'D9ZZ*^;;RTW)78],"\&,]%$EC$*V% Z'1:A):
M3W/D[<W#JIE0HZ71J@-:6L'5F0DK=J!U67D%^F-Y(H%V=-PPG233U#=@I>8R
MO&>,>7>X#W'HL5Y=#[DZE:"KRCXZ4T'70SXH3<L<6P/3ZO0TX]9*"6B%JA6J
M5J@-5*@]L]?NF./.H8?(-..^T-+A3:W*-BP-0JP(5,'2X$UAJ>,!&JT7-SO6
MT!SW=>EYS8 :+8W6JU-NEFD-VF\94NTROSBT9\$="^A.UG 2A^ ;.U0D,V(Q
MB^Y>M.A/4Q#4VE&C]?*VQ.QW^^9 FQ/-@QHMC=9+H_4$^JTSZ)C]P:$;>J\"
M5>TNOSBTI_S4<VP$86*XS$V=Q,-#K_"<DT9X3(#.%VLNU9I2H]4(N])NC\QN
M7_O-F@<U6AJMUZ;?!KVAV=&%Y;77_+)Y&>Z=3;5R,"W#"Q([N"6O6=3#\>8+
MVXOFX#QK/M6:4J/5 +LR''?-P<'IU:\"4\V!&BV-5AW0>IJSD/I^4^U,UQ':
MRZL3(V")$2Y89"?0HN&'<6PX=A0MT<&^MR-7LZC6G1JM!E@:JX-)&WACR5N&
M53.A1DNC50>T*E=P?=.R>E@1_"VC^HJ]YJ94ZO^]==VJM=O<%"#U124:M=I9
M&<OL=]KF0%_,U!Q/1Z/51,G5J-5$WW4';;-C=;4$OTJO^J49=E=H;\+$]K=<
M=:07?4TQQQJM)J%5N4'I6&:OWS%'[<Y;AE4SH49+HU4'M)YBHVTX'IG]H59P
MK]-E;LIJY!^VG]J)%P8 F:A6IQ=Q.J"@46N@47E?#[>Y*3+\08.D15:CUD1%
M5P_WN2DR7*[H&N$UCY4O:H3H.4LVAYDU2VH%^32H'7K)P*L"ZPT=K]'2K-%Z
M[>*L=9_6?:]8FNOH9;\T%^\,K;_E[G+?LR>>[R5+?7UY7:R/1NN5HO4T9N?-
MPZJ94*.ET:H#6EK!U9D)Z^A#-V5Y<K9:WDZOZ72$1D=HFF-)^L..V>V]Z*6#
M6FPU6J]=;K62>]'S'N.!.1J_:-&A5R*VBJ_,/^(-TQ5U4]*$,LM_IG'B39<O
MT.IQ;(13XS-SV'S"(J-KF4:G;0U,(YDQXR2<+^Q@:<QL=V/!#5%O@Q>$QH)V
M&&!>I!%TP*AM>[&(PA_>W$Z8OS3>]:U6VYA[OH]YT\ &SLRP(W"P[VS/1[R-
M)(2WIN!N&]CU-$W2B*+6-K^<A0>Q9\!&MS,@M6.UC!N%5-N/0Z W+J%7%*W^
M/0#6<XWK! B";QBPF^VKT?$MQ/=:_1UI+Z7;-+PICLI4!M =M.K/)6<!K8#B
M&+%$SH@8O/QOL8N 0&49/?F)4=/X9@?V+<-JX(83!K$'4,> &Z-+W+W$\&)C
M'@)*OO<=X4UF=D"W\< 'U.@P'XLPH@3[$)>M/G:$O9=T9MS#M-#+$TD=<UME
M&W/(+:F?T)S*<? ^2D>!1+ILP0(7AY$NX$$DX98%Q%O\O7(N==-(X@6,Z(4@
M))[DFV0&+&:XWA0Z9%10?<+X2_E-1#!HVJU9*VX3$]NEB;=YE*70 R__R1SD
M_G*"[8"/?.';08"DQPF,D=UZC"B?V]_Y>  2S@[8?FGWG^P8>B&T[$!Y6,Z@
MS^X832>TE821YX (EA C" :4N>R6DQW> 3NI*(<YRN7,@O 5@7: S$F.:8%W
M)\SW@-Y8L"PRF>!8I$E5E"#_@O>(72? )%,OB;?QK5VN@&GX\*&_B8<C!IVS
MHIX&N.Y@IEVBRT:KOWH^Q;!O;2^(81Q)7$H.T/(N3X4G*M[E&:,/4FOB=;,+
MG#*8WV4#--N:[0">2@F4.QN8*87QDK8"B!AH-."W1>0A;\,_T*[GD_:;I* 9
M@<7E8X@\.P*OA8.+7Z71!%@,93&)4F)I^0OR(9^F.(V<&1 +K(: 4L]QRS@&
MVM)@87NN8<_!?1(,#!S@<VD6.FEB^S3'\8P)SK(=)THE#<;"7J+8*+/REU_2
M^.C6MA<?STB4;NP?G[W8 8T#8G8#2'[R0^?[W_[C?_U%/G>=P!>ST$=]<OJO
M%+3_>9BPDI=PJ#@75VSZUY__L 8__PV[_<^C(W;[X^A(^E@';&B?7]R<&E;'
M.#*N;RY._L_?+[Y^/KVZY@\:I__W][.;/\IVM6OAPZG<ADHT!3,0H;Y!S>'%
M<<J,<=]LM]OX'\PC3#,)',S-'/D#P3>-=^U6NVW!=$:<T4SBEK+W%I$4\0VO
M<N=IY3%0]$M4AD00)@X8,2A6AC8VF0&3@F)U60QC)JX%#N;ODQDSH0D[(?&!
MYN%/\N3AWW^E -/4XYP>H\KUO;F7B#]MU$8)B^8@1BXNYE"[3I:J=A/I-KW!
MKV K0[""9+"]"$0@!"FI5-5(7EOA@H=9ZN".X$.*'T[G"S]<,F:0H!D7"\*'
M^DRSWJNGXVE6+-" 1TO4MM4V0,. ,06[8%R"FJ)^O&:,XR(PSL''((L'MA -
M7=O<Q)J?)&M^EJQIV&ZX0)'8\$8).L9[?%8^-/R5$!-_C7[]8 KWYA[$!AX,
M^#+E#KH D8D5#8V6(3/6'4$ZEWGJYM:^8T4'!CY+KQY4TFUD@__#E4*X$-(.
MNB4!CRW)M0I_ (E@CL=-&1=[[L2Q"/R1.9FF-$#' Y4=_,,$KT.;;@X6O(%6
M$EQTZ!M^(A<+G>7[6<B]?.$I[_*Z]+PR$Q^XO^#%1?!+G$[ +?9LU&P*).+N
M3W_)G2;N=S*R=(;-G6]H,UW@('H/J&ILEJ_SRA?88,3O\7^L87^EE56,^4S
M7^07I DHV0!#(@"H*YQ?I%YQ%H%EY93Q3M2W-KEQJZT]L?5\P%1*>((0#!#,
MBY?00H1;I6D4SC-*Y5*+V2 58LKQ\E8#EVWNCMYU[?60ZCT OX>W ;D.  ^Z
MI2R(N>@Q?K$M/.*3)09&);'.F%>R*.<V6O3ABC8B@<$_YZ&KFNII40-L CO>
M >U&8#RU/>$>X?#X,!=\'848HN<&XDD!A,SW=C&: $]SC9EF@9)/&*$^NG9
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MG[U!JTOOBJ]1'AWFW:$>DY85/7BY1YO@T@!M<+S:T!A(-F$ND7)\S[+$&(2
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M4P91/ OO,0]&8'651R <.YZ)7$P1YT'U1.-$+-;W],L")9R4N?W#FZ=S29+
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M/]0')"VYS4*M>LD=F3UK:+;']7?\:BNYK\#?&R^2IY9C7YS?N0FQ5EUVYI_
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M5K=M3:UO?-_60JYNZW@,_+=I6\>R!HS5.R>6=V"4MP_! &=IRK+T+/(_!-X
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M@=.,E5&W&6$S$(+S-/%TJI/@4@1!-IUGO*@)=H+B$!? &@*'@H64!.E?UJN
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M$@<8Q5&V5!KIQWEHQ;!14F5[$OF(/ .&N5Y<Q R>M-3!T#.]KUXZ02<)#C,
M\XIQ?M5RG',&#SEH_X&.$.?<"%S0='Y*C94 K,DAVY G,BRHN&8+-R$E+LFM
MSM<*29%/.-0)FE6S*\W,S!LTRVYHAX"^DE,XSGQ<)QSF@J7#)."L]T*9F3G,
MRC(Q#5>!U,)XLA,JV7/R3&9N:*9(F)%L@2D?<42Q3B$FI:.=QC)U,-K5*3-&
M]//) ES(HK9$_F!<[#2_VJ=E2UIU67!)P<S]\0IE'LC=S\"4GX/TKT/(JY4X
M68B4A5BM6+]Y20F;+A9!7R(GQB%S<0$ZC)71A: P")Y*=Q!EH_ 5(2DJPI*P
M"K RPBV+NO37(*4]CWX1?L(^!,;#W%.",&>4H$KNDQ)7$<*X^7R>6]<UUL;<
ME>=PE#-,M,6UQ6>Y\PL_O<@2"M_;NFM'5P326<F38W7&!)ZM8!4]4-2(&\LZ
MG)7?I+ V?*.E96Y9X@D*-<>Y^'00B6@ZS[G%TW#>,W4*VJ>0]W,_$>(D[G/9
M!PM@Y4]TV,\H,5!QNX]Q[N));7W0OJ<L3)E#+">CT8#%Y:&Z_. 3#(U1OK1J
MF,T=%7X\&V2C6:CI2ZD3,P!B/"GHZ]W?)^P>-Z'*LL3T%X9+\-&+O'LZ,Q2%
MA8OR&)2%>1N0E" \0>'!@1?]!7N5CERT;V%221!25@(I1%;\B $#?"RU8"-Z
MF>9(W,;6KR 68E!D>6Z+&@D>P1OD^7OZ)"$I@;;@C$F!Q<%,:;LC#X"^F*'R
M2**&1HN35"L*2HH)UQ!"P9ST67A/N/&HT#N F\RF&0SYP7M$;)0[PP:+2FO%
MZ*K75*=L-+M;R,,W\O.DEQQ=O\01RJ(0Z1WZD8%& GY6Y#BUKCC],%HN]%?C
MT=![%-DWD3>4/CA.1TWWQB(M2BT BG74SN$\M\9@:6).(8H P 3=Z:7GZA+!
M:LK?]UZ"AD(*)S#%\ [A&'WGI6#DXO:^",(9D@U#(2AWD$H36"%"U5I4ID(?
M3BS])1\PE(,,^2 4-23[!$A/8$!3]@.P,I%?,>&,WA#J\R.9^,P_ ?Y/0(!8
MT8Q,*C16C?% ],TR4JZ)Z?DQRIV8J.*<JBDI;#0:7CB<J9CFO9%\CN:O-)7"
M)]+KZ5CQ<2Q\+H?!3J68R QE9!48!ELYZ$63Y^YEGA1=S!?%E>9YW3"$2I,M
M+5O0_+V"<4T>/_-AR3+2HL[C5)H*^^3QTR:GHY6K9RMRNH&91:BMTCG,%X;X
M I<N8*M%J#?R$A^>/3V?71;X= [2KY0_YA7&DL)NO>4J%3LK:)TSR.!W1@D$
M*'K?L8B-@NP&%"/QT@L98)G,0! 86812147>]*M,O+\P32S*QB&?4Q(,9EQ-
M\G@5 -@V S2:>/I4;#W N1W/8 5D>D6BL1H(K*:(%=C/]Q[/D15BBDXWKF'=
MQ[ 4D9$1.O>J"!BIIWCNJ4Q=+0",!T!6K=Y1)$G:$90Q.Q/%;!E-7.*N  GJ
MY+E2D0/>^(?;<1IVITFC_</MVHU6K\?S0!;,OAJ_SHD77N"GEH)K,!@GH*%Q
M6X&QE=R+%%R^PS U36VO4FMV!4^;_/\9H&$ZSEGD7X#Z$,93?.<]A_2B6X#C
MQ4]@C=FJ+9![S]?O<>*![L'3[Q(F$GMXL8>@K%*(1)T6_*6J"$'E&@+-2PF^
M!A'S-*>L1B,K_QQH$\/;EPD=\(=3I(OB$_>.0'FE!)+/B\3-5!J=8*V#NI(V
ME/L./HYAB4*2^\3B(@6<6XIJ04 <Q"!(<&NJPKB)%\U&H,K.J.0(ESG$\)I4
M]OW9<)7+M:K)9"[U)FNW?/7WL]"YF)#3_N?\I)T52U_J$9X?5 \@RY:->14]
MJ25Z<@40^7W.P06IJOQE5+4420W$$/=P; BSBR6@M5)R/\- #KH_\!B)0"(D
M&&$284E5@<D=!PT^HLEGXI@C7B,;F*1#@A6R"CKF_I )/"0\1\%77O$I\^90
M?6[H0NMA'&)JOW2!T0'NI3$^]D3'(JE3%Q()%>PDR!:ZHT,3)64ACX/I5+OS
M])R4<T]8<#0-69>=%-\@3/4?0ZSD(0<2OD>@.)F1!F6/&38O81=ZTQ2?%>?G
M_%K%@S^%2:V62D5F0%<A,2)#\6:.]FK G"R@1:3XIL@)R*\5CVHKON*!J=(%
M%(1'303W+<@S0#5@N=10R0PY#W@:AP\(W>!D5:BX@!]*L2IC$NU>(A?Y?**F
M3*M7\,BMBP7\HOQ.A_1)6PQ%R4D0J=31&8KK(9Z@HI!F@?L ^,EGIA=2+8;P
MT#2X^TRAHAH%4 )^/DR@?&R+G'&EM8#MU2&=E3(Y'\/!:$+VA!I5!H+_/6C9
M=. ?PH$MD:/-JC!;=6SGWF+R+5*3R)M&%7-HGB%K464QK]Z@L#/F0"[255-3
M6:7G)]Z?L':!F<--KWK3((.)_R^R[R]< "1&GB9NGP;GIA.@ J^;EPHY^2X,
M[[81VRLX/ZC(.4AE2! %*E@_0Q''-TO#XM$(I8$FQZ.7YL# 3@<X//KM^5A,
MDI*KZT$9PSPF@LW],'V<-!O?!#<_XC"O/BV(5:W'?B;+7JE$U>OD@B;OA=>C
M#W%T_P&P]7G9YR&P[V]F[A#B=T((BL+42L$0*G]+^>&&38-H'%F.2?K_0\ >
MA3O4R.3E*0V\0AKE,)88<<\JCQ3K3)1AD QGDS237G\?0X;F*36'"GI0118\
M&A_HP@.)>&K]CM*>!Q$BX<.E,SW-.651<OZIVIW,(LQ^$N6S1J(*/Q,X9V92
MLAO%4!28H. +)5]@N2@"G)$W3>T*"Y$3-C@&0WBOF%%^A%/K:B21$LDLRRD@
M52T";]8$"&J@,A!D7/'!_&[E3Y"Q$9\"**FRYN>'ET@+I$2*6)%(>KQY<@F
M8GZ7AFF_TK+/K94(0S%.XA(&+"N?,'A0!9UIKO]H-OH=M^&T'%.K\/P''9D*
MYAN)HN#%V<_2E,N63S&L3)O[-1R[U6BW6N9H,A%^S8%:PAW+<#V\Y*E45&TB
M=G)B*T+>C).#,(4E,L%J*]AXE.MK0JI[CZ;]^Q@G%$ %;B6F%C7B03I6S9!D
MMQ5]"".3 0]+GS\.G,"@R5_(KV1]DQZI.$LF4<G(@24B!YRYRU PK&N?*NC%
M3!H<G)A/6C(A'\[C809Z_2#FQH+';QSF,;ZY$NH275$8+U+^C)DWYSY^1+4?
MIA<_1E(2D,M@ +HT3%EA^R1CT7JC1Q3B1@6#M% N,'C)"*]5,DK> ?]9IM,.
M)GPJOB"S#AJGG(@E:S9'5Q!KHSE!5HH/SZ@SIH$Y>0W=TR4_1,K"4!3E#E6Q
M+2GD6*(,8B\1]:^B7*-!A;JFO3#%:-R0$."^=TK%(<5?9D#[8MLV$#YG/$H;
MY'EOJ>A0I3*B\ZCC.[AF&1K/N&AK+0OJF$1H)$>.Q7 \5>8#BF?HB41BKIK>
MY(.J&A?BFQ/$("WHBL.BQXJ?+692GY& G$\FLJZIS,&88\/<,T*UQ2P'L7L5
M%0DN=3X1%B1 (^,R'28>&NSE$G6!1)0)26?B3+B+;V>4VIU@TT#Y[24H ZJ%
MW"'(5(D8,H9"F/A._<+;X*F^=RO]CQ0(E&GV1H";]H^(@W@&V%2!'9$DE:PF
M,GZYY6J\PC.@5%>ZD2D E//1.BN%@-P@,^ZS6-C&RGJ=>D^T"93_R$ FD38T
MFD=J</G5/%(F'.\>C:EL'IAAD1.\PASXN0,\F1?!7&NFE!TQ+56YR1-PQI2^
MP2U)G3\*"X'I.ERU'[ 1IA]SDO+C2>2%D4J)4R])T:$>9E@6J,A)&@BUVI/E
M;DQF>(I^'BBHM%;%3YX@42EIO$T?NM-T\T&9XBV[_N5U\$<JG%!=86"&/D],
MD[&9? "!X@8D [379A:%P5^B21QVG9+>E7DZJ\8S!1BH1F,6]%<2HC#2/VRN
MUK5.'6L">C52:ZNPU'PNW>9B)>_YECQW$,+GCG;$F=P1&CLN@'*^I@OI:U*/
M&T*G3"C=+=IN)6<"DV696'/Z$ =H^<@,UY K.:M<7Z+<9V6V&H%6&1[J+/5P
M#WE!R/UOL,%)NU06 >6CH(EH>E=U_AM:K?Q$-_0[,F\Q/ M+&T^P6$JI32([
M5/IEYBO )0S$;I'PF4_IFQ,^0L( AXBJ/?'[G$=['7&CI>HNQ T=/[([0$-U
M"I&17V.9'V6)EHSB@]PWG*<!NA.0PX1X+Q/L8DRB0E91%IWSF!S],"]_J,H%
M8^5.P^YU&JU67UJ58*)V&VZ_N2OI<[ )D L/T[GJ!]A]Z)?'597%KW.6/Q%^
M%@G2<[O;<*6JXSO''(531H<D,H,[YM(<Q)#Q:*0!<J073D?D".N<5I5A_ ^G
M>=I6IPU?__YI5W]3BOAVR1)7F<B46Z3CD<5@B%IR1*,, "(_Q6@JBBZ[ITJE
MU%,TT\9(%\S52)$/B!0K<S$Q&?(>#!@L<*).<#QR(T2LE'"KA/>^&=X,="PZ
M@G/Y\%Z*N0SXSWM=1;:#,_MEZIKF4AK0#ZAJA(WYE:=R&K:%?+%07B?L25T/
M,0!FD2E)41R=%'[(94DW,#&+/4G_@F0+T6-P'"?9"6YN>DD4Q N/B0YRID9O
M"(I?3["M-R^QIX,H82+_BP=66+JW%(FUN,=DMR\INQZ]E_GO+V.(ZDHVC<C:
MJ;TH97DOQ3B,[Y]4S\0I!L<2+?66%JD9/H8@%2TMT69"S4%E))3WWQ6!*#QI
MB"%T./Q+%.!?5,I+C' &(B\8>M*II"IO15Z-C!KGG71F5:]9N:"*>I5JHZH8
M9&]=Y53C+4)T69"JTI*:+EHUVCD^WZ:7SCBC)QIY/T6X/5OX8KX#=E[3T_1N
M* AE2"G'$,5&95C3B"L6JO-%*UM403%(GO$2?EZ+-B2US@^ $(D,SF"+BC7+
M/S;?E?E--E?]I%NG'H)AED.(R/Z._&18\V V9%@AK^_$?B$6ID.];*]I74WL
M5MH[/+5!]#"!O;>K?:?[IW^=4NL)>B/_- B14#4JR4U@=7L$>1(9LD+XR(UR
MU_S>EG' QS' ?3KAY3GI;  V0N"A$_,4;>%<A18=9_)6!:4_T2;"]"%/Q ,U
M:55C1K_H7J561 >O\?_*PFD:1SG1#4JT://("U:'3]))?SY&CSLFPT4P[T%P
M:I6\+S-=<G(%>8.(& IJ@60M90\IW&0EB+K"@M10>>+(@H^S!0(R#TT,F1_*
M4QR#>K3X."_SBCD;7+:)L?'!,@J6=OB8<] #&_.+$)A,#BWKTFM$2?C](Z!1
M\7,,U/SA7\#;/LM5??$FTQ)O(@Q'/%?JFN-GGZ$G0[&QIY>=XT6V ATR)9P1
MYQKY\H O^GP3[AC WPQ@!2IPHJ];S[Q,I.<N"J*[7ZY'UUHZO(3 O^8%!%K>
M<[QPH@9F*SQNN.<\ZP:,W(EG_0KKC84Y#>LJ&IYBE]U/[,'SD362J6B,UK H
M(.38]C\)4@3"[$HU*[<^@,C"E7Z%/[S&(=ZA/@VJ_V\!3LZZ LZ._#0_).?"
MW,"_>LCFDO^MCQ1S"_ET\'_6NP +%,<15Q[/8\#W0P: Q1NOS2MU=*V%[I=.
M!7Z"OVY8#$>3=(M]9E/>L@T[N!!]7@E3^?6IM81@ZE PSP$1A=#)H:CD!)'L
MW2M+*PY?EI>F'2_I=1$57!1N8RGU\'";32:B?!2)9/ (6 K)/2I_4D3/$JRW
M)XU6%=8CZ3-U<8OY-HFE"P9K[G%WI&!L&";%!L)*F#"LCB9S53M>>0+.V3T8
M@ZJ+)^:1X0\?.5I<N5 3=KM\PF8A7*YOX(+9868;!2D>>%:-*86M,2>7,#K^
MC!-1\K_ 1C(=,[+$3Q<\XL#HP]8H.Q+E\K3/0V5+I.9EC%4$D2F'KB)_AIU]
M0&2<>YD',F+&=))^'A/ZCK:X-MCT2X:]]F<<4"\<W9V%^-FD^D>>ST@+@V%5
MT/B8,I0^>>)\,^I=Z,?/C!IYX LP-C+$*RZBL/.VA4W0A'\2O\55DM_E:JC%
M=1A-FZ_D:_-N%EF7%@BZL/2-S'!@X@89[NW@1A;3ERK HS]:KX+7< AC=H1W
M+[QX(T%T?5/%3_ 8/&>T5()1RQ[#*<.C\"RP^C@8!"KGKO@TSQ:AVCR.^I-"
M7*1<4PX<+H;NODXW->!L]!P:W)4O>ROZN)?]!>3(-UXLP^D,6Y_2@53\E6KU
M$RP@4*2@U1/>9Y)]0S;+Z'4Y*;ZXY!DM&1$[4"5@0L&\YOCT\NJ]R:&PT46"
M()D1^"Q:*(SG.VF90?DD\J814<@O>PP\&3C05&0>#L!"B]N#LS$=8V:F<O4V
M;6L :AB<X1A)$E:-CQN!"@11NT0&9!PX/NH+YS@UFJ17<7+\;4,KQ9GPG,5T
MJ4-(+MX1G*-2HS$RQF0*&3HRA7TLJNB)5)A?D.<:G6Z@;P(8!/%PS";YWW4G
M";J@,*5T<=E$-WC LS+A,<Q$]Y40#;8QG4OH/?F0R  ,4Q!@:9EQHO:F6#Q0
MA?X4=?"T/<NV1FI6TFH%38G@4ZYE>D-1F"M51 J8J@$#K2S&XCI):IEFMY&E
M:0>)[CN("KFP@1WO1.6.<;R3ZZ)D:ERBH*"6I?_B9.;4,>V0^7-<<"V>!G@B
MO8,U]V:&EGO#2W^I-QIUK49=B5#'E9+34HDK-!S6:H]XYC!Z2@@:ET?HC.6;
ME.[^&5GOE?@0'8]+#DPC'B2[^GD3] )J7X=:6]"-*:0I2HRD[O7[Y?5[Z]7O
MY!%1(*Y)J&@,7I.*-DO55+GB81_#G5/F)L#R+<610F$$BWW&XV?B%]J<)\K-
M-1%&#/(0V.;\2=^7"7ZJW6F<9",P/[&8POH=[V)*N($G'20T#GY\QAA8T>A=
M'?O2;2Z713<V,9[WTFRT8&'/M>E<&MF8H]Z<6W7I8P88T0](5/_27R(V+HH%
M1?1+QJL\'A/#?#FJS'O*U_H;)@"7JS(8Q@U=H]H/9#7J@;FV@\K769;*WBMW
MH6S!!S(;\P9UYB@#1?-Z1/U!2(2\>R)=FYN.TG($NQ$X$@X'+<BD P(OE9W
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MH+P.+3=&5:3;K_"75A70QLB; UI'".\"T-J"=A? UA"FS6:_V5>E$5O/KIK
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M01%@JQ,+(&AHS7ZX10$.GW/JC/P=C,F*T=7C:.L'Y$_L9+PVM1Z1X46 -S@
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M*&(4\]\%YB_\OS1\?/L_4$L#!!0    ( ,2"?TJ*!E]LK%H  ,/? P 5
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M.BD(I29(&K^ ?UUFGUW"KR[?O;_\YMWK+XEW8'/I!R4J[MH/G>W:B3?..@I
ME<EK-]JP+M]]]^[]-^\.+:'K;AHY:B%U\N[[[[]_P_]:^)AUYJ7YU\6^/[P1
M?RQ_[+?PDFOYC[_ZIW^+HX ^TB7A!'^?[K?T#[]._,TVH+^6OUO'=%G?6Q#'
M;Z#]FY"NG)1ZH-;O0:WOO@.U_K/\]9VSH,&O"7SYZ7'2R-CWI;Y$HS<#L?A
M8S_RQF$_7BNMAV7Z*77B%,%VH?U0C,_9^D)[L5QH.1BS$5LE^S%[:,F9%6LH
M_/N._53BF7Y):>A1+^,:NFF9P9P*7R%8OUG'D5OL\JL 5LTH_JJHAZ_<[=J_
MS!8O+B5;\?YS%M+K79)&&QJ/7#?:A8SYVRAF]N'2,'56=+:4OT\>J4O]9V<1
MT*QC+M ?ONK?SYN"#-!728J8)M&.-:]08__Y3S3G7,E?*90,]+Z"#8^1AHV4
MAI>?GK[Z(R-,7$F9.!EILHQBLLV)DVB9_2TA<4[_W]X<1+%9=B]R=QOH"C;?
MX70PBET2Q1Z-Y2&FJ!(G=K-?L!\50L@OWK@1V^RVZ64VEKSY,HXV&*O-V(JP
M _+&R!1F'3(I_<#G@S5;3MC);T/GSA>:7#N!NPM@01JE\S6]I4RU3L"6_73'
M.M\_LK\DHT62QHZ;UDQJ4SUCIKEAZ3 3O\P*6+?/F2$I<$/<G!WBI"1=4[(4
M')$D8XG$P-/O+9H!AM5;G!.GL)[^L^1C'"6,;ASOV4E^M(&I6&/Q=5]AK+>%
M*L82>;?,X$2_Q.$=&]I;D"RK=HZNK \](5K$+QJWRE#Z&^J$Z2Y<^6Q_&"4)
M39/KI>>,MMLX>J;>/?5\MLRPG67#ID]R0U/'#]I6<$1G&+/'RX"9'0?JQ.'D
MR?7MS8@XD@&R$1S :86S0#S!@T56B%=@T5@-64%_F[YRO!NZ2,=?MC1,ZJX/
ME0\PME=/"V-/K$=F(HN44-$G^:]W_VUHL>W/;)I?AS4X/CNWJEU!K*!PI,IT
M'%-QE$HC\A+[*;WTHA=^YCI<)!+X(YRSQ";"F[JRS8+=3Z(@X/]^3=C1(]AY
M-+D@BUU*_(2$44H"?^.+KR_JKBG$"3WXCA9_^=JB-:)^-(KSOF56]9_+GQ*Z
MW 5W_C--9DMV>!-+RART,Z=?TBO6U>>:&:[5##/ON_"%60T$'68]C!#8(S=
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M%GZ *?)M8:5DO_K/<9CZZ5Y.O$>ZA<M$N.*!GU4OA?+SOE-$EP_,#!']$TF
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MP/$M:]!P#L'TB#V@&) &M1LEJ;\1A5%7JYA7R&9&'.Z<H 2?F]?^8E?EF#K
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MRJ[CF6_-YFB2P!KNU2"-G048'G"Q30EEZ$2E\9\#_ (B(J,05H/9L@$@MB,
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M%JB29'K<H,Z"C]<8L)LS2:.:-J.\LE^=7%*L"S99EKQL)\!$<8@,"$A_=OP
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M2,AF&3^Q"@H7K+6?$!I0$5W//O$\'N?H?@8B\%(CGVE>UC1DI]W W<EQX/U
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MGVU]*ND4>=<M(EHV)_NIZ#@AN[?5#IF4X<;42>@-%?^=A"/7C7?4F\,56)9
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M7,G2R;UT4EOP#,Y&)_/S7>3=>=*U!XK)QAR&S8M>0H$ZQ_X 0_<:'FA CXG
M7#X>;:[UEV@7>+*F&#MG,*'<P$D2P0(CFAE/<+C>< <C/$T*M;QROF8B)FF-
M/<(!A?\.6.<V1RI<@.IB\(;RSX#W D!TX3-(P"ETL'#8B%_ 4>G5XFO>C![*
M<ZX9V_R?(LT:QD80X'F@6>%D(;X;4"=F<K-=A5EQ4NVJGKNJ*FNY$SY<R'^(
M('.(6U@V] GWI6Z8FEZ]$^P?V/(BIF$HFT:_; '1'18R9COO!$PR=.J+O[O
M5, /B8N]&';*K95^@=V*C]"S'P7YQ&$V&RW^*K(,F,@>!6:9;-!#GH5Q05Z]
M_YKU7VA*OT#87G8$O7KB8RMFSZMOOBY2/M(\E[]&]WY238^27W$C=)VM. DO
MR3IBIIF?!;+V-NW^VAM"\230;>=%E!G.<$5&&73!B)^G:K+AU>7A$9VABA2C
M91@2F<535IX?VD#Q^BM5"S9C!(B7T,W6\6-8!0"XN[:<>^4+U#MH/374,VC>
M)7]V,_8&VI]391GW<M<6V7:#T*7'O19K0(77\1R$8OK!E-:MFDU?(D/JVJ@;
M2R(9'\JTAM04YH<!YI7WIC*TSN'Y>DT#CH3#CD)4^)KAE+1+:';78.>@_,D\
M)LF.73WV< Y919$GCG0)C9]]%PHBB#SP$!P9[ PCZE3S,RG\P?$ 7B'AY:">
M*:"RLC-R]K)?ER(N@7H(9'Q&&W9=6M"00I$&Z&T#;_VL&1PU1=6)'[(B#4XA
M3,NCVYA='[A:_B<6_+7IW*<PXTK0HW().$,9@+92OY6/C,'_&ROF>\@K6D&7
MEAA&N[R->/_]JO8:-H='Y^6>K2(QNX,IK:+TK3'CJ., Y1QT7L@FZ]!6"ZD3
MNM%0&O4^9)ZM'\4/W G_2#-?D?#.C;R_[A+N"KRAB1O[6[D]UYE2YV[P.;C]
M^,9YI\N$++/!OBHY3LA%C.6 EALE*64GHH@_OER)XQ4D$<M:MTV6JFJ&MDQ-
MOG"6".4A^8%*$B"<@FT6J:F*(POL,D;#6=PC3=A1W5VS@]\-?:9!Q(]^TCW2
M:G0Z+;%VUX$[G.D),OPD7R!DF>EUT$;5^KH.%@*L9[=(?&\O I;5^=M:35#0
M/)K\H **/UT]36Y^(9/I]>Q^;,@)89)Q[?*\::D^+SP1+:*=>%5)!#_B[15^
ML8J>:1SR!5M@S0D(7_C3M42:RZHVIM1=AU$0K=B>&[#[>!@]2\@Z=KMG]FA5
ML(2NXDL@15U,^-3%A%H>2#IV</KB0B8?0CJ4U+;(W/KIJ7LU'L./'%#Y!3 +
MV'_&A](U(W:R6;'Y[8>KV5*<MVNL4+\MQ@ [<XA*(\B*^? ?"O3@43JG"%Y*
M0=/0)G$2&?7CY$3HA;N'\((UC_Q(R L- OBO1S?P&X]NHP3B%GBX$X3E)-P!
MG3VF$T"E]],=#SHH1(0(W^YG/_02Z4,6R*W<,[UVGD6PPXJ=HP&Y$5#NF6TS
M45EG+F]1H2_SVOSCB),+LO97ZV!/ I^IT.-9[.)"6'#++Q@_;)MS/#_@X3QL
MZ^,PJ> 7_QQ&+Z$,JA'1.YDQ) !_[_ ]T(_!T;.+P://>V6_VT.<;2)<U(F_
M"OF=%+93/_G,^UE#G ]XQV5HU8*Z#CP%E/^69;4)U$KPJDL9W:8*4UG(!MOK
MF7:8_E9QM-OR3V'[%PEV;#O/\^MLVI\[VWQQK>RW] R*$9<7:2^".P*VHP)K
M1:NI 9PX;?Y0CWQ9M"V8>A'DDH<O0?B>)1;91S$U<''=1J[_MGTE0N!J-N7L
M+Y@MM]([Q@!D5VT+SXDY$V'<3ZD3IW>6,SD./7M95!;!V $* 8\L%8DU/&G$
MD[&;L/F&U.>G 1%/&% >#2I>RN6C> IH1;MX;],^55%5<1>JFVO#[3%3FHJ+
MZEWSZVKY&^RN44L1LSI X93 OD?56CFKJWVS:H<S@1N9V31WOJA+3C=\C#6*
M=AXPUI'US($\LK!P6[(T]<2O&HW&&)PJ?S>KYWC+;@9. %7L;MEOJL;2]B4F
MCU=!'64F62E.T3>!S@GOW1)3T9"_F-2KH_[3)GD+H"2.DR1R)F>[E&>WL(M5
MC;UH-,*G@.OP9" CO(@1=2%!HDB!E$4FI:^7XY1Q[<'J?T69A?0)HAI]&LMR
M+=2[Y:_W+IPB5W2V+ 29Y![/FBM-WYXP5R D]QA+9*1%/"BCG3G,V"8(CS#;
MG#S'.BE$'4'<IV#!T UA  6H;A2G4\30=PBD,HMW#A.3 >-W2'P77I_]8,<(
MCV454D:=+R.U_HCV%C@_A18W./]% @FEW*/*B1PJK^9("\;NY,:D4<TLI%3#
M7\&U-%.^FNN;W: 8W++D4JG<TC5_!)B$A=N!>.S[*2L*-\IJPC7<[0QT; "]
MVY!LJ <\3BY[:JD4U+/$I,UKK ;_VZ0Y(-)"\PSG4K6Q^9K&E*>7U^P8ZC:H
M)$]=CI"7B2RQ6V*1,C($Z) #(4/;AE&!5!L'5K#!4U)UE5/*/.UD@/TG!X>F
M@\>AK-B;>)%_W"Q^]U;\OYK9H=$(,SWT><+,#P'*!\]_9"GI9&@6 *%"?O?V
M@E&"_S.%IF)6+F4@GA'YAIXL^CHJSI:.!HD(5:H\J6;TU'@"NBU184K=N$.=
M<8H/Z64C4X,"G%DFU<S1)$G^G/WT%XLF4$=]E0):>IBH*6B#VRAF>UL6?GCO
M>'0>L5_P"D]1#'T>/RKU[<4<1$(GK@W"*.31T(XD+<"9! 9- KG/!_(G05PP
M+K@^*H-)!9P7P:&3$IM1'KH;/<+W)M/I[_T0X+_N_&6MOZWF*Y2/K9DJRJ\F
MNR4;T2\)6,>F'&DXEG6R+#*N=PE=[@+.? 9VQ_[Q3+T+LEWO$YXG(:$AV*=Y
MG(M 0>,P76S)AY:+7>*'4)E!0.FE/!HT]*2[FPGL!/0?0 LG=C,VVTW)M:B8
M86?(J+\%!) U]3X">$BCB[#V8V,Y];4\8):(K$,!B6*)G>B)W9A6WZS[,UC-
MSU'\>1+RJ%4U/$?Y8V-64\L#QFJ@0UAFMZ)+6\VF5NY&LVE6_CEJ3M_013KA
MUQ4>VZU?;;JQH;DZTRK>4/FAD@I/_SD&E(YAAXOECLUW>4:<[8;/ D<ID<BJ
M-]3E];K(-^\N"-/U!\M,5%^7S06JM08:4Z-,S@M>^+K-\]/T):YB62MUU%5S
M^M-X.I\]_D)>S4=7=^,GF]R#"KG+=:[4:A\T&8>C8@%,0UJ$QA(9\ZKU2[NY
M@:2<3GRB$G,:T/<$*4NLKJ]B:A)SNH\@(KU;Q.6P*P+OWS],@#H0T;:O48G;
M:BY06=IY]R3K__>6F(VF]*7<:\U!&#2[ [(;'P18HW>U_Y10;Q+>9AC7(T#7
M;@OW[]"!@;R0CKQBDT9X>G;F4<GI$$G(1"'NT\K&JY+<G43 ,R7,=%12339-
M'VNU<3XV'$<1'0TW/XT^4X()WP;1BRSX>F3%%FT9>$WU-^@SGXX;&)UP^ 0#
MAMW6T8D,6X-WDX:=D_O[,VP-36D:MNXPG]VP9P(,H_\)JJZ#$QER"Z]&3E 9
M/0#\RFD5K/COPXA;M*1IO*HA'=#+"BE9ZRA@BDW@FIKN>7S5/7<9-CE86]N@
M?:LZ'.&# 8MD1,4O(JB1_WKWWP;/\\;$@1I?M.D(KY#)LGFEI9,C;Z^VU0TW
M>T9>5O'LP?'9O+YVMKYJ]K2WP<X>+8Y0?IB<  $*E^RZ*&E89F1:FJ@:F?[@
M#/E^*G"Z).QJX\-I^2O\BVDM5=1K0P8X)DM*668P#1(?/Y(V*WHXHYA!:(U(
M%P 'L^!%=6-2-,*:C!Y/J%1E'E#DBTR05]*,OK;M[J.GAZI==1B<X<SLHP!*
M9 R-2F5_VM<B52NLH6ERA;$T24+4)2U7/))F9]ME15,I5;/K,E;#V5T'1!"M
M)EB+.S4:B(0!200,B 0TBZR# >FBCJJA&84 ,?50+Q-3"UQ-.(I<X]-\8P/\
M8[R*%]SS>X9M538Q@9EGF76I57'\X*XU+N=TJRB.9BT-S#M43![)&GT.MIW*
MU&I0>QS.?!J[B\(5 -E6D[>N12ESMH=/F1[$/QKLK%,76,OKP^]I$A4ML\4^
MBJE:9^^11"20QXY'9>A*\LB+=T"\W1U-DAS(X3:*;Z+=(EWN@NS+BH5@>D*E
MFN.X1[F<@?0!C#[.B5^0@"?A9/1Y+*\G.3@TB);D-^\^7'SWW;<7WW[_';^4
M_.;]]Q???'A_\;NWWUU O@[46V7']L!$+,I VE(E/CU2B7.?\/!F=GJDJ1/G
MF>U,*4/J]4+&4P,K/CNUNJ(P+?M?FW**D,-62K0W,$=/BQOY,PV"/T$5A2?J
M),PZ/'[FJSK>U=_CT2(5G""Q7>!5"BA<BI(1&0TBB%AB?=K*.$:'U!D71&DQ
M<=M</E*V3_I0E9H?[#[&#F#9L7VR<!']%#)ES=>4=?)V$@+"'9O[$,9;LX>9
MZ1=5I,RD9*A+@'18+&'%E*R(FR99"69$/NB!';(#?OAB"AR1G"5>O=%4+;2A
M]:/:T9+A]#3TQF-4UZ4::<:G6?^E) ,RRW&:,E#MINN]9B/,(J#/$V:&Y]CH
M\O&E!)'>=M4_GRCZ]:BB/!2)XTVX3ASOV8'QQ8DAV9VR'X7 =+EDIT%(-']V
M_,"1=9P8PSLX8>YX1CK[CO]!ZDE,7QHZ?*ISK3DOB4TG1GVE%V=E1Z/&Y-Z)
MYU9 1/O924399>K-HYJ9UOPM+O].P8&1-W$HPD5>V!7#D?TSTS(%YV)" "5H
M2T]!AL\J5"BCG%>H8U 8B#%>\/1'I[B)73GA9QH_L?L4$P,N6=,HI<DD!. 7
MOF356'[/CG  9!C>D8]EO$SLVBD?E01QX81.R($'PIG(L%"$]\ 88MFIE: &
M,#NI,H:'-,,HM(QPAIX22*C-]L"MQL_0<)HG"-T2\:6^?@#7D$SK'_3 Y-TH
M$0A(41Q'+P"?L(-BH66\?R<Y$E:X$.DBM>GPUJ:Z(]!,;.2:^H V"_.BPHQ%
M$34Y6U[-;A2'M>9VI@YN2L[,'>(  3Q#JN/Y.H(:V!RC=X(SG1'9NIWO>LMX
MSN.>4D]-1S\]\T24KHE73NC_32"BA][3H:;O<9ZX&GT6TQNJA U>"E1LZ./'
MT73R?T;SR6Q*1M,;\C3Y.)W<3JY'TSD975_//DWGD^E'\C"[FUQ/QD_D1HE=
M.[2Q&M!@J72+(4/ [ W2.T 3#>B<IF]Q>X"" QQ\SO7L?DSFH_]@YO1*]&\7
M@HY"^/*"IZ/_06N70'56>D/%?R=A]L(H2QOS]\F&,!?-Q@9JD'3@T6 $P59T
M;SA7S;PX[4EKM3)9,G_ZZ:2F,$I7.SSG#+NAVRCQ4YZ*("JU:,^OFJ;F9U<S
M?[B4-GF23:.\_EMR\JF%DZ5U8M4*9/V\:E:(>E8IK&_ P%_-; 7S*0HGR4N0
M%<=-YD-CV!1EZY]2)TZ;;-]*CL>AUY_?LP1+ZV9UV)+*T9"XVS#[FKX^4?:U
MF4TJS[O>RKQK]^\I[[K)@'2&8M!<:Z9TGQW,Q"XRI>GXBT2G!PSM%S]HLBFM
MI@:RLK7Y0WHT)1U93N""A-26=Z(^RJC)XNXV6OV=(-/H>I>D[&Y=*J!['\5T
MOG;"8B'=)R>H+7S3M0>,PZ0GMRAXH(BXDF;E&6;#(V\8W4H!9JA.8:K8S0D%
M5OG4S0L^M(>II_**?B>,<2,F)4V/0ICX2E 'F=OR,6JJ*7E S2J:$J\F:H^O
MYS^8FCQ&1%#.D[ZB##X=E.HH6;Z>65E3+GHLHAAE>=)FSU"'/DY<!+J>8S0"
MR079QO[&B?U@ST,*/'_)AI%"= T[EG]Z_?2:FR>\E-JR6*,4UK'<<\L8&Z_L
M#-_5K-AM7Y^@FG.1"V2N3U.Y8R!QV@K.785 U&Y6"#/TLJVA$(UZS4?&U=_8
MV:EGXZ>SY9T3>I\2>N]\::G U_(QQM35/*  *7COO(8=9+SLF)%L! 63E?G,
MR*!5H$\R7U.@[_(?!?K^3@OTJ<VGN"QHSL/^JP+/O'69+>X"R#V^@?1HU\^L
MLKHLM'V-61<TN, L#-#][^$VG!%@)_\#!4/K@B$9] -/F^2!ZWWJ^"%$;/-4
M(K8(T"2%/=+G ->BU!=,>4AF Z!@\N*G:^*09+< GWOJ@T<XBGEOI77#A?)@
MT#%,+X Q@9\/O1:)V33I-,:F..MTS=Q$\6J1_\&'Y)%R<O,H>VNMF8&:#<V4
MJ-;A#>41/A1E=@ZDF!$)HV;&FP6$&B]";4JT#G6G^XLX>(Q7)S755Y;6-D_4
MB?;@QX,WP]E+"'CHU^QPXCRP7VR<'\42E;!#]6SY(PVV213>4P#:"$:;[94?
MI=1=AU$0K?;7T5WJU7GJ3D(&>8H^F=S(\W?1K0R<D0A8 VA^SAP1W)&,/;C$
MP;>20R)9)/_*3J _D!*;Y#IZ?4$8JVW[RM^3%E4KQRGXLVB-.:7Z*R?HT\[>
M 0%,G60]"CWX#T#'/;/;&E]=,PR#^K^+^H -GE54EV@ 5 /R8-:K R5>2<22
MR6%2.T=XJ::&>SBCAS*\-W[B!E'"[ONJ.J=-7V--5<$%ZDUM-A\_D8?1+[Q8
MKN$040-\MT:%EIFW; 8IA*].#AW;.?=B_\!#_ZJQJIT6]X8N3K.8M_.+?8I^
ME77X-<E($%X[)%ES!P7_H<"-9?;91V5Z*[K&& ]GR6..<#-;CK^X_#%/9#_6
M,]Y@R9VZP%IR'WY1#W2<'ER#,HKB04L\?2:0%VOA\:2/EJK&VWM8;2S =QU!
M\N.._4[^,0I[5IOLVOEPA?MT9$2AL%2J4M;5\[,- ]RL]OH7^],VD?X.M]LH
MIOY*HD&[^WGLA$D@4H%S;U^- TVK&<8AUH4OC'E*.L25A$AZH%1P[QIR4)F6
M2O-ER5G"0RH/A6-'J)BZ@9,D/,>[(B9_WETY[,#U"B#NOH:-:JFGH>2BX4N'
M0XXGQ*,)^Z.3@5<*D#Q J'02 O%!T<9WR9IZ*_'([$ D>?$=BC'EY"2H0+N%
MCOR0D;F4OVAG(5T[3!DQ%?WS1W> 1K\L4&$,[NQZ7>YB,T4O6><I.MP._$B?
M:;AK+'";_QF["U;IX#Q+O"_#E_D^'+;>WF6'EMAODYC5+;%VQ,]5X.?!B6?Q
M$[QW>S\YP8ZRFQ?W,C=8JV9CLX5_5#RBWGRJ18"V3DR>@8IE5M5-)>W%@+3&
M;<@5$L(]J#=V8@CZ*(<NL(W;;[I_:#3$KZJZO.'66T&%4$G&,N/3U\+Q8M=I
MB 9,CG7=>$>]#*(7+B"M18*:OT<GR*HX0:7(BLYM+="HE/TH-59K&/I?$;,0
MCWGTE(%$U-P(Z[["7 !;J!H'\3!TNT.RK(1P!;QQ'J@G;W5YG9F%  <@R9I"
M"A1'WEL>D/>*HMITLVG15_$BH[*L4Q6/ <P=INZG_6815;.YC_^.*0Y32PF9
M( *W8=DO$1U;,O*- A<+OC3KUDQLV4,<003]K1\G:3&?5%Y$:M:W+JU-18)I
M<FDNP&LK")(E4*SD&L>"Z"EBM0S*J1^"94#><P98:>JL*6ZJBPFC@.NAF"\'
M?QGMTG44^W\[JIK;\B$2>+Z%-NI)0U9A%E5ZG+QO<V#Q2,:[9"*%NPR1URV)
MM>5I*C*@>4%E"6 (^W0R]VN&&N^R%N!@!F_L8F];X9)V=5:@X%5&B$(2R%]X
M[J*$W3O8;/L4^KQ0$60 WU(/*JSGN8(/NYBIMQ[HHW=?2!P"G 38V)!R_1TJ
M\ET$ T1P0):"A6+V_U9R80[*X/1:T$$Z.)DVSH"&@--H!2S!P-0P6/I+X 9U
MJ?M5:6&TZ%<]-YB)65?Q2V2NVO*JWT$1K:6K6L:EO[W45QJ1J*]J$/=.S3&6
MU(=/C%E=C:9_&C^*$\83X+*/'^:CZ?68E,)3+01G[Z.HHMGU'E%$70&>F#W.
M\JSK$J:./D%5 &B@AP)<J227&]KM,:RJ-O&/,501%,Z\"^*D#:Z\BS) 0 X+
MP"L&NL52]CR\(<OP+_T%BMEP/Z GJW)(3$BX /\5:A6*MFOGF?*T_06E(<_
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M#@#NE7_ROF ])&GL^>FAG=![ .%OKZ6KO6TH8;D7)L#__A$]O0T )/C\C?Q
MI/_;FW<W^^'U'_A7?Q9?7X)'2#X:I7-O"VKR,HN5Y"L3:\556;W8/[2(?\Q9
M?<T<!/L2;W=>C-M[@RD/@T/M=8RV#> ["($X*KS*$BP-VI&*7OCZ%8H#$!>S
M]#70=V./=./5R_8!A138JW_O%]XUW>A _W EH \*N+A9"LZ5/_<+YJIF=)1_
MO#+*"Q!#A%4(QE[*@[M:KI^XUW2E$_"W*Q%@88D"(M4D]!XIP%?_WB_ :[K1
M@?[I2D 74H^P-+$73K'5\O5W\,)<-^OE^@4\0U<Z 7^_$@&C+"9Z3F#B>^%G
MX,7LV899M%\TL#6F,_&?UQT*:+M%T2I%_I<5MM!!XF0IV<X0$X ]+GB5^L6.
M# ITGGZ^*D_$G1"/<+=Y1#%[PJJ6ZB,3-3WIT/]RW2%2#. EV*$X)98QAC%+
MV(.#7KR/9+ T9VR^WEV5EH\HS#"(<=%EV'S4R_61B#-=&0Q<:_];2/4)A.'O
M$7J.5L!+4 2":9)D(&8RP2K?1T:8NC.8N?:&^61N3/!O:*.#5;)?;##U9?!P
M[2UU(5>QV91CHERVSUQ4=&:P<:W]=:'"(GL(H3\)D5=W[=++] M]BHX,U*^U
MV3[N_,<@\6.8R\%S;I2+]0M[NJ8,^ ];[7^\/5-OAG^A^!1IY,Q7SFPZMEQ[
M?&O-K/G(7GVP;7?5]NB(W>#USXO8LES0O==>\I!WFBQY\^AYN_R[;T&8)H??
MY*"4.OO^UW]:20+2A'%\Q"ATR4"\5-*]?2\E<+VLG@'*1YH,1X&&W9P;M2=B
MY"4;!N[YGTR F=%-RF@7:I@&[A)@B:&?@H#(AR=T\H_]KPP^>2%6J&Z+25?K
M"2EB]=4=[M%/V<E9(K!\'^'=:[($/L"??@C!#"2)%8;HF81-3% \1ME#NL["
M0TG*P7O;E@RGZB*0NCDTO&!1V4N&>YJ3;D!\TB69@W2/ FN1D:IK.)L-@5!W
MYD@??5;P1/I.XJ)5MMN%\-Q+QBIE.,Y,Y;HY7&P_(J;1$U8!Q2^8=D;'KQ0Q
M''>Z6MT<*+8'?1&#G0<#^^L.1 G@3SOTLCVA@:%H-\>*BO8:,GN,ON!?4XQ]
M3/@*:[$&N%@P*]1F2IF+F*+4"_.2BA<";$4LLMC?> E(G/44PQH]0KPJ%8IP
MU@9!1</Y:@)!-P>.ETQF: ?B]&41>H5+"IOO.^)I8J\HW"J&4R6G=D?GCY>L
M\]5^A*6TO_IA1GQ7[Q$*GF%8#Q-M5+4GK,G!T-'9Y:4+%'=EZ@L#_&DL/X6\
MWF*DAIT9]!Y@"%,(R'XJC]$A7F%L[Y-)(7T1>"^EJYO ,(]:>1RZ"=E6PJ"<
MQYE302]+3?LB@S_CO=('!\;">R%>B]Q#)>>_H=7H+V=<'$P;9EC8.,.S^ED_
M8U/&*-]KPE@8F.HMW?>MW%'8:(Q5:O2:,C8.W5S+N."X+DM2M 7Q83O))XQ5
MNK]D,?4WS?,ZSH"+EB#T4A LO%@\&W(J])<N'@JFN6UG*'IT0;P=H0@KE/EY
M[ CR(CYMHEK]Y4Z(ASH_+]UK>.M%7["D>'X&N_R"^QREX#!-4YR%_/+](T("
M@VYNAK0?0V7I^..&5K)_%''U-LV5*VV8#\HBES?%-?IO2T+.4>0W=5)0ZO3(
MFT33V+3-$ED,4_9BB'OE20N.I2#=A#'CC=T=Z[:"/#RF>9O&>W^TZWTM:<ZR
MT^F%>T882V73?$IB/GI,@@3R^F:\Q@<=/3[::'Z8H<\#M#B<GN5"?_3"K+X7
MXI74RT0SRXVJJ6EK1^GF/H^+LV)](N)<1].6"2L(8"',PH/!-!IY.YAZK) '
M5ND^<<+4V+1U9 E2#T8@L+TX(C>I+-_/MEGN$<1&"/0A:SV1J-@GPF1P,'"M
M\5&TAH?;AR>1BU,2M,6P;T"4P"<PC7RT!3.4L RUEHWUB>.V>)EV>'&NM;3-
MURN^:'H:=RPA\'VU##LRWB87Z\T?-9IO-R^LI3UW/]CN=&3-U-]UKC5OT,WG
MFF3ZYB\W]J+$RUU1R2+OD!N00M\+QS#Q0Y1D&"F9+6VC=C29OYQK>J>[7X+@
MCD9M&##+M^&W8D$W TW=QI-Q1X(CCA/5K_%1CC\;-M!C!MO 9=J.M>K<P-H[
M,<EN!H)\A[T <9X'4,JSPZS<8XJ;PF3:KK<J=Y'3T<K2#8KAOT$@1>M9I<'1
M>0Z+@1O@,WGS1&M-*-Q7&"A]!SA,V\/29&7GEI6M-5 2)=+-ZML!E]S/#==)
MF9H#8%0*(--N99^E/!8NC[P:PV)1=F'4%^AW)BQW5625'B)K_/507_1?@T3K
M4E6&R)W$,G@,$KR^?W'EXO^_L^?NRIDX"WMIN5/\5VL^'CEWBZ7]P9ZOIA_M
MF;-2XFYL\#6]WL<&@FHZ 'T"42;T-9X5TW5<6X@AD%+S\&=A6CUP/6C"=MTU
MO8L.X@3HO(L^0DGJK/>:,6?M<AGS>:KI9)JC[IAKZE,,4S!&S_44PIR"YH-/
MT\XT7]K[&"7)(D9K9JA(N83YF%?T,<WCY>Q [)&W-O99O43+%KN\^41P=#7-
MF[4"87@2E'5<62VDEP!A1ZH$8M34,RW*\SV(L#:A%056L(51_A)H"I\ GP]1
MK1X1) 3 M&5[B?'$6)"LPV,\%80HS][%YXM?IT=L"90W;8'':^$3)"^4BU,Q
M2U7I$5-\U4TS#J;;G0=CTI?.4Q=.\*R0@A#/"2POH&SM'M$G#8AI]L29EK+F
M79_8H2BI[FR+'L6SRAX2&+P4P;V4()WJWWN )44ITTZ2CGH(0]!I)7O  5=1
MTTZ&\M"K0D"2-U5R%\FOU(.MI$!KT\[4B=\G2<G"50B-%R^ D>4EB:<6USQZ
MI/I:W=]%U]NT+>=!,OZ6I5ZJ?WS4M#1M'YFK)#*2*F7Z1D%-0],VAZ>U;H(5
M':$(+X 97@/WBR&*DENP1O'^/I7K?06)_14KBP6'D1>_3%.PS>_CXYH8PS!?
M/@6377=?[%OGZ!3]KM^?.0I%GT.I1?I"$%T_T[:9<Y *C?)JF;[@S]#0-#N/
M=^]T@L<M?-SGZ/%?2M$T6/?\O\("^^!_L\)FPLHZ:]S?>.N@^H_UK4MTA;EQ
M^VZ.GA?TE$'R+F)1WW[]D(_@$"DLV*DSBYN_1V=K:MK(JDMZZR70)X<Y,,Q2
MIG]=5$LO0Z)^QF/J3'_3-NN?\*2^P9)93]@L?@3S;/L 8F>="U\**I7CL65C
M_:&W+5I\WX#>@-R5ZXQ^_^#,QO9R9?_W_=3]K#H(E_(%<P)O*<(IV<*--E[T
M"))I))V.3K:6KLPJ'MX18Z9<2A)K1B$] [LA^M6T*E4E39NMC_(5JA"3#46
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M;*PW:4C&*;7&XCX-$9"Q$UEE%25S._8ZF^P?=S%,P/&;Y%A.O(]KW(3.Q5^
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M9A34F#M2$M-2KF.JIMVG@=N/;0F0V67[@S-'WZYMO3+%"R\F$RYU,T,KUA^
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H:2TR,#$V,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  #!& 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
